PART He-P
4023 WASTE DISPOSAL
Statutory Authority RSA 125-F:5,V
He-P 4023.01 Disposal Requirements.
(a)
A licensee shall dispose of radioactive material only:
(1) By transfer to an authorized recipient as
provided in He-P 4023.06 or in He-P 4030 or to the U.S. Department of Energy;
(2) By decay in storage;
(3) By release in effluents within the limits in
He-P 4020.14; or
(4) As authorized pursuant to He-P 4023.02, He-P
4023.03, He-P 4023.04, He-P 4023.05, or He-P 4023.08.
(b)
A person shall have a specific license to receive waste containing
licensed material from other persons
for:
(1) Treatment prior to disposal;
(2) Treatment or disposal by incineration;
(3) Decay in storage;
(4) Disposal at a land disposal facility licensed
pursuant to He-P 4062; or
(5) Storage until transferred to a storage or
disposal facility authorized to receive the waste.
Source. #5903, eff 2-1-95; ss by #6827, eff 8-6-98;
ss by #8481, eff 11-5-05; ss by #10604, eff 5-23-14
He-P 4023.02 Method for Obtaining Approval of Proposed
Disposal Procedures.
(a) A licensee or applicant for a license may
apply to the DHHS/RHS in accordance with He-P 4030 for approval of proposed
procedures to dispose of licensed material generated in the licensee's
operations.
(b) Each application shall include:
(1) A description of the waste containing
licensed material to be disposed of, including the physical and chemical
properties that have an impact on risk evaluation, and the proposed manner and
conditions of waste disposal;
(2) An analysis and evaluation of pertinent
information on the nature of the environment;
(3) The nature and location of other potentially
affected licensed and unlicensed facilities; and
(4) Analyses and procedures to ensure that doses
are maintained ALARA and within the dose limits in He-P 4020.
Source. #5903, eff 2-1-95; ss by #6827, eff 8-6-98;
ss by #8481, eff 11-5-05; ss by #10604, eff 5-23-14
He-P 4023.03 Disposal by Release into Sanitary Sewerage.
(a) A licensee may discharge licensed material
into sanitary sewerage if each of the following conditions is satisfied:
(1) The material is readily soluble, or is
readily dispersible biological material, in water;
(2) The quantity of licensed or other radioactive
material that the licensee releases into the sewer in one month divided by the
average monthly volume of water released into the sewer by the licensee does
not exceed the concentration listed in Table 4090.1, Table III of He-P 4090;
(3) If more than one radionuclide is released:
a. The licensee shall determine the fraction of
the limit in Table 4090.1, Table III of He-P 4090 represented by discharges
into sanitary sewerage by dividing the actual monthly average concentration of
each radionuclide released by the licensee into the sewer by the concentration
of that radionuclide listed in Table 4090.1, Table III of He-P 4090; and
b. The sum of the fractions for each
radionuclide required by He-P 4023.03(a)(3)a. shall not exceed unity; and
(4) The total quantity of licensed and other
radioactive material that the licensee releases into the sanitary sewerage in a
year does not exceed 185 GBq (5 Ci) of hydrogen-3, 37 GBq (1 Ci) of carbon-14,
and 37 GBq (1 Ci) of all other radioactive materials combined.
(b) Excreta from individuals undergoing medical
diagnosis or therapy with radioactive material shall not be subject to the
limitations contained in He-P 4023.03(a).
Source. #5903, eff 2-1-95; ss by #6827, eff 8-6-98;
ss by #8481, eff 11-5-05; ss by #10604, eff 5-23-14
He-P 4023.04 Treatment or Disposal by Incineration. A licensee may treat or dispose of licensed
material by incineration only in the form and concentration specified in He-P
4023.05 or as specifically approved by the DHHS/RHS pursuant to He-P 4023.02.
Source. #5903, eff 2-1-95; ss by #6827, eff 8-6-98;
ss by #8481, eff 11-5-05; ss by #10604, eff 5-23-14
He-P 4023.05 Disposal of Specific Wastes.
(a) A licensee shall dispose of the following
licensed material as if it were not radioactive:
(1) 1.85 kBq (0.05 mCi), or less, of
hydrogen-3 or carbon-14 per gram of medium used for liquid scintillation
counting; and
(2) 1.85 kBq (0.05 mCi), or less, of
hydrogen-3 or carbon-14 per gram of animal tissue, averaged over the weight of
the entire animal.
(b) A licensee shall not dispose of tissue having
been treated with radioactive material pursuant to He-P 4023.05(a)(2) in a
manner that would permit its use either as food for humans or as animal feed.
(c)
The licensee shall maintain records in accordance with He-P 4021.09.
Source. #5903, eff 2-1-95; ss by #6827, eff 8-6-98;
ss by #8481, eff 11-5-05; ss by #10604, eff 5-23-14
He-P 4023.06 Transfer for Disposal and Manifests.
(a)
This section shall:
(1) Control transfers of low-level radioactive
waste by any waste generator, waste collector, or waste processor licensee who
ships low-level waste either directly, or indirectly through a waste collector
or waste processor, to a licensed low-level waste land disposal facility as
defined in He-P 4003;
(2) Establish a manifest tracking system; and
(3) Supplement existing requirements concerning
transfers and recordkeeping for those wastes.
(b)
Any licensee shipping radioactive waste intended for ultimate disposal
at a licensed land disposal facility shall document the information required on
NRC’s Uniform Low-Level Radioactive Waste Manifest and transfer this recorded
manifest information to the intended consignee in accordance with Appendix G to
10 CFR 20.
(c)
Each shipment manifest shall include a certification by the waste
generator as specified in Appendix G to 10 CFR 20, as appropriate.
(d)
Each person involved in the transfer of waste for disposal or in the
disposal of waste, including the waste generator, waste collector, waste
processor, and disposal facility operator, shall comply with the requirements
specified in Appendix G to 10 CFR 20, as appropriate.
(e)
Any licensee shipping byproduct material, as defined in He-P 4003.01(v)(3),
(4), and (5), intended for ultimate disposal at a land disposal facility under
10 CFR 61 shall document the information required on the NRC’s Uniform
Low-Level Radioactive Waste Manifest and transfer this recorded manifest
information to the intended consignee in accordance with He-P 4023.06.
Source. #5903, eff 2-1-95; ss by #6827, eff 8-6-98;
ss by #8481, eff 11-5-05; ss by #10604, eff 5-23-14
He-P 4023.07
Compliance with Environmental and Health Protection Regulations. Nothing in He-P 4023.01, He-P 4023.02, He-P
4023.03, He-P 4023.04, He-P 4023.05, He-P 4023.06 or He-P 4023.08 shall relieve
the licensee from complying with other applicable federal, state and local
regulations or rules governing any other toxic or hazardous properties of
materials that may be disposed of under He-P 4023.01, He-P 4023.02, He-P
4023.03, He-P 4023.04, He-P 4023.05, He-P 4023.06 or He-P 4023.08.
Source. #5903, eff 2-1-95; ss by #6827, eff 8-6-98;
ss by #8481, eff 11-5-05; ss by #10604, eff 5-23-14
He-P 4023.08
Disposal of Certain Byproduct Material.
(a) Licensed material, as defined in He-P
4003.01(v)(3), (4), and (5), may be disposed of in accordance with 10 CFR 61,
even though it is not defined as low-level radioactive waste. Therefore, any licensed byproduct material
being disposed of at a facility, or transferred for ultimate disposal at a
facility licensed under 10 CFR 61, shall meet the requirements of He-P 4023.06.
(b) A licensee may dispose of byproduct material, as defined in He-P 4003.01(v)(3), (4) and (5), at a disposal facility authorized to dispose of such material in accordance with any applicable federal, state or local rules and regulations or hazardous waste law, including the Solid Waste Disposal Act, as authorized under the Energy Policy Act of 2005.
Source. #10604, eff 5-23-14
Part He-P 4024
DECOMMISSIONING
Statutory Authority RSA 125-F:5,V
He-P
4024.01 Purpose.
(a) This part
provides for removing safely from service a facility or site having radioactive
material, a radiation-producing or radioactivity-inducing machine pursuant to
He-P 4030 through 4036, 4039, 4040, 4044, and 4047.
(b) The
purpose of this part is to conform with 10 CFR 20.1401 – 20.1406, 30.35, 30.36,
40.36, 40.42, 70.25, and 70.38.
Source. #8393, eff 7-23-05; ss by #10492, eff
12-24-13
He-P 4024.02 Scope. This part shall apply to any person licensed
to receive, possess, own, acquire, use, process,
transfer or dispose of radioactive material, and to any person responsible for
decommissioning a facility or site.
Source. #8393, eff 7-23-05; ss by #10492, eff
12-24-13
He-P 4024.03 Exemptions. The following licensees shall be exempt from
this part:
(a) Low-level
waste disposal facility licensees under this chapter including ancillary
facilities that support radioactive waste management and disposal activities;
and
(b) Uranium
and thorium recovery facility licensees under this chapter, or uranium solution
extraction facilities.
Source. #8393, eff 7-23-05; ss by #10492, eff
12-24-13
He-P 4024.04 Minimization
of Contamination. Applicants for
licenses, other than renewals, shall describe in the application how facility
design and procedures for operation shall:
(a) Minimize,
to the extent practicable, contamination of the facility and the environment;
(b)
Facilitate eventual decommissioning;
(c) Minimize,
to the extent practicable, the generation of radioactive waste; and
(d) Conduct, to the extent practical, operations
to minimize the introduction of residual radioactivity into the site, including
the subsurface, in accordance with the existing radiation protection
requirements in He-P 4020.04 and radiological criteria for license termination
in He-P 4024.04, He-P 4024.09, He-P 4024.10, He-P 4024.11, and He-P 4024.13.
Source. #8393, eff 7-23-05; ss by #10492, eff
12-24-13
He-P 4024.05 Continuation of Licenses Beyond Expiration Date.
(a) In accord
with He‑P 4030, each existing license shall not expire until final action
is taken by the DHHS/RHS.
(b) With
respect to possession of radioactive material and residual radioactive
contamination, each specific license continues in effect beyond the expiration
date until the DHHS/RHS notifies the licensee in writing that the license is
terminated, even if:
(1) The
licensee decides not to renew the license;
(2) No
application for license renewal is submitted;
(3) An
application for renewal is denied; or
(4) The
DHHS/RHS modifies or suspends the license.
(c) After the
expiration date specified in the license, each licensee to which He-P
4024.05(b) applies and who possesses radioactive material, including residual
radioactive material, shall:
(1) Limit actions involving radioactive material
to those related to decommissioning; and
(2) Continue to control entry to restricted areas
until they are suitable for release in accordance with DHHS/RHS requirements.
Source. #8393, eff 7-23-05 ss by #10492, eff 12-24-13
He-P 4024.06 Decommissioning
Timeliness.
(a) Each
licensee or person in possession of a non-exempt source of radiation who
decides to terminate all activities involving that source of radiation shall
notify the DHHS/RHS immediately, in writing.
(b) Each
licensee or person responsible for a facility or site which includes a non‑exempt
source of radiation or which may be contaminated by residual radioactivity
shall, no less than 30 days before vacating or relinquishing possession or
control of the facility or site, notify the DHHS/RHS, in writing, of the intent
to vacate.
(c) The
licensee shall notify the DHHS/RHS in writing within 60 days of the
occurrence of any of the following:
(1) The licensee has decided to permanently cease
principal activities at the entire site or in any separate building or outdoor
area that contains residual radioactivity such that the building or outdoor
area is unsuitable for release in accordance with these regulations;
(2) No principal activities under the license
have been conducted for a period of 24 months; or
(3) No principal activities
have been conducted for a period of 24 months in any separate building or
outdoor area that contains residual radioactivity such that the building or
outdoor area is unsuitable for release in accordance with these regulations.
(d) From the
date of notification of the DHHS/RHS required in (a) or (b) above, the licensee
shall either:
(1) Begin decommissioning activities; or
(2) Within 12 months of
notification, submit a decommissioning plan, if required by He-P 4024.07, and begin
decommissioning upon DHHS/RHS approval of that plan.
(e)
Coincident with the notification of the DHHS/RHS required in (a) and (b)
above, the licensee shall maintain in effect all decommissioning financial
assurances established by the licensee pursuant to He-P 4030.09 in conjunction
with a license issuance or renewal or as required by this part.
(f) The
amount of the financial assurance required by paragraph (e) of He-P 4024.06
shall be increased, or may be decreased, as appropriate, to cover the detailed
cost estimate for decommissioning established pursuant to He-P 4024.07(c)5.
(g) The
DHHS/RHS shall approve an alternate schedule for the submission of plans and
for the completion of decommissioning as required pursuant to (a) and (b) above
only if the DHHS/RHS determines that the alternate schedule:
(1) Is
necessary to effectively conduct decommissioning;
(2) Presents
no undue risks to public health and safety; and
(3) Is
otherwise in the public interest.
(h) Any such
request as described in He-P 4024.06(g) shall be submitted no later than 30
days before notification pursuant to He-P 4030.11(b).
(i) The schedule for decommissioning shall not
commence until the DHHS/RHS has made a determination on the request.
Source. #8393, eff 7-23-05; ss by #10492, eff
12-24-13
He-P 4024.07 Decommissioning
Plan.
(a) A
licensee shall submit a decommissioning plan if:
(1) The licensee intends to terminate the license
using radiological criteria specified in He-P 4024.10 and He-P 4024.11;
(2) Otherwise
required by these rules;
(3) Required
by license condition; or
(4) The
procedures and activities necessary to carry out decommissioning of the site or
separate building or outdoor area have not been previously approved by the
DHHS/RHS and the procedures could increase potential health and safety impacts
to workers or to the public, including but not limited to the following cases:
a. Procedures involving techniques not applied
routinely during cleanup or maintenance operations;
b. Workers
entering areas not normally occupied where surface contamination and radiation
levels are significantly higher than routinely encountered during the operation
for which the license was issued;
c. Procedures
that could result in significantly greater airborne concentrations of
radioactive materials than are present during operation; or
d. Procedures that could result in significantly
greater releases of radioactive material to the environment than those
associated with the operation for which the license was issued.
(b)
Procedures with potential health and safety impacts shall not be carried
out prior to approval of the decommissioning plan.
(c) The
proposed decommissioning plan for the facility or site, or separate building or
outdoor area, shall include:
(1) A description of the conditions of the
facility or site sufficient to evaluate the acceptability of the plan;
(2) A description of planned decommissioning
activities;
(3) A description of methods used to ensure
protection of workers and the environment against radiation hazards during
decommissioning;
(4) A description of the radiation survey planned
to demonstrate compliance with He-P 4024.08(d) and He‑P 4024.09(a), or if
applicable, He-P 4024.09 or He-P 4024.11; and
(5) An updated, detailed cost estimate for
decommissioning, comparison of that estimate with present funds set aside for
decommissioning, and a plan for assuring the availability of adequate funds for
completion of decommissioning.
(d) For
decommissioning plans calling for completion of decommissioning later than
24 months after plan approval, the plan shall include a justification for
the delay.
(e) The
proposed decommissioning plan shall be approved by the DHHS/RHS only if the
information therein demonstrates that the decommissioning will be completed as
soon as practicable and that the health and safety of workers and the public
will be adequately protected.
Source. #8393, eff 7-23-05; ss by #10492, eff
12-24-13
He-P 4024.08 Completion of Decommissioning.
(a) The licensee shall complete decommissioning
of the facility or site as soon as practicable but no later than 24 months following the initiation of decommissioning, unless an
alternate schedule addressing the factors in He-P 4024.08(c) is requested with
written justification and approved by the DHHS/RHS.
(b) When
decommissioning involves the entire site, the licensee shall request license
termination upon completion of decommissioning activities.
(c) For
decommissioning plans calling for completion of decommissioning later than
24 months after plan approval, the plan shall include a justification for
the decommissioning schedule warranted by consideration of the following:
(1) Whether it is technically feasible to
complete decommissioning within the allotted 24‑month period;
(2) Whether sufficient waste
disposal capacity is available to allow completion of decommissioning within
the allotted 24‑month period;
(3) Whether a significant volume reduction in
wastes requiring disposal will be achieved by allowing short-lived
radionuclides to decay;
(4) Whether a significant reduction in radiation
exposure to workers can be achieved by allowing short-lived radionuclides to
decay; and
(5) Other site-specific factors which the
DHHS/RHS considers appropriate on a case-by-case basis, including but not
limited to:
a. The regulatory requirements of other
government agencies, lawsuits, groundwater treatment activities, monitored
natural ground-water restoration, actions that could result in more
environmental harm than deferred cleanup; and
b. Other factors beyond the control of the
licensee.
(d) As the
final step in decommissioning, the licensee shall:
(1) Conduct a radiation survey of the premises
where the licensed activities were carried out, and:
a. Submit a report of the results of this survey
in (1) above, unless the licensee demonstrates that the premises are suitable
for release in some other manner;
b. As
appropriate:
1. Report levels of gamma radiation in units of
millisieverts, or microroentgens, per hour at one meter from surfaces; and
2. Report levels of radioactivity, including
alpha and beta:
(i) In units of megabecquerels, or
disintegrations per minute or microcuries, per 100 square centimeters,
removable and fixed, for surfaces;
(ii) In units of megabecquerels, or microcuries,
per milliliter for water; and
(iii) In units of becquerels, or picocuries, per
gram for solids such as soils or concrete; and
c. Specify
the survey instrument(s) used and certify that each instrument is properly
calibrated and tested;
(2) Certify the disposition of all licensed
material including accumulated wastes, by submitting a completed Form RHP-10 containing
the following:
a. Name of licensee;
b. Address of licensee;
c. Department(s) of licensee, as applicable;
d. License number of licensee;
e. Individual isotope user(s);
f. The name of the certifying
official duly authorized by the licensee to certify that licensable quantities
of radioactive material under the jurisdiction of the DHHS/RHS are not
possessed by the licensee, and to request that the license be terminated; and
g. The dated signature of the certifying
official of the licensee;
(3) Clearly indicate on the form required by
(d)(2) above whether:
a. All use of radioactive materials authorized
by the license has been terminated;
b. Radioactive contamination has been removed to
the level outlined in He‑P 4024.09 to the extent practicable;
c. No radioactive material has ever been
procured or possessed by the licensee under the authorization granted by the
licensee’s license;
d. All radioactive material previously procured
or possessed under the authorization granted by the license has been disposed
of by:
1. Transfer to another licensed entity
authorized to possess the material and provide the recipient entity’s name,
address, and the license number and radiation regulatory licensing authority;
2. Decay, survey, and disposal as non‑radioactive
trash; or
3. A method in compliance with the provisions of
He‑P 4023;
e. Radiation surveys or the equivalent as
specified in He‑P 4024.08(d) are attached; and
f. Additional pages containing additional
information are attached;
(4) Include, as additional attached pages to the
Form RHP-10, a clear and detailed description of the method of disposal of
radioactive material, if the licensee disposed of radioactive material using a
method other than that indicated in He‑P 4024.08(d)(3)d.1. or 2. above;
and
(5) Include, as additional attached pages to the
form, report(s) of detailed radiation surveys required by He‑P 4024.08(d)(1).
Source. #8393, eff 7-23-05; ss by #10492, eff
12-24-13
He-P 4024.09 Termination of a License Without
Restriction.
(a) A site
shall be considered acceptable for unrestricted use only if:
(1) The residual radioactivity that is
distinguishable from background radiation results in a TEDE to an average
member of the critical group that does not exceed 0.10 millisievert (10 mrem)
per year, including that from groundwater sources of drinking water; and
(2) The residual radioactivity has been reduced
to levels that are as low as reasonably achievable (ALARA), taking into account
consideration of any detriments, such as accidental deaths, expected to
potentially result from decontamination and waste disposal.
(b) Specific
licenses, including expired licenses, shall be terminated upon written notice
to the licensee only when the DHHS/RHS determines that:
(1) Radioactive material has been properly
disposed;
(2) Reasonable effort has been made to eliminate
residual radioactive contamination, if present;
(3) Documentation is provided to the DHHS/RHS
that:
a. A radiation survey has been performed which
demonstrates that the premises are suitable for release in accordance with
DHHS/RHS requirements; or
b. Other information submitted by the licensee
is sufficient to demonstrate that the premises are suitable for release in
accordance with DHHS/RHS requirements; and
(4) Records
required by He-P 4030.10(n)(6) to be submitted to the DHHS/RHS prior to license
termination have been received by the DHHS/RHS.
Source. #8393, eff 7-23-05; ss by #10492, eff
12-24-13
He-P 4024.10 License
Termination Under Restricted Conditions.
A site shall be considered acceptable for license termination under
restricted conditions only if:
(a) The
licensee can demonstrate that further reductions in residual radioactivity
necessary to comply with the provisions of He‑P 4024.09 would result in
net public or environmental harm or were not being made because the residual
levels associated with restricted conditions are ALARA, taking into account
consideration of any detriments, such as accidental deaths, expected to potentially
result from decontamination and waste disposal;
(b) The
licensee has made provisions for legally enforceable institutional controls
that provide reasonable assurance that the TEDE from residual radioactivity
distinguishable from background to the average member of the critical group
will not exceed 0.10 millisievert (10 mrem) per year, including that from
groundwater sources of drinking water;
(c) The
licensee has provided sufficient financial assurance to enable an independent
third party, including a governmental custodian of a site, to assume and carry
out responsibilities for any necessary control and maintenance of the
site. Acceptable financial assurance
mechanisms shall include:
(1) Funds
placed into a trust segregated from the licensee’s assets and outside the
licensee’s administrative control, and in which the adequacy of the trust funds
is to be assessed based on an assumed annual one percent real rate of return on
investment;
(2) A
statement of intent in the case of federal, state, or local government
licensees, as described in He-P 4030.09(j)(5); or
(3) When a
governmental entity is assuming custody and ownership of a site, an arrangement
that is deemed acceptable by such governmental entity;
(d) The
licensee has submitted a decommissioning plan to the DHHS/RHS indicating the
licensee's intent to decommission in accordance with He-P 4024.06(c) and
specifying that the licensee intends to decommission by restricting use of the
site;
(e) The
decommissioning plan required by (d) above sufficiently demonstrates:
(1) How the
input of individuals and institutions in the community who may be affected by
the decommissioning has been sought and incorporated, as appropriate, to
include at a minimum the following:
a.
Participation by representatives of a broad cross section of community
interests who might be affected by the decommissioning;
b. An opportunity for a comprehensive, collective
discussion on the issues by the participants represented; and
c. A publicly
available summary of the results of all such discussions, including a
description of the individual viewpoints of the participants on the issues and
the extent of agreement and disagreement among the participants on the issues;
(2) Whether
provisions for institutional controls proposed by the licensee provide
reasonable assurance that the TEDE from residual radioactivity distinguishable
from background to the average member of the critical group will not exceed the
applicable limit in He-P 4020 through He-P 4023;
(3) Whether
provisions for institutional controls will impose undue burden on the local
community or other affected parties; and
(4) Whether
the licensee has provided sufficient financial assurance to enable an
independent third party, including a governmental custodian of a site, to
assume and carry out responsibilities for any necessary control and maintenance
of the site; and
(f) Residual
radioactivity at the site has been reduced so that if the institutional
controls were no longer in effect, there is reasonable assurance that the TEDE
from residual radioactivity distinguishable from background to the average
member of the critical group is as low as reasonably achievable and would not
exceed either:
(1) One
millisievert (100 mrem) per year; or
(2) Five
millisievert (500 mrem) per year provided the licensee:
a.
Demonstrates that further reductions in residual radioactivity necessary
to comply with the one millisievert/year (100 mrem/y) value of He-P
4024.09(e)(3)a. are not technically achievable, would be prohibitively expensive,
or would result in net public or environmental harm;
b. Makes
provisions for durable institutional controls; and
c. Provides
sufficient financial assurance, using an acceptable mechanism listed in He-P
4024.10(c), to enable a responsible government entity or independent third
party, including a governmental custodian of a site, to:
1. Carry out periodic rechecks of the site no
less frequently than every 5 years to assure that the institutional controls
remain in place as necessary to meet the criteria of He-P 4024.10(b); and
2. Assume and carry out responsibilities for any
necessary control and maintenance of those controls.
Source. #8393, eff 7-23-05; ss by #10492, eff 12-24-13
He-P 4024.11 Alternate Criteria for License Termination.
(a) The
DHHS/RHS shall terminate a license using alternate criteria greater than the
dose criteria of He-P 4024.09(a), He-P 4024.10(b), and He-P 4024.10(e)(1)a.1.
only if the licensee:
(1) Provides assurance that public health and
safety would continue to be protected, and that it is unlikely that the dose
from all man-made sources combined, other than medical, would be more than the
one millisievert/year (100 mrem/y) limit of He-P 4020.13 and He-P 4020.14, by
submitting an analysis of possible sources of exposure;
(2) Has employed, to the extent practical,
restrictions on site use according to the provisions of He-P 4024.10 in
minimizing exposures at the site;
(3) Reduces doses to ALARA levels, taking into
consideration any detriments such as traffic accidents expected to potentially
result from decontamination and waste disposal;
(4) Has submitted a decommissioning plan to the
DHHS/RHS indicating the licensee's intent to decommission in accordance with
this part and specifying that the licensee proposes to decommission by use of
alternate criteria; and
(5) Has provided sufficient financial assurance
in the form of a trust fund to enable an independent third party, including a
governmental custodian of a site, to assume and carry out responsibilities for
any necessary control and maintenance of the site.
(b) The
licensee shall document in the decommissioning plan required by (a)(4) above,
how the advice of individuals and institutions in the community who may be
affected by the decommissioning has been sought and addressed, as appropriate,
following analysis of that advice.
(c) In
seeking the advice described in (b) above, the licensee shall provide for:
(1) Participation by representatives of a broad
cross section of community interests who may be affected by the
decommissioning;
(2) An opportunity for a comprehensive,
collective discussion on the issues by the participants represented; and
(3) A publicly
available summary of the results of all such discussions, including a
description of the individual viewpoints of the participants on the issues and
the extent of agreement and disagreement among the participants on the issues.
(d) The use
of alternate criteria to terminate a license shall require the approval of the
DHHS/RHS after consideration of the staff’s recommendations addressing comments
provided by federal, state, and local governments and any public comments
submitted pursuant to He-P 4024.13.
Source. #8393, eff 7-23-05; ss by #10492, eff
12-24-13
He-P 4024.12 Requirement
to Use Peak Annual TEDE. When
calculating TEDE to the average member of the critical group, the licensee
shall determine the peak annual TEDE dose expected within the first 1000 years
after decommissioning.
Source. #8393, eff 7-23-05; ss by #10492, eff
12-24-13
He-P 4024.13 Public
Notification and Public Participation.
Upon the receipt of a decommissioning plan from the licensee, a proposal
by the licensee for release of a site pursuant to He-P 4024.10 or He-P 4024.11,
or whenever the DHHS/RHS deems such notice to be in the public interest, the
DHHS/RHS shall:
(a) Notify
and solicit comments from:
(1) Local and
state governments in the vicinity of the site and any Indian Nation or other
indigenous people that have treaty or statutory rights that could be affected
by the decommissioning; and
(2) The U.S.
Environmental Protection Agency for cases where the licensee proposes to
release a site pursuant to He-P 4024.11; and
(b) Publish a
notice in a forum, such as local newspapers, letters to state or local
organizations, or other appropriate forum, that is readily accessible to
individuals in the vicinity of the site, and solicit comments from affected
parties.
Source. #8393, eff 7-23-05; ss by #10492, eff
12-24-13
He-P 4024.14 Applicability
of Decommissioning Criteria Following License Termination. After a site has been decommissioned and the
license terminated in accordance with the criteria in this part, additional
cleanup shall be required if:
(a) Based on
new information, the DHHS/RHS determines that the criteria of this part were
not met; and
(b) Residual
radioactivity remaining at the site could result in significant threat to
public health and safety.
Source. #8393, eff 7-23-05; ss by #10492, eff
12-24-13
PARTS He-P 4025-
4029 - RESERVED
PART He-P
4030 LICENSING OF RADIOACTIVE MATERIAL
Statutory
Authority RSA 125-F:5,V
Revision Note:
Doc. #6942,
effective 2-1-99, repealed Parts He-P 2030, 2031, 2032, 2033, 2034, 2035, 2042
and 2093 relative to Radiation and Radioactive Material and adopted new rules
to replace them and renumbered them as He-P 4030, 4031, 4032, 4033, 4034, 4035,
4093 and 4096.
He-P 4030.01 Requirements.
(a) No person shall manufacture, produce,
receive, possess, use, transfer, own, or acquire byproduct materials, except as
authorized pursuant to a license issued by the department of health and human
services radiological health section (DHHS/RHS), or as otherwise provided in
this chapter.
(b) In addition to the requirements of He‑P
4030:
(1) All licensees shall be subject to the
requirements of He‑P 4001, He‑P 4003, He‑P 4019 through He-P
4024, He-P 4037, and He-P 4090 or its equivalent 10 CFR 20 Appendix B, through
He-P 4096;
(2) Licensees engaged in industrial radiographic
operations shall be subject to the requirements of He‑P 4034;
(3) Licensees using byproduct materials in the
healing arts shall be subject to the requirements of He‑P 4035;
(4) Licensees engaged in land disposal of
byproduct material shall be subject to the requirements of He‑P 4062;
(5) Licensees engaged in wireline and subsurface
tracer studies shall be subject to the requirements of He‑P 4039;
(6) Licensees engaged in the manufacture or
transfer of certain items containing byproduct material shall be subject to He‑P
4032;
(7) Licensees of broad scope for other than human
use shall be subject to He‑P 4033;
(8) General licenses shall be subject to He‑P
4031;
(9) Licensees engaged in irradiator operations
shall be subject to the requirements of He-P 4036; and
(10) Licensees that possess and use
accelerator-produced byproduct material or discrete sources of radium 226 shall
be subject to the requirements of He-P 4030.
(c) All applications, supplements, and supporting
documents submitted to DHHS/RHS shall:
(1) Be the original document and one copy;
(2) Be dated and include an original signature of
the applicant, licensee, the applicant or licensee’s management that performs
decision making functions for the applicant or licensee, or a person duly
authorized in writing by the applicant, licensee or the applicant or licensee’s
management to make binding commitments and to sign documents on the licensee or
applicant’s behalf.
(3) The signed application shall include a
certificate of the applicant’s or the licensee’s information, as follows:
“I certify under
penalty of law that this document and all attachments were prepared in
conformity with the New Hampshire Rules for the Control of Radiation
under my direction or supervision. The
information submitted is, to the best of my knowledge and belief, true,
accurate, and complete. I am aware that
there are significant penalties for submitting false information, including the
possibility of fine and imprisonment for knowing violations.”;
(4) Include the certificate in He-P 4030.01(c)(2)
above as part of any document submitted to DHHS/RHS with the application, or
filed thereafter; and
(5) Be mailed to DHHS/RHS as specified in He-P
4001.08.
(d) Documentation including attached sheets of
information, supplements, sketches, and drawings may be submitted on paper
sized 8 ½ x 11 inches, any larger drawings shall be folded to size 8 ½ x 11
inches.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16; ss by #13421, eff 7-29-22
He-P 4030.02 Exemptions, Source Material.
(a) Any person shall be exempt from He‑P
4030 to the extent that such person receives, possesses, uses, owns, transfers,
or delivers source material in any chemical mixture, compound, solution, or
alloy in which the source material is by weight less than 1/20 of 1 percent
(0.05 percent) of the mixture, compound, solution, or alloy.
(b) Any person shall be exempt from He‑P
4030 to the extent that such person receives, possesses, uses, or transfers
unrefined and unprocessed ore containing source material.
(c) Any person shall be exempt from He-P 4019
through He-P 4023 and He‑P 4030 to the extent that such person receives,
possesses, uses, or transfers:
(1) Any quantities of thorium contained in:
a. Incandescent gas mantles;
b. Vacuum tubes;
c. Welding rods;
d. Electric lamps for illuminating purposes
provided that each lamp shall not contain more than 50 milligrams of thorium;
e. Germicidal lamps, sunlamps, and lamps for
outdoor or industrial lighting provided that each lamp shall not contain more
than 2 grams of thorium;
f. Rare earth metals and compounds, mixtures,
and products containing not more than 0.25 percent by weight thorium, uranium,
or any combination of these; or
g. Personnel neutron dosimeters, provided that
each dosimeter shall not contain more than 50 milligrams of thorium;
(2) Source material contained in the following
products:
a. Glazed ceramic tableware, manufactured before
August 27, 2013, provided that the glaze shall not contain more than 20 percent
by weight source material;
b. Glassware, containing not more than 2 percent
by weight source material or, for glassware manufactured before August 27,
2013, 10 percent by weight source material; but not including commercially
manufactured glass brick, pane glass, ceramic tile, or other glass or ceramic
used in construction; or
c. Piezoelectric ceramic containing not more
than 2 percent by weight source material.
(3) Photographic film, negatives, and prints
containing uranium or thorium;
(4) Any finished product or part fabricated of,
or containing, tungsten-thorium or magnesium-thorium alloys, provided that the
thorium content of the alloy shall not exceed 4 percent by weight and that this
exemption shall not be deemed to authorize the chemical, physical, or
metallurgical treatment or processing of any such product or part;
(5) Uranium contained in counterweights installed
in aircraft, rockets, projectiles, and missiles, or stored or handled in
connection with installation or removal of such counterweights, provided that:
a. Each counterweight has been impressed with
the following legend clearly legible through any plating or other covering:
“DEPLETED URANIUM”;
b. Each counterweight is durably
and legibly labeled or marked with the identification of the manufacturer and
the statement: “UNAUTHORIZED ALTERATIONS PROHIBITED”;
c. This exemption shall not authorize the
chemical, physical, or metallurgical treatment or processing of any such
counterweights other than repair or restoration of any plating or other
covering; and
d. The requirements specified in He-P
4030.02(c)(5)a. and b. need not be met by counterweights manufactured prior to
December 31, 1969, provide that such counterweights were manufactured under a
specific license issued by the Atomic Energy Commission and were impressed with
the legend required by He-P 4030.02(c)(5)b. in effect on June 30, 1969;
(6) Natural or depleted uranium metal used as
shielding constituting part of any shipping container, provided that:
a. The shipping container is conspicuously and
legibly impressed with the legend: “CAUTION - RADIOACTIVE SHIELDING – URANIUM”;
and
b. The uranium metal is encased in mild steel or
equally fire resistant metal of minimum wall thickness of 1/8 inch (3.2 mm);
(7) Thorium or uranium contained in or on
finished optical lenses and mirrors, provided that each lens or mirror does not
contain more than 10 percent by weight of thorium or uranium, for lenses
manufactured before August 27, 2013, 30 percent by weight of thorium and that
the exemption contained in He-P 4030.02(c) does not authorize either:
a. The shaping, grinding, or polishing of such
lens, mirror, or manufacturing processes other than the assembly of such lens
or mirror into optical systems and devices without any alteration of the lens
or mirror; or
b. The receipt, possession, use, or transfer of
uranium or thorium contained in contact lenses, in spectacles, or in eyepieces
in binoculars or other optical instruments; or
(8) Thorium contained in any finished aircraft
engine part containing nickel-thoria alloy, provided that:
a. The thorium shall be dispersed in the
nickel-thoria alloy in the form of finely divided thoria such as thorium
dioxide; and
b. The thorium content in the nickel-thoria
alloy shall not exceed 4 percent by weight.
(d) The exemptions in He-P 4030.02(c) shall not
authorize the manufacture of any of the products described.
(e) No person shall initially transfer for sale or
distribution a product containing source material to persons exempt under He-P
4030.02(c), or the equivalent regulations of an agreement state, or the Nuclear
Regulatory Commission, unless authorized by a license issued under Nuclear
Regulatory Commission regulation at 10 CFR 40.52 to initially transfer such
products for sale or distribution.
(f)
Persons authorized to manufacture, process, or produce these materials
or products containing source material by DHHS/RHS, or an agreement state, and
persons who import finished products or parts, for sale or distribution shall
be authorized by a license issued under the Nuclear Regulatory Commission
regulation 10 CFR 40.52 for distribution only and are exempt from the
requirements of He-P 4019 through He-P 4023, and He-P 4030.09(a)(1) and (a)(2).
(g)
Persons initially distributing source material in products covered by
the exemptions in He-P 4030.02(c) before August 27, 2013, without specific
authorization may continue such distribution for one year beyond this date.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16; amd by #13047, eff
6-20-20
He-P 4030.03 Exemptions, Byproduct Materials Other Than
Source Materials.
(a) Except as provided in He‑P
4030.03(i)-(k), or an equivalent regulation of an agreement state, or the
Nuclear Regulatory Commission, any person shall be exempt from He‑P 4030,
He-P 4031 through He-P 4034, He-P 4036, and He-P 4039 to the extent that such
person receives, possesses, uses, transfers, owns, or acquires products or
materials containing byproduct material in concentrations not in excess of
those listed in He‑P 4093. This
exemption shall not be deemed to authorize the import of byproduct material or
products containing byproduct material.
(b) No person shall introduce byproduct material
into a product or material knowing or having reason to believe that it will be
transferred to persons exempt under He‑P 4030.03(a) or equivalent
regulations of an agreement state, or the Nuclear Regulatory Commission, except
in accordance with a license issued pursuant to 10 CFR 32.11.
(c) Except for persons who apply byproduct
material, or incorporate byproduct material into the following products, or
persons who initially transfer for sale or distribution the following products
containing byproduct material, any person shall be exempt from this chapter to
the extent that such person receives, possesses, uses, transfers, owns, or
acquires the following products:
(1) Timepieces or hands or dials of timepieces
which shall contain not more than the following specified quantities of
byproduct material and which shall not exceed the following specified levels of
radiation:
a. 25 millicuries of tritium per timepiece;
b. 5 millicuries of tritium per hand;
c. 15 millicuries of tritium per dial to include
bezels when used;
d. 100 microcuries of promethium 147 per watch
or 200 microcuries of promethium 147 per any other timepiece;
e. 20 microcuries of promethium 147 per watch
hand or 40 microcuries of promethium 147 per other timepiece hand;
f. 60 microcuries of promethium 147 per watch
dial or 120 microcuries of promethium 147 per other timepiece dial to include
bezels when used;
g. The levels of radiation from hands and dials
containing promethium 147 shall not exceed, when measured through 50 milligrams
per square centimeter of absorber:
1. For wrist watches, 0.1 millirad per hour at
10 centimeters from any surface;
2. For pocket watches, 0.1 millirad per hour at
1 centimeter from any surface; and
3. For any other timepiece, 0.2 millirad per
hour at 10 centimeters from any surface; and
h. 0.037 megabecquerel (1 microcurie) of radium
226 per timepiece in intact timepieces manufactured prior to November 30, 2007;
(2) Precision balances containing not more than 1
millicurie of tritium per balance or not more than 0.5 millicurie of tritium
per balance part manufactured before December 17, 2007;
(3) Marine compasses containing not more than 750
millicuries of tritium gas and other marine navigational instruments containing
not more than 250 millicuries of tritium gas manufactured before December 17,
2007;
(4) Electron tubes, provided that:
a. Each tube shall not contain more than one of
the following specified quantities of byproduct material:
1. 150 millicuries of tritium per microwave
receiver protector tube or 10 millicuries of tritium per any other electron
tube;
2. 1 microcurie of cobalt 60;
3. 5 microcuries of nickel 63;
4. 30 microcuries of krypton 85;
5. 5 microcuries of cesium 137; and
6. 30 microcuries of promethium 147; and
b. The level of radiation due to byproduct
material contained in each electron tube containing byproduct material shall
not exceed 1 millirad per hour at 1 centimeter from any surface when measured
through 7 milligrams per square centimeter of absorber;
(5) Ionizing radiation measuring instruments
containing, for purposes of internal calibration or standardization, one or
more sources of byproduct material provided that:
a. Each source shall contain no more than one
exempt quantity set forth in He‑P 4096;
b. Each instrument shall contain no more than 10
exempt quantities;
c. For purposes of He-P 4030.03(c)(5), an
instrument’s source(s) may contain either one type or different types of
radionuclides, and an individual exempt quantity may be composed of fractional
parts of one or more of the exempt quantities in He‑P 4096, provided that
the sum of such fractions shall not exceed unity; and
d. For purposes of He-P 4030.03(c)(5), 0.05
microcurie of americium 241 shall be considered an exempt quantity under He‑P
4096;
(6) Other radiation producing devices which
contain not more than the following specified quantities of radioactive
material:
a. Static elimination devices which contain, as
a sealed source or sources, byproduct material consisting of a total of not
more than 18.5 megabecquerels (500 microcuries) of polonium 210 per device;
b. Ion generating tubes designed for ionization
of air that contain, as a sealed source or sources, byproduct material
consisting of a total of not more than 18.5 megabecquerels (500 microcuries) of
polonium 210 per device or of a total of not more than 1.85 gigabecquerels (50
millicuries) of hydrogen 3 (tritium) per device; and
c. Devices authorized before October 23, 2012
for use under the general license then provided in He-P 4031.04, or the
equivalent regulations of agreement states, or Nuclear Regulatory Commission
regulations pursuant to 10 CFR 31.3, and which were manufactured, tested, and
labeled by the manufacturer in accordance with the specifications in a specific
license issued by DHHS/RHS, or an agreement state or the Nuclear Regulatory
Commission; or
(7) Ionization chamber smoke detectors containing
not more than 1 microcurie of americium 241 per detector in the form of a foil
and designed to protect life and property from fires.
(d) Except for persons who manufacture, process,
produce, or initially transfer for sale or distribution, gas and aerosol
detectors containing byproduct material, any person shall be exempt from the
requirements in He-P 4019, He-P 4020, He-P 4021, He-P 4030 through He-P 4036,
and He-P 4039 to the extent that such person receives, possesses, uses,
transfers, owns, or acquires:
(1) Byproduct material in gas and aerosol
detectors designed to protect health, safety, or property, and manufactured,
processed, produced, or initially transferred in accordance with a specific
license issued under Nuclear Regulatory Commission pursuant to 10 CFR Part
32.26, which license authorizes the initial transfer of the product for use
under 10 CFR 32.26, and a certificate of registration in accordance with 10 CFR
32.210; and
(2) Gas and aerosol detectors manufactured or
distributed before November 30, 2007, in accordance with a specific license
issued by He-P 4032.10 authorizing distribution to persons exempt from
regulatory requirements. This exemption
shall not apply to any person who desires to manufacture, process, or produce
gas and aerosol detectors containing byproduct material, or to initially
transfer such products for use under He-P 4030.03(d) after November 30, 2007.
(e) Except for persons who manufacture, process,
produce, or initially transfer for sale or distribution self-luminous products,
any person shall be exempt from these rules to the extent that such person
receives, possesses, uses, transfers, owns, or acquires tritium, krypton 85, or
promethium 147 in self-luminous products manufactured, processed, produced, or
initially transferred in accordance with a specific license issued by the
Nuclear Regulatory Commission pursuant to 10 CFR Part 32.22. This exemption does not apply to tritium,
krypton 85, or promethium 147 used in products primarily for frivolous
purposes, or in toys, or adornments.
(f) Any person who desires to manufacture,
process or produce, or initially transfer for sale or distribution,
self-luminous products containing tritium, krypton 85, or promethium 147 for
use under He-P 4030.03(e), shall apply for a license issued by the Nuclear
Regulatory Commission pursuant to 10 CFR Part 32.22, and for a certificate of
registration pursuant to 10 CFR Part 32.210.
(g) Except as provided in He‑P 4030.03(i)
and (k), any person shall be exempt from these rules to the extent that such
person receives, possesses, uses, transfers, owns, or acquires byproduct
material in individual quantities, each of which does not exceed the applicable
quantity set forth in He‑P 4096.
(h) Any person who possesses byproduct material
received or acquired before September 25, 1971, under the general license
formerly provided in He-P 4031, shall be exempt from the requirements for a
license set forth in He‑P 4030 through He-P 4034, He-P 4036 and He-P 4039
to the extent that such person possesses, uses, transfers or owns such
byproduct material.
(i) The provisions of He-P 4030.03(g) and (h)
shall not authorize the production, packaging, or repackaging, or transfer of
byproduct material for purposes of commercial distribution, or the
incorporation of byproduct material into products intended for commercial
distribution.
(j) No person shall, for purposes of commercial
distribution, transfer byproduct material in the individual quantities set
forth in He‑P 4096, knowing or having reason to believe that such
quantities of byproduct material will be transferred to persons exempt under He‑P
4030.03(h) or (i) or equivalent regulations of the Nuclear Regulatory
Commission, or an agreement state, except in accordance with a specific license
issued by the Nuclear Regulatory Commission pursuant to 10 CFR 32.18, or
equivalent regulations of an agreement state.
(k) For the purpose of producing an increased
radiation level, no person shall combine quantities of byproduct material
covered by this exemption so that the aggregate quantity exceeds the limits set
forth in He-P 4096, except for byproduct material combined within a device
placed in use before May 3, 1999, or otherwise permitted by the regulations in
He-P 4030.
(l) A manufacturer, processor, or producer of a
product or material, shall be exempt from the requirements for a license set
forth in He-P 4031 through He-P 4036 and He-P 4039 to the extent that the
person transfers byproduct material contained in a product or material in
concentrations not in excess of those specified in He-P 4093 and introduced in
the product or material by a licensee holding a specific license issued by
DHHS/RHS expressly authorizing such introduction. This exemption shall not apply to the
transfer of byproduct material contained in any food, beverage, cosmetic, drug,
or other commodity or product designed for ingestion or inhalation by, or for
application to, a human being.
(m) Except for persons who manufacture, process,
produce, or initially transfer for sale or distribution industrial devices
containing byproduct material designed and manufactured for the purpose of
detecting, measuring, gauging or controlling thickness, density level,
interface location, radiation, leakage or qualitative or quantitative chemical
composition, or for producing an ionized atmosphere, any person shall be exempt
from the requirements for a license set forth in He-P 4019 through He-P 4024,
He-P 4030 through He-P 4036, and He-P 4039, or the requirements of an agreement
state and the Nuclear Regulatory Commission in section 81 of the Atomic Energy
Act, to the extent that:
(1) Such persons receive, possess, use, transfer,
own, or acquire byproduct material, in these certain detecting measuring,
gauging, or controlling devices, and certain devices for producing an ionized
atmosphere, and manufactured, processed, produced or initially transferred in
accordance with a specific license issued under He-P 4030.03 or an agreement
state, or the Nuclear Regulatory Commission 10 CFR Part 32.30;
(2) Persons who desire to manufacture, process,
produce, or initially transfer for sale or distribution industrial devices
containing byproduct material for use under He-P 4030.03(m), shall apply for a
license in accordance with the Nuclear Regulatory Commission pursuant to 10 CFR
Part 32.30, and for a certificate of registration in accordance with 10 CFR
32.210; and
(3) This exemption shall not apply to sources not
incorporated into a device, such as calibration and reference sources.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16; ; amd by #13047, eff
6-2-20; ss by #13421, eff 7-29-22
He-P 4030.04 Exemptions, U.S. Government Contractors
and Carriers. Any Nuclear Regulatory
Commission (NRC) and U.S. Department of Energy (DOE) prime contractor of the
following categories operating in New Hampshire shall be exempt from He-P 4030
to the extent that such prime contractor under his prime contract manufactures,
produces, receives, possesses, uses, transfers, owns, or acquires byproduct
material:
(a) Prime contractors performing work for the
Nuclear Regulatory Commission or DOE at U.S. Government-owned or controlled
sites, including the transportation of byproduct material to or from such site
and the performance of contract services during temporary interruptions of such
transportation;
(b) Prime contractors performing research in, or
development, manufacture, storage, testing or transportation of, atomic weapons
or components thereof; or
(c) Prime contractors using or operating nuclear
reactors or other nuclear devices in a U.S. Government-owned vehicle or vessel;
and
(d) Any other prime contractor or subcontractor
manufactures, produces, transfers, receives, acquires, owns, possesses, or uses
byproduct material under his prime contract or subcontract when DHHS/RHS and
the Nuclear Regulatory Commission jointly determine that:
(1) Under the terms of the contract or
subcontract, there is adequate assurance that the work thereunder can be
accomplished without undue risk to the public health and safety; and
(2) The exemption of such contractor or
subcontractor is otherwise authorized by law as stated in 10 CFR 30.12.
(e) Common and contract carriers, freight
forwarders, warehouse workers and the U.S. Postal Service are exempt from the
regulations in He-P 4030 through He-P 4036, He-P 4038, and He-P 4039 to the
extent that they transport or store byproduct material in the regular course of
carriage for another or storage incident thereto.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16; amd by #13047, eff 6-2-20
He-P 4030.05 Radioactive Drug: Capsules Containing
Carbon-14 Urea for “In Vivo” Diagnostic Use for Humans.
(a) Except as provided in He-P 4030.05(b) and
(c), any person is exempt from the requirements for a license set forth in He-P
4030 and He-P 4035, provided that such person receives, possesses, uses,
transfers, owns, or acquires capsules containing 37 kilobecquerels
(1microcurie) of carbon-14 urea each, allowing for nominal variation that may
occur during the manufacturing process, for “in vivo” diagnostic use for
humans.
(b) Any person who desires to use the capsules
for research involving human subjects shall apply for and receive a specific
license pursuant to He-P 4035.
(c) Nothing in this section shall relieve persons
from complying with applicable FDA, federal, and other state requirements
governing receipt, administration, and use of drugs.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16; amd by #13047, eff
6-20-20
He-P 4030.06 Types of Licenses. Licenses for byproduct materials shall be one
of the following:
(a) General licenses, as provided in He-P 4031,
which grant authority to persons for certain activities involving byproduct
material, are effective without the filing of an application with DHHS/RHS or
the issuance of licensing documents to the particular persons. However, registration with DHHS/RHS may be
required by the particular general license, as described in He-P 4031;
(b) Specific licenses which require the
submission of an application to DHHS/RHS and the issuance of a licensing
document by DHHS/RHS, under the provisions of this part and He-P 4032 through
He-P 4036, and He-P 4039; and
(c) Specific licenses by rule, which are issued
by DHHS/RHS without the necessity of filing an application for a specific
license, in either of the following two circumstances:
(1) When a site must be timely remediated for
contamination from byproduct materials that are subject to licensing under
these rules but are unlicensed; or
(2) When radioactive materials existing as a
result of improper handling, spillage, accidental contamination, or unregulated
or illegal possession, transfer, or receipt, must be stored and those materials
have not been licensed under these rules.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8488, eff 11-18-05; ss by #8959, eff 8-7-07; ss
by #10896, INTERIM, eff 7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16
He-P 4030.07 Specific Licenses, Filing of Application. Application for specific licenses shall be
filed and processed in compliance with the following provisions:
(a)
A completed application form for a specific license shall:
(1) Be filed on one of the following forms:
a. DHHS/RHS-1 “Application for Radioactive
Material License” (July 2022) and DHHS/RHS-1 Supplement A “Training and
Experience” (July 2022);
b. DHHS/RHS–1M
“Application for Radioactive Material License – Medical” (July 2022), and the
following supplements as applicable:
1.
DHHS/RHS-1M Supplement A “Radiation Safety
Officer Training or Associate Radiation Safety Officer Training, Experience and Preceptor Attestation,” (July
2022), in accordance with He-P 4035.61;
2.
DHHS/RHS-1M Supplement B-Diagnostic
“Authorized User Training, Experience and Preceptor Attestation” (July 2022),
in accordance with He-P 4035.63, He-P 4035.64, He-P 4035.68, or He-P 4035.71;
3.
DHHS/RHS-1M Supplement B-Sources “Authorized
User Training, Experience and Preceptor Attestation” (July 2022), in accordance
with He-P 4035.59, He-P 4035.67. He-P 4035.69, or He-P 4035.71;
4.
DHHS/RHS-1M Supplement B-Therapy “Authorized
User Training, Experience and Preceptor Attestation” (July 2022), in accordance
with He-P 4035.65, He-P 4035.66, or He-P 4035.71;
5.
DHHS/RHS-1M Supplement C “Authorized Medical
Physicist or Ophthalmic Physicist Training, Experience and Preceptor
Attestation” (July 2022), in accordance with He-P 4035.32 or He-P 4035.70; or
6.
DHHS/RHS-1M Supplement D “Authorized Nuclear
Pharmacist Training, Experience and Preceptor Attestation” (July 2022), in
accordance with He-P 4035.74; or
c. DHHS/RHS–3
“Application for Radioactive Material License–Source Material”. (July 2022);
(2) If submitted on DHHS/RHS-1M “Application for
Radioactive Material License–Medical” (July 2022), then the following shall
apply:
a. Answers to questions 7 through 23 on the
application shall be made on separately attached sheets which identify the item
number by a heading located in the lower right corner of each page, and which
includes the date of the application and the question number with which it is
associated;
b. If answers to
questions 7 through 23 on the application are made following an appendix to the
medical licensing guide, then the date of the referenced guide and the appendix
letter shall be specified;
c. All documentation including, attached sheets
of information, supplements, sketches, and drawings, shall be identified
indicating the correlating item number on the DHHS/RHS-1M “Application for
Radioactive Material License–Medical” (July 2022), by a heading which includes
the item number and the purpose of the document submitted;
d. All applicable sections of He-P 4035 shall be
listed to describe the radioisotopes and quantities of licensed material used,
including those used in remote afterloader units, teletherapy units, gamma
stereotactic radiosurgery units, and in a list to be provided that specifies
any emerging technologies devices;
e. If a supplement for a radiation safety
officer is submitted, it shall identify the name, license, or permit number of
a supervising individual’s training if the individual is a radiation safety
officer, an authorized user, an authorized medical physicist, or an authorized
nuclear pharmacist, or if more than one supervising individual is required by He-P 4035, separate sheets shall be used to document each
individual’s training;
f. If a supplement requires a preceptor
attestation, the attestation shall be:
1. Completed and signed by the individual’s
preceptor;
2. If more than one preceptor is necessary to
document experience, then a separate preceptor attestation shall be obtained
from each preceptor; and
3. Each preceptor shall provide, direct, or
verify the individual’s training and experience, but such preceptor does not
need to be the individual’s supervisor;
g. If a supplement for a medical physicist is
submitted, training and work experience shall be listed and shall have been
conducted in clinical radiation facilities that provide high-energy external
beam therapy photons and electrons with energies greater than or equal to one
million electron volts and brachytherapy services.
h. The following training and work experience
shall be documented as follows:
1. The required one year full-time medical
physicist training and one year of full time work experience as required by
He-P 4035 shall be not concurrent
years; and
2. The supervising medical physicist shall meet
the training and experience requirements in He-P 4035.70 and He-P 4035.73 for
the use for which the individual is seeking authorization; and
i. Any supervising authorized user shall have
the experience in administering dosages in the same dosage category or
categories as the individual requesting authorized user status as required in He-P 4035.
(b) DHHS/RHS shall at any time after the filing
of the original application, and before the expiration of the license, require
further statements or information when necessary for DHHS/RHS to determine
whether the application shall be granted or denied, or whether a license shall
be modified or revoked.
(c) Each application submitted shall meet the
requirements of He-P 4030.01(c).
(d) An application for a license may include a
supplement for a license authorizing one or more activities.
(e) Applications, supplements, and documents
submitted to DHHS/RHS may be made available for public inspection except that
DHHS/RHS shall withhold any document or part thereof from public inspection if
disclosure of its content is related to safety and security of radioactive
materials or to confidential information about the license application or
statements on the license.
(f) An application for a license to receive and
possess byproduct material for commercial waste disposal by land burial or for
the conduct of any other activity which might negatively affect the quality of
the environment according to the criteria set forth in 10 CFR 30.32(f) and 10
CFR 51, shall be filed at least 9 months prior to commencement of construction
of the plant or facility in which the activity will be conducted and shall be
accompanied by an environmental report.
(g) Each application for a byproduct material
license, other than a license exempted from He‑P 4070, or a request for
an amendment of a license filed in accordance with He-P 4030.13, shall be
accompanied by the fee prescribed in He‑P 4070.
(h) Except as provided in He-P 4030.07(h)(2), an
application for a specific license to use, manufacture, process, or produce
byproduct material in the form of a sealed source, in a device that contains
the sealed source, or gas or aerosol detectors containing byproduct material
manufactured after November 30, 2007, shall meet the following requirements in
(1) and (2) below:
(1) For sealed sources and devices allowed to be
distributed without registration of safety information in accordance with He-P
4030.07(h)(3) below, the applicant shall supply only the manufacturer, model
number, radionuclide, and quantity; and
(2) If it is not feasible to identify each sealed
source and device individually, the applicant shall propose constraints on the
number and type of sealed source and devices to be used and the conditions
under which they will be used, in lieu of identifying each sealed source and
device; and one of the following:
a. Identify the sealed source or device that
contains a sealed source by manufacturer and model number registered with DHHS/RHS,
an agreement state, or in the Nuclear Regulatory Commission “Registry of
Radioactive Sealed Sources and Devices” pursuant to 10 CFR 32.210, or for a
source or a device containing radium 226 or accelerator-produced radioactive
material with DHHS/RHS under provisions of He-P 4032.11; or
b. Include in the application the information
identified in He‑P 4032.11(b); or
(i)
Except as provided in He-P 4030.07(i)(1) and (i)(2), an application for
a specific license to use, manufacture, process, or produce byproduct material
in the form of a sealed source, in a device that contains the sealed source, or
gas or aerosol detectors containing byproduct material manufactured after
November 30, 2007, shall meet the following requirements in (1) or in (2)
below:
(1) For sources or devices manufactured before
October 23, 2012 that are not registered with
DHHS/RHS, with an agreement state, or with the U.S. Nuclear Regulatory
Commission under 10 CFR 32.210, and for which the applicant is unable to
provide all categories of information specified in He-P 4032.11(b) or 10 CFR
32.210(c), the applicant shall provide both:
a. All available information identified in He-P
4032.11(b) or in 10 CFR 32.210(c) concerning the source, and, if applicable,
the device; and
b. Sufficient additional information to
demonstrate that there is a reasonable assurance that the radiation safety
properties of the source or device are adequate to protect health and minimize
danger to life and property. Such
information shall include a description of the source or device, a description
of radiation safety features, the intended use and associated operating
experience, and the results of a recent leak test; or
(2) For sealed sources and devices allowed to be
distributed without registration of safety information, the applicant shall
supply only the manufacturer, model number, radionuclide, and quantity, and in
the following cases calibration and reference sources containing no more than:
a. Thirty seven megabecquerels (1 millicurie),
for beta and/or gamma emitting radionuclides; or
b. Three hundred and seventy kilobecquerels (10
microcuries), for alpha emitting radionuclides.
(j) As provided by He-P 4030.09(b), certain
applications for specific licenses filed under He‑P 4030 and He-P 4032
through He-P 4035 shall contain a proposed decommissioning funding plan
pursuant to He-P 4030(e) or a certification of financial assurance for
decommissioning.
(k) Applications to possess byproduct materials
in unsealed form, on foils or plated sources, or sealed in glass in excess of the quantities in He-P 4030.08, Table 4030.1,
shall meet all of the requirements below:
(1) Each application shall contain one of the
following:
a. An evaluation showing that the maximum dose
to a person offsite due to a release of radioactive materials would not exceed
one rem effective dose equivalent or 5 rems to the thyroid; or
b. An emergency plan for responding to a release
of radioactive material;
(2) In order for the application to be approved,
the evaluation in He-P 4030.07(i)(1)a. above shall include one of the following
precautions or safety measures:
a. The radioactive material is physically
separated so that only a portion could be involved in an accident;
b. All or part of the radioactive material is
not subject to release during an accident because of the way it is stored or
packaged;
c. The release fraction in the respirable size
range would be lower than the release fraction shown in Table 4030.1 due to the
chemical or physical form of the material;
d. The solubility of the radioactive material
would reduce the dose received;
e. Facility design or engineered safety features
in the facility would cause the release fraction to be lower than shown in
Table 4030.1;
f. Operating restrictions or procedures would
prevent a release fraction as large as that shown in Table 4030.1; or
g. Other factors appropriate for the specific
facility;
(3) An emergency plan for responding to a release
of radioactive material submitted under He‑P 4030.07(i)(1)b. shall
include the following information:
a. A description of the licensee’s facility and
the uncontrolled area near the site;
b. An identification of each type of radioactive
material accident for which protective actions may be needed;
c. A classification system for classifying
accidents as alerts or site area emergencies;
d. Identification of the means of detecting each
type of accident in a timely manner;
e. A description of the means and equipment for mitigating
the consequences of each type of accident, including those provided to protect
workers onsite, and a description of the program for maintaining the equipment;
f. A description of the methods and equipment to
assess releases of radioactive materials;
g. A description of the responsibilities of
licensee personnel should an accident occur, including identification of
personnel responsible for promptly notifying offsite response organizations and
DHHS/RHS, and also responsibilities for developing,
maintaining, and updating the plan;
h. A commitment to and description of the means
to promptly notify offsite response organizations and request offsite
assistance, including medical assistance for the treatment of contaminated
injured onsite workers;
i. A commitment to establish a control point;
j. A commitment to
establish a notification and coordination plan such that the unavailability of
some personnel, parts of the facility, and some equipment will not prevent the
notification and coordination;
k. Acknowledgment that the licensee shall also
commit to notify DHHS/RHS immediately after notification of the appropriate
offsite response organizations and not later than one hour after the licensee
declares an emergency;
l. A description of the types of information on
facility status, radioactive releases, and recommended protective actions, if
necessary, to be given to offsite response organizations and to DHHS/RHS;
m. A description of the frequency, performance
objectives, and plans for the training that the licensee shall provide workers
on how to respond to an emergency including any special instructions and
orientation tours the licensee would offer to fire, police, medical, and other
emergency personnel, and documentation that the training shall:
1. Familiarize personnel with site-specific
emergency procedures; and
2. Thoroughly prepare site personnel for their
responsibilities in the event of accidental scenarios postulated as most
probable for the specific site, including the use of team training for such
scenarios;
n. A description of the means of restoring the
facility to a safe condition after an accident;
o. Provisions for conducting quarterly
communications checks with offsite response organizations and biennial onsite
exercises to test response to simulated emergencies; and
p. A certification that the applicant has met
its responsibilities under the Emergency Planning and Community Right-to-Know
Act of 1986, Title III, Pub. L. 99-499, if applicable to the applicant’s
activities at the proposed place of use of the byproduct material;
(4) The exercises required by He‑P
4030.07(i)(3)o. above shall provide for:
a. Quarterly communications checks with offsite
response organizations which shall include the check and update of all
necessary telephone numbers;
b. The invitation to offsite response
organizations to participate in the biennial exercises;
c. Accident scenarios postulated as most
probable for the specific site and which scenarios shall not be known to most
exercise participants; and
d. Critiques of
each exercise using individuals not having direct implementation responsibility
for the plan and which shall evaluate the appropriateness of the plan,
emergency procedures, facilities, equipment, training of personnel, and overall
effectiveness of the response and deficiencies found by the critiques which
shall be corrected by the licensee;
(5) The licensee shall allow the offsite response
organizations expected to respond in case of an accident 60 days to comment on
the licensee’s emergency plan before submitting it to DHHS/RHS; and
(6) The licensee shall provide any comments
received within the 60 days to DHHS/RHS with the emergency plan.
(l) An application from a medical facility or an
educational institution to produce Positron Emission Tomography (PET)
radioactive drugs for noncommercial transfer to licensees in its consortium
authorized for medical use under He-P 4035, or equivalent agreement state, or
NRC requirements shall include:
(1) A request for authorization for production of
PET radionuclides or evidence of an existing license issued under He-P 4030, or
equivalent requirements of an agreement state, or the NRC for a PET
radionuclide production facility within its consortium from which it receives
PET radionuclides;
(2) Evidence that the applicant is qualified to
produce radioactive drugs for medical use by meeting one of the criteria in
He-P 4032.05(a)(2);
(3) If the applicant is a pharmacy,
identification of individual(s) authorized to prepare the PET radioactive
drugs, and documentation that the individual(s) meet(s) the requirements of an
authorized nuclear pharmacist as specified in He-P 4032.05(b)(2); and
(4) Information identified in He-P 4032.05(a)(3)
on the PET drugs to be commercially transferred to members of its consortium.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16; amd by #13047, eff 6-2-20;
ss by #13421, eff 7-29-22; ss by #13619, eff 4-26-23
He-P 4030.08 Quantities of Radioactive Materials
Requiring Consideration of the Need for an Emergency Plan for Responding to a
Release. These quantities shall be
as set forth in Table 4030.1 below:
Table 4030.1
Quantities of Radioactive Materials Requiring Consideration
of the Need for an
Emergency Plan for Responding to a Release
Radioactive Material |
Release Fraction |
Quantity (curies) |
Actinium-228 |
0.001 |
4,000 |
Americium-241 |
0.001 |
2 |
Americium-242 |
0.001 |
2 |
Americium-243 |
0.001 |
2 |
Antimony-124 |
0.01 |
4,000 |
Antimony-126 |
0.01 |
6,000 |
Barium-133 |
0.01 |
10,000 |
Barium-140 |
0.01 |
30,000 |
Bismuth-207 |
0.01 |
5,000 |
Bismuth-210 |
0.01 |
600 |
Cadmium-109 |
0.01 |
1,000 |
Cadmium-113 |
0.01 |
80 |
Calcium-45 |
0.01 |
20,000 |
Californium-252 |
0.001 |
9 (20 mg) |
Carbon-14
(carbon dioxide) |
0.01 |
50,000 |
(non-carbon
dioxide) |
0.01 |
50,000 |
Cerium-141 |
0.01 |
10,000 |
Cerium- 144 |
0.01 |
300 |
Cesium-134 |
0.01 |
2,000 |
Cesium-137 |
0.01 |
3,000 |
Chlorine-36 |
0.5 |
100 |
Chromium-51 |
0.01 |
300,000 |
Cobalt-60 |
0.001 |
5,000 |
Copper-64 |
0.01 |
200,000 |
Curium-242 |
0.001 |
60 |
Curium-243 |
0.001 |
3 |
Curium-244 |
0.001 |
4 |
Curium-245 |
0.001 |
2 |
Europium-152 |
0.01 |
500 |
Europium-154 |
0.01 |
400 |
Europium-155 |
0.01 |
3,000 |
Germanium-68 |
0.01 |
2,000 |
Gadolinium-153 |
0.01 |
5,000 |
Gold-198 |
0.01 |
30,000 |
Hafnium-172 |
0.01 |
400 |
Hafnium-181 |
0.01 |
7,000 |
Holmium-166m |
0.01 |
100 |
Hydrogen-3 |
0.5 |
20,000 |
Iodine-125 |
0.5 |
10 |
Iodine-131 |
0.5 |
10 |
Indium-114m |
0.01 |
1,000 |
Indium-192 |
0.001 |
40,000 |
Iron-55 |
0.01 |
40,000 |
Iron-59 |
0.01 |
7,000 |
Krypton-85 |
1.0 |
6,000,000 |
Lead-210 |
0.01 |
8 |
Manganese-56 |
0.01 |
60,000 |
Mercury-203 |
0.01 |
10,000 |
Molybdenum-99 |
0.01 |
30,000 |
Neptunium-237 |
0.001 |
2 |
Nickel-63 |
0.01 |
20,000 |
Niobium-94 |
0.01 |
300 |
Phosphorus-32 |
0.5 |
100 |
Phosphorous-33 |
0.5 |
1,000 |
Polonium-210 |
0.01 |
10 |
Potassium-42 |
0.01 |
9,000 |
Promethium-145 |
0.01 |
4,000 |
Promethium-147 |
0.01 |
4,000 |
Radium-226 |
0.001 |
100 |
Ruthenium-106 |
0.01 |
200 |
Samarium-151 |
0.01 |
4,000 |
Scandium-46 |
0.01 |
3,000 |
Selenium-75 |
0.01 |
10,000 |
Silver-110m |
0.01 |
1,000 |
Sodium-22 |
0.01 |
9,000 |
Sodium-24 |
0.01 |
10,000 |
Strontium-89 |
0.01 |
3,000 |
Strontium-90 |
0.01 |
90 |
Sulfur-35 |
0.5 |
900 |
Technetium-99 |
0.01 |
10,000 |
Technetium-99m |
0.01 |
400,000 |
Tellurium-127m |
0.01 |
5,000 |
Tellurium-129m |
0.01 |
5,000 |
Terbium-160 |
0.01 |
4,000 |
Thulium-170 |
0.01 |
4,000 |
Tin-113 |
0.01 |
10,000 |
Tin-123 |
0.01 |
3,000 |
Tin-126 |
0.01 |
1,000 |
Titanium-44 |
0.01 |
100 |
Vanadium-48 |
0.01 |
7,000 |
Xenon-133 |
1.0 |
900,000 |
Yttrium-91 |
0.01 |
2,000 |
Zinc-65 |
0.01 |
5,000 |
Zirconium-93 |
0.01 |
400 |
Zirconium-95 |
0.01 |
5,000 |
Any other
beta-gamma emitter |
0.01 |
10,000 |
Mixed fission
products |
0.01 |
1,000 |
Mixed corrosion
products |
0.01 |
10,000 |
Contaminated
equipment beta-gamma |
0.001 |
10,000 |
Irradiated
material, any form other than solid
noncombustible |
0.01 |
1,000 |
Irradiated
material, solid non- Combustible |
0.001 |
10,000 |
Mixed
radioactive waste, beta- gamma |
0.01 |
1,000 |
Packaged mixed
waste, beta-gamma1 |
0.001 |
10,000 |
Any other alpha emitter |
0.001 |
2 |
Contaminated
equipment alpha |
0.0001 |
20 |
Packaged waste,
alpha1 |
0.0001 |
20 |
Combinations of
radioactive materials listed
above2 |
- |
- |
1Waste packaged in
Type B containers does not require an emergency plan.
2For combinations
of radioactive materials, consideration of the need for an emergency plan is
required if the sum of the ratios of the quantity of each radioactive material
authorized to the quantity listed for that material in Table 4030.1 exceeds
one.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16
He-P 4030.09 Specific Licenses, Requirements for
Issuance.
(a) A specific license application shall be
approved if DHHS/RHS determines that:
(1) The applicant is qualified by reason of
training and experience to use the material in question for the purpose
requested in accordance with these rules in such a manner as to protect the
public health and minimize danger to life or property;
(2) The applicant’s proposed equipment,
facilities, calibration and all other procedures are adequate to minimize
danger to protect the public health and minimize danger to life or property;
(3) The applicant satisfies any applicable
special requirements in He-P 4031 through He-P 4036 and He-P 4039, and Nuclear
Regulatory Commission 10 CFR 37; and
(4) In the case of an application for a license
to receive and possess byproduct material for commercial waste disposal by land
burial, the applicant shall satisfy any applicable special requirements in He-P
4023 and He-P 4062.
(b) In the case of an application for a license
to receive and possess byproduct material to conduct any activity which
DHHS/RHS determines might negatively affect the quality of the environment, the
license application for the facility in which the activity will be conducted
shall be reviewed and approved by DHHS/RHS before commencement of construction
of the plant or the plant or facility in which the activity will be conducted.
Commencement of
construction shall include:
(1) Non-construction activities if the activity
has a reasonable nexus to radiological safety and security, any clearing of
land, excavation, or other substantial action that would adversely affect the
environment;
(2) The installation of a foundation, or in-place
assembly, erection, fabrication, or testing for any structure, system, or
component of a facility or activity subject to He-P 4030.09(b) that have a
reasonable nexus to radiological safety or security; and
(3) Building necessary roads for site
exploration, making borings to determine foundation conditions, or performing
other preconstruction monitoring or testing to establish background information
related to the suitability of the site or the protection of environmental
values.
(c) Issuance of a specific license authorizing
the activities of He-P 4030.09(b) shall be based upon a consideration by
DHHS/RHS of the environmental, economic, technical, and other benefits in
comparison with the environmental costs available alternatives and a
determination that the action called for is the issuance of the proposed
license, with any appropriate conditions to protect environmental values.
(d) Commencement of construction in violation of
He‑P 4030.09(b) prior to review and approval by DHHS/RHS, shall be
grounds for denial of a license to receive and possess byproduct material in
such plant or facility.
(e) Each applicant for a specific license
authorizing the possession and use of special nuclear material, source
material, or unsealed byproduct material in quantities and amounts in excess of
those indicated in Table 4030.2 below shall submit a decommissioning funding
plan.
Table 4030.2 Quantities and Amounts Requiring
Decommissioning Funding Plan
Type of
Material |
Exceeding |
Special Nuclear
Material |
105
times He‑P 4091 |
Source Material |
100 millicuries
in readily dispersible form |
Byproduct
Material (Unsealed) |
Half-life
greater than 120 days and in quantities exceeding 105 times the
applicable quantities set forth in He‑P 4091 |
(f) The decommissioning funding plan shall be
submitted when a combination of isotopes is involved, if R divided by 105
is greater than 1, where R is the sum of the ratios of quantity of each isotope
to the applicable value in He‑P 4091.
(g) Each applicant for or holder of a specific
license authorizing possession and use of special nuclear material, sealed
sources, or plated foils of half-life greater than 120 days and 1012
times the applicable quantities (or when a combination of isotopes is involved
if R, as defined in He-P 4030.09(f), divided by 1012 is greater than
1) indicated in Table 4030.3 shall:
(1) Submit to DHHS/RHS a decommissioning funding
plan as described in He-P 4030.09(i); or
(2) Submit to DHHS/RHS a certification that
financial assurance for decommissioning shall be provided in the amount
prescribed by Table 4030.3 below using one of the methods described in He-P
4030.09(j); and
(3) Submit to DHHS/RHS as a part of the
certification, a copy of the financial instrument obtained to satisfy the
requirement of He‑P 4030.09(j).
(4) If, in surveys made under He-P 4022.01(a),
residual radioactivity in the facility and environment, including the
subsurface, is detected at levels that would, if left uncorrected, prevent the
site from meeting the He-P 4024.09(a) criteria for unrestricted use, the
licensee shall submit a decommissioning funding plan within one year of when
the survey is completed.
Table 4030.3 Financial Assurance Amounts for
Decommissioning
Type of Radioactive Material |
Exceeding |
Assurance Amount |
Special Nuclear Material |
Greater than 104
but less than or equal to 105 times the applicable quantities as
indicated in He-P 4091. For a
combination of isotopes, if R, as defined in He-P 4030.09(f) divided by 104
is greater than 1 but R divided by 105 is less than or equal to 1. |
$1,125,000 |
|
Greater than 103
but less than or equal to 104 times the applicable quantities as
indicated in He-P 4091. For a
combination of isotopes, if R, as defined in He-P 4030.09(f) divided by 103
is greater than 1 but R divided by 104 is less than or equal to 1. |
$225,000 |
Source Material |
Greater than 10
millicuries but less than or equal to 100 millicuries in a readily
dispersible form. For a combination of
isotopes, if R, as defined in He‑P 4030.09(f) divided by 103
is greater than 1 but R divided by 104 is less than or equal to 1. |
$113,000 |
Byproduct
Material |
Half-life
greater than 120 days and in quantities: |
|
|
Greater than 104
but less than or equal to 105 times applicable quantities in
unsealed form as indicated in He-P 4091.
For a combination of isotopes, if R, as defined in He-P 4030.09(f)
divided by 104 is greater than 1 but R divided by 105
is less than or equal to 1. |
$1,125,000 |
|
Greater than 103
but less than or equal to 104 times the applicable quantities in
unsealed form as indicated in He-P 4091.
For a combination of isotopes, or if R, as defined in He-P 4030.09(f)
divided by 103 is greater than 1 but R divided by 104
is less than or equal to 1. |
$225,000 |
|
Greater than 1010
but less than or equal to 1012 times the applicable quantities in
sealed sources or plated sources. For
a combination of isotopes, if R, as defined in He‑P 4030.09(f) divided
by 1010 is greater than 1, but R divided by 1012 is
less than or equal to 1. |
$113,000 |
(h) Certification shall state that the
appropriate assurance shall be obtained after the application has been approved
and the license issued but prior to the receipt of licensed material.
(i) Each decommissioning funding plan shall be
submitted for review and approval by DHHS/RHS, and shall contain a detailed
cost estimate for decommissioning, and a description of the method of assuring
funds for decommissioning including a means of adjusting cost estimates and
associated funding levels over the life of the facility as set forth below:
(1) A detailed cost estimate for decommissioning
shall be in an amount reflecting:
a. The cost of an independent contractor to
perform all decommissioning activities;
b. The cost of meeting the He-P 4024.09 criteria
for unrestricted use, provided that if the applicant or licensee can
demonstrate its ability to meet the provisions of He-P 4024.10, the cost
estimate may be based on meeting the He-P 4024.10 criteria;
c. The volume of onsite subsurface material
containing residual radioactivity that will require remediation to meet the
criteria for license termination; and
d. An adequate contingency factor pursuant to 10
CFR 30.35(e)(1)(i)(D);
(2) Identification of and justification for using
the key assumptions contained in the decommissioning cost estimate;
(3) A description of the method of assuring funds
for decommissioning from He-P 4030.09(j), including means for adjusting cost
estimates and associated funding levels periodically over the life of the
facility;
(4) A certification by the licensee that
financial assurance for decommissioning has been provided in the amount of the
cost estimate for decommissioning;
(5) A signed original financial instrument
obtained to satisfy the requirements of He-P 4030.09(j), unless a previously
submitted and accepted financial instrument continues to cover the cost
estimate for decommissioning; and
(6) At intervals not to exceed 3 years, the
decommissioning funding plan shall be resubmitted with adjustments as necessary
to account for changes in costs and the extent of contamination;
a. The amount of financial assurance shall not
be adjusted downward, until the updated decommissioning funding plan is
approved; and
b. The decommissioning funding plan shall update
the information submitted with the original, or prior approved plan, and shall
specifically consider the effect of the following events on decommissioning
costs:
1. Spills of radioactive material producing
additional residual radioactivity in onsite subsurface material;
2. Waste inventory increasing above the amount
previously estimated;
3. Waste disposal costs increasing above the
amount previously estimated;
4. Facility modifications;
5. Changes in authorized possession limits;
6. Actual remediation costs that exceed the
previous cost estimate;
7. Onsite disposal; and
8. Use of a settling pond; and
(7) Waste collectors and waste processors, also
known as waste handling licensees as defined in He-P 4003.01, shall provide
financial assurance in an amount based on a decommissioning funding plan as
described in He-P 4030.09(i)(1). The
decommissioning funding plan shall include:
a. The cost of disposal of the maximum quantity,
by volume, of radioactive material which could be present at the licensee’s
facility at any time; and
b. The cost to remediate the licensee’s site to
meet the license termination criteria of He-P 4030.17.
(j) The financial instrument shall include the
licensee’s name, license number, and the name, address, and other contact
information of the issuer, and, if a trust is used, the name, address and other
contact information of the trustee. When
any of the foregoing information changes the licensee shall, within 30 days,
submit the financial instruments reflecting such changes. The financial instrument shall be a signed
original or signed original duplicate, except where a copy of the signed
original is specifically permitted.
Financial assurance for decommissioning shall be provided by any one or
more of the following methods:
(1) Prepayment;
(2) A surety method or insurance;
(3) An external sinking fund;
(4) Any other funding methods which shall be
demonstrated by the applicant or licensee to provide comparable assurance to
methods listed in He-P 4030.09(g)(1) through (3); and
(5) In the case of state, or local government
licensees, a statement of intent containing a cost estimate for decommissioning
or an amount based on Table 4030.3, and indicating that funds for
decommissioning shall be obtained when necessary.
(k) The prepayment method in He-P 4030.09(j)(1)
above shall be:
(1) In the form of a trust, escrow account,
government fund, certificate of deposit, or deposit of government securities;
(2) Deposited prior to the start of operation
into an account segregated from licensee assets and outside the licensee’s
administrative control of cash or liquid assets that will retain their value
over the projected operating life of the facility; and
(3) In an amount such that the principal plus
accumulated earnings shall be sufficient to pay the necessary costs.
(l) The surety method or insurance in He-P
4030.09(j)(2) above shall be in the form of a surety bond, letter of credit,
line of credit, secured interest or other guarantee method such that the costs
shall be paid should the licensee default.
(m) Any surety or insurance under He-P 4030.09(l)
shall contain the following conditions:
(1) The surety or insurance shall be open-ended
or, if written for a specified term, such as 5 years, shall be renewed
automatically unless 90 days or more prior to the renewal date, the issuer
notifies DHHS/RHS, the trust account, and the licensee of its intention not to
renew;
(2) The surety or insurance shall provide that
the beneficiary may automatically collect prior to the expiration without proof
of forfeiture if the licensee fails to provide a replacement acceptable to
DHHS/RHS within 30 days after receipt of notification of cancellation;
(3) The beneficiary of the surety or insurance
shall be a trust account and trustee such as a state or federal government
agency or entity which has the authority to act as a trustee and whose trust
operations are regulated and examined by a federal or state agency; and
(4) The surety or insurance shall remain in
effect until DHHS/RHS has terminated the license.
(n) An external sinking fund in He-P
4030.09(j)(3) shall be:
(1) In the form of a trust, escrow account,
government fund, certificate of deposit or deposit of government securities;
(2) Established and maintained by the periodic
deposit of a prescribed amount into an account segregated from licensee assets
and outside the licensee’s administrative control;
(3) In a total amount for which the periodic
deposits plus accumulated earnings shall be sufficient to pay the necessary
costs at the time termination of operation is expected;
(4) Deposited to at least annually; and
(5) Coupled with a surety method or insurance,
the value of which may decrease by the amount being accumulated in the sinking
fund.
(o) Each person licensed under He-P 4030 shall
keep records of information important to the safe and effective decommissioning
of the facility in a specific location reserved for this purpose until the site
is released for unrestricted use and the license terminated by DHHS/RHS.
(p) If records of relevant information are kept
for other purposes, reference to these records and their locations shall be
allowed to be kept with the records for decommissioning.
(q) Records important to decommissioning shall
consist of:
(1) Records of spills or other unusual
occurrences involving the spread of contamination in and around the facility,
equipment, or site, which may be limited to instances:
a. When contamination remains after any cleanup
procedures; or
b. When there is reasonable likelihood that
contaminants may have spread to inaccessible areas such as seepage into porous
materials such as concrete;
(2) Information on identification of involved
radionuclides, quantities, chemical and physical forms, and concentrations, if
known;
(3) As-built drawings and modifications of
structures and equipment in restricted areas where byproduct materials are used
or stored, and of locations of possible inaccessible contamination such as
buried pipes, but if drawings are not available, the licensee shall substitute
appropriate records of available information concerning these areas and
locations;
(4) Except for areas containing only sealed
sources, provided the sealed sources have not leaked or no contamination
remains after any leak, or radioactive material having only half lives of less
than 65 days, a list contained in a single document and updated every 2 years,
of the following:
a. All areas designated and formerly designated
restricted areas as defined in He-P 4003;
b. All areas outside of restricted areas that
require documentation under He-P 4030.09(q);
c. All areas outside of restricted areas where
current and previous wastes have been buried as documented under He-P 4021.09;
and
d. All areas outside of restricted areas that
contain material such that, if the license expired, the licensee would be
required to either decontaminate the area to meet the criteria for
decommissioning in He-P 4024, or apply for approval for disposal under He-P
4023.02; and
(5) Records of the cost estimate performed for
the decommissioning funding plan or of the amount certified for
decommissioning, and records of the funding method used for assuring funds if
either a funding plan or certification is used.
(r) Before licensed activities are transferred or
assigned in accordance with He-P 4030.15, licensees shall transfer all records
required by He-P 4030.09(o) to the new licensee, and the new licensee shall be
responsible for maintaining these records until the license is terminated.
(s) Each license issued or granted pursuant to
He-P 4030.09, He-P 4031 through He-P 4036, and He-P 4039 shall be subject to
all the provisions of the RSA 125-F, as amended, now or hereafter in effect,
and to all valid rules, regulations and orders of DHHS/RHS.
(t) No license issued or granted pursuant to He-P
4030.09, He-P 4031 through He-P 4036, and He-P 4039 of this regulation nor any
right under a license shall be transferred, assigned or in any manner disposed
of, either voluntarily or involuntarily, directly or indirectly, through
transfer of control of any license to any person, unless DHHS/RHS shall after
securing full information find that the transfer is in accordance with RSA
125-F, and shall give its consent in writing.
(u) In providing financial assurance under He-P
4030.09, each licensee shall use the financial assurance funds only for
decommissioning activities and each licensee shall monitor the balance of funds
held to account for market variations.
The licensee shall replenish the funds, and report such actions to
DHHS/RHS, as follows:
(1) If, at the end of a calendar quarter, the
fund balance is below the amount necessary to cover the cost of
decommissioning, the licensee shall increase the balance to cover the cost, and
shall do so within 30 days after the end of the calendar quarter;
(2) If at any time, the fund balance falls below
75 percent of the amount necessary to cover the cost of decommissioning, the
licensee shall increase the balance to cover the cost, and shall do so within
30 days of the occurrence; and
(3) Within 30 days of taking the actions required
by He-P 4030.09(u)(1) or (u)(2) above the licensee shall provide a written
report of such actions to DHHS/RHS, and state the new balance of the fund.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; amd by #8488, eff 11-18-05; amd by #8800, INTERIM, eff
2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16
He-P 4030.10 Specific Licenses, Issuance.
(a) Upon a determination that an application
meets the requirements of the applicable sections of He-P 4000, He-P 4030, and
RSA 125-F, DHHS/RHS shall issue a specific license authorizing the proposed
activity.
(b) DHHS/RHS shall incorporate into any license
issued pursuant to this part and He-P 4031 through 4036, and He-P 4039, at the
time of issuance or thereafter, by appropriate rule or order, such additional
requirements and conditions with respect to the licensee’s receipt, possession,
use, and transfer of byproduct material as it deems appropriate or necessary in
order to:
(1) Protect the public health and minimize danger
to life or property;
(2) Require such reports and the keeping of such
records, and to provide for such inspections of activities under the license as
may be appropriate or necessary; and
(3) Prevent loss or theft of material subject to
this part.
(c) Specific licenses shall be issued to named
persons upon applications filed pursuant to He‑P 4030.
(d) Each license issued pursuant to this part and
parts He-P 4031 through 4036, and He-P 4039, shall be subject to all of the
provisions of RSA 125-F and to the administrative rules in chapter He-P 4000. Said licenses shall also
be subject to any temporary orders issued pursuant to the governor’s state of emergency by the commissioner when necessary to protect
the health and safety of employees, the general public, or the security of certain types of
radioactive materials during the declared state of emergency.
(e) Neither the license nor any right under the
license issued or granted pursuant this part and parts He-P 4031 through 4036,
and He-P 4039, shall be assigned or otherwise transferred in violation of the
provision of RSA 125-F.
(f) Each person licensed by DHHS/RHS pursuant to
this part shall confine his or her use and possession of the material licensed
to conditions specified on the license, such as:
(1) Standard licensing conditions as set forth in
these rules, or
(2) Conditions formulated specifically for an
individual license.
(g) Each licensee shall notify DHHS/RHS in
writing when the licensee decides to permanently discontinue all activities
involving materials authorized under the license.
(h) Each general licensee that is required to
register by He-P 4031, and each specific licensee, shall notify DHHS/RHS in
writing immediately following the filing of a voluntary or involuntary petition
for bankruptcy under any Chapter of Title 11 of the United States Code by or
against:
(1) The licensee;
(2) An entity, as that term is defined in 11
U.S.C. 101(15), controlling the licensee or listing the license or licensee as
property of the estate; or
(3) An affiliate, as that term is defined in 11
U.S.C. 101(2), of the licensee.
(i) The notification specified in He-P 4030.10(h)
shall indicate the bankruptcy court in which the petition for bankruptcy was
filed and the date of the filing of the petition.
(j) Each licensee shall notify DHHS/RHS of
radiological incidents and events, as follows:
(1) As soon as possible but not later than 4
hours after the discovery of an event that prevents immediate protective
actions necessary to avoid exposures to radiation or radioactive materials that
could exceed the limits specified in He-P 4020, or releases of licensed
material that could exceed the limits specified in He-P 4020; and
(2) Within 24 hours after the discovery of any of
the following events involving licensed material:
a. An unplanned contamination event that:
1. Requires access to the contaminated area, by
workers or the public, to be restricted for more than 24 hours by imposing
additional radiological controls or by prohibiting entry into the area;
2. Involves a quantity of radioactive material
greater than 5 times the lowest annual limit of intake specified in He-P 4090
or the equivalent 10 CFR 20 Appendix B for the material; and
3. Requires access to the area to be restricted
for a reason other than to allow isotopes with a half-life of less than 24
hours to decay prior to decontamination;
b. An event in which equipment is disabled or
fails to function as designed when:
1. The equipment is required by the rules or
license condition to prevent releases exceeding regulatory limits, to prevent
exposures to radiation and radioactive materials exceeding the limits specified
by He-P 4020, or to mitigate the consequences of an accident;
2. The equipment is required to be available and
operable when it is disabled or fails to function; and
3. No redundant equipment is available and
operable to perform the required safety function;
c. An event that requires unplanned medical
treatment at a medical facility of an individual with spreadable radioactive
contamination on the individual’s clothing or body; and
d. An unplanned fire or explosion damaging any
licensed material or any device, container, or equipment containing licensed
material when:
1. The quantity of radioactive material involved
is greater than 5 times the lowest annual limit on intake specified in for the material; and
2. The damage affects the integrity of the
licensed material or its container.
(k) Licensees shall make reports to DHHS/RHS
required by He-P 4030.10(j)(1) and (2) above, by telephone via the New Hampshire state police
communications center at (603) 271-3636.
(l) To the extent that the information is
available at the time of notification, the information provided in the
telephonic report pursuant to (k) above shall include:
(1) The caller’s name and call back telephone
number;
(2) A description of the event, including date
and time;
(3) The exact location of the event;
(4) The isotopes, quantities, and chemical and
physical form of the licensed material involved; and
(5) Any personnel radiation exposure data
available.
(m) Each licensee who makes a report required by
He-P 4030.10(j)(1) or (2) shall submit to DHHS/RHS a written follow-up report
within 30 days of the initial report, which includes the following information:
(1) A description of the event, including the
probable cause and the manufacturer and model number (if applicable) of any
equipment that failed or malfunctioned;
(2) The exact location of the event;
(3) The isotopes, quantities, and chemical and
physical form of the licensed material involved;
(4) Date and time of the event;
(5) Corrective actions taken or planned and the
results of any evaluations or assessments; and
(6) The extent of exposure of individuals to
radiation or to radioactive materials without identification of individuals by
name.
(n) Relative to records, each person who receives
byproduct material pursuant to a license issued pursuant He-P 4030 through He-P
4039 shall:
(1) Keep records showing the receipt, transfer,
and disposal of the source or byproduct material, as follows:
a. The licensee shall retain each record of
receipt of source or byproduct material
as long as the material is possessed and for 3 years following transfer or
disposal of the source or byproduct material;
b. The licensee who transferred the radioactive
material shall retain each record of transfer of source or byproduct material
until DHHS/RHS terminates each license that authorizes the activity that is
subject to recordkeeping requirement;
c. The licensee who disposed of the source or
byproduct material shall retain each record of disposal of radioactive material
until the license that authorizes disposal of the material is terminated; and
d. If source or byproduct material is combined
or mixed with other licensed material and subsequently treated in a manner that
makes direct correlation of a receipt record with transfer, export, or
disposition record impossible, the licensee shall use evaluative techniques,
such as, first-in-first-out, to make the records that are required by He-P 4030
account for 100 percent of the material received;
(2) Retain each record that is required by this
chapter or by license condition for the period specified by the applicable rule
or license condition, except that if a retention period is not otherwise
specified by rule or license condition, the record shall be retained until the
license authorizing the activity that is subject to the recordkeeping
requirement is terminated;
(3) Retain records required to be maintained
pursuant to this chapter in the following format:
a. The original;
b. A reproduced
copy, if such reproduced copy is duly authenticated by authorized personnel;
c. Microform, if such microform is duly
authenticated by authorized personnel and is capable of producing a clear and
legible copy after storage for the period specified by the rules; or
d. Stored in electronic media with the
capability for producing legible, accurate, and complete records during the
required retention period;
(4) Ensure that all pertinent information,
including stamps, initials, and signatures, are included on all required
records, including letters, drawings, specifications;
(5) Maintain adequate safeguards against
tampering with and loss of records;
(6) Prior to termination of a license authorizing
possession of radioactive material with a half-life greater than 120 days, in
an unsealed form, forward the following records to DHHS/RHS:
a. Records of disposal of licensed material made
under He-P 4023; and
b. Records required by He-P 4021.03(c)(4);
(7) At the time of transfer of a radioactive
material license authorizing possession of radioactive material with a
half-life of greater than 120 days, in an unsealed form, transferred or
assigned in accordance with He-P 4030.15 to a new licensee, transfer the
following records to the new licensee and the new licensee will be responsible
for maintaining these records until the license is terminated, the following:
a. Records of disposal of licensed material made
under He-P 4023; and
b. Records required by He-P 4021.03(c)(4); and
(8) Prior to license termination, forward the
records to DHHS/RHS as required by He-P 4030.09(o) – (r).
(o) Relative to licensees preparing
technetium-99m radiopharmaceuticals from molybdenum- 99/technetium-99m
generators or rubidium-82 from strontium-82/rubidium-82 generators, each
licensee shall test the generator eluates for molybdenum-99 breakthrough or strontium-82
and strontium- 85 contamination, respectively, in accordance with He-P
4035.32(a) through (d). The licensee
shall record the results of each test and retain each record for 3 years after
the record is made. The licensee shall
report the results of any test that exceeds the permissible concentration
listed in He-P 4035.32(a) at the time of the generator elution, in accordance
with He-P 4035.32(e).
(p) Relative to licensees authorized under He-P
4030.07(k) to produce:
(1) PET radioactive drugs for noncommercial
transfer to medical use licensees in its consortium shall not relieve the
licensee from complying with applicable DHHS/RHS, or agreement state, or
federal requirements governing radioactive drugs; and
(2) PET radioactive drugs for noncommercial
transfer to medical use licensees in its consortium, the licensees shall
satisfy:
a. The labeling requirements in He-P
4032.05(a)(4) for each PET radioactive drug transport radiation shield and each
syringe, vial, or other container used to hold a PET radioactive drug intended
for noncommercial distribution to members of the licensees consortium; and
b. The requirement for using instrumentation to
measure the radioactivity of the PET radioactive drugs intended for
noncommercial distribution to members of the licensees’ consortium and meet the
procedural, radioactivity measurement, instrument test, instrument check, and
instrument adjustment requirements of He-P 4032.05(d).
(q) Relative to pharmacies authorized under He-P
4030.07(k) to produce PET radioactive drugs for noncommercial transfer to
medical use licensees in its consortium, each pharmacy shall require that any
individual who prepares PET radioactive drugs shall be:
(1) An authorized nuclear pharmacist that meets
the requirements in He-P 4032.05(b)(2);
(2) An individual under the supervision of an
authorized nuclear pharmacist as specified in He-P 4035.11; or
(3) An individual
working as an authorized nuclear pharmacist who meets the requirements of He-P
4032.05(b)(2).
(r) Relative to portable gauge licensees, each
licensee shall:
(1) Secure the portable gauges such that each
portable gauge license shall use a minimum of 2 independent physical controls
that form tangible barriers to secure portable gauges from unauthorized
removal, whenever portable gauges are not under the control and constant
surveillance of the licensee; and
(2) Maintain utilization logs for 3 years for
each source of radiation which contains the following information:
a. A description, including the make, model, and
serial number of each sealed source and each device in which the sealed source
is located;
b. The location and dates of use, including the
dates removed and returned to storage; and
c. The identity and signature of the user of the
device.
(s) Relative to licensee’s survey instruments,
each licensee shall:
(1) Keep
sufficient calibrated and operable radiation survey instruments at each
location where sources of radiation are present to make the radiation surveys
required by He-P 4022;
(2) Have each radiation survey instrument
calibrated:
a. At energies appropriate for use and at
intervals not to exceed 12 months or after instrument servicing, except for
battery changes;
b. For linear scale instruments, at 2 points
located approximately one-third and two-thirds of full scale on each scale. For
logarithmic scale instruments, at mid-range of each decade, and at 2 points of
at least one decade. For digital instruments, at 3 points between 0.02 and 10
millisieverts (2 and 1,000 mrem) per hour; and
c. So that an accuracy within plus or minus 20
percent at the calibration source can be demonstrated at each point checked;
and
(3) Maintain records of the annual calibrations
of its radiation survey instruments and retain each record for 3 years after it
is made.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8488, eff 11-18-05; ss by #8959, eff 8-7-07; ss
by #10896, INTERIM, eff 7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16;
amd by #13047, eff 6-2-20; ss by #13421, eff 7-29-22
He-P 4030.11 Specific Licenses, Expiration.
(a) Except as provided in He-P 4030.12 for
license renewal, each specific license shall expire annually at the end of one
year.
(b) Each licensee shall notify DHHS/RHS, in
writing, and request termination of the license when the licensee decides to
terminate all activities involving byproduct material authorized under the
license. This notification and request
for termination of the license shall include the reports and information
specified in He-P 4030.11(d)(4) and (5).
(c) No less than 30 days before the expiration
date specified in the license, the licensee shall either:
(1) Submit an application for license renewal
under He-P 4030.12; or
(2) Notify DHHS/RHS, in writing, if the licensee
decides not to renew the license.
(d) If a licensee does not submit an application
for license renewal under He‑P 4030.12, the licensee shall, on or before
the expiration date specified in the license:
(1) Terminate use of radioactive material;
(2) Remove radioactive contamination in
accordance with He-P 4023;
(3) Dispose of radioactive material in accordance
with He-P 4023;
(4) Submit a completed DHHS/RHS-10 “Certificate-Disposition
of Radioactive Material” (July 2022) in accordance with He-P 4030.01(c); and
(5) Submit a radiation survey report of the
licensed permanent location(s) of use and storage to confirm that the removable
and fixed contamination levels are in accordance with levels specified in He-P
4021.21, as follows:
a. Report levels of radiation in units of
microrad per hour of beta and gamma radiation at 1 centimeter and gamma
radiation at 1 meter from surfaces;
b. Report levels of radioactivity, including
alpha, in:
1. Units of transformations per minute per 100
square centimeters or microcuries per 100 square centimeters removable and
fixed on surfaces;
2. Microcuries per milliliter in water; and
3. Picocuries per gram in contaminated solids
such as soils or concrete; and
c. Specify the survey or measurement
instrument(s) used for conducting the survey and certify that each instrument
was properly calibrated and tested.
(e) If no residual radioactive contamination attributable
to activities conducted under the license is detected, the licensee shall
submit a certification that no detectable radioactive contamination of the
location(s) was found.
(f) If detectable levels of residual radioactive
contamination attributable to activities conducted under the license are found,
the license shall continue to be in effect beyond the expiration date, with
respect to possession of residual radioactive material present as contamination
until such time as DHHS/RHS notifies the licensee in writing that the license
is terminated. During this time the
licensee shall be subject to the provisions of He-P 4030.11(h).
(g) If detectable levels of residual radioactive
contamination attributable to activities conducted under the license are found,
the licensee shall submit a plan for decontamination of the residual
radioactive contamination which shall include in addition to the information
submitted under He‑P 4030.11(d)(4) and (5), any expected levels of
residual radioactive contamination which will remain at the time the license is
terminated.
(h) Each licensee who possesses residual
radioactive material under He‑P 4030.11(d)(3), following the expiration
date specified in the license, shall:
(1) Limit actions involving radioactive material
to those related to decontamination and other activities related to preparation
for release for unrestricted use; and
(2) Continue to control entry to restricted areas
until the licensee has met the provisions of He‑P 4020 for release for unrestricted
use and DHHS/RHS has notified the licensee in writing that the license is
terminated.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16; ss by #13421, eff 7-29-22
He-P 4030.12 Specific Licenses, Renewal.
(a) Except as provided in (b) below, in order to
renew a license, a licensee shall file a completed application for renewal of
specific licenses annually using DHHS/RHS-1.1 “Application for Annual Renewal
of Radioactive Material License” (July 2022); and submit the applicable fee as
required by He-P 4070.
(b)
Not more often than once every 7 years after filing an application
according to He-P 4030.07, the licensee shall renew the license by submitting a
completed application as listed in He-P 4030.07(a) and applicable supplements,
as requested by DHHS/RHS in order to fully review the license. The completed application shall comply with
He-P 4030.07.
(c) In any case in which a licensee, not less
than 30 days prior to expiration of his existing license, has filed an
application in proper form as stated in (a) or (b) above, for renewal, or for a
new license authorizing the same activities, such existing license shall not
expire until the application has been finally determined by DHHS/RHS.
(d) If a licensee does not submit an application
for license renewal, the licensee shall comply with the provisions of He-P
4030.10(n) and He-P 4030.17(d).
(e) Each application submitted shall meet the
requirements of He-P 4030.01(c).
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16; ss by #13421, eff 7-29-22
He-P 4030.13 Specific Licenses, Amendment at Request of
Licensee. Requests for amendment of
a license shall:
(a) Be filed in accordance with He‑P
4030.07;
(b) Specify the respects in which the licensee desires
its license to be amended and the grounds for such amendment;
(c) Be submitted for review and authorization by
DHHS/RHS prior to implementing the activity as stated in the initial request
for the license to be amended; and
(d) Be submitted in a business letter format.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16
He-P 4030.14 Specific Licenses, DHHS/RHS Action of
Applications to Renew or Amend. In
considering an application by a licensee to renew or amend its license,
DHHS/RHS shall apply the criteria set forth in this chapter for granting of an
initial license.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16
He-P 4030.15 Specific Licenses, Inalienability. No license issued or granted under He-P 4000,
and no right to possess or utilize byproduct material granted by any license
issued pursuant to this part shall be transferred, assigned, or in any manner
disposed of, either voluntarily or involuntarily, directly or indirectly,
through transfer of control of any license to any person unless DHHS/RHS, after
securing full information, find that the transfer is in accordance with the
provisions of the act, and gives its consent in writing.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16
He-P 4030.16 Specific Licenses, Transfer of Source or
Byproduct Material.
(a) No licensee shall transfer source or byproduct
material except as authorized pursuant to Part He-P 4030.
(b) Except as otherwise provided in its license
and subject to the provisions of He-P 4030.16(c) and (d), any licensee may
transfer source or byproduct material:
(1) To DHHS/RHS only after receiving prior
approval from DHHS/RHS;
(2) To the U.S. Department of Energy;
(3) To any person exempt from He‑P 4000 to
the extent permitted under such exemption;
(4) To any person authorized to receive such
source or byproduct material under terms of a general license or its equivalent
or a specific license or equivalent licensing document, issued by DHHS/RHS, the
Nuclear Regulatory Commission, an agreement state, or to any person otherwise
authorized to receive such source or byproduct material by the Federal
government of any agency thereof, DHHS/RHS, an agreement state; or
(5) As otherwise authorized by DHHS/RHS in
writing.
(c) Before transferring source or byproduct
material to a specific licensee of DHHS/RHS, the Nuclear Regulatory Commission,
an agreement state, or a licensing state prior to receipt of the byproduct
material, the transferor licensee shall verify that the transferee’s license
authorizes the receipt of the type, form, and quantity of source or byproduct
material to be transferred.
(d) The following methods for the verification
required by He-P 4030.16(c) shall be acceptable:
(1) The transferor may have in its possession,
and have read, a current copy of the transferee’s specific license or
registration certificate;
(2) The transferor may have in its possession a
written certification by the transferee that it is authorized by license or
registration certificate to receive the type, form, and quantity of source or
byproduct material to be transferred, specifying the license or registration
certificate number, issuing agency, and expiration date;
(3) For emergency shipments the transferor may
accept oral certification by the transferee that it is authorized by license or
registration certificate to receive the type, form, and quantity of source or
byproduct material to be transferred, the oral certification shall specify the
license or registration certificate number, issuing agency, and expiration
date, and shall be confirmed in writing within 10 days;
(4) The transferor may obtain other sources of
information compiled by a reporting service from official records of DHHS/RHS,
the Nuclear Regulatory Commission, or the licensing agency of an agreement
state as to the identity of licensees and the scope and expiration dates of
licenses and registration; or
(5) When none of the methods of verification
described in He‑P 4030.16(d)(1) through (4) are readily available or when
a transferor desires to verify that information received by one of such methods
is correct or up-to-date, the transferor may obtain and record confirmation
from DHHS/RHS, the Nuclear Regulatory Commission, or the licensing agency of an
agreement state that the transferee is licensed to receive the source or
byproduct material.
(e) Preparation for shipment and transport of
source or byproduct material shall be in accordance with the provisions of He‑P
4037.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16; ss by #13047, eff 6-2-20
He-P 4030.17 Specific Licenses, Modification,
Revocation, and Termination.
(a) The terms and conditions of all licenses
shall be subject to amendment, revision, or modification or the license may be
suspended or revoked by reason of amendments to the act, or by reason of rules,
and orders issued by DHHS/RHS.
(b) Any license may be revoked, suspended, or
modified, in whole or in part, for any material false statement in the
application or any statement of fact required under provisions of the act, or
because of conditions revealed by such application or statement of fact or any
report, record or inspection or other means which would warrant DHHS/RHS to
refuse to grant a license on an original application, or for violation of, the
terms and conditions of the act, or the license, or of any rule, regulation, or
order of DHHS/RHS.
(c) Except in cases of willfulness or those in
which the public health, interest, or safety requires otherwise, no license
shall be modified, suspended, or revoked unless, prior to the institution of
proceedings therefor, facts or conduct which may warrant such action shall have
been called to the attention of the licensee in writing and the licensee shall
have been accorded an opportunity to demonstrate or achieve compliance with all
lawful requirements.
(d) DHHS/RHS shall terminate a specific license
upon request submitted by the licensee to DHHS/RHS in writing, provided that
the licensee shall meet the requirements of He‑P 4030.11.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10896, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11006, eff 1-15-16
He-P 4030.18 Reciprocal
Recognition of Specific Licenses.
(a) Subject to He‑P 4000, any person who
holds a specific license from the Nuclear Regulatory Commission, an agreement
state, as defined in He-P 4003.01 and issued by the agency having jurisdiction
where the licensee maintains an office for directing the licensed activity and
at which radiation safety records are normally maintained, shall hereby be
granted a general license to conduct the activities authorized in such
licensing document within this state, except in areas of exclusive federal
jurisdiction, for a period not in excess of 180 days in any calendar year,
provided that:
(1) The licensing document shall not limit the
activity authorized by such document to specified installations or locations;
and
(2) The out-of-state licensee shall notify
DHHS/RHS as described in (d) below at
least 3 working days prior to engaging in such activity and receive DHHS/RHS
approval, except as provided in (e) below.
(b) DHHS/RHS shall grant the approval required by
He-P 4030.18(a)(2) above when a general licensee meets all of the requirements
under He-P 4030.18.
(c) The notification required by He-P
4030.18(a)(2) above shall indicate the location, period, and type of proposed
possession and use within this state.
(d) The notification to DHHS/RHS, as specified in
He-P 4001.08, shall be accompanied by a copy of the pertinent out of state
licensing document, a copy of the licensee’s operating and emergency
procedures, an annual fee as specified in He-P 4070, and a completed
DHHS/RHS-15 “Radioactive Material Reciprocity Application” (July 2022) with the
following certification:
“I hereby certify
that all information provided in this application is true and complete, I have
read and understand the provisions under He-P 4030.18, and I understand that
activities, including storage, conducted in New Hampshire under this general
license are limited to 180 days during any calendar year.”
(e) If, for a specific case, the 3-day period
required by He-P 4030.18(a)(2) above would endanger the public health and
safety, the licensee shall request a
waiver from DHHS/RHS to proceed sooner.
(f) The
out-of-state licensee shall submit in its initial request for reciprocity the
applicable New Hampshire annual license fee in accordance with He-P 4070.
(g) The reciprocity fee required by (f) above
shall cover a period of one year.
(h) The
requirement in (f) above shall not waive the requirement for filing additional
written notifications during the remainder of the calendar year following the
receipt of the initial notification from a person engaging in activities under
the general license provided in He-P 4030.18(a).
(i) The out-of-state licensee shall comply with
all:
(1) Applicable rules of DHHS/RHS; and
(2) Terms and
conditions of the licensee’s licensing document, except any such terms and
conditions which are contrary to applicable rules of DHHS/RHS.
(j) The out-of-state licensee shall supply
additional information, either telephonically or in writing, as requested by
DHHS/RHS for the purposes of protecting public and worker health and safety and
ensuring the safe use of byproduct sources within the state.
(k) The out-of-state licensee shall not transfer
or dispose of byproduct material possessed or used under the general license
provided in this section except by transfer to a person:
(1) Specifically licensed by DHHS/RHS, an
agreement state, or by the Nuclear Regulatory Commission to receive such
material; or
(2) Exempt from the requirements for a license
for such material under He-P 4030.03.
(l) Before byproduct materials are used at a
temporary job site within the state at any federal facility, the jurisdictional
status of the job site shall be determined by the licensee.
(m) If the jurisdictional status of a temporary
job site within the state at a federal facility is unknown, the licensee shall
contact the federal agency to determine if the job site is under exclusive
federal jurisdiction.
(n) In areas of exclusive federal jurisdiction,
the general licensee shall be subject to all applicable rules, regulations,
orders and fees of the Nuclear Regulatory Commission.
(o) Authorization for possession and use of
byproduct materials at temporary job sites under exclusive federal jurisdiction
shall be obtained from the Nuclear Regulatory Commission by either:
(1) Filing a Nuclear Regulatory Commission
Form-241 in accordance with 10 CFR 150.20(b); or
(2) Applying for a specific Nuclear Regulatory
Commission license.
(p) Before byproduct material is used by a
specific licensee at a temporary job site in another state, authorization shall
be obtained from that state if it is an agreement state, or from the Nuclear
Regulatory Commission for any non-agreement state, either by filing for
reciprocity or applying for and obtaining a specific license.
(q)
Notwithstanding the provisions of He-P 4030.18(a), any person who holds a
specific license issued by an agreement state, or the Nuclear Regulatory
Commission, authorizing the holder to manufacture, install, or service a device
described in He-P 4031.04(c) within an area subject to the jurisdiction of the
licensing body shall be considered by DHHS/RHS to have a general license to
install and service such device in this state provided that:
(1) Such person shall file a report with DHHS/RHS
within 30 days after the end of each calendar quarter in which any device is
transferred to or serviced in this state;
(2) The report required by He-P 4030.18(q)(1)
above shall identify each general licensee by:
a. Name and address;
b. The type of device transferred; and
c. The quantity and type of byproduct material
contained in the device;
(3) The device shall have been manufactured,
labeled, installed, and serviced in accordance with applicable provisions of
the specific license, or equivalent licensing document, issued to such person
by the Nuclear Regulatory Commission or an agreement state;
(4) Such person shall assure that any labels
required to be affixed to the device under regulations of the authority which
licensed manufacture of the device bear a statement that “Removal of this label
is prohibited”;
(5) In the event that a label, as specified in
He-P 4030.18(q)(4) above, is missing or damaged, such person shall affix a
label in accordance with the regulations of the authority which licensed
manufacture of the device; and
(6) The holder of the specific license shall
furnish to each general licensee to whom the licensee transfers such device or
on whose premises he or she installs such device a copy of the general license
contained in He-P 4031.02.
(r) In accordance with RSA 125-F:10, DHHS/RHS
shall withdraw, limit, or qualify its acceptance of any specific license or
equivalent licensing document issued by another agency, or any product
distributed pursuant to such licensing document, upon determining that such
action is necessary in order to protect the public health and minimize the
danger to life or property.
(s) A licensee to whom action has been taken as
described in He-P 4030.18(r) shall be afforded a hearing within 15 days on
application, in the form of a written request, to DHHS/RHS requesting such
hearing.
(t) A hearing held relative to action taken under
He-P 4030.18(r) shall be conducted in accordance with He-C 200.
Source. (See Revision Note at part heading for He-P
4030) #6942, eff 2-1-99; ss by #7919, eff 7-18-03; ss by #8488, eff 11-18-05;
ss by #8959, eff 8-7-07; ss by #10896, INTERIM, eff 7-22-15, EXPIRES: 1-18-16;
ss by #11006, eff 1-15-16; ss by #13421, eff 7-29-22
He-P 4030.19 Requirements for License to Initially
Transfer Source Material for Use Under the ‘Small Quantities of Source
Material' General License. An
application for a specific license to initially transfer source material for
use under He-P 4031.03, equivalent regulations of an agreement state, or
Nuclear Regulatory Commission under 10 CFR 40.22, shall be approved if:
(a) The
applicant satisfies the general requirements specified in He-P 4030.09; and
(b) The applicant submits adequate information on,
and DHHS/RHS approves the methods to be used for quality control, labeling, and
providing safety instructions to recipients.
Source. #13047, eff 6-2-20
He-P 4030.20 Conditions of Licenses to Initially
Transfer Source Material for Use Under the ‘Small Quantities of Source
Material’ General License: Quality Control, Labeling, Safety Instructions, and
Records and Reports.
(a)
Each person licensed under He-P 4030.19 shall label the immediate
container of each quantity material with the type of source material and
quantity of material and the words, “radioactive material.”
(b) Each person licensed under He-P 4030.19 shall
ensure that the quantities and concentrations of source material are as labeled
and indicated in any transfer records.
(c) Each person licensed under He-P 4030.19 shall
provide the information specified in this paragraph to each person to whom
source material is transferred for use under He-P 4031.03, equivalent
provisions in agreement state regulations, or Nuclear Regulatory Commission
under 10 CFR 40.54. This information
shall be transferred before the source material is transferred for the first
time in each calendar year to the particular recipient. The required information includes:
(1) A copy of He-P 4030.03 and He-P 4030.16,
equivalent regulations of an agreement state, or Nuclear Regulatory Commission
10 CFR 40.22 and 40.51; and
(2) Appropriate radiation safety precautions and
instructions relating to handling, use, storage, and disposal of the material.
(d)
Each person licensed under He-P 4030.19 shall report transfers as
follows:
(1) File a report with DHHS/RHS. The report shall include the following
information:
a. The name, address, and license number of the
person who transferred the source material;
b. For each general licensee under He-P 4031.03,
equivalent agreement state provisions to who greater than 50 grams (0.11 lb) of
source material has been transferred in a single calendar quarter, or Nuclear
Regulatory Commission 10 CFR 40.22, the name and address of the general
licensee to whom source material is distributed; a responsible agent, by name
and/or position and phone number, of the general licensee to whom the material
was sent; and the type, physical form, and quantity of source material transferred;
and
c. The total quantity of each type and physical
form of source material transferred in the reporting period to all such
generally licensed recipients;
(2) File a report with DHHS/RHS that identifies
all persons, operating under provisions of He-P 4031.03, to whom greater than
greater than 50 grams (0.11 lb) of source material has been transferred within
a single calendar quarter. The report
shall include the following information specific to those transfers made to
DHHS/RHS being reported to:
a. The name, address, and license number of the
person who transferred the source material;
b. The name and address of the general licensee
to whom source material was distributed; a responsible agent, by name and/or
position and phone number, of the general licensee to who the material was
sent; and the type, physical form, and quantity of source material transferred;
and
c. The total quantity of each type and physical
form of source material transferred in the reporting period to such generally
licensed recipients within New Hampshire;
(3) Submit each report by January 31 of each year
covering all transfers for the previous calendar year. If no transfers were made to persons
generally licensed under He-P 4031.03, equivalent agreement state provisions
during the current period, or Nuclear Regulatory Commission 10 CFR 40.22, a
report shall be submitted to DHHS/RHS indicating so. If no transfers have been made to general
licensees in New Hampshire during the reporting period, this information shall
be reported to DHHS/RHS upon request.
(e) Each person licensed under He-P 4030.19 shall
maintain all information that supports the reports required by He-P 4030.20
concerning each transfer to a general licensee for a period of one year after
the event is included in a report to DHHS/RHS.
Source. #13047, eff 6-2-20
PART He-P
4031 GENERAL LICENSES
Revision Note:
Doc. #6942, effective
2-1-99, repealed Parts He-P 2030, 2031, 2032, 2033, 2034, 2035, 2042 and 2093
relative to Radiation and Radioactive Material and adopted new rules to replace
them and renumbered them as He-P 4030, 4031, 4032, 4033, 4034, 4035, 4093 and
4096.
PART
He-P 4031 GENERAL LICENSES
Statutory Authority: RSA 125‑F:5,V
He-P 4031.01 Purpose and Scope.
(a)
This part establishes general licenses for the possession and use of
byproduct material and a general license for ownership of byproduct material.
(b)
Specific provisions of He-P 4030 shall be applicable to general licenses
established by this part.
(c)
The specific provisions of He-P 4030 applicable to the general licenses
are specified in He-P 4031.02.
Source. (See Revision Note at part heading for He-P
4031) #6942, eff 2-1-99; ss by #8481, eff 11-5-05; ss by #10604, eff 5-23-14
He-P 4031.02
Terms and Conditions. The
general license provided in this part shall be subject to the general
provisions of He-P 4030.01, 4030.03(b), 4030.10(a), (c), (d), (i) and (j), He-P
4030.15, He-P 4030.16, He-P 4030.17, He-P 4001, He-P 4003, He-P 4019, He-P
4020, He-P 4021, He-P 4022, He-P 4023, and He-P 4037, unless indicated
otherwise in the specific provision of the general license.
Source. (See Revision Note at part heading for He-P
4031) #6942, eff 2-1-99; ss by #8481, eff 11-5-05; ss by #10604, eff 5-23-14
He-P 4031.03
General Licenses - Source Material.
(a) A
general license shall be issued authorizing commercial and industrial firms,
research, educational, and medical institutions, and state and local government
agencies to receive, possess, use, and transfer uranium and thorium, in their
natural isotopic concentrations and in the form of depleted uranium, for
research, development, educational, commercial, or operational purposes, in the
following forms and quantities:
(1) No
more than 1.5 kg (3.3 lb) of uranium and thorium in dispersible forms, which
shall include gaseous, liquid, and powder forms, at any one time, and under the
following conditions:
a. Any
material processed by the general licensee that alters the chemical or physical
form of the material containing source material shall be accounted for as a
dispersible form;
b. A
person authorized to possess, use, and transfer source material under He-P
4032.03(a) shall not receive more than a total of 7 kg (15.4 lb) of uranium and
thorium in any one calendar year;
c.
Persons possessing source material in excess of these limits in b. above
may:
(i)
Continue to possess up to 7 kg (15.4 lb) of uranium and thorium at any
one time for one year until the DHHS/RHS takes final action on a pending
application submitted on or before August 27, 2014, for a specific license for
such material; and
(ii)
Continue to receive up to 70 kg (154 lb) of uranium or thorium in any
one calendar year until December 31, 2014, or until the DHHS/RHS takes final
action on a pending application submitted on or before August 27, 2014, for a
specific license for such material;
(2) No
more than a total of 7 kg (15.4 lb) of uranium and thorium at any one time, and
under the following conditions:
a. A
person authorized to possess, use, and transfer source material under this
paragraph shall not receive more than a total of 70 kg (154 lb) of uranium and
thorium in any one calendar year; and
b. A
person shall not alter the chemical or physical form of the source material
possessed under He-P 4032.03(a) unless it is accounted for under the limits of
He-P 4032.03(a)(1);
(3) No
more than 7 kg (15.4 lb) of uranium, removed during the treatment of drinking
water, at any one time. In addition, a
person shall not remove more than 70 kg (154 lb) of uranium from drinking water
during a calendar year under He-P 4032.03(a); or
(4) No
more than 7 kg (15.4 lb) of uranium and thorium at laboratories for the purpose
of determining the concentration of uranium and thorium contained within the
material being analyzed at any one time.
In addition, a person authorized to possess, use, and transfer source
material under He-P 4032.03(a) shall not receive more than a total of 70 kg
(154 lb) of source material in any one calendar year.
(b) Persons who receive, possess, use, or transfer source material pursuant to the
general license issued in He-P 4031.03(a):
(1) Shall be prohibited from administering
source material, or the radiation therefrom, either externally or internally,
to human beings except as may be authorized by the DHHS/RHS in a specific
license;
(2)
Shall not abandon such source material;
(3)
Shall dispose of such source material as follows:
a. A cumulative total of 0.5 kg (1.1 lb) of
source material in a solid, non-dispersible form may be transferred each
calendar year, by a person authorized to receive, possess, use, and transfer
source material under this general license to persons receiving the material
for permanent disposal. The recipient of
source material transferred under the provisions of this paragraph shall be
exempt from the requirements to obtain a license under this part to the extent
the source material is permanently disposed.
This provision shall not apply to any person who is in possession of
source material under a specific license issued under He-P 4032 or He-P 4033;
or
b. In accordance with He-P 4023.01;
(4) Shall be subjected to the provisions in He-P
4001.03, He-P 4001.05, He-P 4001.07, He-P 4001.08, He-P 4003.01, He-P 4024,
He-P 4030.15 through He-P 4030.17, and He-P 4031.03;
(5)
Shall respond to written requests from the DHHS/RHS to provide
information relating to the general license within 30 calendar days of the date
of the request, or other time specified in the request. If the person cannot provide the requested
information within the allotted time, the person shall, within that same time
period, request a longer period to supply the information by providing the
DHHS/RHS, a written justification for the request; and
(6)
Shall not export such source material except in accordance with 10 CFR
Part 110.
(c) Any person who receives, possesses, uses, or transfers source material in accordance with He-P 4031.03(a)
shall conduct activities so as to minimize contamination of the facility and
the environment. When activities
involving such source material are permanently ceased at any site, if evidence
of significant contamination is identified, the general licensee shall notify
the DHHS/RHS about such contamination and may consult with the DHHS/RHS as to
the appropriateness of sampling and restoration activities to ensure that any
contamination or residual source material remaining at the site where source material
was used under this general license is not likely to result in exposures that
exceed the limits in He-P 4024.09.
(d) Any person who
receives, possesses, uses, or transfers source material in accordance with the
general license granted in He-P4031.03(a) shall be exempt from the provisions
of He-P 4019, He-P 4020, and He-P 4021 to the extent that such receipt,
possession, use, and transfer are within the terms of this general license,
except that such person shall comply with the provisions of He-P 4023.01 and
He-P 4024.09 to the extent necessary to meet the provisions of He-P
4031.03(b)(2) and (c). However, this exemption shall not apply to any person
who also holds a specific license issued under He-P 4032 or He-P 4033.
(e) A
general license shall be issued to receive, acquire, possess, use, or transfer
depleted uranium provided that:
(1) The depleted uranium is contained in
industrial products or devices for the purpose of providing a concentrated mass
in a small volume of the product or device in accordance with the provisions of
He-P 4031.03(e)(2), (3), and (4);
(2) The depleted uranium authorized in He-P
4031.03(e)(1) is contained only in industrial products or devices which have
been manufactured in accordance with a specific license issued to the
manufacturer by the U.S. Nuclear Regulatory Commission or an Agreement State
which authorizes manufacture of the products or devices for distribution to
persons generally licensed by the U.S. Nuclear Regulatory Commission or an
Agreement State;
(3) A person who receives, acquires, possesses,
or uses depleted uranium pursuant to the general license established by He-P
4031.03(e)(1):
a. Shall not introduce such depleted uranium, in
any form, into a chemical, physical, or metallurgical treatment or process,
except when a treatment or process is for repair or restoration of the plating
or covering of the depleted uranium;
b. Shall not abandon such depleted uranium;
c. Shall transfer or dispose of depleted uranium
only by transfer in accordance with the provisions of He-P 4030.15;
d. Shall furnish the transferee a copy of this
rule when depleted uranium is transferred in accordance with He-P
4031.03(e)(3)c;
e. Shall furnish the transferee a copy of He-P
4031 accompanied by a note explaining that use of the product or device is
regulated by the U.S. Nuclear Regulatory Commission or an Agreement State in
the case where the transferee receives the depleted uranium pursuant to a
general license contained in the U.S. Nuclear Regulatory Commission's or an
Agreement State's regulation equivalent to He-P 4031.03(e)(1);
f. Shall report within 30 days of any transfer,
a report in writing to the DHHS/RHS the name and address of the person
receiving the depleted uranium pursuant to such transfer; and
g. Shall not export depleted uranium except in
accordance with a license issued by the U.S. Nuclear Regulatory Commission
pursuant to 10 CFR 110; and
(4) Any person receiving, acquiring, possessing,
using, or transferring depleted uranium pursuant to the general license
established by He-P 4031.03(e) shall be exempt from the requirements of He P
4019 through He-P 4023 with respect to the provisions of He-P 4031.
(f)
No person shall initially transfer or distribute source material to
persons generally licensed under He-P 4031.03(a)(1) or (a)(2), equivalent
regulations of an Agreement State, or Nuclear Regulatory Commission, unless
authorized by a specific license issued in accordance with He-P 4032.03(a)(1)
and (a)(2), equivalent provisions of an Agreement Statement, or Nuclear
Regulatory Commission 10 CFR 40.54. This
prohibition shall not apply to analytical laboratories returning processed
samples to the client who initially provided the sample. Initial distribution of source material to
persons generally licensed by He-P 4031.03(a) before August 27, 2013 without
specific authorization, shall continue for 1 year beyond August 27, 2013. Distribution shall also be continued until
DHHS/RHS or the Nuclear Regulatory Commission takes final action on pending
application for license or license amendments to specifically authorized
distribution submitted on or before August 27, 2014.
Source. (See Revision Note at part heading for He-P
4031) #6942, eff 2-1-99; ss by #8481, eff 11-5-05 (from He-P 4031.01); ss by
#10604, eff 5-23-14; amd by #11198, eff 10-12-16; amd by #11198, eff 10-12-16
He-P
4031.04 General Licenses - Byproduct
Material Other Than Source Material.
(a) Reserved.
(b) A general
license shall be issued to commercial and industrial firms and to research,
educational and medical institutions, individuals in the conduct of their
business, and state or local government agencies to own, receive, acquire,
possess, use or transfer in accordance with the provisions of He-P 4031.04(c),
(d), and (e), byproduct material, excluding special nuclear material, contained
in any fixed device designed and manufactured for the purpose of detecting,
measuring, gauging or controlling thickness, density, level, interface
location, radiation, leakage, or qualitative or quantitative chemical
composition, or for producing light or an ionized atmosphere.
(c) The general
license in He-P 4031.04(b) shall apply only to byproduct material contained in
devices which have been manufactured or initially transferred and labeled in
accordance with the specifications contained in a specific license issued by
the DHHS/RHS pursuant to He-P 4032 or in accordance with the specifications
contained in a specific license issued by the U.S. Nuclear Regulatory
Commission or an Agreement State which authorizes distribution of devices to
persons generally licensed by the NRC or an Agreement State.
(d) Devices
containing byproduct material as described in He-P 4031.04(c) above shall have
been received only from one of the specific licensees specified in He-P
4031.04(c) or through a transfer made in accordance with He-P 4031.04(e)(9).
(e) Any person who owns, receives, acquires,
possesses, uses, or transfers byproduct material in a device pursuant to the
general license in He-P 4031.04(b) shall:
(1) Assure that
all labels affixed to the device at the time of receipt, and bearing a
statement that removal of the label is prohibited, shall be maintained thereon
and shall comply with all instructions and precautions provided by such labels;
(2) Assure that
the device is tested for leakage of radioactive material and proper operation
of the on-off mechanism and indicator, if any, at no longer than 6-month
intervals or at such other intervals as are specified on the label; however:
a. Devices
containing only krypton shall not be required to be tested for leakage of
radioactive material; and
b. Devices
containing only tritium or not more than 3.7 MBq (100 microcuries) of other
beta and/or gamma emitting material or 370 kBq (10 microcuries) of alpha
emitting material and devices held in storage in the original shipping
container prior to initial installation shall not be required to be tested for
any purpose;
(3) Assure that
the tests required by He-P 4031.04(e)(2) and other testing, installation,
servicing, and removal from installation involving the radioactive materials,
its shielding or containment, are performed:
a. In
accordance with the instructions provided by the labels; or
b. By a person
holding a specific license from the DHHS/RHS, the NRC, or an Agreement State,
to perform such activities;
(4) Maintain
records showing compliance with the requirements He-P 4031.04(e)(2) and (3)
which:
a. Show the
results of tests; and
b. Show the
dates of performance of, and the names of persons performing, testing,
installing, servicing, and removal from installation concerning the radioactive
material, its shielding or containment;
(5) Retain
records as follows:
a. Each record
of a test for leakage or radioactive material required by He-P 4031.04(e)(2)
shall be retained for 3 years after the next required leak test is performed or
until the sealed source is transferred or disposed of;
b. Each record
of a test on the “on-off” mechanism and indicator required by He-P
4031.04(e)(2) shall be retained for 3 years after the next required test of the
on-off mechanism and indicator is performed or until the sealed source is
transferred or disposed of; and
c. Each record
that is required by He-P 4031.04(e)(3) shall be retained for 3 years from the
date of the recorded event or until the device is transferred or disposed of;
(6) Upon the
occurrence of a failure of or damage to, or any indication of a possible
failure of or damage to, the shielding of the radioactive material or the
on-off mechanism or indicator, or upon the detection of 185 becquerel (0.005
microcurie) or more removable radioactive material, shall immediately suspend
operation of the device until it has been repaired by the manufacturer or other
person holding a specific license from the DHHS/RHS, the NRC, or an Agreement
State to repair such devices, or disposed of by transfer to a person authorized
by a specific license to receive the radioactive material contained in the
device and, within 30 days, furnish to the DHHS/RHS a report containing a brief
description of the event and the remedial action taken, and in the case of
detection of 185 becquerel (0.005 microcurie) or more removable radioactive
contamination or failure of or damage to a source likely to result in
contamination of the premises or the environs, a plan for ensuring that the
premises and environs are acceptable for unrestricted use, must be furnished to
the DHHS/RHS, in accordance with the criteria set out in He-P 4021.20, and He-P
4024;
(7) Not abandon
the device containing byproduct material;
(8) Not export
the device containing byproduct material except in accordance with 10 CFR 110;
(9) Except as
provided in He-P 4031.04(e)(10), transfer or dispose of the device containing
byproduct material only by:
a. Export as
provided by He-P 4031.04(e)(8);
b. By transfer
to a general licensee as authorized by He-P 4031.04(e)(10); or
c. By transfer
to a specific licensee of the DHHS/RHS, the NRC, or an Agreement State whose
specific license authorizes him to receive the device and within 30 days after
transfer or export of a device to a specific licensee shall furnish to the
DHHS/RHS a report containing identification of the device by manufacturer's or
initial transferor’s name, model number, and serial number, and the name,
address, and license number of the person receiving the device, and the date of
the transfer;
(10) Transfer
byproduct material in a device pursuant to the general license in He-P
4031.04(b) if the general license holder obtains pre-approval from DHHS/RHS
and:
a. Verifies
that the specific license authorizes the possession and use, or applies for and
obtains an amendment to the license authorizing the possession and use;
b. Removes,
alters, covers, or clearly and unambiguously augments the existing label
required by He-P 4031.04(e)(1) so that the device is labeled in compliance with
He-P 4022.14, except that the manufacturer, model number, and serial number
shall be retained;
c. Obtains the manufacturer’s or initial transferor’s
information concerning maintenance that would be applicable under the specific
license, such as leak testing procedures; and
d. Reports the
transfer under He-P 4031.04(e)(9);
(11) Transfer
the device to another general licensee only:
a. Where the
device remains in use at a particular location, in which case the transferor
shall give the transferee a copy of this rule and any safety documents
identified in the label on the device and, within 30 days of the transfer,
report to the DHHS/RHS the manufacturer's or initial transferor’s name, model
number, and serial number of the device transferred, the name and address of
the transferee, and the name, position, and telephone number of a responsible
individual identified by the transferee in accordance with He-P 4031.04(e)(14) to
have knowledge of and authority to take actions to ensure compliance with these
rules, and who may constitute a point of contact between the DHHS/RHS and the
transferee; or
b. Where the
device is held in storage by an intermediate person in the original shipping
container at its intended location of use prior to initial use by a general
licensee;
(12) Comply
with the provisions of He-P 4021.12 and 4021.13 for reporting radiation
incidents, theft, or loss of licensed material, but shall be exempt from the
other requirements of He-P 4019 through He-P 4023;
(13) Respond to
written requests from the DHHS/RHS to provide information relating to the
general license within 30 calendar days of the date of the request, or other
time specified in the request, except that if the general licensee is unable to
provide the requested information within the allotted time, it shall, within
that same time period, request a longer period to supply the information by
providing the DHHS/RHS a written justification for the request;
(14) Appoint an
individual responsible for having knowledge of the appropriate rules and
requirements, and for ensuring day-to-day compliance with the appropriate rules
and requirements, and vested with the authority for taking required actions to
comply with appropriate rules and requirements, although not relieving the
general licensee of its responsibility in this regard;
(15) Register
each device containing at least 370 MBq (10 mCi) of cesium-137, 3.7 MBq (0.1
mCi) of strontium-90, 37 MBq (1 mCi) of cobalt-60, 37 MBq (1 mCi) of
americium-241, or 3.7 MBq (0.1 mCi) of radium-226, or any other transuranic,
based on the activity indicated on the device label. Each address for a location of use, as
described under He-P 4031.04(e)(16) of this section, represents a separate
general licensee and requires a separate registration and fee;
(16) Register
any and all devices meeting the criteria set out in He-P 4031.04(e)(15)
annually with the DHHS/RHS and submit the fee required by He-P 4070. Registration shall be done by verifying,
correcting, and/or adding to the information provided in a request for
registration received from the DHHS/RHS.
The registration information shall be submitted to the DHHS/RHS within
30 days of the date of the request for registration or as otherwise indicated
in the request. In addition, a general
licensee holding devices meeting the criteria of He-P 4031.04(e)(15) of this
section is subject to the bankruptcy notification requirement in He-P
4030.10(h)-(i);
(17) In
registering devices, furnish the following information and any other
information specifically requested by the DHHS/RHS:
a. Name and
mailing address of the general licensee;
b. Information
about each device: the manufacturer (or initial transferor), model number,
serial number, the radioisotope and activity (as indicated on the label);
c. Name, title, and telephone number of the
responsible person designated as a representative of the general licensee under
He-P 4031.04(e);
d. Address or
location at which the device(s) are used and/or stored. For portable devices, the address of the
primary place of storage;
e. Certification by the responsible
representative of the general licensee that the information concerning the
device(s) has been verified through a physical inventory and checking of label
information; and
f. Certification
by the responsible representative of the general licensee that they are aware
of the requirements of the general license;
(18) Report
changes to the mailing address for the location of use or a change in name of
general licensee to the DHHS/RHS within 30 days of the effective date of the
change. For a portable device, a report
of address change is only required for a change in the device’s primary place
of storage; and
(19) Not hold
devices that are not in use for longer than 2 years. If devices with shutters are not being used,
the shutter shall be locked in the closed position. The testing required by He-P 4031.04(e) need
not be performed during the period of storage only; however, when devices are
put back into service or transferred to another person, and have not been
tested within the required test interval, they shall be tested for leakage
before use or transfer and the shutter tested before use. Devices kept in standby for future use shall
be excluded from the 2-year time limit if the general licensee performs
quarterly physical inventories of these devices while they are in standby.
(f) The general license in He-P 4031.04(b) shall
not authorize the manufacture or import of devices containing byproduct
material.
(g) The general
license provided in He-P 4031.04(b) shall be subject to the provisions of He-P
4001 through He-P 4003, He-P 4030.10, He-P 4030.16, He-P 4030.17, and He-P
4037.
(h) A general license is hereby issued to own,
receive, acquire, possess, and use tritium or promethium 147 contained in
luminous safety devices for use in aircraft, provided:
(1) Each device
contains not more than 370 GBq (10 curies) of tritium or 11.1 GBq (300
millicuries) of promethium 147; and
(2) Each device
has been manufactured, assembled or initially transferred in accordance with a
license issued by the U.S. Nuclear Regulatory Commission or each device has
been manufactured or assembled in accordance with the specifications contained
in a specific license issued by the DHHS/RHS or an Agreement State to the
manufacturer or assembler of such device for distribution to persons generally
licensed by an Agreement State pursuant to licensing requirements equivalent to
the previsions of 10 CFR Part 32.53 of the regulations of the U.S. Nuclear
Regulatory Commission.
(i) Persons who
own, receive, acquire, possess, or use luminous safety devices pursuant to the
general license in He-P 4031.04(h) shall be exempt from the requirements of
He-P 4019 through 4023, except that they shall comply with the provisions of
sections He-P 4021.12 and He-P 4021.13.
(j) The general
license in He-P 4031.04(h) shall not authorize the manufacture, assembly,
repair, import or export of luminous safety devices containing tritium or
promethium 147.
(k) The general
license in He-P 4031.04(h) shall not authorize the ownership, receipt,
acquisition, possession or use of promethium 147 contained in instrument dials.
(l) The general
license in He-P 4031.04(h) shall be subject to the provisions of He-P 4001
through He-P 4003, He-P 4030.10, He-P 4030.16, He-P 4030.17 and He-P 4037.
(m) A general
license shall be issued to those persons listed below to own, receive, acquire,
possess, use, and transfer in accordance with the provisions of He-P 4031.04(p),
(q) and (s) americium 241 or radium 226 in the form of calibration or reference
sources:
(1) Any person
who holds a specific license issued by the Agency which authorizes him to
receive, possess, use, and transfer byproduct materials, source material; and
(2) Any person
who holds a specific license issued by the U.S. Nuclear Regulatory Commission
which authorizes him to receive, possess, use, and transfer special nuclear
material.
(n) [Reserved].
(o) A general
license shall be issued to any person to own, receive, possess, use, and
transfer radium in the form of calibration or reference sources in accordance
with equivalent provisions of He-P 4031.04(p), (q), and (s) who holds a
specific license issued by the Agency which authorizes him to receive, possess,
use, and transfer radioactive material.
(p) The general licenses in He-P 4031.04(m) and (o) shall apply only to calibration or
reference sources which have been manufactured in accordance with the
specifications contained in a specific license issued to the manufacturer or
importer of the sources by the U.S. Nuclear Regulatory Commission, pursuant to
section 32.57 of 10 CFR Part 32 or Section 70.39 of 10 CFR Part 70 or which
have been manufactured in accordance with the specifications contained in a
specific license or equivalent licensing document issued to the manufacturer by
the DHHS/RHS, or an Agreement State pursuant to licensing requirements
equivalent to those contained in Section 32.57 of 10 CFR Part 32 or Section
70.39 of 10 CFR Part 70 of the regulations of the U.S. Nuclear Regulatory
Commission.
(q) The general licenses provided in He-P
4031.04(m) and (o) shall be subject to the provisions of He-P 4001 through He-P
4003, He-P 4019 through He-P 4023, He-P 4030.10, He-P 4030.16, He-P 4030.17 and
He-P 4037.
(r) Persons who own, receive, acquire, possess,
use, and transfer one or more calibration or reference sources pursuant to He-P
4031.04(m) or (o):
(1) Shall not
possess at any one time, at any one location of storage or use, more than 0.185
MBq (5 microcuries) of americium 241 and 0.185 MBq (5 microcuries) of radium
226 in such sources;
(2) Shall not
receive, possess, use, or transfer such source unless the source, or the
storage container, bears a label which includes one of the following statements
or a substantially similar statement which contains the information called for
in the following statement:
"The receipt, possession, use and transfer of
this source, Model___________, Serial No.______________, are subject to a
general license and the regulations of the Nuclear Regulatory Commission or of
a state with which the Commission has entered into an agreement for the
exercise of regulatory authority. Do not
remove this label. CAUTION-RADIOACTIVE MATERIAL
THIS SOURCE CONTAINS (AMERICIUM 241) or (RADIUM-226,
as appropriate)
DO NOT TOUCH RADIOACTIVE PORTION OF THIS SOURCE
(Name of Manufacturer or Initial Transferor)”
(3) Shall not
transfer, abandon, or dispose of such source except by transfer to a person
authorized by a license from the DHHS/RHS, the U.S. Nuclear Regulatory
Commission, or an Agreement State to receive the source;
(4) Shall store
such source, except when the source is being used, in a closed container
designed and constructed to contain americium 241or radium-226 which might
otherwise escape during storage; and
(5) Shall not
use such source for any purpose other than the calibration of radiation
detectors or the standardization of other sources.
(s) The general licenses in He-P 4031.04 He-P
4031.04(m) and (o) shall not authorize the manufacture, import or export of
calibration or reference sources containing americium-241or radium-226.
(t) A general
license shall be issued to own radioactive material without regard to quantity. Notwithstanding any other provisions of this
part, this general license does not authorize the manufacture, production,
transfer, receipt, possession, use, import or export of byproduct material,
except as authorized in a specific license.
(u) A general license shall be issued to own,
receive, acquire, possess, use, and transfer strontium 90 contained in ice
detection devices, provided each device contains not more than 1.85 MBq (50
microcuries) of strontium 90 and each device has been manufactured or initially
transferred in accordance with a specific license issued by the U.S. Nuclear
Regulatory Commission or each device has been manufactured in accordance with
the specifications contained in a specific license or equivalent licensing document
issued by the DHHS/RHS, or an Agreement State to the manufacturer of such
device pursuant to licensing requirements equivalent to those of 10 CFR Part
32.61 of the regulations of the U.S. Nuclear Regulatory Commission.
(v) Persons who own, receive, acquire, possess,
use, or transfer strontium 90 contained in ice detection devices pursuant to
the general license in He-P 4031.04(u) shall:
(1) Upon
occurrence of visually observable damage, such as a bend or crack or
discoloration from overheating, to the device, discontinue use of the device
until it has been inspected, tested for leakage and repaired by a person
holding a specific license or equivalent licensing document from the Nuclear
Regulatory Commission or an Agreement State to manufacture or service such
devices; or shall dispose of the device pursuant to the provisions of those
rules;
(2) Assure that
all labels affixed to the device at the time of receipt, and which bear a
statement which prohibits removal of the labels, are maintained thereon; and
(3) Be exempt
from the requirements of He-P 4019 through He-P 4023, except that such person
shall comply with the provisions of He-P 4023, He-P 4021.12 and He-P 4021.13.
(w) The general license in He-P 4031.04(u) shall
not authorize the manufacture, assembly, disassembly, repair, or import of
strontium 90 in ice detection devices.
(x) The general
license in He-P 4031.04(u) shall be subject to the provisions of He-P 4001
through He-P 4003, He-P 4030.10, He-P 4030.16, He-P 4030.17, and He-P 4037.
Source. #8481, eff
11-5-05 (from He-P 4031.02); ss by #10604, eff 5-23-14; amd by #11198, eff
10-12-16; amd by #12625, eff 9-26-18
He-P
4031.05 General License to Install
Devices Generally Licensed in He-P 4031.04(b). Any person who holds a specific license
issued by an Agreement State or the U.S. Nuclear Regulatory Commission,
authorizing the holder to manufacture, install, or service a device described
in He-P 4031.04(b) within such Agreement State or non-Agreement State, is
hereby granted a general license to install and service such device in this
state and a general license to install and service such device in offshore
waters, as defined in 10 CFR 150.3 provided:
(a) The device
has been manufactured, labeled, installed, and serviced in accordance with
applicable provisions of the specific license issued to such person by the
Agreement State or, the Nuclear Regulatory Commission; and
(b) Such person
assures that any labels required to be affixed to the device under regulations
of the Agreement State or the Nuclear Regulatory Commission, which licensed
manufacture of the device bear a statement that removal of the label is
prohibited.
Source. #8481, eff
11-5-05 (from He-P 4031.03); ss by #10604, eff 5-23-14; amd by #12625, eff
9-26-18
He-P 4031.06 General License for Certain Items and
Self-luminous Products Containing Radium-226.
(a)
A general license is hereby issued to any person to acquire, receive,
possess, use, or transfer, in accordance with provisions of He-P 4031.06(b),
(c), and (d), radium-226 contained in the following products manufactured prior
to November 30, 2007.
(1) Antiquities originally intended for use by
the general public. For the purposes of
He-P 4031.06(a)(1), antiquities mean products originally intended for use by
the general public and distributed in the late 19th and early 20th
centuries, such as radium emanator jars, revigators, radium water jars, radon
generators, refrigerator cards, radium bath salts, and healing pads;
(2) Intact timepieces containing greater than 37
kBq (1 microcurie), nonintact timepieces, and timepiece hands and dials no
longer installed in timepieces;
(3) Luminous items installed in air, marine, or
land vehicles;
(4) All other luminous products, provided that no
more than 100 items are used or stored at the same location at any one time;
(5) Small radium sources containing no more than
37 kBq (1 microcurie) of radium-226. For
the purposes of He-P 4031.06(a)(5), “small radium sources” means discrete
survey instrument check sources, sources contained in radiation measuring
instruments, sources used in educational demonstrations (such as cloud chambers
and spinthariscopes), electron tubes, lightning rods, ionization sources,
static eliminators, or as designated by the DHHS/RHS.
(b)
Persons who acquire, receive, possess, use, or transfer byproduct
material under the general license issued in He-P 4031.06(a) are exempt from
the provisions of He-P 4001.03, He-P 4019 through He-P 4023, and He-P
4030.10(j), to the extent that the receipt, possession, use, or transfer of
byproduct material is within the terms of the general license; provided,
however, that this exemption shall not be deemed to apply to any such person
specifically licensed under He-P 4031.
(c)
Any person who acquires, receives, possesses, uses, or transfers
byproduct material in accordance with the general license in He-P 4031.06(a):
(1) Shall notify the DHHS/RHS should there be
any indication of possible damage to the product so that it appears it could
result in a loss of the radioactive material.
A report containing a brief description of the event, and the remedial
action taken, shall be furnished to the DHHS/RHS within 30 days;
(2) Shall not abandon products containing
radium-226. The product, and any
radioactive
material from the
product, shall be disposed of according to He-P 4023 or by transfer to a person
authorized by a specific license to receive the radium-226 in the product or as
otherwise approved by the DHHS/RHS;
(3) Shall not export products containing
radium-226 except in accordance with U.S. Nuclear Regulatory Commission 10 CFR
110;
(4) Shall dispose of products containing
radium-226 at a disposal facility authorized to dispose of radioactive material
in accordance with any federal or state solid or hazardous waste law, including
the Solid Waste Disposal Act, as authorized under the Energy Policy of 2005, by
transfer to a person authorized to receive radium-226 by a specific license
issued under He-P 4030, or equivalent regulations of an agreement state, or as
otherwise approved by the U.S. Nuclear Regulatory Commission;
(5) Shall respond to written requests from the
DHHS/RHS to provide information relating to the general license within 30
calendar days of the date of the request, or other time specified in the
request. If the general licensee cannot
provide the requested information within the allotted time, the general
licensee shall, within the same time period, request a longer period to supply
the information by providing the DHHS/RHS, a written justification for the
request.
(d)
The general license in He-P 4031.06(a) does not authorize the
manufacture, assembly, disassembly, repair, or import of products containing
radium-226, except that timepieces may be disassembled and repaired.
Source. #11198, eff 10-12-16
PART He-P
4032 SPECIFIC LICENSES FOR MANUFACTURE
OR TRANSFER OF CERTAIN ITEMS CONTAINING BYPRODUCT MATERIAL
Statutory
Authority RSA 125-F:5,V
Revision Note:
Doc. #6942,
effective 2-1-99, repealed Parts He-P 2030, 2031, 2032, 2033, 2034, 2035, 2042
and 2093 relative to Radiation and Radioactive Material and adopted new rules
to replace them and renumbered them as He-P 4030, 4031, 4032, 4033, 4034, 4035,
4093 and 4096.
He-P 4032.01 Purpose.
(a) This part prescribes requirements for the
issuance of specific licenses to persons who manufacture or initially transfer
items containing byproduct material for sale or distribution to:
(1) Persons exempted from the licensing requirements
of He-P 4030; or
(2) Persons generally licensed under He-P 4031 or
He-P 4035.
(b) This part shall prescribe requirements for
manufacturers or initial transferors of sealed source or devices containing
sealed sources which are to be used by persons specifically licensed under He-P
4030 and U.S. Nuclear Regulatory Commission (NRC) in 10 CFR Part 37 or
equivalent regulations of the NRC, an agreement state or a licensing state.
Source. (See Revision Note at part heading for He-P
4032) #6942, eff 2-1-99; ss by #8488, eff 11-18-05; ss by #8959, eff 8-7-07; ss
by #10983, eff 11-24-15
He‑P
4032.02 Scope. The provisions and requirements of this part
shall be in addition to, and not in substitution for, other requirements of
He-P 4000. In particular, the provisions
of He-P 4030 apply to applications, licenses and certificates of registration
subject to He-P 4032, and the provisions of the Nuclear Regulatory Commission
in 10 CFR Part 37 apply to applications and licenses subject to He-P 4032.
Source. (See Revision Note at part heading for He-P
4032) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. # 8959, eff 8-7-07; ss by #10983, eff
11-24-15
He-P 4032.03 Licensing the Manufacture and Distribution
of Devices to Persons Generally Licensed.
(a) An application for a specific license to
manufacture or initially transfer devices containing byproduct material,
excluding special nuclear material, to persons generally licensed under He-P
4031.04, or equivalent regulations of the NRC, or an agreement state as
established by the Atomic Energy Act of 1954, or a licensing state shall be
approved if:
(1) The applicant satisfies the general
requirements of He-P 4030.09;
(2) The applicant submits complete information
relating to the design, manufacture, prototype testing, quality control,
labels, proposed uses, installation, servicing, leak testing, operating and
safety instructions, and potential hazards of the device which shall ensure
that:
a. The device can be safely operated by persons
not having training in radiological protection;
b. Under ordinary conditions of handling,
storage, and the use of the device, the byproduct material contained in the
device cannot be released or inadvertently removed from the device;
c. Under ordinary conditions of handling,
storage, and the use of the device, it is unlikely that any person will receive
in one year a dose in excess of 10% of the annual limits specified in He-P
4020.05; and
d. Under accident conditions (such as fire and
explosion) associated with handling, storage, and use of the device, it is
unlikely that any person would receive an external radiation dose or dose
commitment in excess of the organ doses in Table 4032.1 below:
Table 4032.1 Organ Doses Under Accident Conditions
Body Part |
Organ Dose |
Whole body; head
and trunk; active blood-forming organs; gonads,
or lens of eye |
15 rems (150
mSv) |
Hands and
forearms; feet and localized areas of skin averaged
over areas no longer than 1 square
centimeter |
200 rems (2 Sv) |
Other organs |
50 rems (500
mSv); |
(3) Each device bears a durable, legible, clearly
visible label or labels, which contain in a clearly identified and separate
statement:
a. Instructions and precautions necessary to
ensure safe installation, operation, and servicing of the device or
identification of operating and service manuals used to provide this
information;
b. The requirement, or exemption of a
requirement, for leak testing, or for testing any on-off mechanism and
indicator, to include the maximum time interval for such testing, the
identification of radioactive material by isotope, the quantity of
radioactivity, and the date of determination of the quantity; and
c. The information called for in the following
statement in the same form:
1. “The receipt, possession, use and transfer of
this device Model_____ Serial No._____ are subject to a general license or the
equivalent and the regulations of the NRC, the Agreement State or the Licensing
State which has regulatory authority.”;
2. “This label shall be maintained on the device
in a legible condition.”;
3. “Removal of this label is prohibited.”;
4. The words, “CAUTION - RADIOACTIVE MATERIAL”;
and
5. The name of the manufacturer or distributor;
(4) Each device having a separable source housing
that provides the primary shielding for the source also bears on the source
housing, a durable label containing:
a. The device model number and serial number;
b. The isotope and quantity;
c. The words, “CAUTION - RADIOACTIVE MATERIAL”;
d. The radiation symbol described in He‑P
4022.11; and
e. The name of the manufacturer or initial
distributor;
(5) Each device meeting the
criteria of He-P 4031.04(e)(15), bears a permanent, such as embossed, etched,
stamped, or engraved, label affixed to the source housing if separable, or the
device if the source housing is not separable, that includes the words,
“CAUTION-RADIOACTIVE MATERIAL”, and, if practicable, the radiation symbol
described in He-P 4022.11; and
(6) The device has been registered in the NRC
Sealed Source and Device Registry.
(b) Should an applicant under He-P
4032.03(a)(3)b. desire that a device be required to be leak tested or tested
for proper operation of the on-off mechanism and indicator, at intervals
greater than 6 months, DHHS/RHS shall consider at least the following
information in determining the acceptable interval:
(1) Primary containment (source capsule);
(2) Protection of primary containment;
(3) Method of sealing containment;
(4) Containment construction materials;
(5) Form of contained radioactive material;
(6) Maximum temperature withstood during
prototype test;
(7) Maximum pressure withstood during prototype
tests;
(8) Maximum quantity of contained radioactive
material;
(9) Radiotoxicity of contained radioactive
material; and
(10) Operating experience with identical devices
or similarly designed and constructed devices.
(c) In the event the applicant under He-P
4032.03(a) desires that the general licensee under He-P 4031, or under
equivalent regulations of the NRC, an agreement state, or a licensing state, be
authorized to install the device, collect the sample to be analyzed by a
specific licensee for leakage of byproduct material, service the device, test
the on-off mechanism and indicator, or remove the device from installation, the
applicant shall:
(1) Include written instructions to be followed
by the general licensee;
(2) Include the estimated calendar-quarter doses
associated with such activity or activities, and bases for such estimates; and
(3) Demonstrate that performance of such activity
or activities by an individual untrained in radiological protection is unlikely
to cause that individual to receive a calendar-quarter dose in excess of 10% of
the limits specified in He-P 4020.05(a).
(d) If a device containing byproduct material is
to be transferred for use under the general license contained in He-P
4031.04(b), each person that is licensed under He-P 4032.03 shall provide to
each person to whom a device is to be transferred, prior to transferring the
device, the following:
(1) A copy of the general license contained in
He-P 4031.04(b), except if paragraphs He-P 4031.04(e)(2) through (e)(4) or He-P
4031.04(e)(15) do not apply to the particular device, those paragraphs may be
omitted;
(2) A copy of He-P 4031.02, He-P 4030.10(n), He-P
4021.12, He-P 4021.13, and He-P 4021.19;
(3) A list of the services that can only be
performed by a specific licensee;
(4) Information on acceptable disposal options
including estimated costs of disposal; and
(5) An indication that DHHS/RHS shall take
enforcement action for improper disposal.
(e) If the transfer specified in He-P 4032.03(d)
is through an intermediate person, the information to be provided as described
in He-P 4032.03(d) shall also be provided to the intended user prior to initial
transfer to the intermediate person.
(f) If byproduct material is to be transferred in
a device for use under the equivalent general license of an agreement state or
equivalent regulations of the NRC, or a licensing state each person that is
licensed under He-P 4032.03 shall provide to each person to whom a device is to
be transferred, prior to transferring the device, the following:
(1) A copy of the agreement state’s regulations
equivalent to He-P 4031.04, He-P 4031.02, He-P 4030.10(n), He-P 4021.12, and
He-P 4021.13, a copy of 10 CFR §§31.5, 31.2, 30.51, 20.2201, and 20.2202, or
(2) A copy of He-P 4031.04, He-P 4030.02, He-P
4030.10(n), He-P 4021.12, and He-P 4021.13, except if certain paragraphs of
these rules do not apply to the particular device, those paragraphs may be
disregarded;
a. If a copy of the agreement state’s
regulations equivalent to New Hampshire rules as listed in this paragraph, is
provided to a prospective general licensee in lieu of the applicable agreement
state’s, licensing state’s or NRC regulations, the copy of the agreement
state’s, licensing state’s or equivalent regulations of the NRC shall be
accompanied by a note explaining that use of the device is regulated by the
agreement state, licensing state or NRC, as applicable; and
b. If certain paragraphs of the regulations do
not apply to the particular device, those paragraphs may be omitted;
(3) A list of the services that can only be
performed by a specific licensee;
(4) Information on acceptable disposal options
including estimated costs of disposal; and
(5) The name or title, address, and phone number
of the contact at the agreement state or licensing state regulatory agency or
NRC from which additional information may be obtained.
(g) If the transfer specified in He-P 4032.03(f)
is through an intermediate person, the information to be provided as described
in He-P 4032.03(f) shall also be provided to the intended user prior to initial
transfer to the intermediate person.
(h) In lieu of the requirements of He-P
4032.03(d) through (g) above, the applicant may propose an alternative approach
to informing customers, subject to approval by DHHS/RHS. In its review of such a request, DHHS/RHS
shall ensure that the proposed alternative approach to informing customers:
(1) Meets the essential objectives of He-P
4032.03(d) through (g);
(2) Provides the same information as required by
He-P 4032.03(d) through (g); and
(3) Is not harmful to public health and safety.
(i) Each device that is transferred after
November 17, 2005, shall meet the labeling requirements in He-P 4032.03(a)(3)
through (a)(5).
(j) If a notification of bankruptcy has been made
under He-P 4030.10(h) or the license is to be terminated, each person licensed
under He-P 4032.03 shall provide, upon request, to DHHS/RHS, the NRC, any
appropriate agreement state, or licensing state records of final disposition
required under He-P 4032.03(m) and (n).
(k) Each person licensed under He-P 4032.03 to
initially transfer devices to generally licensed persons shall:
(1) Report, in a clear and legible report, to
DHHS/RHS all transfers of such devices to persons for use under the general
license in He-P 4031.03 and all receipts of devices from persons licensed under
He-P 4031.03 including:
a. The identity of each general
licensee by name and mailing address, and address location of
use. If there is no mailing address for
the location of use, an alternative address for the general licensee shall be
submitted along with information on the actual location of use;
b. The name, title, and telephone number of the
individual identified by the general licensee as having knowledge of and
authority to take required actions to ensure compliance with the applicable
rules, and who may constitute a point of contact between DHHS/RHS and the
general licensee;
c. The date of transfer;
d. The type, model number, and serial number of
device transferred;
e. The quantity and type of byproduct material
contained in the device;
f. If one or more intermediate persons will
temporarily possess the device at the intended place of use prior to its
possession by the user, the general licensee shall provide the same information
for both the intended user and each intermediate person, which shall clearly
designate and identify the intermediate person(s); and
g. The identity of the specific licensee
submitting the report, including the license number of the specific licensee;
(2) Report, in a clear and legible report, to
DHHS/RHS all receipts of devices from persons licensed under He-P 4031.03,
including, for devices received from persons generally licensed under He-P
4031.03:
a. The identity of the general licensee by name
and address;
b. The type, model number, and serial number of
the device received;
c. The date of receipt, and, in the case of
devices not initially transferred by the reporting licensee, the name of the
manufacturer or initial transferor; and
(3) Report to DHHS/RHS the identity of the
general licensee, the device, and the changes to information on the device
label, if the licensee authorized under He-P 4032.03 makes changes to a device
possessed by a general licensee authorized under He-P 4031.04(b), such that the
label must be changed to update required information;
(4) Report to DHHS/RHS if no transfers have been
made to or from persons generally licensed under He-P 4031.04(b) during the
reporting period;
(5) Report to the NRC, on NRC Form 653 “Transfers
of Industrial Devices Report” or in a clear and legible report containing all
data required by the form, all transfers of such devices to persons for use
under the NRC general license in section 31.5 of 10 CFR 31;
(6) Report to the responsible agreement state,
licensing state agency or the NRC all transfers of such devices to persons for
use under a general license in the agreement state’s licensing state’s or NRC
regulations equivalent to He-P 4031;
(7) Identify in the report required by He-P
4032.03(k)(5) or (6), the following:
a. The identity of each general licensee by name
and mailing address, and address location of use; if there is no mailing
address for the location of use, an alternative address for the general
licensee shall be submitted along with information on the actual location of
use;
b. The name, title, and telephone number of the
individual identified by the general licensee as having knowledge of and
authority to take required actions to ensure compliance with the applicable
rules, and who may constitute a point of contact between the agency and the
general licensee;
c. The date of transfer;
d. The type, model, and serial number of the
device transferred;
e. The quantity and type of byproduct material
contained in the device; and
f. The identity of the specific licensee
submitting the report, including the license number of the specific licensee;
(8) Report to the NRC, on NRC Form 653 “Transfers
of Industrial Devices Report” or in a clear and legible report containing all
data required by the form, all receipts of such devices from persons authorized
under the NRC general license in section 31.5 of 10 CFR 31;
(9) Report to the responsible agreement state, or
licensing state agency or the NRC all receipts of such devices from persons
authorized under a general license in the agreement state’s, licensing state’s
or NRC regulations equivalent to He-P 4031.04;
(10) Include in the report for devices received
from persons generally licensed under agreement state, licensing state, or NRC
regulations equivalent to He-P 4031.04:
a. The identity of the general licensee by name
and address;
b. The type, model number, and serial number of
the device received;
c. The date of receipt, and, in the case of
devices not initially transferred by the reporting licensee, the name of the
manufacturer or initial transferor; and
d. The identity of the specific licensee
submitting the report, including the license number of the specific licensee;
(11) Report to the responsible agreement state or
licensing state agency or the NRC, the identity of the general licensee, the
device, and the changes to information on the device label, if the licensee
authorized under He-P 4032.03 makes changes to a device possessed by a general
licensee authorized under regulations equivalent to He-P 4031.04(b), such that
the label must be changed to update required information;
(12) Report to the NRC, if no transfers have been
made to or from NRC general licensees during the reporting period;
(13) Report to the agreement state or licensing
state agency or the NRC regulated state if no transfers have been made to or
from that agreement state or licensing state or the NRC regulated state during
the reporting period;
(14) Keep records showing:
a. The name of each general licensee or intermediate
person to whom transfers of byproduct material in devices for use pursuant to
the general license provided in He‑P 4031.04, or equivalent regulations
of the NRC, an agreement state or licensing state have been made;
b. Address of each general licensee or
intermediate person to whom transfers of byproduct material in devices for use
pursuant to the general license provided in He‑P 4031.04, or equivalent
regulations of the NRC, an agreement state or licensing state have been made;
c. The point of contact for each general
licensee or intermediate person to whom transfers of byproduct material in
devices for use pursuant to the general license provided in He-P 4031.04, or
equivalent regulations of the NRC, an agreement state or licensing state have
been made;
d. The date of each transfer of byproduct
material;
e. Identification of the radioisotope contained
in each device transferred;
f. The quantity of radioactivity in each device
transferred;
g. The identity of any intermediate person; and
h. The requirements of He-P 4031 specifics for
this transfer;
(15) Cover each calendar quarter in its reports
submitted under He-P 4032;
(16) Submit reports required in He-P 4032.03
within 30 days of the end of the calendar quarter; and
(17) Indicate in reports required in He-P 4032.03,
the period covered by the report.
(l) In the event that one or more intermediate
persons will temporarily possess the device at the intended place of use prior
to its possession by the user, the licensee shall provide the same information
for both the intended user and each intermediate person, and shall clearly
designate the identity of the intermediate person(s); and
(m) Each person licensed under He-P 4032.03 shall
maintain all information concerning transfers and receipts of devices that
supports the reports required by this section.
(n) Records required by (l) shall be maintained
for a period of 3 years following the date of the recorded event.
Source. (See Revision Note at part heading for He-P
4032) #6942, eff 2-1-99; ss by #8488, eff 11-18-05; ss by #8959,
eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4032.04 Licensing the Introduction of Byproduct
Material Into Products in Exempt Concentrations.
(a) In addition to the requirements in He-P
4030.09, a specific license authorizing the introduction of byproduct material
into a product or material owned by or in the possession of the licensee or
another to be transferred to persons exempt under paragraph He-P 4030.03 shall
be issued if:
(1) The applicant submits:
a. A description of the product or material into
which the byproduct material will be introduced;
b. The intended use of the byproduct material
and the product into which it is introduced;
c. The method of introduction;
d. The initial concentration of the byproduct
material in the product or material;
e. The control methods to ensure that no more
than the specified concentration is introduced into the product or material;
f. The estimated time interval between
introduction and transfer of the product or material; and
g. The estimated concentration of the byproduct
material in the product or material at the time of transfer by the licensee;
and
(2) The applicant provides written statements in
the application that:
a. The concentrations of byproduct material at
the time of transfer will not exceed the concentration in He‑P 4093;
b. That reconcentration of the byproduct
material in concentrations exceeding those in He-P 4093 is not likely;
c. That use of lower concentrations is not
feasible; and material shall not be incorporated in any food, beverage,
cosmetic, drug, or other commodity or product designed for ingestion or
inhalation by, or application to, a human being.
(b) Each person licensed under He-P 4032.04 shall
file an annual report with DHHS/RHS.
(c) The annual report in (b) above shall:
(1) Identify:
a. The type and quantity of each product or
material into which radioactive material has been introduced during the
reporting period;
b. Name and address of the person who owned or
possessed the product or material into which byproduct material has been
introduced at the time of introduction;
c. The type and quantity of radionuclide
introduced into each such product or material; and
d. The initial concentrations of the
radionuclide in the product or material at the time of transfer of the
byproduct material by the licensee;
(2) Indicate if no transfers of byproduct
material have been made pursuant to He-P 4032.04 during the reporting period;
(3) Cover the year ending June 30; and
(4) Be filed within 30 days thereafter.
Source. (See Revision Note at part heading for He-P
4032) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4032.05 Manufacture, Preparation, or Distribution
of Radiopharmaceuticals Containing Byproduct Material for Medical Use.
(a) An application for a specific license to
manufacture, prepare, or distribute radiopharmaceuticals containing byproduct
material for use by persons licensed pursuant to He-P 4035 shall be approved
if:
(1) The applicant satisfies the requirements
specified in He-P 4030.09;
(2) The applicant submits evidence that the
applicant is at least one of the following:
a. Registered with the U.S. Food and Drug
Administration (FDA) as the owner or operator of a drug establishment that
engages in the manufacture, preparation, propagation, compounding, or
processing of a drug under 21 CFR 207.20(a);
b. Registered or licensed with a state or
federal agency as a drug manufacturer;
c. Licensed as a pharmacy by a state board of
pharmacy;
d. Operating as a pharmacy within a federal
medical institution; or
e. A Positron Emission Tomography (PET) drug
production facility licensed by a state or federal agency;
(3) The applicant submits the following
information:
a. The radionuclide;
b. The chemical and physical form;
c. The packaging including maximum activity per
vial, syringe, generator, or other container of the radioactive drug; and
d. The shielding provided by the packaging of
the byproduct material shall be appropriate for safe handling and storage of
radiopharmaceuticals by group licensees in accordance with He-P 4037.04; and
(4) The applicant satisfies the following
labeling requirements:
a. A label shall be affixed to each transport
radiation shield of a radioactive drug to be transferred for commercial
distribution;
b. The label shall include:
1. The radiation symbol and the words “CAUTION,
RADIOACTIVE MATERIAL” or “DANGER, RADIOACTIVE MATERIAL”;
2. The name of the radioactive drug or its
abbreviation; and
3. The quantity of radioactivity at a specified
date and time, except in the case of radioactive drugs with a half-life greater
than 100 days, for which the time may be omitted;
c. A label shall be affixed to each syringe,
vial, or other container used to hold a radioactive drug to be transferred for
commercial distribution;
d. The label required in He‑P4032.05(a)(4)c.
shall include:
1. The radiation symbol and the words “CAUTION,
RADIOACTIVE MATERIAL” or “DANGER, RADIOACTIVE MATERIAL”; and
2. An identifier that ensures that the syringe,
vial, or other container can be correlated with the information on the
transport radiation shield label; and
e. The labels, leaflets, or brochures required
by He‑P 4032.03(a)(4) shall be in addition to the labeling required by
the Food and Drug Administration (FDA), and shall be separate from or, if
approved by the FDA may be combined with, the labeling required by FDA.
(b) A licensee described by He-P 4032.05(a)(2)c.
or (a)(2)d.:
(1) Shall prepare radioactive drugs for medical
use, and shall ensure that the radioactive drug is prepared by an authorized
nuclear pharmacist, as specified in He-P 4032.05(b)(2) and (b)(3), or an
individual under the supervision of an authorized nuclear pharmacist, as specified
in He‑P 4035;
(2) Shall allow a pharmacist to work as an
authorized pharmacist only if:
a. This individual qualifies as an authorized
nuclear pharmacist as defined in He‑P 4035;
b. This individual
meets the requirements specified in He‑P 4035 and the licensee has
received an approved license amendment identifying this individual as an
authorized nuclear pharmacist; or
c. This individual
is designated as an authorized nuclear pharmacist in accordance with He-P
4032.05(b)(3);
(3) Shall name a pharmacist as defined in He-P
4003.01(df) as an authorized nuclear pharmacist as defined in He-P 4035.03(c),
only if:
a. The individual was a nuclear pharmacist
preparing only radioactive drugs containing accelerator-produced radioactive
material; and
b. The individual practiced at a pharmacy at a
government agency or federally recognized Indian Tribe before November 30, 2007
or at all other pharmacies before August 8, 2009, or an earlier date as noticed
by the NRC;
(4) Shall provide to DHHS/RHS:
a. A copy of each individual’s certification by
a specialty board whose certification process has been recognized by the
Nuclear Regulatory Commission or an agreement state as specified in He-P
4035.74(a) with the written attestation signed by a preceptor as required by
He-P 4035.74(b)(2); or
b. The Nuclear Regulatory Commission or
agreement state license or licensing state license; or
c. A Nuclear Regulatory Commission master
materials licensee permit; or
d. The permit issued by a licensee of broad
scope, or the authorization from a commercial nuclear pharmacy authorized to
list its own authorized nuclear pharmacist; or
e. Documentation that only accelerator-produced
radioactive materials were used in the practice of nuclear pharmacy at a
government agency or federally recognized Indian Tribe before November 30, 2007
or at all other locations of use before August 8, 2009, or an earlier date as
noticed by the Nuclear Regulatory Commission; or
f. A copy of the state pharmacy licensure or
registration, no later than 30 days after the date that the licensee allows
pursuant to He-P 4032.05(b)(2)a. and (b)(2)c., the individual to work as an
authorized nuclear pharmacist;
(c) The actions authorized in He-P 4032.05(b)(1)
and (b)(2) are permitted in spite of more restrictive language in license
conditions.
(d) A licensee authorized under He-P 4032.05
shall:
(1) Possess and use instrumentation to measure
the radioactivity of radioactive drugs;
(2) Have procedures for use of the
instrumentation;
(3) Measure, by direct measurement or by
combination of measurements and calculations, the amount of radioactivity in
dosages of alpha-, beta-, or photon-, emitting radioactive drugs prior to
transfer for commercial distribution; and
(4) Perform tests before initial use,
periodically, and following repair, on each measurement instrument for
accuracy, linearity, and geometry dependence, as appropriate for the use of the
instrument, and make adjustments when necessary; and
(5) Check each measurement instrument for
constancy and proper operation at the beginning of each day of use.
(e) Nothing in this section relieves the licensee
from complying with applicable FDA, other federal, and state requirements
governing radioactive drugs.
Source. (See Revision Note at part heading for He-P
4032) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4032.06 Manufacture and Distribution of Generators
or Reagent Kits for Preparation of Radiopharmaceuticals Containing Byproduct
Material.
(a) An application for a specific license to
manufacture and distribute generators or reagent kits containing byproduct
material or reagent kits not containing byproduct material used for preparation
of radiopharmaceuticals by persons licensed pursuant to He-P 4035 shall be
approved if:
(1) The applicant satisfies the general
requirements specified in He‑P 4030.09;
(2) The applicant submits evidence that:
a. The generator or reagent kit is to be
manufactured, labeled, and packaged in accordance with the Federal Food, Drug,
and Cosmetic Act or the Public Health Service Act, such as a new drug
application (NDA) approved by the Food and Drug Administration (FDA), a
biological product license issued by FDA, or a “Notice of Claimed
Investigational Exemption for a New Drug” (IND) that has been accepted by the
FDA; or
b. The manufacture and distribution of the
generator or reagent kit are not subject to the Federal Food, Drug, and
Cosmetic Act and the Public Health Service Act;
(3) The applicant submits the following
information:
a. The radionuclide;
b. The chemical and physical form;
c. The packaging including maximum activity per
package; and
d. The shielding provided by the packaging of
the byproduct material contained in the generator or reagent kit;
(4) The label affixed to the generator or reagent
kit contains information on the radionuclide, quantity, and date of assay; and
(5) The label affixed to the generator or reagent
kit, or the leaflet or brochure which accompanies the generator or reagent kit,
contains:
a. Radiation safety information on the
procedures to be followed and the equipment and shielding to be used in eluding
the generator or processing byproduct material with the reagent kit; and
b. A statement that this generator or reagent
kit is approved for use by persons licensed by the DHHS/RHS pursuant to He‑P
4035 or under equivalent licenses of the Nuclear Regulatory Commission, an
agreement state or licensing state.
(b) The labels, leaflets, or brochures required
by He‑P 4032.06(a)(4) and (a)(5) are in addition to the labeling required
by FDA and they may be separate from, or if approved by the FDA may be combined
with, the labeling required by FDA.
Source. (See Revision Note at part heading for He-P
4032) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4032.07 Manufacture and Distribution of Sources or
Devices Containing Byproduct Material for Medical Use.
(a) An application for a specific license to
manufacture and distribute sources and devices containing byproduct material to
persons licensed pursuant to He-P 4035 for use as a calibration, transmission,
or reference source, or sources for the uses in manual brachytherapy, or sealed
sources for diagnosis, or sealed source for the use in a remote afterloader
unit, teletherapy unit, or gamma stereotactic radiosurgery unit in accordance
with He-P 4035 shall be approved if:
(1) The applicant satisfies the general
requirements in He-P 4030.09;
(2) The applicant submits the following radiation
safety information for each type of source or device:
a. The byproduct material contained, its
chemical and physical form, and amount;
b. Details of design and construction of the
source or device;
c. Procedures for, and results of, prototype
tests to demonstrate that the source or device maintains its integrity under
stresses likely to be encountered in normal use and accidents;
d. For devices containing byproduct material,
the radiation profile of a prototype device;
e. Details of quality control procedures to
ensure that production sources and devices meet the standards of the design and
prototype tests;
f. Procedures and standards for calibrating
sources and devices;
g. Legend and methods for labeling sources and
devices for their radioactive content; and
h. Instruction for
handling and storing the source or device from the radiation safety standpoint,
as follows:
1. These instructions shall be included on a
durable label attached to the source or device or attached to a permanent
storage container for the source or device; or
2. If the instructions are too lengthy for such
label, they may be summarized on the label and printed in detail on a brochure
which is referenced on the label;
(3) The label affixed to the source or device, or
to the permanent storage container for the source or device, contains the
following information:
a. The radionuclide;
b. Quantity;
c. Date of assay; and
d. A statement that includes the name of source
or device which is licensed by DHHS/RHS for distribution to persons licensed
pursuant to He‑P 4035 or under equivalent licenses of the Nuclear
Regulatory Commission, an agreement state, or licensing state; and
(4) The source or device has been registered in
the Sealed Source and Device Registry.
(b) In the event the applicant desires that the
source or device be required to be tested for leakage of radioactive material
at intervals longer than 6 months:
(1) The application shall include sufficient
information to demonstrate that such longer interval is justified by
performance characteristics of the source or device or similar sources or
devices and by design features that have a significant bearing on the
probability or consequences of leakage of radioactive material from the source;
and
(2) In determining the acceptable interval for
test of leakage of radioactive material, DHHS/RHS will consider information
that includes, but is not limited to:
a. Primary containment (source capsule);
b. Protection of primary containment;
c. Method of sealing containment;
d. Containment construction materials;
e. Form of contained radioactive material;
f. Maximum temperature withstood during prototype
tests;
g. Maximum pressure withstood during prototype
tests;
h. Maximum quantity of contained radioactive
material;
i. Radiotoxicity of contained radioactive
material; and
j. Operating
experience with identical sources or devices or similarly designed and
constructed sources or devices.
Source. (See Revision Note at part heading for He-P
4032) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4032.08 Special Requirements for the Manufacture,
Assembly, Repair, or initially transfer of Luminous Safety Devices for Use in
Aircraft. An application for a specific
license to manufacture, assemble, or repair luminous safety devices containing
tritium or promethium-147 for use in aircraft, for distribution to persons
generally licensed under He-P 4031.04(h) shall be approved if:
(a) The applicant satisfies the general
requirements specified in He-P 4030.09; and
(b) The applicant satisfies the requirements of
10 CFR 32.53, 32.54, 32.55 and 32.56.
Source. (See Revision Note at part heading for He-P
4032) #6942, eff 2-1-99; ss by #8800, INITERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4032.09 Licensing the Distribution of Byproduct
Material in Exempt Quantities.
(a) An application for specific license to
distribute byproduct material other than source or byproduct material to
persons exempted from licensing pursuant to He‑P 4030.08 may be approved
if:
(1) The byproduct material is not contained in
any food, beverage, cosmetic, drug, or other commodity designed for ingestion
or inhalation by, or application to, a human being;
(2) The byproduct material is in the form of
processed chemical elements, compounds, or mixtures, tissue samples, bioassay
samples, counting standards, plated or encapsulated sources, or similar
substances, identified as radioactive and to be used for its radioactive
properties, but is not incorporated into any manufactured or assembled
commodity, product, or device intended for commercial distribution; and
(3) The applicant submits copies of prototype
labels and brochures and DHHS/RHS approves such labels and brochures.
(b) The license for exempt quantities issued
under He‑P 4032.09 shall be subject to the following conditions:
(1) No more than 10 exempt quantities as listed
in He-P 4092.01, which may be composed of fractional parts, shall be sold or
transferred in a single transaction, provided that the sum of the fractional
parts shall not exceed one;
(2) Each exempt quantity shall be separately and
individually packaged;
(3) No more than 10 packaged exempt quantities
shall be contained in any outer package for transfer to persons exempt pursuant
to He-P 4030.03;
(4) The outer package shall be such that the dose
rate at the external surface of the package does not exceed 0.5 millirem per
hour;
(5) The immediate container of each quantity or
separately packaged fractional quantity of radioactive material shall bear a
durable, legible label which:
a. Identifies the radionuclide and the quantity
of radioactivity; and
b. Bears the words “Radioactive Material”; and
(6) In addition to the labeling information
required by He‑P 4032.09, the label affixed to the immediate container,
or an accompanying brochure, shall:
a. State that the contents are exempt from
licensing state requirements;
b. Bear the words “Radioactive Material – Not
for Human Use – Introduction into Foods, Beverages, Cosmetics, Drugs, or
Medicinal, or into Products Manufactured for Commercial Distribution is
Prohibited – Exempt Quantities Should Not be Combined”; and
c. Set forth additional radiation safety
precautions and instructions relating to the handling, use, storage, and
disposal of the byproduct material.
(c) Each person licensed under He‑P 4032.09
shall maintain records identifying, by name and address, each person to whom
byproduct material is transferred for use under He‑P 4030.03 or the
equivalent regulations of the Nuclear Regulatory Commission or an agreement
state or licensing state, and the kinds and quantities of byproduct material
transferred.
(d) An annual summary report shall be filed with
DHHS/RHS, as follows:
(1) Each report shall state the total quantity of
each radionuclide transferred under the specific license;
(2) Each report shall cover the year ending June
30;
(3) Each report shall be filed within 30 days
after the end of the quarter; and
(4) If no
transfers of byproduct material have been made pursuant to this section during
the reporting period, the report shall so indicate.
Source. (See Revision Note at part heading for He-P
4032) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4032.10 Licensing the Incorporation of Byproduct
Material Other than Source or Byproduct Material into Gas and Aerosol Detectors.
(a) In addition to the requirements set forth in
He‑P 4030.09, an application for a specific license authorizing the
incorporation of byproduct material other than source or byproduct material
into gas and aerosol detectors to be distributed to persons exempt under He‑P
4030.03 shall only be approved if the application satisfies requirements
equivalent to those contained in 10 CFR 32.26.
(b) The maximum quantity of radium-226 in each
device shall not exceed 0.1 microcurie.
Source. (See Revision Note at part heading for He-P
4032) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4032.11 Special Requirements for License to
Manufacture, Import or Initially Distribute Sealed Sources or Devices
Containing Sealed Sources to Persons Having a Specific License.
(a) An application for a license to manufacture
or initially distribute sealed sources or devices containing sealed sources for
initial transfer to persons having a specific license to receive such sealed
sources or devices shall be approved subject to the following conditions:
(1) The applicant satisfies the general
requirements specified in He‑P 4030.09; and
(2) The licensee subject to He‑P 4032.11
shall not transfer a sealed source or device containing a sealed source to any
person except in accordance with the requirements of He‑P 4030.16.
(b) Any manufacturer or initial distributor of a
sealed source or device containing a sealed source whose product is intended
for use under a specific license may submit a request to DHHS/RHS for
evaluation of radiation safety information about its product and for its
registration, as follows:
(1) A request for evaluation of a sealed source
or device containing a sealed source shall be submitted in duplicate and shall
include information required by He‑P 4032.11(b)(2) or (b)(3), as
applicable, demonstrating that the radiation safety properties of such source
or device will not endanger public health and safety or property;
(2) A request for evaluation of a sealed source
shall include the following radiation safety information:
a. Proposed uses for the sealed source;
b. Chemical and physical form and maximum
quantity of byproduct material in the sealed source;
c. Details of design of the sealed source,
radiation and its shielding including blueprints, engineering drawings, or
annotated drawings;
d. Details of construction of the sealed source
including a description of materials used in construction;
e. Radiation profile of a prototype sealed
source;
f. Procedures for and results of prototype
testing;
g. Details of quality control procedures to be
followed in manufacture;
h. A description or facsimile of labeling to be
affixed to the sealed source;
i. Leak testing procedures; and
j. Any additional
information, including experimental studies and tests, required by DHHS/RHS to
facilitate a determination of the safety of the sealed source, as required by
He‑P 4030.09;
(3) A request for evaluation of a device
containing a sealed source shall include the following radiation safety
information:
a. Proposed uses for the device;
b. Manufacturer, model number, chemical and
physical form, and maximum quantity of radioactivity in the sealed source or
sources to be used in the device;
c. Details of design of the sealed source,
including blueprints, engineering drawings, or annotated drawings;
d. Details of construction of the sealed source,
including a description of materials used in construction;
e. Radiation profile of a prototype device;
f. Procedures for and results of prototype
testing;
g. Details of quality control procedures to be
followed in manufacture;
h. A description or facsimile of labeling to be
affixed to the device;
i. Leak testing procedures;
j. A description of potential hazards in
installation, service, manufacture, handling, use, and operation of the device;
k. Information about installation, service, and
maintenance procedures;
l. Handling, operating, and safety instructions;
and
m. Any additional
information, including experimental studies and tests, required by DHHS/RHS to
facilitate a determination of the safety of the device as required by He‑P
4030.09;
(4) The person submitting a request for
evaluation of a product shall manufacture and distribute the product in
accordance with:
a. The statements and representations, including
the quality control program, described in the request; and
b. The provisions of the evaluation sheet
prepared by DHHS/RHS and submitted to the U.S. Department of Health and Human
Services, for filing in the “Radioactive Material Reference Manual” or in the
U.S. Nuclear Regulatory Commission, for filing in the “Registry of Radioactive
Sealed Sources and Devices.” and
(5) The request for review shall be mailed to
DHHS/RHS office, “ATTN: SSDR”.
(c) DHHS/RHS shall apply the radiation safety
criteria described in 10 CFR 32.210(d).
(d) After completion of the evaluation, DHHS/RHS
shall issue a certificate of registration to the applicant described in 10 CFR
32.210(e).
(e) Authority to manufacture or initially
distribute a sealed source or device to specific licensees shall be provided in
the license without the issuance of a certificate of registration described in
10 CFR 32.210(g).
(f) After the certificate is issued, DHHS/RHS
shall conduct an additional review described in 10 CFR.32.210(h).
(g) When inactivating certificates of
registration of sealed sources and devices, DHHS/RHS shall apply the
inactivation criteria described in 10 CFR 32.211.
Source. (See Revision Note at part heading for He-P
4032) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4032.12 Prohibition. No person shall introduce byproduct material
into a product or material knowing or having reason to believe that it will be
transferred to persons exempt under He‑P4030.03 or equivalent regulations
of an Agreement State, the Nuclear Regulatory Commission or Licensing State,
except in accordance with a license issued pursuant to He‑P 4032.04 or
the general license provided in He‑P 4030.18.
Source. (See Revision Note at part heading for He-P
4032) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4032.13 Serialization of Nationally Tracked
Sources.
(a) Each licensee who manufactures a nationally
tracked source after February 6, 2007 shall assign a unique serial number to
each nationally tracked Source. Serial numbers shall be composed only of
alpha-numeric characters.
Source. #10983, eff 11-24-15
He-P 4032.14 Special Requirements for License to
Manufacture or Initially Transfer Calibration Sources Containing Americium-241
or Radium-226 for Distribution to Persons Generally Licensed Under He-P
4031.04(r).
(a) An application for a specific license to
manufacture or initially transfer calibration or reference sources containing
americium-241 or radium-226 for distribution to persons generally licensed
under He-P 4031.04(r), shall be approved if:
(1) The applicant satisfies the general
requirements of He-P 4030.09;
(2) The applicant submits sufficient information
regarding each type of calibration or reference source pertinent to evaluation
of the potential radiation exposure, including:
a. Chemical and
physical form and maximum quantity of americium-241 or radium-226 in the
source;
b. Details of construction and design;
c. Details of the method of incorporation and binding
of the americium-241 or radium-226 in the source;
d. Procedures for and results of prototype
testing of sources, which are designed to contain more than 185 becquerel
(0.005 microcurie) of americium-241 or radium-226, to demonstrate that the
americium-241 or radium-226 contained in each source will not be released or be
removed from the source under normal conditions of use;
e. Details of quality control procedures to be
followed in manufacture of the source;
f. Description of labeling to be affixed to the
source or the storage container for the source; and
g. Any additional information, including
experimental studies and tests, required by DHHS/RHS to facilitate a
determination of the safety of the source;
(3) Each source will contain no more than 185
kilobecquerel (5 microcurie) of americium-241 or radium-226; and
(4) DHHS/RHS determines, with respect to any type
of source containing more than 185 becquerel (0.005 microcurie) of
americium-241 or radium-226, that:
a. The method of incorporation and binding of
the americium-241 or radium-226 in the source is such that the americium-241 or
radium-226 will not be released or be removed from the source under normal
conditions of use and handling of the source; and
b. The source has
been subjected to and has satisfactorily passed the appropriate tests
prescribed by He-P 4032.14(d).
(b) Each person licensed under He-P 4032.14 shall
affix to each source, or storage container for the source, a label which shall
contain sufficient information relative to safe use and storage of the source
and shall include the following statement or information:
“The receipt,
possession, use and transfer of this source, Model __, Serial No. __, are
subject to a general license and the regulations of the DHHS/RHS, the NRC, an
Agreement State, or a Licensing State.
Do not remove this label.
CAUTION--RADIOACTIVE MATERIAL-- THIS SOURCE CONTAINS (AMERICIUM-241) OR
(RADIUM-226). DO NOT TOUCH RADIOACTIVE
PORTION OF THIS SOURCE (Name of Manufacturer or Transferor).”
(c) Each person licensed under He-P 4032.14 shall
perform a dry wipe test upon each source containing more than 3.7 kilobecquerel
(0.1 microcurie) of americium-241 or radium-226 before transferring the source
to a general licensee under He-P 4031.04(r).
This test shall be performed by wiping the entire radioactive surface of
the source with a filter paper with the application of moderate finger
pressure. The radioactivity on the paper
shall be measured using methods capable of detecting 185 becquerel (0.005 microcurie)
of americium-241 or radium-226. If a
source has been shown to be leaking or losing more than 185 becquerel (0.005
microcurie) of americium-241 or radium-226 by the methods described in He-P
4032(c), the source shall be rejected and shall not be transferred to a general
license under He-P 4031.04(r), or equivalent regulations of the NRC, an
agreement state or a licensing state.
(d) The applicant shall subject at least five
prototypes of each source that is designed to contain more than 0.185
kilobecquerel (0.005 microcurie) of americium-241 or radium-226 to tests as
follows:
(1) The initial quantity of radioactive material
deposited on each source is measured by direct counting of the source;
(2) The sources are subjected to tests that
adequately take into account the individual, aggregate, and cumulative effects
of environmental conditions expected in service that could adversely affect the
effective containment or binding of americium-241 or radium-226, such as
physical handling, moisture, and water immersion;
(3) The sources are inspected for evidence of
physical damage and for loss of americium-241 or radium-226, after each stage
of testing, using methods of inspection adequate for determining compliance
with the criteria in He-P 4032.14(d)(4); and
(4) Source designs are rejected for which the
following has been detected for any unit:
Removal of more than 0.185 kilobecquerel (0.005 microcurie) of
americium-241 or radium-226 from the source or any other evidence of physical
damage.
Source. #10983, eff 11-24-15
He-P 4032.15 Manufacture and Distribution of Byproduct
Material for Certain In Vitro Clinical or Laboratory Testing Under General
License. An application for a
specific license to manufacture or distribute byproduct material for use under
the general license of He-P 4031.06 shall be approved if:
(a) The applicant satisfies the general
requirements specified in He-P 4030.09;
(b) The radioactive material is to be prepared
for distribution in prepackaged units of:
(1) Carbon-14 in units not exceeding 370
kilobecquerel (10 microcurie) each;
(2) Cobalt-57 in units not exceeding 370
kilobecquerel (10 microcurie) each;
(3) Hydrogen-3 (tritium) in units not exceeding
1.85 megabecquerel (50 microcurie) each;
(4) Iodine-125 in units not exceeding 370
kilobecquerel (10 microcurie) each;
(5) Mock Iodine-125 in units not exceeding 1.85
kilobecquerel (0.05 microcurie) of iodine-129 and 185 becquerel (0.005
microcurie) of americium-241 each;
(6) Iodine-131 in units not exceeding 370 kilobecquerel
(10 microcurie) each;
(7) Iron-59 in units not exceeding 740
kilobecquerel (20 microcurie) each; and
(8) Selenium-75 in units not exceeding 370
kilobecquerel (10 microcurie) each.
(c) Each prepackaged unit bears a durable,
clearly visible label:
(1) Identifying the radioactive contents as to
chemical form and radionuclide, and indicating that the amount of radioactivity
does not exceed 370 kilobecquerel (10 microcurie) of iodine-125, iodine-131,
carbon-14, cobalt-57, or selenium-75; 1.85 megabecquerel (50 microcurie) of
hydrogen-3 (tritium); 740 kilobecquerel (20 microcurie) of iron-59; or Mock
Iodine-125 in units not exceeding 1.85 kilobecquerel (0.05 microcurie) of
iodine-129 and 185 becquerel (0.005 microcurie) of americium-241 each; and
(2) Displaying the radiation caution symbol
described in He-P 4022.11(c). and the words, "CAUTION, RADIOACTIVE
MATERIAL", and "Not for Internal or External Use in Humans or
Animals".
(d) The following statement or information shall
appear on a label affixed to each prepackaged unit or appears in a leaflet or
brochure which accompanies the package:
“This radioactive material may
be received, acquired, possessed, and used only by physicians, veterinarians,
clinical laboratories, or hospitals and only for in vitro clinical or
laboratory tests not involving internal or external administration of the
material, or the radiation therefrom, to human beings or animals. Its receipt,
acquisition, possession, use, and transfer are subject to the regulations and a
general license of the DHHS/RHS or the NRC or of a state with which the NRC has
entered into an agreement for the exercise of regulatory authority. (Name of
Manufacturer).”
(e) The label affixed to the unit, or the leaflet
or brochure which accompanies the package, contains adequate information as to
the precautions to be observed in handling and storing such byproduct material. In the case of the Mock Iodine-125 reference
or calibration source, the information accompanying the source shall also
contain directions to the licensee regarding the waste disposal requirements
set out in He-P 4023.01 of these rules.
Source. #10983, eff 11-24-15
He-P 4032.16 Ice
Detection Devices Containing Strontium-90; Requirements for License to
Manufacture or Initially Transfer.
An application for a specific license to manufacture or initially
transfer ice detection devices containing strontium-90 for distribution to
persons generally licensed under the Nuclear Regulatory Commission 10 CFR 31.10
shall be approved if:
(a) The applicant satisfies the general
requirements specified in He-P 4030.09; and
(b) The applicant satisfies the requirements of
10 CFR 32.61 and 32.62.
Source. #10983, eff 11-24-15
PART He-P
4033 SPECIFIC LICENSES OF BROAD SCOPE
FOR OTHER THAN HUMAN USE
Revision Note:
Doc. #6942,
effective 2-1-99, repealed Parts He-P 2030, 2031, 2032, 2033, 2034, 2035, 2042
and 2093 relative to Radiation and Radioactive Material and adopted new rules
to replace them and renumbered them as He-P 4030, 4031, 4032, 4033, 4034, 4035,
4093 and 4096.
He-P 4033.01 Purpose. This part shall prescribe requirements for
the issuance of specific licenses of broad scope for byproduct material and
certain regulations governing holders of such licenses.
Source. (See Revision Note at part heading for He-P
4033) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4033.02 Scope.
The provisions and requirements of this part shall be in addition to,
and not in substitution for, other requirements of this chapter. In particular, the provisions of He-P 4030
and He-P 4038 apply to applications and licenses subject to this part.
Source. (See Revision Note at part heading for He-P
4033) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4033.03 Types of Specific Licenses of Broad Scope.
(a) Type A specific license of broad scope shall
be a specific license authorizing receipt, acquisition, ownership, possession,
use, and transfer of any chemical or physical form of a quantity of byproduct
material usually in the multi-curie range specified in the license, but not
exceeding quantities specified in the license, for any authorized purpose.
(b) A Type B specific license of broad scope
shall be:
(1) A specific license which allows any chemical
or physical form of byproduct material specified in He‑P 4033.07, Table 4033.1,
for any authorized purpose;
(2) A specific license whereby the possession
limit, if only one radionuclide is possessed thereunder, shall be the quantity
specified for that radionuclide in He‑P 4033.07, Table 4033.1, Column 1;
or
(3) A specific license whereby if 2 or more
radionuclides are possessed thereunder, the possession limit for each shall be
determined as follows:
a. For each radionuclide, determine the ratio of
the quantity possessed to the applicable quantity specified in He‑P
4033.07, Table 4033.1, Column 1, for that radionuclide; and
b. The sum of the ratios for all radionuclides
possessed under the license shall not exceed unity.
(c) A Type C specific license of broad scope
shall be:
(1) A specific license authorizing receipt,
acquisition, ownership, possession, use, and transfer of any chemical or
physical form of byproduct material specified in He P 4033.07, Table 4033.1,
for any authorized purpose;
(2) A specific license whereby the possession
limit, if only one radionuclide, is possessed thereunder, shall be the quantity
specified for that radionuclide in He‑P 4033.07, Table 4033.1, Column 2;
or
(3) A specific license whereby if two or more
radionuclides are possessed thereunder, the possession limit shall be determined
for each as follows:
a. For each radionuclide, determine the ratio of
the quantity possessed to the applicable quantity specified in He‑P
4033.07, Table 4033.1, Column 2, for that radionuclide; and
b. The sum of the ratios for all radionuclides
possessed under the license shall not exceed unity.
Source. (See Revision Note at part heading for He-P
4033) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4033.04 Application for Specific Licenses of Broad
Scope. An application for specific
license of broad scope shall be made according to the requirements set forth in
He-P 4033.05.
Source. (See Revision Note at part heading for He-P
4033) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4033.05 Requirements for the Issuance of Specific
Licenses of Broad Scope.
(a) An application for a Type A specific license
of broad scope shall be approved if:
(1) The applicant satisfies the requirements
specified in He-P 4030.09;
(2) The applicant has engaged in a reasonable
number of activities involving the use of byproduct material; and
(3) The applicant has established administrative
controls and provisions relating to organization and management, procedures,
record keeping, material control and accounting, and management review that are
necessary to ensure safe operations, including:
a. The establishment of a radiation safety
committee composed of a radiological safety officer, a representative of
management, and persons trained and experienced in the safe use of radioactive
material;
b. The appointment of a radiological safety
officer who is qualified by training and experience in radiation protection,
and who is available for advice and assistance on radiological safety matters;
and
c. The establishment of appropriate
administrative procedures to ensure:
1. Control of procurement and use of byproduct
material;
2. Completion of safety evaluations of proposed
uses of radioactive material which take into consideration such matters as the
adequacy of facilities and equipment, training and experience of the user, and
the operating or handling procedures; and
3. Review, approval, and recording by the
radiation safety committee of safety evaluations of proposed uses prepared in
accordance with He-P 4033.05(a)(3)c.2. prior to use of the byproduct material.
(b) An application for a Type B specific license
of broad scope shall be approved if:
(1) The applicant satisfies the general
requirements specified in He‑P 4030.09; and
(2) The applicant has established administrative
controls and provisions relating to organization and management, procedures,
record keeping, material control and accounting, and management review that are
necessary to ensure safe operations, including:
a. The appointment of a radiological safety
officer who is qualified by training and experience in radiation protection,
who is available for advice and assistance on radiological safety matters; and
b. The establishment of appropriate
administrative procedures to ensure:
1. Control of procurement and use of byproduct
material;
2. Completion of safety evaluations of proposed
uses of byproduct material which take into consideration such matters as the
adequacy of facilities and equipment, training and experience of the user and
the operating or handling procedures; and
3. Review, approval, and recording by the
radiological safety officer of safety evaluations of proposed uses prepared in
accordance with He‑P 4033.05(b)(2)b.2., prior to use of the byproduct
material.
(c) An application for a Type C specific license
of broad scope may be approved if:
(1) The applicant satisfies the requirements
specified in He‑P 4030.09;
(2) The applicant submits a statement that
byproduct material shall be used only by, or under the direct supervision of,
individuals who have received:
a. A college degree at the bachelor level, or
equivalent training and experience, in the physical or biological sciences or
in engineering; and
b. At least 40 hours of training and experience
in the safe handling of radioactive materials, and in the characteristics of
ionizing radiation, units of radiation doses and quantities, radiation
detection instrumentation, and biological hazards of exposure to radiation
appropriate to the type and forms of radioactive material to be used; and
(3) The applicant has established administrative
controls and provisions relating to procurement of byproduct material,
procedures, record keeping, material control, and accounting and management
review necessary to ensure safety operations.
Source. (See Revision Note at part heading for He-P
4033) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4033.06 Conditions of Specific Licenses of Broad
Scope.
(a) Unless specifically authorized pursuant to
other sections of He‑P 4033, persons licensed under this section shall
not:
(1) Conduct tracer studies outside of the
licensee’s controlled area of byproduct
material;
(2) Receive, acquire, own, possess, use,
transfer, or import devices containing 100,000 curies or more of byproduct
material in sealed sources to be used for irradiation of materials;
(3) Conduct activities for which a specific
license issued by the DHHS/RHS is required; or
(4) Add or cause the addition of byproduct
material to any food, beverage, cosmetic, drug, or other product designed for
ingestion or inhalation by, or application to, a human being.
(b) Each Type A specific license of broad scope
issued by the DHHS/RHS shall be subject to the condition that byproduct
material possessed under the license shall be used only by, or under the direct
supervision of, individuals approved by the licensee’s radiation safety
committee.
(c) Each Type B specific license of broad scope
issued by the DHHS/RHS shall be subject to the condition that byproduct
material possessed under the license shall be used only by, or under the direct
supervision of, individuals approved by the licensee’s radiological safety
officer.
(d) Each Type C specific license of broad scope
issued by the DHHS/RHS shall be subject to the condition that byproduct
material possessed under the license shall be used only by, or under the direct
supervision of, individuals who satisfy the requirements of He‑P
4033.05(c).
Source. (See Revision Note at part heading for He-P
4033) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4033.07 License Quantities for License of Broad
Scope. License quantities for
licenses of broad scope shall be as described in Table 4033.1.
Table 4033.1 Quantities of Byproduct Material for Licenses
of Broad Scope
Byproduct
Material |
Column 1 (curies) |
Column 2 (curies) |
Antimony-122 |
1.0 |
0.01 |
Antimony-124 |
1.0 |
0.01 |
Antimony-125 |
1.0 |
0.01 |
Arsenic-73 |
10.0 |
0.1 |
Arsenic-74 |
1.0 |
0.01 |
Arsenic-76 |
1.0 |
0.01 |
Arsenic-77 |
10.0 |
0.1 |
Barium-131 |
10.0 |
0.1 |
Barium-140 |
1.0 |
0.01 |
Beryllium-7 |
10.0 |
0.1 |
Bismuth-210 |
0.1 |
0.001 |
Bromine-82 |
10.0 |
0.1 |
Cadmium-109 |
1.0 |
0.01 |
Cadmium-115m |
1.0 |
0.01 |
Cadmium-115 |
10.0 |
0.1 |
Calcium-45 |
1.0 |
0.01 |
Calcium-47 |
10.0 |
0.1 |
Carbon-14 |
100.0 |
1.0 |
Cerium-141 |
10.0 |
0.1 |
Cerium-143 |
10.0 |
0.1 |
Cerium-144 |
0.1 |
0.001 |
Cesium-131 |
100.0 |
1.0 |
Cesium-134m |
100.0 |
1.0 |
Cesium 134 |
0.1 |
0.001 |
Cesium-135 |
1.0 |
0.01 |
Cesium-136 |
10.0 |
0.1 |
Cesium-137 |
0.1 |
0.001 |
Chlorine-36 |
1.0 |
0.01 |
Chlorine-38 |
100.0 |
1.0 |
Chromium-51 |
100.0 |
1.0 |
Cobalt-57 |
10.0 |
0.1 |
Cobalt-58m |
100.0 |
1.0 |
Cobalt-58 |
1.0 |
0.01 |
Cobalt-60 |
0.1 |
0.001 |
Copper-64 |
10.0 |
0.1 |
Dysprosium-165 |
100.0 |
1.0 |
Dysprosium-166 |
10.0 |
0.1 |
Erbium-169 |
10.0 |
0.1 |
Erbium-171 |
10.0 |
0.1 |
Europium-152
(9.2 h) |
10.0 |
0.1 |
Europium-152 (13
y) |
0.1 |
0.001 |
Europium-154 |
0.1 |
0.001 |
Europium-155 |
1.0 |
0.01 |
Fluorine-18 |
100.0 |
1.0 |
Gadolinium-153 |
1.0 |
0.01 |
Gadolinium-159 |
10.0 |
0.1 |
Gallium-72 |
10.0 |
0.1 |
Germanium-71 |
100.0 |
1.0 |
Gold-198 |
10.0 |
0.1 |
Gold-199 |
10.0 |
0.1 |
Hafnium-181 |
1.0 |
0.01 |
Holmium-166 |
10.0 |
0.1 |
Hydrogen-3 |
100.0 |
1.0 |
Indium-113m |
100.0 |
1.0 |
Indium-114m |
1.0 |
0.01 |
Indium-115m |
100.0 |
1.0 |
Indium-115 |
1.0 |
0.01 |
Iodine-125 |
0.1 |
0.001 |
Iodine-126 |
0.1 |
0.001 |
Iodine-129 |
0.1 |
0.01 |
Iodine-131 |
0.1 |
0.001 |
Iodine-132 |
10.0 |
0.1 |
Iodine-133 |
1.0 |
0.01 |
Iodine-134 |
10.0 |
0.1 |
Iodine-135 |
1.0 |
0.01 |
Iridium-192 |
1.0 |
0.01 |
Iridium-194 |
10.0 |
0.1 |
Iron-55 |
10.0 |
0.1 |
Iron-59 |
1.0 |
0.01 |
Krypton-85 |
100.0 |
1.0 |
Krypton-87 |
10.0 |
0.1 |
Lanthanum-140 |
1.0 |
0.01 |
Lutetium-177 |
10.0 |
0.1 |
Manganese-52 |
1.0 |
0.01 |
Manganese-54 |
1.0 |
0.01 |
Manganese-56 |
10.0 |
0.1 |
Mercury-197m |
10.0 |
0.1 |
Mercury-197 |
10.0 |
0.1 |
Mercury-203 |
1.0 |
0.01 |
Molybdenum-99 |
10.0 |
0.1 |
Neodymium-147 |
10.0 |
0.1 |
Neodymium-149 |
10.0 |
0.1 |
Nickel-59 |
10.0 |
0.1 |
Nickel-63 |
1.0 |
0.01 |
Nickel-65 |
10.0 |
0.1 |
Niobium-93m |
1.0 |
0.01 |
Niobium-95 |
1.0 |
0.01 |
Niobium-97 |
100.0 |
1.0 |
Osmium-185 |
1.0 |
0.01 |
Osmium-191m |
100.0 |
1.0 |
Osmium-191 |
10.0 |
0.1 |
Osmium-193 |
10.0 |
0.1 |
Palladium-103 |
10.0 |
0.1 |
Palladium-109 |
10.0 |
0.1 |
Phosphorus-32 |
1.0 |
0.01 |
Phosphorus-33 |
10.0 |
0.1 |
Platinum-191 |
10.0 |
0.1 |
Platinum-193m |
100.0 |
1.0 |
Platinum-193 |
10.0 |
0.1 |
Platinum-197m |
100.0 |
1.0 |
Platinum-197 |
10.0 |
0.1 |
Polonium-210 |
0.01 |
0.0001 |
Potassium-42 |
1.0 |
0.01 |
Praseodymium-142 |
10.0 |
0.1 |
Praseodymium-143 |
10.0 |
0.1 |
Promethium-147 |
1.0 |
0.01 |
Promethium-149 |
10.0 |
0.1 |
Radium-226 |
0.01 |
0.0001 |
Rhenium-186 |
10.0 |
0.1 |
Rhenium-188 |
10.0 |
0.1 |
Rhodium-103m |
1,000.0 |
10.0 |
Rhodium-105 |
10.0 |
0.1 |
Rubidium-86 |
1.0 |
0.01 |
Rubidium-87 |
1.0 |
0.01 |
Ruthenium-97 |
100.0 |
1.0 |
Ruthenium-103 |
1.0 |
0.01 |
Ruthenium-105 |
10.0 |
0.1 |
Ruthenium-106 |
0.1 |
0.001 |
Samarium-151 |
1.0 |
0.01 |
Samarium-153 |
10.0 |
0.1 |
Scandium-46 |
1.0 |
0.01 |
Scandium-47 |
10.0 |
0.1 |
Scandium-48 |
1.0 |
0.01 |
Selenium-75 |
1.0 |
0.01 |
Silicon-31 |
10.0 |
0.1 |
Silver-105 |
1.0 |
0.01 |
Silver-110m |
0.1 |
0.001 |
Silver-111 |
10.0 |
0.1 |
Sodium-22 |
0.1 |
0.001 |
Sodium-24 |
1.0 |
0.01 |
Strontium-85m |
1,000.0 |
10.0 |
Strontium-85 |
1.0 |
0.01 |
Strontium-89 |
1.0 |
0.01 |
Strontium-90 |
0.01 |
0.0001 |
Strontium-91 |
10.0 |
0.1 |
Strontium-92 |
10.0 |
0.1 |
Sulphur-35 |
10.0 |
0.1 |
Tantalum-182 |
1.0 |
0.01 |
Technetium-96 |
10.0 |
0.1 |
Technetium-97m |
10.0 |
0.1 |
Technetium-97 |
10.0 |
0.1 |
Technetium-99m |
100.0 |
1.0 |
Technetium-99 |
1.0 |
0.01 |
Tellurium-125m |
1.0 |
0.01 |
Tellurium-127m |
1.0 |
0.01 |
Tellurium-127 |
10.0 |
0.1 |
Tellurium-129m |
1.0 |
0.01 |
Tellurium-129 |
100.0 |
1.0 |
Tellurium-131m |
10.0 |
0.1 |
Tellurium-132 |
1.0 |
0.01 |
Terbium-160 |
1.0 |
0.01 |
Thallium-200 |
10.0 |
0.1 |
Thallium-201 |
10.0 |
0.1 |
Thallium-202 |
10.0 |
0.1 |
Thallium-204 |
1.0 |
0.01 |
Thulium-170 |
1.0 |
0.01 |
Thulium-171 |
1.0 |
0.01 |
Tin-113 |
1.0 |
0.01 |
Tin-125 |
1.0 |
0.01 |
Tungsten-181 |
1.0 |
0.01 |
Tungsten-185 |
1.0 |
0.01 |
Tungsten-187 |
10.0 |
0.1 |
Vanadium-48 |
1.0 |
0.01 |
Xenon-131m |
1,000.0 |
10.0 |
Xenon-133 |
100.0 |
1.0 |
Xenon-135 |
100.0 |
1.0 |
Ytterbium-175 |
10.0 |
0.1 |
Yttrium-90 |
1.0 |
0.01 |
Yttrium-91 |
1.0 |
0.01 |
Yttrium-92 |
10.0 |
0.1 |
Yttrium-93 |
1.0 |
0.01 |
Zinc-65 |
1.0 |
0.01 |
Zinc-69m |
10.0 |
0.1 |
Zinc-69 |
100.0 |
1.0 |
Zirconium-93 |
1.0 |
0.01 |
Zirconium-95 |
1.0 |
0.01 |
Zirconium-97 |
1.0 |
0.01 |
Any Byproduct
material other than alpha
emitting material not
listed above. |
0.1 |
0.001 |
Source. (See Revision Note at part heading for He-P
4033) #6942, eff 2-1-99; ss by #8800, INTERIM eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
PART He-P 4034 RADIATION SAFETY
REQUIREMENTS FOR INDUSTRIAL RADIOGRAPHIC OPERATIONS
Revision Note:
Doc. #6942,
effective 2-1-99, repealed Parts He-P 2030, 2031, 2032, 2033, 2034, 2035, 2042
and 2093 relative to Radiation and Radioactive Material and adopted new rules
to replace them and renumbered them as He-P 4030, 4031, 4032, 4033, 4034, 4035,
4093 and 4096.
He-P 4034.01 Purpose. This part prescribes requirements for the
issuance of licenses or registration for the industrial use of sources of radiation
and radiation safety requirements for persons using these sources of radiation
in industrial radiography.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. # 8959, eff 8-7-07; ss by #10983, eff
11-24-15
He-P 4034.02 Scope.
The provision and requirements of this part are in addition to, and not
in substitution for, other requirements of these regulations and cover both
radiation machines and sealed sources containing byproduct material but do not
apply to medical uses of byproduct material.
In particular, the requirements and provisions of He-P 4038 apply to
applications and license subject to this part.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. # 8959, eff 8-7-07; ss by #10983, eff
11-24-15; ss by #12930, eff 11-26-19
He-P 4034.03 Definitions. The following definitions shall apply to this
part:
(a)
“ALARA” (acronym for "as low as is reasonably achievable") means
making every reasonable effort to maintain exposures to radiation as far below
the dose limits specified in He-P 4020 as is practical consistent with the
purpose for which the licensed activity is undertaken, taking into account the
state of technology, the economics of improvements in relation to state of
technology, the economics of improvements in relation to benefits to the public
health and safety, and other societal and socioeconomic considerations, and in
relation to utilization of nuclear energy and licensed materials in the public
interest;
(b)
“Annual refresher safety training” means a review conducted or provided
by the licensee or registrant for its employees on radiation safety aspects of
industrial radiography. The review may include, as appropriate, the
results of internal inspections, new procedures or equipment, new or revised
regulations, accidents or errors that have been observed, and should also
provide opportunities for employees to ask safety questions;
(c) “Associated equipment” means
equipment that is used in conjunction with a radiographic exposure device to
make radiographic exposures that drives, guides, or otherwise comes in contact
with the source, (e.g., guide tube, control tube, control (drive) cable,
removable source stop, “J” tube and collimator when it is used as an exposure
head);
(d) “Cabinet radiography” means
industrial radiography conducted in an enclosure or cabinet so shielded that
every location on the exterior meets the dose limits for the individual member
of the public as specified in He‑P
4020;
(e)
“Cabinet x-ray system” means an x-ray system with the x-ray tube
installed in an enclosure independent of existing architectural structures
except the floor and is intended to contain at least that portion of a material
being irradiated, provide radiation attenuation, and exclude personnel from its
interior during generation of radiation.
The term includes “cabinet” and x-ray systems designed primarily for the
inspection of carry-on baggage at airline, railroad, and bus terminals and in
similar facilities. An x-ray tube used
within a shielded part of a building, or x-ray equipment that might temporarily
or occasionally incorporate portable shielding, is not a cabinet x-ray system;
(f) “Certifiable cabinet x-ray system”
means an existing uncertified x-ray system that has been modified to meet the
certification requirements specified in 21 CFR 1010.2;
(g)
“Certified cabinet x-ray system” means an x-ray system that has been
certified in accordance with 21 CFR 1010.2 as being manufactured and assembled
pursuant to the provisions of 21 CFR 1020.40;
(h)
“Certifying entity” means an independent certifying organization meeting
the requirements in He‑P 4034 Appendix A, Parts II and III, or the
equivalent requirements of an Agreement State or in Nuclear Regulatory
Commission 10 CFR 34 appendix A;
(i)
“Collimator” means a radiation shield that is placed on the end of the
guide tube or directly onto a radiographic exposure device to restrict the size
of the radiation beam when the sealed source is cranked into position to make a
radiographic exposure;
(j)
“Control cable” means the cable that is connected to the source assembly
and used to drive the source to and from the exposure location. The term includes “drive cable”;
(k)
“Control drive mechanism” means
a device that enables the source assembly to be moved into and out of the
exposure device;
(l) “Control tube” means a protective
sheath which connects the control drive mechanism to the radiographic exposure
device for guiding the control cable;
(m) “Exposure head” means a device
that locates the gamma radiography sealed source in the selected working
position. The term includes “source stop”;
(n)
“Field station” means a facility from which sources of radiation may be
stored or used and from which equipment is dispatched;
(o)
“Guide tube” means a flexible or rigid, “J” tube, for guiding the source
assembly and the attached control cable from the exposure device to the
exposure head which may also include the connections necessary for attachment
to the exposure device and to the exposure head. The term includes “projection sheath”;
(p)
“Hands-on experience” means experience in all of those areas considered
to be directly involved in the radiography process, and includes taking
radiographs, calibration of survey instruments, operational and performance
testing of survey instruments and devices, film development, posting of
radiation areas, transportation of radiography equipment, posting of records,
and radiation area surveillance;
(q) “Independent certifying
organization” means an independent organization that meets all of the criteria
of He-P 4034 Appendix A;
(r) “Industrial radiography” means an
examination of the structure of materials by nondestructive methods, utilizing
ionizing radiation to make radiographic images;
(s)
“Lay-barge radiography” means industrial radiography performed on any
water vessel used for laying pipe;
(t)
“Offshore platform radiography” means industrial radiography conducted
from a platform over a body of water;
(u) “Permanent radiographic
installation” means an enclosed shielded room, cell, or vault, not located at a
temporary job site, in which radiography is performed;
(v) “Practical examination” means a
demonstration through application of the safety rules and principles in
industrial radiography including use of all appropriate procedures and
equipment to be used by radiographic personnel;
(w)
“Radiation safety officer for industrial radiography” means an
individual with the responsibility for the overall radiation safety program on
behalf of the licensee or registrant and who meets the requirements of He-P
4034.16;
(x)
“Radiographer” means any individual who performs or who, in attendance
at the site where the sealed sources or sources of radiation are being used,
personally supervises industrial radiographic operations and who is responsible
to the licensee or registrant for assuring compliance with the requirements of
DHHS/RHS rules and the conditions of the license or the registration;
(y)
“Radiographer certification” means written approval received from a
certifying entity stating that an individual has satisfactorily met certain
established radiation safety, testing, and experience criteria;
(z) “Radiographer’s assistant” means any
individual who under the direct supervision of a radiographer, uses
radiographic exposure devices, sealed sources or related handling tools, or
radiation survey instruments in industrial radiography;
(aa)
“Radiographic exposure device” means any instrument containing a sealed
source fastened or contained therein, in which the sealed source or shielding
thereof may be moved, or otherwise changed, from a shielded to unshielded
position for purposes of making a radiographic exposure. The term includes
“camera” or “projector”;
(ab)
“Radiographic operations” means all activities associated with the
presence of radioactive source in a
radiographic exposure device or with a radiation machine to include use,
transport (except when being transported by a common or contract transport)
performing surveys to confirm the adequacy of boundaries, setting up equipment,
and any activity inside restricted area boundaries;
(ac)
“S-tube” means a tube through which the radioactive source travels when
inside a radiographic exposure device;
(ad) “Shielded position” means the
location within the radiographic exposure device or source changer where the
sealed source is secured and restricted from movement;
(ae)
“Source assembly” means an assembly that consists of the sealed source
and a connector that attaches the source to the control cable and may include a
stop ball used to secure the source in the shielded position;
(af) “Source changer” means a device
designed and used for replacement of sealed sources in radiographic exposure
devices which may also be used for transporting and storing sealed sources;
(ag)
“Storage area” means any location, facility, or vehicle which is used to
store or to secure a radiographic exposure device, a storage container, a
sealed source, or a radiation machine when it is not in use and which is locked
or has a physical barrier to prevent accidental exposure, tampering with, or
unauthorized removal of the device, container, source, or radiation machine;
(ah) “Storage container” means a
container in which sealed sources are secured and stored;
(ai)
“Temporary jobsite” means a location where radiographic operations are
conducted and where licensed material may be stored other than those
location(s) of use authorized on the license; and
(aj) “Underwater radiography” means
industrial radiography performed when the radiographic exposure device and/or
related equipment are beneath the surface of the water.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12626, eff 9-26-18; amd by #12930, eff 11-26-19
He-P 4034.04 Exemptions.
(a)
Certified and certifiable cabinet x-ray systems, including those
designed to allow admittance of individuals, shall be exempt from the
requirements of this part except that:
(1) No registrant shall permit any individual to
operate a cabinet x-ray system until the individual has received a copy of, and
instruction in the operating procedures for the unit;
(2) Tests for
proper operation of interlocks shall be conducted and recorded at intervals not
to exceed 6 months;
(3) The registrant shall perform an evaluation to
determine compliance with He‑P 4020.13(a) through (f), and 21 CFR
1020.40, at intervals not to exceed one year; and
(4) Records of the evaluation required in (a)(1) –
(a)(3) above shall be maintained for DHHS/RHS inspection until disposal is
authorized by DHHS/RHS.
(b)
Certified and certifiable cabinet x-ray systems shall be maintained in
compliance with 21 CFR 1020.40, and no modification shall be made to the system
unless prior DHHS/RHS approval has been granted.
(c)
Industrial uses of hand-held light intensified imaging devices are
exempt from the regulations in this part if the exposure level 18 inches from
the source of radiation to any individual does not exceed 2 millirem per hour.
(d)
Industrial uses of hand-held light intensified imaging devices with
exposure levels that exceed the 2 millirem per hour level shall meet the
applicable requirements of this part and He-P 4040 or He-P 4030, as applicable.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4034.05 Licensing and Registration Requirements
for Industrial Radiography Operations.
DHHS/RHS shall approve an application for a specific license for the use
of sealed sources in industrial radiography or a registration for use of
radiation machines if:
(a)
The applicant or registrant satisfies the general requirements specified
in He-P 4040 for radiation machine facilities or He-P 4030 for use of sealed
sources in industrial radiography, and any special requirements contained in
this part;
(b)
The applicant submits an adequate program for training radiographers and
radiographers’ assistants that meets the requirements of He‑P 4034.17;
(c)
The applicant or registrant submits procedures for verifying and
documenting the certification status of radiographers and for ensuring that the
certification of individuals acting as radiographers remains valid;
(d)
The applicant or registrant submits written operating and emergency
procedures as described in He‑P 4034.18;
(e) The applicant or registrant submits a
description of a program for inspections of the job performance of each
radiographer and radiographer’s assistant at intervals not to exceed 6 months
as described in He‑P 4034.17(e);
(f)
The applicant or registrant submits a description of the applicant’s
overall organizational structure as it applies to the radiation safety
responsibilities in industrial radiography, including specified delegation of
authority and responsibility;
(g)
The applicant or registrant submits the qualifications of the
individual(s) designated as the Radiation Safety Officer as described in He‑P
4034.16 and potential designees responsible for ensuring that the licensee’s or
registrant’s radiation safety program is implemented in accordance with
approved procedures;
(h)
An applicant intends to perform leak testing of sealed sources or
exposure devices containing depleted uranium (DU) shielding, or intends to
analyze their own wipe samples, the applicant describes the procedures for
performing these tests to include:
(1) Methods of collecting the samples;
(2) Qualifications of the individual who analyzes
the samples;
(3) Instruments to be used; and
(4) Methods of analyzing the samples;
(i)
The applicant or registrant intends to perform calibrations of survey
instruments and alarming ratemeters, the applicant describes methods to be used
and the experience of the person(s) who will perform the calibrations;
(j)
All calibrations of survey instruments and alarming ratemeters are
performed according to the procedures described and at the intervals prescribed
in He‑P 4034.09 and He‑P 4034.20(p);
(k) The applicant or registrant identifies and
describes the location(s) of all field stations and permanent radiographic
installations;
(l) The applicant or registrant identifies the
locations where all records required by this and other parts of these
regulations will be maintained;
(m)
A license application or radiation machine use includes underwater
radiography, a description of the following is included:
(1) Radiation safety procedures and radiographer
responsibilities unique to the performance of underwater radiography;
(2) Radiographic equipment and radiation safety
equipment unique to underwater radiography; and
(3) Methods for gas-tight encapsulation of
equipment;
(n)
An application or radiation machine use includes offshore platform or
lay-barge radiography, a description of the following is included:
(1) Transport procedures for sealed source to be
used in industrial radiographic operations;
(2) Storage facilities for sealed source; and
(3) Methods for restricting access to radiation
areas; and
(o)
Each registrant complies with the requirements, as appropriate, of He‑P
4034.04 for use of radiation machines in industrial radiographic operations.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12626, eff 9-26-18; amd by #12930, eff 11-26-19
He-P 4034.06 Performance Requirements for Industrial
Radiography Equipment. Equipment
used in industrial radiographic operations shall meet the following minimum
criteria:
(a)
Each radiographic exposure device, source assembly or sealed source, and
all associated equipment shall meet the requirements specified in American
National Standard Institute, N432-1980 “Radiological Safety for the Design and
Construction of Apparatus for Gamma Radiography,” (published as NBS Handbook
136, issued January 1981). This publication has been approved for incorporation
by reference by the Director of the Federal Register in accordance with 5
U.S.C. 552(a) and 1 CFR Part 51. This publication may be purchased from the
American National Standards Institute, Inc., 25 West 43rd Street, New York, New
York 10036; Telephone: (212) 642–4900. Copies of the document are available for
inspection at the Nuclear Regulatory Commission Library, 11545 Rockville Pike,
Rockville, Maryland 20852. A copy of the document is also on file at the
National Archives and Records Administration (NARA). For information on the
availability of this material at NARA, call 202-741-6030, or go to: http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html.
(b)
In addition to the requirements specified in He‑P 4034.06(a), the
following requirements apply to radiographic exposure devices, source changers,
source assemblies and sealed sources:
(1) The licensee shall ensure that each
radiographic exposure device has attached to it a durable, legible, clearly
visible label bearing the:
a. Chemical symbol and mass number of the
radionuclide in the device;
b. Activity and the date on which this activity
was last measured;
c. Model or product code and serial number of
the sealed source;
d. Manufacturer’s identity of the sealed source;
and
e. Licensee’s name, address, and telephone
number;
(2) Radiographic exposure devices intended for
use as Type B transport containers shall meet the applicable requirements of He‑P
4037; and
(3) Modification of radiographic exposure
devices, source changers, and source assemblies and associated equipment is
prohibited, unless the design of any replacement component, including source
holder, source assembly, controls, or guide tubes would not compromise the
design safety features of the system;
(c)
In addition to the requirements specified in He‑P 4034.06(a) and
(b) of this section, the following requirements shall apply to radiographic
exposure devices, source assemblies, source changers, and associated equipment
that allow the source to be moved out of the device for radiographic
operations:
(1) The coupling between the source assembly and
the control cable shall be designed in such a manner that the source assembly
will not become disconnected if cranked outside the guide tube. The coupling
must be such that it cannot be unintentionally disconnected under normal and
reasonably foreseeable abnormal conditions;
(2) The device shall automatically secure the
source assembly when it is cranked back into the fully shielded position within
the device;
(3) This securing system required in He‑P
4034.06(c)(2) shall only be released by means of a deliberate operation on the
exposure device;
(4) The outlet fittings, lock box, and drive
cable fittings on each radiographic exposure device shall be equipped with
safety plugs or covers which must be installed during storage and
transportation to protect the source assembly from water, mud, sand or other
foreign matter;
(5) Each sealed source or source assembly shall
have attached to it or engraved on it, a durable, legible, visible label with
the words: “DANGER -- RADIOACTIVE”;
(6) The label required in He‑P
4034.05(c)(5) shall not interfere with the safe operation of the exposure
device or associated equipment;
(7) The guide tube shall:
a. Be able to withstand a crushing test that
closely approximates the crushing forces that are likely to be encountered
during use; and
b. Be able to withstand a kinking resistance
test that closely approximates the kinking forces that are likely to be
encountered during use;
(8) Guide tubes shall be used when moving the
source out of the device;
(9) An exposure head or similar device designed
to prevent the source assembly from passing out of the end of the guide tube
shall be attached to the outermost end of the guide tube during industrial
radiography operations;
(10) The guide
tube exposure head connection shall be able to withstand the tensile test for
control units specified in ANSI N432-1980; and
(11) Source changers shall provide a system for
ensuring that the source will not be accidentally withdrawn from the changer
when connecting or disconnecting the drive cable to or from a source assembly.
(d)
All radiographic exposure devices and associated equipment in use after
January 10, 1996, shall comply with the requirements of He-P 4034.06; and
(e)
Notwithstanding He-P 4034.06(a), equipment used in industrial
radiographic operations shall not be required to comply with Ҥ 8.9.2(c) of the
Endurance Test in American National Standards Institute N432-1980,” if the
prototype equipment has been tested using a torque value representative of the
torque that an individual using the radiography equipment can realistically
exert on the lever or crankshaft of the drive mechanism.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12626, eff 9-26-18; amd by #12930, eff 11-26-19
He-P 4034.07 Limits on External Radiation Levels from
Storage Containers and Source Changers.
The maximum exposure rate limits for storage containers and source
changers are 2 millisieverts (200 mrem) per hour at any exterior surface, and
0.1 millisieverts (10 mrem) per hour at 1 meter from any exterior surface with
the sealed source in the shielded position.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4034.08 Locking of Radiographic Exposure Devices,
Storage Containers and Source Changers.
(a)
Each radiographic exposure device shall have a lock or outer locked
container designed to prevent unauthorized or accidental removal of the sealed
source from its shielded position.
(b)
The exposure device, or its container, or both shall be kept locked (and
if a keyed-lock, with the key removed at all times) when not under the direct
surveillance of a radiographer or a radiographer’s assistant except at
permanent radiographic installations as stated in He‑P 4034.22.
(c) During radiographic operations the
sealed source assembly shall be secured in the shielded position each time the
source is returned to that position.
(d) Each sealed source storage container and
source changer shall have a lock or outer locked container designed to prevent
unauthorized or accidental removal of the sealed source from its shielded
position.
(e)
Storage containers and source changers shall be kept locked, and if a
keyed-lock, with key removed at all times, when containing sealed sources
except when under the direct surveillance of a radiographer or a radiographer’s
assistant.
(f)
The control panel of each radiation machine shall be equipped with a
lock that will prevent the unauthorized use of an x-ray system or the
accidental production of radiation.
(g)
The radiation machine shall be kept locked and the key removed at all
times except when under the direct visual surveillance of a radiographer or a
radiographer’s assistant.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12626, eff 9-26-18; amd by #12930, eff 11-26-19
He-P 4034.09 Radiation Survey Instruments.
(a) The licensee or registrant shall keep
sufficient calibrated and operable radiation survey instruments at each
location where sources of radiation are present to make the radiation surveys
required by this part and by He-P 4022.
(b)
Instrumentation required by He‑P 4034.09(a) shall be capable of
measuring a range from 0.02 millisieverts (2 mrem) per hour through 0.01
sievert (1 rem) per hour.
(c)
The licensee or registrant shall have each radiation survey instrument
required under He‑P 4034.09(a) calibrated:
(1) At intervals not to exceed 6 months and after
instrument servicing, except for battery changes;
(2) For linear scale instruments, at 2 points
located approximately one-third and two-thirds of full-scale on each scale; for
logarithmic scale instruments, at mid-range of each decade, and at 2 points of
at least one decade; and for digital instruments, at 3 points between 0.02 and
10 millisieverts (2 and 1,000 mrem) per hour; and
(3) So that an accuracy within plus or minus 20
percent of the calibration source can be demonstrated at each point checked.
(d)
The licensee shall maintain records of the results of the instrument
calibrations in accordance with He-P 4034.26.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15; amd by #12930, eff 11-26-19
He-P 4034.10 Leak Testing and Replacement of Sealed
Sources.
(a)
The replacement of any sealed source fastened to or contained in a
radiographic exposure device and leak testing of any sealed source shall be
performed by persons authorized to do so by DHHS/RHS, another agreement state,
or the Nuclear Regulatory Commission.
(b) The opening, repair, or modification of any
sealed source shall be performed by persons specifically authorized to do so by
DHHS/RHS, another agreement state, or the Nuclear Regulatory Commission.
(c)
Each licensee who uses a sealed source shall have the source tested for
leakage at intervals not to exceed 6 months.
(d)
The leak testing of a sealed source shall include:
(1) A method
approved by DHHS/RHS, another agreement state, or the Nuclear Regulatory
Commission;
(2) A wipe sample taken from the nearest
accessible point to the sealed source where contamination might accumulate;
(3) An analysis of the wipe sample for
radioactive contamination which is capable of detecting the presence of 185
becquerel (0.005 mCi) of radioactive material on the
test sample; and
(4) Performance of the wipe sample by a person
specifically authorized by DHHS/RHS, another agreement state, or the Nuclear
Regulatory Commission.
(e)
The licensee shall maintain records of the leak tests in accordance with
He‑P 4034.27.
(f)
Unless a sealed source is accompanied by a certificate from the
transferor that shows that it has been leak tested within 6 months before the
transfer, it shall not be used by the licensee until tested for leakage.
(g)
Sealed sources that are in storage and not in use shall not require leak
testing.
(h)
Sealed sources that are in storage and not in use shall be tested before
use or transfer to another person if the interval of storage exceeds 6 months.
(i)
Any test conducted pursuant to He‑P 4034.10 that reveals the
presence of 185 becquerel (0.005 mCi) or more of
removable radioactive material shall be considered evidence that the sealed
source is leaking.
(j)
If a sealed source is found to be leaking, the licensee shall
immediately withdraw the equipment involved from use and shall have it
decontaminated and repaired or disposed of in accordance with He-P 4000.
(k)
If a sealed source is found to be leaking, a report must be filed with
DHHS/RHS within 5 days of the test, describing the equipment involved, the test
results, and the corrective action taken.
A copy of the report shall be sent to DHHS/RHS in accordance with He-P
4001.08.
(l)
Each exposure device using depleted uranium (DU) shielding and an S-tube
configuration shall:
(1) Be tested for DU contamination at intervals
not to exceed 12 months;
(2) Be analyzed by a method capable of detecting
the presence of 185 becquerel (0.005 mCi) of radioactive
material on the test sample; and
(3) Have the test performed by a person
specifically authorized by DHHS/RHS, another agreement state, or the Nuclear
Regulatory Commission to perform the analysis.
(m)
Should the testing required in He‑P 4034.10(l) reveal the presence
of 185 becquerel (0.005 mCi) or more of removable DU
contamination, the exposure device shall be removed from use until an
evaluation of the wear of the S-tube has been made.
(n)
Should the evaluation in He‑P 4034.10(m) reveal that the S-tube is
worn through, the device shall not be used again.
(o)
DU shielded devices shall not have to be tested for DU contamination
while in storage and not in use.
(p)
Before using or transferring a DU device, the device shall be tested for
DU contamination if the interval of storage exceeds 12 months.
(q)
A record of the DU leak-test shall be made in accordance with He‑P
4034.27.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12930, eff 11-26-19
He-P 4034.11 Quarterly Inventory.
(a)
Each licensee or registrant shall conduct a quarterly physical inventory
to account for all sources of radiation and for all devices containing depleted
uranium which have been received and possessed under the license.
(b)
The licensee or registrant shall maintain records of the quarterly
inventory in accordance with He-P 4034.28.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12930, eff 11-26-19
He-P 4034.12 Inspection and Maintenance of Radiation
Machines, Radiographic Exposure Devices, Transport and Storage Containers,
Associated Equipment, Source Changers, and Survey Instruments.
(a)
The licensee or registrant shall perform visual and operability checks
on survey meters, radiation machines, radiographic exposure devices, transport
and storage containers, associated equipment and source changers at the start
of each days use, or work shift, to ensure that:
(1) The equipment is in good working condition;
(2) The sources are adequately shielded; and
(3) Required labeling is present.
(b)
Survey instrument operability shall be performed using check sources or
other appropriate means.
(c)
Each licensee or registrant shall conduct a program for inspection and
maintenance of radiation machines, radiographic exposure devices, source
changers, associated equipment, transport and storage containers, and survey
instruments at intervals not to exceed 3 months or before the first use
thereafter to ensure the proper functioning of components important to safety
is in accordance with manufacturer’s specifications.
(d)
Each licensee or registrant shall ensure that all replacement components
for radiation machines, radiographic exposure devices, source changers,
associated equipment, transport and storage containers and survey instruments
meet design specifications.
(e)
If any equipment problems are found, the equipment shall be removed from
service and labeled as defective until repaired.
(f)
The licensee’s inspection and maintenance program shall include
procedures to ensure that Type B packages used to transport radioactive
materials are shipped and maintained in accordance with the certificate of
registration or other approval.
(g)
Records of equipment problems and of any maintenance performed under He‑P
4034.12 shall be made in accordance with He‑P 4034.30.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12930, eff 11-26-19
He-P 4034.13 Permanent Radiographic Installations.
(a)
Each entrance that is used for personnel access to the high radiation
area in a permanent radiographic installation shall be equipped with:
(1) An entrance control of the type described in
He‑P 4022.04(a)(1) that causes the radiation level upon entry into the
area to be reduced; or
(2) Conspicuous visible and audible warning
signals to warn of the presence of radiation as follows:
a. The visible signal must be actuated by
radiation whenever the source is exposed or the machine is energized; and
b. The audible signal must be actuated when an
attempt is made to enter the installation while the source is exposed or the
machine is energized.
(b)
The alarm system described in He‑P 4034.13(a)(2) shall be tested
for proper operation of both the visible and audible signals, with a radiation
source, each day before the installation is used for radiographic operations.
(c) Entrance control devices that
reduce the radiation level upon entry as designated in He‑P 4034.13(a)(1)
shall be tested monthly.
(d)
If an entrance control device or an alarm system is not operating
properly, it shall be immediately labeled as defective and repaired within 7
calendar days.
(e)
An installation with a defective entrance control device or alarm system
may continue to be used for a 7-day period, provided the licensee or registrant
implements the continuous surveillance requirements of He‑P 4034.22 and
an alarming ratemeter is used.
(f)
The licensee’s inspection and maintenance program shall include
procedures to ensure that Type B packages used to transport radioactive
materials are shipped and maintained in accordance with the certificate of registration
or other approval.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12930, eff 11-26-19
He-P
4034.14 Labeling, Storage, and Transportation.
(a) The licensee shall not use a source changer
or a container to store licensed material unless the source changer or the
storage container has securely attached to it a durable, legible, and clearly
visible label bearing the standard trefoil radiation caution symbol in
conventional colors, i.e., magenta, purple or black on yellow background,
having a minimum diameter of 25mm and the wording:
“CAUTION
[or “DANGER”]
RADIOACTIVE
MATERIAL
NOTIFY
CIVIL AUTHORITIES [or “NAME OF COMPANY”]”
(b)
The licensee shall not transport licensed material unless the material
is packaged, and the package is labeled, marked, and accompanied with
appropriate shipping papers in accordance with He‑P 4037.
(c)
Locked radiographic exposure devices, storage containers, and radiation
machines, shall be physically secured to prevent tampering or removal by
unauthorized personnel.
(d)
The licensee shall store licensed material in a manner that will
minimize danger from explosion or fire.
(e)
The licensee shall lock and physically secure the transport package
containing licensed material in the transporting vehicle to prevent accidental
loss, tampering, or unauthorized removal of the licensed material from the
vehicle.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12626, eff 9-26-18; amd by #12930, eff 11-26-19
He-P 4034.15 Conducting Industrial Radiographic Operations.
(a)
Whenever radiography is performed at a location other than a permanent
radiographic installation, the following shall be required:
(1) The radiographer shall be accompanied by at
least one other qualified radiographer or an individual who has at a minimum
met the requirements of He-P 4034.17(c);
(2) The second qualified individual on site shall
observe the operations and be capable of providing immediate assistance to
prevent unauthorized entry into the restricted area; and
(3) Radiography shall not be performed if only
one qualified individual is present.
(b)
All radiographic operations conducted at locations of use authorized on
the license shall be conducted in a permanent radiographic installation unless
otherwise specifically authorized by DHHS/RHS.
(c)
A licensee or registrant shall conduct lay-barge, offshore platform, or
underwater radiography only if procedures have been approved by DHHS/RHS, an
agreement state, or the U.S. Nuclear Regulatory Commission.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12626, eff 9-26-18; amd by #12930, eff 11-26-19
He-P 4034.16 Radiation Safety Officer.
(a)
The Radiation Safety Officer (RSO) shall ensure that radiation safety
activities are being performed in accordance with approved
procedures and regulatory requirements in the daily operation of the licensee’s
or registrant’s program.
(b)
The minimum qualifications, training, and experience for RSOs for
industrial radiography shall be as follows:
(1) Completion of the training and testing
requirements of He‑P 4034.17(a);
(2) 2,000 hours of hands-on experience as a
qualified radiographer in industrial radiographic operations; and
(3) Formal training in the establishment and
maintenance of a radiation protection program.
(c)
In lieu of (b), a licensee may apply to DHHS/RHS for approval of an
individual to serve as RSO when such individual has appropriate training or
experience in the field of ionizing radiation, and in addition, has adequate
formal training with respect to the establishment and maintenance of a
radiation safety protection program.
(d) The specific duties and authorities of the
RSO shall include, but shall not be limited to:
(1)
Establishing and overseeing all operating, emergency, and ALARA
procedures as required by He‑P 4020 through He‑P 4023 and reviewing
these procedures regularly to ensure that the procedures in use conform to
DHHS/RHS rules and the license or registration conditions;
(2) Overseeing
and approving the training program for radiographic personnel to ensure that
appropriate and effective radiation protection practices are taught;
(3) Ensuring
that required radiation surveys and leak tests are performed and documented in
accordance with He‑P 4034, including any corrective measures when levels
of radiation exceed established limits;
(4) Ensuring
that personnel monitoring devices are calibrated, if applicable, and used
properly by occupationally exposed personnel;
(5) Ensuring
that records are kept of the personnel monitoring results;
(6)
Ensuring that timely notifications are made as required by He‑P
4021.14; and
(7) Ensuring
that working operations are conducted safely, that corrective actions are
implemented, and that unsafe operations are terminated.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12626, eff 9-26-18; amd by #12930, eff 11-26-19
He-P 4034.17 Training.
(a)
The licensee or registrant shall not permit any individual to act as a
radiographer until the individual:
(1) Has received training in the subjects in He-P
4034.17(h) in addition to a minimum of 2 months of on-the-job training;
(2) Is certified through a radiographer
certification program by a certifying entity in accordance with the criteria
specified in He-P 4034 Appendix A. (An independent organization that would like
to be recognized as a certifying entity shall submit its request to DHHS/RHS).
(3) Has received
training in the subjects outlined in He-P 4034.17(h) and demonstrated an
understanding of these subjects by successful completion of a written
examination.
(b)
In addition to (a) above, the licensee or registrant shall not permit
any individual to act as a radiographer until the individual:
(1) Has received copies of, and instruction in
the requirements described in, the rules contained in this part, applicable
sections of He-P 4001.07, He-P 4019 through He-P 4023, and He-P 4037, the
license or registration under which the radiographer will perform industrial
radiography, and the licensee’s or registrant’s operating and emergency
procedures;
(2) Has demonstrated an understanding of the
licensee’s license and operating and emergency procedures by successful
completion of a written or oral examination covering this material;
(3) Has received
training in the use of the registrant’s radiation machines, or the licensee’s
radiographic exposure devices, sealed sources, in the daily inspection of
devices and associated equipment, and in the use of radiation survey
instruments; and
(4) Has demonstrated understanding of the use of
radiographic exposure devices, sources, survey instruments, and associated
equipment described in He-P 4034.17(b)(1) and (b)(3) by successful completion
of a practical examination covering this material.
(c)
The licensee shall not permit any individual to act as a radiographer’s
assistant until the individual:
(1) Has received copies of, and instruction in
the requirements described in, the rules contained in this part, applicable
sections of He-P 4001.07, He-P 4019 through He-P 4023, and He-P 4037, the
license or registration under which the radiographer’s assistant will perform
industrial radiography, and the licensee’s or registrant’s operating and
emergency procedures;
(2) Has demonstrated an understanding of items in
He-P 4034.17(c)(1) by successful completion of a written examination on the
subjects covered;
(3) Under the personal supervision of a
radiographer, has developed competence in the use of the registrant’s radiation
machines, or the licensee’s radiographic exposure devices, sealed sources, in
the daily inspection of devices and associated equipment, and in the use of
radiation survey instruments; and
(4) Has demonstrated
understanding of the use of the equipment described in He-P 4034.17(c)(3) by
successful completion of a practical examination on the use of such equipment.
(d)
The licensee or registrant shall provide annual refresher safety
training for each radiographer and radiographer’s assistant at intervals not to
exceed 12 months.
(e)
Except as provided in He-P 4034.17(f)(3), the RSO or designee shall
conduct an inspection program of the job performance of each radiographer and
radiographer’s assistant to ensure that DHHS/RHS rules, license or registration
requirements, and the applicant’s operating and emergency procedures are
followed.
(f)
The inspection program required in He-P 4034.17(e) shall:
(1) Include observation of the performance of each
radiographer and radiographer’s assistant during an actual industrial
radiographic operation, at intervals not to exceed 6 months;
(2) Provide that, if a
radiographer or a radiographer’s assistant has not participated in an
industrial radiographic operation for more than 6 months since the last
inspection, the radiographer shall demonstrate knowledge of the training
requirements of He‑P 4034.17(b)(3) and the radiographer’s assistant shall demonstrate knowledge of the training
requirements of He-P 4034.17(c)(3) by a practical examination before these
individuals can next participate in a radiographic operation; and
(3) Provide written document to ensure that
DHHS/RHS rules, license or registration requirements, and operating and
emergency procedures are followed in those situations where:
a. The individual serves as both radiographer
and RSO; and
b. Performs all radiography operations, such
that an inspection program is not required.
(g)
The licensee or registrant shall maintain records of all required
training, including certification documents, written and practical
examinations, refresher safety training, and inspections of job performance in
accordance with He-P 4034.32.
(h)
The licensee or registrant shall include the following subjects in the
training program required in He-P 4034.17(a):
(1) Fundamentals of radiation safety including:
a. Characteristics of gamma radiation;
b. Units of radiation dose and quantity of
radioactivity;
c. Hazards of exposure to radiation;
d. Levels of radiation from licensed materials
or sources of radiation; and
e. Methods of controlling radiation dose (time,
distance, and shielding);
(2) Radiation detection instruments including:
a. Use, operation, calibration, and limitations
of radiation survey instruments;
b. Survey techniques; and
c. Use of personnel monitoring equipment;
(3) Equipment to be used including:
a. Operation and control of radiographic
exposure equipment, remote handling equipment, and storage containers,
including pictures or models of source assemblies pigtails;
b. Operation and control of radiation machines;
c. Storage, control, and disposal of licensed
material or sources of radiation; and
d. Inspection and maintenance of equipment;
(4) The requirements of this chapter and
pertinent regulations in the Code of Federal Regulations; and
(5) Case histories of accidents in radiography.
(i)
Records of radiographer certification maintained in accordance with He-P
4034.32(a) shall provide appropriate affirmation of certification requirements
specified in He-P 4034.17(a)(1) and (a)(2).
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12626, eff 9-26-18; amd by #12930, eff 11-26-19
He-P 4034.18 Operating and Emergency Procedures.
(a)
Operating and emergency procedures shall include, as a minimum, instructions
in the following:
(1) Appropriate handling and use of licensed
sealed sources, radiographic exposure devices, and sources of radiation so that
no person is likely to be exposed to radiation doses in excess of the limits
established in He‑P 4020;
(2) Methods and occasions for conducting
radiation surveys;
(3) Methods for posting and controlling access to
radiographic areas;
(4) Methods and occasions for locking and
securing radiographic exposure devices, transport and storage containers,
sealed sources, and sources of radiation;
(5) Personnel monitoring and the use of personnel
monitoring equipment;
(6) Transporting sealed sources and equipment to
field locations, including packing of radiographic exposure devices and storage
containers in the vehicles, placarding of vehicles when required, and control
of the sealed sources and equipment during transportation as required in He‑P
4037 and U.S. Department of Transportation 49 CFR Parts 171-173;
(7) The inspection, maintenance, and operability
checks of radiographic exposure devices, radiation machines, survey
instruments, alarming ratemeters, transport containers, and storage containers;
(8) Steps that shall be taken immediately by
radiography personnel in the event a pocket dosimeter is found to be off-scale
or an alarming ratemeter alarms unexpectedly;
(9) The procedure(s) for identifying and
reporting defects and noncompliance, as required by He‑P 4034.38;
(10) The procedure for notifying proper persons in
the event of an accident or incident;
(11) Minimizing exposure of persons in the event
of an accident or incident, including a source disconnect, a transport
accident, or loss of a source of radiation;
(12) Source recovery procedure if licensee will
perform source recovery; and
(13) Maintenance of records.
(b) The licensee or registrant shall maintain
copies of current operating and emergency procedures in accordance with He-P
4034.33 and He-P 4034.37.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12626, eff 9-26-18; ss by #12930, eff 11-26-19
He-P 4034.19 Supervision of Radiographers’ Assistants.
(a)
The radiographer’s assistant shall be under the personal supervision of
a radiographer when using sources of radiation, radiographic exposure devices,
associated equipment, sealed sources, or conducting radiation surveys required
by He‑P 4034.21(b) to determine that the sealed source has returned to
the shielded position or the radiation machine is off after an exposure.
(b)
The personal supervision required in He‑P 4034.19(a) shall
include:
(1) The radiographer’s physical presence at the
site where the sealed sources or sources of radiation are being used;
(2) The availability of the radiographer to give
immediate assistance if required; and
(3) The
radiographer’s direct observation of the assistant’s performance of the
operations referred to in this section.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12626, eff 9-26-18
He-P 4034.20 Personnel Monitoring.
(a)
The licensee or registrant shall not permit any individual to act as a
radiographer or a radiographer’s assistant unless, at all times during
radiographic operations, each individual wears, on the trunk of the body, a
combination of direct reading dosimeter, an alarming ratemeter, and a personnel
dosimeter that is processed and evaluated by an accredited National Voluntary
Laboratory Accreditation Program (NVLAP) processor.
(b)
At permanent radiography installations where alarming or warning devices
are in routine use, or during radiographic operations using radiation machines,
the wearing of an alarming ratemeter is not required.
(c)
Pocket dosimeters shall:
(1) Have a range from zero to 2 millisieverts
(200 mrem); and
(2) Be recharged at the start of each shift.
(d)
Electronic personal dosimeters shall only be used in place of
ion-chamber pocket dosimeters.
(e)
Each personnel dosimeter shall be assigned to and worn by only one
individual.
(f)
Film badges shall be exchanged at periods not to exceed one month and
other personnel dosimeters processed and evaluated by an accredited NVLAP
processor shall be replaced at periods not to exceed three months.
(g)
After replacement, each personnel dosimeter shall be processed as soon
as practicable.
(h)
Direct reading dosimeters, such as pocket dosimeters or electronic
personal dosimeters, shall:
(1) Be read at the beginning and end of each
shift;
(2) Have the exposures recorded at the beginning
and end of each shift; and
(3) Be recorded in records maintained in
accordance with He‑P 4034.34.
(i)
Pocket dosimeters, or electronic personal dosimeters, shall be checked
at periods not to exceed 12 months in order to verify that readings are within
plus or minus 20 percent of the true radiation exposure.
(j)
Records resulting from the check of pocket dosimeters or electronic
personal dosimeters shall be maintained in accordance with He‑P 4034.34.
(k)
If an individual’s pocket dosimeter is found to be off-scale, or the
electronic personal dosimeter reads greater than 2 millisieverts (200 mrem) and
the possibility of radiation exposure cannot be ruled out as the cause:
(1) The individual’s personnel dosimeter shall be
sent for processing within 24 hours;
(2) The individual shall not resume work
associated with the use of licensed material or sources of radiation until a
determination of the individual’s radiation exposure has been made by the RSO
or the RSO’s designee; and
(3) The results of this determination shall be
included in the records maintained in accordance with He-P 4034.34.
(l)
If the personnel dosimeter that is required by He-P 4034.20(a) is lost
or damaged, the worker shall cease work immediately until a replacement
personnel dosimeter is provided and the exposure is calculated for the time
period from issuance to loss or damage of the personnel dosimeter.
(m)
The results of the calculated exposure required in He‑P 4034.20(l)
and the time period for which the personnel dosimeter was lost or damaged shall
be included in the records maintained in accordance with He‑P 4034.34.
(n)
Reports received from the accredited NVLAP personnel dosimeter processor
shall be retained in accordance with He‑P 4034.34.
(o)
Each alarming ratemeter shall:
(1) Be checked to ensure that the alarm functions
properly before using at the start of each shift;
(2) Be set to give an alarm signal at a preset
dose rate of 5 millisieverts per hour (500 mrem/hr), with an accuracy of plus
or minus 20 percent of the true radiation dose rate;
(3) Require special means to change the preset
alarm function;
(4) Be calibrated at periods not to exceed 12
months for correct response to radiation; and
(5) Have the records of alarm ratemeter
calibrations maintained by the licensee in accordance with He‑P 4034.34.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12626, eff 9-26-18
He-P 4034.21 Radiation Surveys. The licensee or registrant shall:
(a)
Conduct surveys with a calibrated and operable radiation survey
instrument that meets the requirements of He-P 4034.09;
(b)
Using a survey instrument meeting the requirements of He-P 4034.21(a),
conduct a survey of the radiographic exposure device and the guide tube after
each exposure when approaching the device or the guide tube. The survey shall determine that the sealed
source has returned to its shielded position before exchanging films,
repositioning the exposure head, or dismantling equipment;
(c)
Survey radiation machines after each exposure to determine that the
machine is off;
(d)
Conduct a survey of the radiographic exposure device with a calibrated
radiation survey instrument whenever the source is exchanged and whenever a
radiographic exposure device is placed in a storage area as defined in He-P
4034.03(ag), to ensure that the sealed source is in its shielded position; and
(e)
Maintain records in accordance with He‑P 4034.35.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12626, eff 9-26-18
He-P 4034.22 Surveillance. During each radiographic operation the
radiographer, or the other individual present, as required by He-P 4034.15,
shall maintain continuous direct visual surveillance of the operation to
protect against unauthorized entry into a radiation area or a high radiation area,
as defined in He-P 4003.01, except at permanent radiographic installations
where all entryways are locked and the requirements of He-P 4034.13 are met.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12626, eff 9-26-18; ss by #12930, eff 11-26-19
He-P 4034.23 Posting.
(a)
All areas in which industrial radiography is being performed shall be
conspicuously posted as required by He-P 4022.12.
(b)
The exceptions listed in He-P 4022.13 of this chapter do not apply to
industrial radiographic operations.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12626, eff 9-26-18
He-P 4034.24 Records for Industrial Radiography. Each licensee or registrant shall maintain a
copy of its license or registration, licensed conditions, documents
incorporated by reference, and amendments to each of these items, until
superseded by new documents approved by DHHS/RHS, or until DHHS/RHS terminates
the license or registration.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12626, eff 9-26-18
He-P 4034.25 Records of Receipt and Transfer of Sources
of Radiation.
(a)
Each licensee or registrant shall maintain records showing the receipts
and transfers of sealed sources, devices using DU for shielding, and radiation
machines, and retain each record for 3 years after it is made.
(b)
These records shall include the date, the name of the individual making
the record, radionuclide, number of becquerels (curies) or mass (for DU), and
manufacturer, model, and serial number of each sealed source, source of
radiation, or device, as appropriate.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12626, eff 9-26-18
He-P 4034.26 Records of Radiation Survey Instruments. Each licensee or registrant shall maintain
records of the calibrations of its radiation survey instruments that are
required under He-P 4034.09 and retain each record for 3 years after it is
made.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4034.27 Records of Leak Testing of Sealed Sources
and Devices Containing DU.
(a)
Each licensee shall maintain records of leak test results for sealed
sources and for devices containing DU in units of becquerels (mCi).
(b)
The licensee shall retain each record for 3 years after it is made or
until the source in storage is removed.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4034.28 Records of Quarterly Inventory.
(a)
Each licensee or registrant shall maintain records of the quarterly
inventory of sealed sources of radiation, including devices containing depleted
uranium as required by He‑P 4034.11, and retain each record for 3 years.
(b) The record shall include the date of the
inventory, name of the individual conducting the inventory, radionuclide,
number of becquerels (curies) or mass (for DU) in each device, location of
sources of radiation or devices, and manufacturer, model, and serial number of
each sealed source of radiation and/or device, as appropriate.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12930, eff 11-26-19
He-P 4034.29 Utilization Logs.
(a)
Each licensee or registrant shall maintain utilization logs showing for
each source of radiation the following information:
(1) A description, including the make, model, and
serial number of the radiation machine or the radiographic exposure device,
transport, or storage container in which the sealed source is located;
(2) The identity and signature of the
radiographer assigned to keep the log of the equipment or devices described in
(1) above;
(3) The plant or site where used and dates of
use, including the dates removed and returned to storage; and
(4) For permanent radiographic installations, the
dates each radiation machine is energized.
(b)
The licensee or registrant shall retain the logs required by He‑P
4034.29(a) for 3 years after the log is made.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12930, eff 11-26-19
He-P 4034.30 Records of Inspection and Maintenance of
Radiation Machines, Radiographic Exposure Devices, Transport and Storage
Containers, Associated Equipment, Source Changers, and Survey Instruments.
(a)
Each licensee or registrant shall maintain records specified in He-P
4034.12 of equipment problems found in daily checks and quarterly inspections
of radiation machines, radiographic exposure devices, transport and storage
containers, associated equipment, source changers, and survey instruments; and
retain each record for 3 years after it is made.
(b)
The record shall include the date of check or inspection, name of
inspector, equipment involved, any problems found, and what repair or
maintenance, if any, was performed.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He‑P 4034.31 Records of Alarm System and Entrance
Control Checks at Permanent Radiographic Installations. Each licensee or registrant shall maintain
records of alarm system and entrance control device tests required by He-P
4034.13 and retain each record for 3 years after it is made.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He‑P 4034.32 Records of Training and Certification. Each licensee or registrant shall maintain
the following records for each radiographer and each radiographer’s assistant
for 3 years after the record is made:
(a) Records of training to include radiographer
certification documents and verification of certification status, copies of
written tests, dates of oral and practical examinations, and names of
individuals conducting and receiving the oral and practical examinations;
(b)
Records of annual refresher safety training to include a list the topics
discussed during the refresher safety training, the dates the annual refresher
safety training was conducted, and the names of the instructors and attendees;
and
(c)
Records of semi-annual inspections of job performance to include a list
showing the items checked and any non-compliance observed by the RSO.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12930, eff 11-26-19
He-P 4034.33 Copies of Operating and Emergency
Procedures.
(a)
Each licensee or registrant shall maintain a copy of current operating
and emergency procedures until DHHS/RHS terminates the license or registration.
(b)
Superseded material in the operating and emergency procedures shall be
retained for 3 years after the change is made.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4034.34 Records of Personnel Monitoring. Each licensee or registrant shall maintain
the following exposure records specified in He-P 4034.20:
(a)
Direct reading dosimeter readings and yearly operability checks required
by He‑P 4034.20(i) and (j) for 3 years after the record is made;
(b)
Records of alarming ratemeter calibrations for 3 years after the record
is made;
(c)
Reports received from the film badge, TLD, or OSL processor until
DHHS/RHS terminates the license or registration; and
(d)
Records of estimates of exposures as a result of off-scale personal
direct reading dosimeters, or lost or damaged film badges, TLDs, or OSLs, until
DHHS/RHS terminates the license or registration.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4034.35 Records of Radiation Surveys.
(a)
Each licensee shall maintain a record of each exposure device survey
conducted before the device is placed in storage as specified in He-P
4034.21(d).
(b)
Each record shall be maintained for 3 years after it is made.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12930, eff 11-26-19
He-P 4034.36 Form of Records.
(a) Each record required by He-P 4034 shall be
legible throughout the specified retention period.
(b)
The record shall be the original or a reproduced copy or a microform
provided that the copy or microform is authenticated by an individual
authorized by the registrant or licensee and that the microform is capable of
reproducing a clear copy throughout the required retention period.
(c) The record shall also be stored in
electronic media with the capability for producing legible, accurate, and
complete records during the required retention period, if electronic media is
available.
(d)
Records, such as letters, drawings, and specifications, shall include
information, such as stamps, initials, and signatures.
(e)
The licensee or registrant shall maintain safeguards against tampering
with and loss of records.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
He-P 4034.37 Location of Documents and Records.
(a)
Each licensee or registrant shall maintain copies of records required by
He‑P 4034 and other applicable parts of these rules at the location
specified in He‑P 4034.05(l).
(b)
Each licensee or registrant shall also maintain copies of the following
documents and records sufficient to demonstrate compliance at each applicable
field station and each temporary job site:
(1) The license or registration authorizing the
use of sources of radiation;
(2) A copy of He-P 4003, He-P 4019 through He-P
4023, and He-P 4034;
(3) Utilization records for each radiographic
exposure device dispatched from that location as required by He-P 4034.29;
(4) Records of equipment problems identified in
daily checks of equipment as required by He‑P 4034.30(a);
(5) Records of alarm system and entrance control
checks required by He‑P 4034.31, if applicable;
(6) Records of direct reading dosimeter and/or
electronic personal dosimeters readings as required by He-P 4034.34;
(7) Operating and emergency procedures required
by He-P 4034.33;
(8) Evidence of the latest calibration of the
radiation survey instruments in use at the site, as required by He-P 4034.26;
(9) Evidence of the latest calibrations of
alarming ratemeters and operability checks of pocket dosimeters and/or
electronic personal dosimeters as required by He-P 4034.34;
(10) Survey records as required by He-P 4034.35
and He-P 4021.03 as applicable, for the period of operation at the site;
(11) The shipping papers for the transportation of
radioactive materials required by He‑P 4037; and
(12) When operating under reciprocity pursuant to
He-P 4030.18, a copy of the Agreement State license or registration, or NRC
license authorizing the use of licensed materials or sources of radiation.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
ss by #12930, eff 11-26-19
He-P 4034.38 Notifications.
(a)
In addition to the reporting requirements specified in He-P 4021 and
He-P 4030.10(j) through (m), each licensee or registrant shall provide a
written report to DHHS/RHS within 30 days of the occurrence of any of the
following incidents involving radiographic equipment:
(1) Unintentional disconnection of the source
assembly from the control cable;
(2) Inability to retract the source assembly to
its fully shielded position and secure it in this position;
(3) Failure of any
component, which is critical to safe operation of the device, to properly
perform its intended function;
(4) Failure of an indicator on a radiation
machine to show that radiation is being produced;
(5) Failure of an exposure switch to terminate
production of radiation when switched to the off position; or
(6) Failure of a safety interlock to terminate
x-ray production.
(b)
The licensee or registrant shall include the following information in
each report submitted under He-P 4034.38(a), and in each report of overexposure
submitted under He-P 4021.14 which involves failure of safety components of
radiography equipment:
(1) Description of the equipment problem;
(2) Cause of each incident, if known;
(3) Name of the manufacturer and model number of
equipment involved in the incident;
(4) Place, date, and time of the incident;
(5) Actions taken to establish normal operations;
(6) Corrective actions taken or planned to
prevent recurrence; and
(7) Names and qualifications of personnel
involved in the incident.
(c)
Any licensee or registrant conducting radiographic operations or storing
sources of radiation at any location not listed on the license or registration
for a period in excess of 180 days in a calendar year, shall notify DHHS/RHS
prior to exceeding the 180 days.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15;
amd by #12930, eff 11-26-19
He-P 4034.39 Specific Requirements for Radiographic
Personnel Performing Industrial Radiography.
(a)
At a job site, the following shall be supplied by the licensee or
registrant:
(1) At least one operable, calibrated survey
instrument for each exposure device or radiation machine in use;
(2) A current whole body individual monitoring
device such as: film badge, TLD, or OSL for each worker;
(3) An operable, calibrated pocket dosimeter with
a range of zero to 200 milliroentgens for each worker;
(4) An operable, calibrated, alarming ratemeter
for each worker; and
(5) The appropriate barrier ropes and caution
signs.
(b)
Each radiographer at a job site shall have on their person a valid
certification ID card issued by a certifying entity.
(c)
Industrial radiographic operations shall not be performed if any of the
items in He‑P 4034.39(a) are not available at the job site or are
inoperable.
(d) During an inspection, DHHS/RHS shall terminate
an operation if any of the items in He‑P 4034.39(a) are not available or
operable, or if the required number of radiographic personnel is not present.
(e) Operations terminated under the conditions of
He‑P 4034.39(d) shall not be resumed until all required conditions are
met.
Source. (See Revision Note at part heading for He-P
4034) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10983, eff 11-24-15
PART He-P
4035 USE OF RADIONUCLIDES IN THE HEALING
ARTS
Revision Note:
Doc. #6942,
effective 2-1-99, repealed Parts He-P 2030, 2031, 2032, 2033, 2034, 2035, 2042
and 2093 relative to Radiation and Radioactive Material and adopted new rules
to replace them and renumbered them as He-P 4030, 4031, 4032, 4033, 4034, 4035,
4093 and 4096.
He-P 4035.01 Purpose. This part shall establish requirements and
provisions for the medical production, preparation, compounding, and use of
byproduct material in the healing arts and for issuance of licenses authorizing
the medical use of this material which provide for the radiation safety of
workers, the general public, patients, and human research subjects.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13473, eff
10-25-22
He-P 4035.02 Scope.
(a) The requirements and
provisions of this part shall be in addition to, and not in substitution for,
other parts in this chapter.
(b) The requirements and
provisions of He‑P 4019 through He‑P 4023, He‑P 4030, He‑P
4037, He-P 4038, He‑P 4070, and He-P 4071 apply to applicants and
licensees subject to He‑P 4035 unless specifically exempted.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.03 Definitions.
(a) “Address of use” means the
building or buildings that are identified on the license and where byproduct
material may be prepared, received, used, or stored.
(b) “Area of use” means a
portion of an address of use that has been set aside for the purpose of
preparing, receiving, using, or storing byproduct material.
(c) “Associate radiation safety
officer” means an individual who:
(1) Meets the requirements in
He-P 4035.61 and He-P 4035.73; and
(2) Is currently identified as
an associate radiation safety officer for the types of use of byproduct
material for which the individual has been assigned duties and tasks by the
radiation safety officer on:
a. A specific medical use
license issued by DHHS/RHS, an agreement state, or the Nuclear Regulatory
Commission; or
b. A medical use permit issued
by a Nuclear Regulatory Commission master material licensee.
(d) “Authorized medical
physicist” means an individual who:
(1) Meets the requirements in
He-P 4035.70 and He-P 4035.73; or
(2) Is identified as an
authorized medical physicist or teletherapy physicist on:
a. A specific medical use
license issued by DHHS/RHS, or an agreement state, or the Nuclear Regulatory
Commission;
b. A medical use permit issued
by a Nuclear Regulatory Commission master material licensee;
c. A permit issued by DHHS/RHS, or an agreement state, or the Nuclear
Regulatory Commission broad scope medical use licensee; or
d. A permit issued by a Nuclear
Regulatory Commission master license broad scope medical use permittee.
(e) “Authorized nuclear
pharmacist” means a person who is a “licensed pharmacist” as defined in RSA
318:1, VII, and who:
(1) Meets the requirements in He-P 4035.73, He-P 4035.74(a), and NH
pharmacy board administrative rule Ph 405.03;
(2) Is identified as an
authorized nuclear pharmacist on:
a. A specific license issued by
DHHS/RHS, or an agreement state, or the Nuclear Regulatory Commission that
authorizes medical use, or the practice of nuclear pharmacy;
b. A permit issued by a Nuclear Regulatory Commission master material
licensee that authorizes medical use or the practice of nuclear pharmacy;
c. A permit issued by DHHS/RHS, or an agreement state, or the Nuclear
Regulatory Commission broad scope medical use licensee that authorizes medical
use or the practice of nuclear pharmacy; or
d. A permit issued by a Nuclear
Regulatory Commission master material license broad scope medical use permittee
that authorizes medical use or the practice of nuclear pharmacy; or
(3) Is identified as an
authorized nuclear pharmacist by a commercial nuclear pharmacy that has been
authorized to identify authorized nuclear pharmacists; or
(4) Is designated as an
authorized nuclear pharmacist in accordance with He-P 4032.05(b)(2), or by an
equivalent agreement state regulation, or by the Nuclear Regulatory Commission
pursuant to 10 CFR 32.72(b)(4).
(f) “Authorized user” means a
physician, dentist, or podiatrist who:
(1) Meets the applicable
requirements for an authorized user as listed in in He-P 4035.59, He-P 4035.63,
He-P 4035.64, He-P 4035.65, He-P 4035.66, He-P 4035.68, or He-P 4035.69, and
He-P 4035.73, or
(2) Is identified as an
authorized user on:
a. A DHHS/RHS, or an agreement
state, or Nuclear Regulatory Commission license that authorizes the medical use
of byproduct material;
b. A permit issued by a Nuclear
Regulatory Commission master material licensee that is authorized to permit the
medical use of byproduct material;
c. A permit issued by DHHS/RHS,
or an agreement state, or a Nuclear Regulatory Commission specific licensee of
broad scope that is authorized to permit the medical use of byproduct material;
or
d. A permit issued by a Nuclear
Regulatory Commission master material license broad scope permittee that is
authorized to permit the medical use of byproduct material.
(g) “Brachytherapy” means a
method of radiation therapy in which sources are utilized to deliver a
radiation dose at a distance of up to a few centimeters by surface,
intracavitary, intraluminal, or interstitial application.
(h) “Brachytherapy source”
means a radioactive source, or a manufacturer-assembled source train, or a
combination of these sources that is designed to deliver a therapeutic dose
within a distance of a few centimeters.
(i) “Client’s address” means
the area of use or a temporary job site for the purpose of providing mobile
medical service in accordance with He-P 4035.26.
(j) “Dedicated check source”
means a radioactive source that is used to assure the constant operation of a
radiation detection or measurement device over several months or years.
(k) “Dentist” means an
individual licensed to practice dentistry in New Hampshire, another state or
territory of the United States, the District of Columbia, or the Commonwealth
of Puerto Rico.
(l) “High dose-rate remote
afterloader” (HDR) means a brachytherapy device that remotely delivers a dose
rate in excess of 12 gray (1200 rads) per hour at the point or surface where
the dose is prescribed.
(m) “Low dose-rate remote
afterloader” (LDR) means a brachytherapy device that remotely delivers a dose
rate of less than or equal to 2 gray (200 rads) per hour at the point or
surface where the dose is prescribed.
(n) “Management” means the
chief executive officer, or other individual having the authority to manage,
direct, or administer the licensee’s activities, or those persons’ delegate or
delegates.
(o) “Manual brachytherapy”
means a type of brachytherapy in which the brachytherapy sources (e.g., seeds,
ribbons) are manually placed topically on or inserted either into the body
cavities that are in close proximity to a treatment site or implanted directly
into the tissue volume.
(p) “Medical event” means an
event that meets the criteria in He-P 4035.14(a) or (b).
(q) “Medical institution” means
an organization in which more than one medical discipline is practiced.
(r) “Medical use” means the
intentional internal or external administration of byproduct material or the
radiation from byproduct material to patients or human research subjects under
the supervision of an authorized user.
(s) “Medium dose-rate remote afterloader” (MDR) means a brachytherapy
device that remotely delivers a dose rate of greater than 2 gray (200 rads) per
hour, but less than or equal to 12 gray (1200 rads) per hour at the point or
surface where the dose is prescribed.
(t) “Mobile medical service”
means the transportation of byproduct material to, and its medical use at, the
client’s address.
(u) “Ophthalmic physicist”
means an individual who:
(1) Meets the requirements in
He-P 4035.32(f)(2) and He-P 4035.73; and
(2) Is identified as an
ophthalmic physicist on a:
a. Specific medical use license
issued by DHHS/RHS, an agreement state, or the Nuclear Regulatory Commission;
b. Permit issued by DHHS/RHS,
an agreement state, or a Nuclear Regulatory Commission broad scope medical use
licensee;
c. Medical use permit issued by
a Nuclear Regulatory Commission master material licensee; or
d. Permit issued by a Nuclear
Regulatory Commission master material licensee broad scope medical use
permittee.
(v) “Output” means the exposure
rate, dose rate, or a quantity related in a known manner to these rates from a
brachytherapy source, teletherapy unit, remote afterloader, or gamma
stereotactic radiosurgery unit for a specified set of exposure conditions.
(w) “Patient intervention” means actions by the patient or human
research subject, whether intentional or unintentional, such as dislodging or
removing treatment devices or prematurely terminating the administration.
(x) “Podiatrist” means an
individual licensed to practice podiatry in New Hampshire, another state or
territory of the United States, the District of Columbia, or the Commonwealth
of Puerto Rico.
(y) “Positron emission tomography (PET) radionuclide production
facility” means a facility operating a cyclotron or accelerator for the purpose
of producing PET radionuclides.
(z) “Preceptor” means an individual who provides, directs, or verifies
training and experience required for an individual to become an authorized
user, an authorized medical physicist, an authorized nuclear pharmacist, a
radiation safety officer, or an associate radiation safety officer.
(aa) “Prescribed dosage” means
the specific activity or range of activity of unsealed byproduct material as
documented:
(1) In a written directive; or
(2) In accordance with the
directions of the authorized user for procedures pursuant to He-P 4035.27 and
He-P 4035.31.
(ab) “Prescribed dose” means:
(1) For gamma stereotactic
radiosurgery, the total dose as documented in the written directive;
(2) For teletherapy, the total
dose and dose per fraction as documented in the written directive;
(3) For manual brachytherapy,
either the total source strength and exposure time or the total dose, as
documented in the written directive; or
(4) For remote brachytherapy
afterloaders, the total dose and dose per fraction as documented in the written
directive.
(ac) “Pulsed dose-rate remote
afterloader” means a special type of remote afterloading brachytherapy device
that uses a single source capable of delivering dose rates in the “high
dose-rate” range, but:
(1) Is approximately one-tenth of the activity of typical high
dose-rate remote afterloader sources; and
(2) Is used to simulate the
radiobiology of a low dose-rate treatment by inserting the source for a given
fraction of each hour.
(ad) “Radiation Safety Officer” means an individual
who:
(1)
Meets the requirements in He-P 4035.61(a) or (c) and He-P 4035.73; or
(2) Is identified
as a radiation safety officer on a specific medical use license issued by
DHHS/RHS, or an agreement state, or the Nuclear Regulatory Commission, or a
medical use permit issued by a Nuclear Regulatory Commission master material
licensee.
(ae)
“Stereotactic radiosurgery” means the use of external radiation in
conjunction with a stereotactic guidance device to very precisely deliver a
therapeutic dose to a tissue volume.
(af) “Structured educational program” means an
educational program designed to impart particular knowledge and practical
education through interrelated studies and supervised training.
(ag) “Teletherapy” means a method of radiation
therapy in which collimated gamma rays are delivered at a distance from the
patient or human research subject.
(ah) “Temporary job site” means
a location where mobile medical services are conducted other than those
location(s) of use authorized on the license.
(ai) “Therapeutic dosage” means
a dosage of unsealed byproduct material that is intended to deliver a radiation
dose to a patient or human research subject for palliative or curative
treatment.
(aj) “Therapeutic dose” means a radiation dose delivered from a source
containing byproduct material to a patient or human research subject for
palliative or curative treatment.
(ak) “Treatment site” means the
anatomical description of the tissue intended to receive a radiation dose, as
described in a written directive.
(al)
“Unit dosage” means a dosage prepared for medical use for administration
as a single dosage to a patient or human research subject without any further
manipulation of the dosage after it is initially prepared.
(am) “Written directive” means an authorized user’s written order for the
administration of byproduct material or radiation from byproduct material to a
specific patient or human research subject, as specified in He-P 4035.13.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.04 License Required.
(a) No person shall
manufacture, produce, prepare, compound, acquire, receive, possess, use, or
transfer byproduct material for medical use except in accordance with a
specific license issued by DHHS/RHS, or an agreement state, or the Nuclear
Regulatory Commission, or as allowed in He-P 4035.04(b) or (c).
(b) A person shall receive,
possess, use, or transfer byproduct material in accordance with He-P 4035 under
the supervision of an authorized user as provided in He‑P 4035.11 unless
prohibited by license condition.
(c) A person shall prepare
unsealed byproduct material for medical use in accordance with He‑P 4035
under the supervision of an authorized nuclear pharmacist, or authorized user
as provided in He‑P 4035.11, unless prohibited by license condition.
(d) A person shall conduct
research involving human subjects using byproduct materials specified on a
license for the uses authorized on the license provided that:
(1) The research is conducted,
funded, supported, or regulated by a federal agency which has implemented the
Federal Policy for the Protection of Human Subjects and in accordance with He-P
4035.04(d)(2)b.; or
(2) The licensee has:
a. Applied for and received
approval of a specific amendment to its license prior to conducting such
research; and
b. Obtained informed consent
from the human subjects and has obtained prior review and approval of the
research activities by an “Institutional Review Board” in accordance with the
meaning of these terms as defined and described in the Federal Policy for the
Protection of Human Subjects.
(e) Nothing in He-P 4035.04(d)
relieves licensees from complying with other requirements in He-P 4035.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss
by #13048, eff 6-2-20; ss by #13473, eff 10-25-22
He-P 4035.05 License
Amendments. A licensee possessing a
license in accordance with He-P 4030 shall receive a license amendment before:
(a) Receiving, preparing, or
using byproduct material for a method or type of medical use not permitted by
the license issued under He-P 4035;
(b) Permitting anyone to work
as an authorized user, an authorized nuclear pharmacist, or an authorized
medical physicist, under the license;
(c) Changing a radiation safety
officer;
(d) Permitting an authorized
user or an individual qualified to be a radiation safety officer under He-P
4035.61 and He-P 4035.73 to:
(1) Function as a temporary
radiation safety officer; and
(2) Perform the functions of a
radiation safety officer in accordance with He-P 4035.10(d);
(e) Permitting an authorized
user or an individual qualified to be an associate radiation safety officer, or
before the radiation safety officer assigns duties and tasks to an associate
radiation safety officer that differ from those for which this individual is
authorized on the license;
(f) Receiving byproduct material that is in excess of the licensed
amount of radionuclide, or a different form, or a different radionuclide than
is authorized on the license;
(g) Receiving a sealed source
from a different manufacturer or of a different model number than authorized by
its license unless the sealed source is used for manual brachytherapy, is
listed in the sealed source and device registry, and is in a quantity and for
an isotope authorized by the license;
(h) Adding to or changing the
areas of use or address or addresses of use identified in the application or on
the license;
(i) Changing statements,
representations, and procedures which are incorporated into the license;
(j) Revising
procedures required by He-P 4035.50 and He-P 4035.55, if those revisions reduce
radiation safety.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #11011, eff
1-15-16; ss by #13048, eff 6-2-20; ss by #13473, eff 10-25-22
He-P 4035.06. Notifications. A licensee shall notify the DHHS/RHS in
writing within 30 days when an authorized user, an authorized nuclear
pharmacist, a radiation safety officer, an associate radiation safety officer,
an authorized medical physicist, or ophthalmic physicist permanently
discontinues performance of duties under the license, or has a name change, has
appointed a temporary radiation safety officer as provided in He-P 4035.10(d),
or has appointed an associate radiation safety officer as provided in He-P 4035.10(c).
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.07 Radiation
Protection Program Changes.
Radiation protection
program requirements shall be as follows:
(a) A
licensee shall revise its radiation protection program without DHHS/RHS
approval if:
(1) The
revision does not require a license amendment;
(2) The
revision is in compliance with the rules and the license;
(3) The
revision has been reviewed and approved by the radiation safety officer and
licensee management;
(4) The
affected individuals are instructed on the revised program before the changes
are implemented; and
(b) A
licensee shall retain a record of each radiation protection program change for
5 years. The record shall include:
(1) A
copy of the old and new procedures;
(2) The
effective date of the change; and
(3) The
signature of the licensee management that reviewed and approved the change.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.08 Radiation
Safety Officer.
(a) A licensee shall appoint a
radiation safety officer who agrees in writing, and with the approval of
DHHS/RHS, to be responsible for implementing the radiation protection program.
(b) The licensee, through the
radiation safety officer, shall ensure that radiation safety activities are
being performed in accordance with approved procedures and regulatory
requirements in the daily operation of the licensee’s byproduct material
program. A licensee’s management may appoint, in writing, one or more associate
radiation safety officers to support the radiation safety officer.
(c) With written agreement of
the licensee’s management, the radiation safety officer shall assign the
specific duties and tasks to each associate radiation safety officer in
accordance with He-P 4035.10(c). These
duties and tasks are restricted to the types of use for which the associated
radiation safety officer is listed on a license. The radiation safety officer shall not delegate
the authority or responsibilities for implementing the radiation protection
program.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #11011, eff
1-15-16; ss by #13048, eff 6-2-20; ss by #13473, eff 10-25-22
He-P 4035.09 Radiation
Safety Committee.
(a) Licensees that are
authorized for two or more different types of uses of byproduct material or two
or more types of units of photon emitting remote afterloader, teletherapy, and
gamma stereotactic radiosurgery shall establish a radiation safety committee to
oversee the uses of byproduct material permitted by the license.
(b) The radiation safety
committee required in He-P 4035.09(a) above shall meet the following
administrative requirements:
(1) Membership shall consist of
at least four individuals, as follows:
a. An authorized user of each
type of use permitted by the license;
b. The radiation safety
officer;
c. A representative of the
nursing service;
d. A representative of
management who is neither an authorized user nor a radiation safety officer;
and
e. Other members may be
included on the radiation safety committee as the licensee deems appropriate;
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.10
Statement of Authorities and Responsibilities.
(a) In addition to the radiation protection
program requirements of He-P 4020.04, a licensee's management shall approve in
writing as set forth in He-P 4030.01(c) the following:
(1) Requests for a license application, renewal,
or amendment before submittal to DHHS/RHS;
(2) Any individual before allowing that
individual to work as an authorized user, authorized nuclear pharmacist, or
authorized medical physicist; and
(3) Radiation protection program changes that do
not require a license amendment and are permitted under He-P 4035.07.
(b) A licensee's management shall appoint a
radiation safety officer, who agrees, in writing, to be responsible for implementing
the radiation protection program. The
licensee, through the radiation safety officer, shall ensure that radiation
safety activities are being performed in accordance with licensee-approved
procedures and regulatory requirements.
(c) A licensee’s management may appoint, in
writing, one or more associate radiation safety officers to support the
radiation safety officer. The radiation safety officer, with written agreement
of the licensee’s management, shall assign the specific duties and tasks to
each associate radiation safety officer. These duties and tasks are restricted
to the types of use for which the associate radiation safety officer is listed
on a license. The radiation safety officer may delegate duties and tasks to the
associate radiation safety officer but shall not delegate the authority or
responsibilities for implementing the radiation protection program.
(d) For up to 60 days each year, a licensee may
permit an authorized user, who may be temporarily appointed as a radiation
safety officer, or an individual qualified to be a radiation safety officer
under He-P 4035.61 and He-P 4035.71, to function as a temporary radiation
safety officer and to perform the functions of a radiation safety officer, as
provided in He-P 4035.10(g), if the licensee takes the actions required in He-P
4035.10(b), (c), (f), (g) and (h) and notifies DHHS/RHS in accordance with He-P
4035.05(d).
(e) A licensee may simultaneously appoint more
than one temporary radiation safety officer in accordance with He-P 4035.10(d),
if needed, to ensure that the licensee has a temporary radiation safety officer
who satisfies the requirements to be a radiation safety officer for each of the
different types of uses of byproduct material permitted by the license.
(f) A licensee shall establish the authority,
duties, and responsibilities of the radiation safety officer in writing.
(g) A licensee shall provide the radiation safety
officer sufficient authority, organizational freedom, time, resources, and
management prerogative; to:
(1) Identify radiation safety problems;
(2) Initiate, recommend, or provide corrective
actions;
(3) Stop unsafe operations; and
(4) Verify implementation of corrective actions.
(h) A licensee shall retain a record of actions
taken under He-P 4035.10(a), He-P 4035.10(b), He-P 4035.10(c),
and He-P 4035.10(e). A license shall
retain a record of actions for 5 years. The record, signed by the licensee
management shall include:
(1) A summary of the actions taken and a
signature of licensee management. The
licensee shall retain a copy of authority, duties, and responsibilities of the
radiation safety officer as required by He-P 4035.10(e);
(2) A signed copy of each radiation safety
officer’s agreement to be responsible for implementing the radiation
safety program, as required by He-P 4035.10(b) and (c), for the duration of the
license; and
(3) For each associate radiation safety officer
appointed under He-P 4035.10(b) and (c), the licensee shall retain, for 5 years
after the associate radiation safety officer is removed from the license, a
copy of the written document appointing the associate radiation safety officer
signed by the licensee’s management.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.11 Supervision.
(a) A licensee who permits the
receipt, possession, use, or transfer of byproduct material by an individual
under the supervision of an authorized user as allowed by He-P 4035.04(b)
shall:
(1) In addition to the requirements in He-P
4019.04, instruct the supervised individual in licensee’s written radiation
protection procedures, written directive procedures, He-P 4035, and the license
conditions with respect to the use of byproduct material; and
(2) Require the supervised individual to follow
the instructions of the supervising authorized user for medical uses of
byproduct material, written radiation protection procedures established by the
licensee, written directive procedures, He-P 4035, and the license conditions
with respect to the medical use of byproduct material.
(b) A licensee that permits the preparation of
byproduct material for medical use by an individual under the supervision of
an authorized nuclear pharmacist, or physician who is an authorized user, as
allowed by He-P 4035.04(c), shall:
(1) In addition to the requirements in He-P
4019.04, instruct the supervised individual in the preparation of byproduct
material for medical use, as appropriate to that individual’s involvement with
byproduct material; and
(2) Require the supervised individual to follow
the instructions of the supervising authorized user or authorized nuclear
pharmacist regarding the preparation of byproduct material for medical use, the
written radiation protection procedures established by the licensee, the
written directive procedures, the applicable sections of He-P 4035, and the
license conditions.
(c) A licensee that permits supervised activities under He-P
4035.04(a) and (b) shall be responsible for the acts and
omissions of the supervised individual.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.12 Mobile Medical
Service Administrative Requirements.
(a) DHHS/RHS shall license
mobile medical services and/or clients of such services, limited to the
following services:
(1) Uptake, dilution and
excretion;
(2) Imaging and localization;
(3) Sealed sources in
diagnosis; and
(4) Certain in-vitro clinical
or laboratory testing.
(b) The client of the mobile
medical service shall be licensed by DHHS/RHS if the client receives or
possesses byproduct material to be used by a mobile medical service.
(c) Mobile medical service
licensees shall obtain a letter signed by the management of each client for
which services are rendered that permits the use of byproduct material at the
client’s address and clearly delineates the authority and responsibility of the
licensee and the client. Each letter
shall be retained 3 years after the last provision of service.
(d) If the client is licensed,
the letter shall document procedures for notification, receipt, storage and
documentation of transfer of byproduct material delivered to the client’s
location for use by the mobile medical service.
(e) A mobile medical service
shall not have byproduct material delivered directly from the manufacturer or
the distributor to the client’s address of use, unless the client has a license
to receive and possess that byproduct material.
(f) Byproduct material
delivered to the client’s address of use shall be received and handled in
conformance with the client’s license.
The mobile medical service shall:
(1) Check instruments used to measure the
activity of unsealed byproduct material for proper function before medical use
at each client's address or on each day of use, whichever is more frequent. At
a minimum, the check for proper function shall include a constancy check;
(2) Check survey instruments for proper operation
with a dedicated check source before use at each client's address; and
(3) Before leaving a client's address, survey all
areas of use to ensure compliance with the requirements in He-P 4022.
(g) A mobile medical service
shall inform a responsible individual, such as a representative of management,
a registered nurse in charge of the patient, or the registered nurse in charge
of the nursing unit, who is on site at each client’s address of use at the time
that radiopharmaceuticals are being administered.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #11011, eff
1-15-16; ss by #13048, eff 6-2-20; ss by #13473, eff 10-25-22
He-P 4035.13 Written
Directives and Procedures for Administrations Requiring a Written Directive.
(a) A written directive shall be dated and signed
by an authorized user before the administration of I-131 sodium iodide greater
than 1.11 megabecquerels (MBq) (30 microcuries (µCi)), any therapeutic dosage
of unsealed byproduct material, or any therapeutic dose of radiation from
byproduct material.
(b) If, because of the emergent nature of the
patient’s condition, a delay in order to provide a written directive would
jeopardize the patient’s health, an oral directive is acceptable. The
information contained in the oral directive shall be documented as soon as
possible, in writing, in the patient’s record. A written directive shall be
prepared within 48 hours of the oral directive.
(c) The written directive shall contain the
patient or human research subject’s name and the following information:
(1) For any administration of
quantities greater than 1.11 megabecquerel (30 microcuries) of sodium iodide
I-131: the dosage;
(2) For an administration of a therapeutic
dosage of unsealed byproduct material other than sodium iodide I-131: the
radioactive drug, dosage, and route of administration;
(3) For gamma stereotactic
radiosurgery: the total dose, treatment site, and values for the target
coordinate settings per treatment for each anatomically distinct treatment
site;
(4) For teletherapy: the total
dose, dose per fraction, number of fractions, and treatment site;
(5) For high dose-rate remote
afterloading brachytherapy: the radionuclide, treatment site, dose per
fraction, number of fractions, and total dose;
(6) For permanent implant
brachytherapy:
a. Before implantation:
treatment site, the radionuclide, and the total source strength; and
b. After implantation but
before the patient leaves the post-treatment recovery area: the treatment site,
the number of sources implanted, the total source strength, and the date; or
(7) For all other
brachytherapy, including low, medium, and pulsed dose rate remote afterloaders:
a. Before implantation: the treatment site, the radionuclide, and
dose; and
b. After implantation but before completion of the procedure: the radionuclide, treatment site, number of
sources, and total source strength and exposure time (or the total dose).
(d) A written revision to an
existing written directive may be made if the revision is dated and signed by
an authorized user before the administration of the dosage of unsealed
byproduct material, the brachytherapy dose, the gamma stereotactic radiosurgery
dose, the teletherapy dose, or the next fractional dose.
(e) If, because of the patient’s condition, a delay in order to
provide a written revision to an existing written directive would jeopardize the patient’s health, an
oral revision to an existing directive
shall be acceptable.
(f) The oral directive shall be
documented as soon as possible in the patient’s record. A revised written
directive shall be signed by the authorized user within 48 hours of the oral
revision.
(g) The licensee shall retain a
copy of each written directive in accordance with He-P 4035.13 for 3 years.
(h) For any administration
requiring a written directive, the licensee shall develop, implement, and
maintain written procedures to provide high confidence that:
(1) The patient or human
subject’s identity is verified before each administration; and
(2) Each administration is in
accordance with the written directive.
(i) At a minimum, the procedures required by
He-P 4035.13(h) shall address the following items that are applicable to the
licensee's use of byproduct material:
(1) Verifying the identity of the patient or
human research subject;
(2) Verifying that the administration is in
accordance with the treatment plan, if applicable, and the written directive;
(3) Checking both manual and computer-generated
dose calculations;
(4)
Verifying that any computer-generated dose calculations are correctly
transferred into the consoles of therapeutic medical units authorized by He-P
4035.29 or He-P 4035.47;
(5) Determining if a medical event, as defined in
He-P 4035.14, has occurred; and
(6) Determining,
for permanent implant brachytherapy, within 60 calendar days from the date the
implant was performed, the total source strength administered outside of the
treatment site compared to the total source strength documented in the
post-implantation portion of the written directive, unless a written
justification of patient unavailability is documented.
(j) A licensee shall retain a copy of the
procedures under He-P 4035.13(h) for the duration of the license.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; amd by #11108, eff
5-25-16; amd by #12054, eff 11-19-16; ss by #13048, eff 6-2-20; ss by #13473,
eff 10-25-22
He-P 4035.14 Notifications and Reports of Medical
Events.
(a) Each licensee shall report any medical event
to DHHS/RHS, except for an event that results from patient intervention, in
which the administration of byproduct material or radiation from byproduct
material, except permanent implant brachytherapy, results in:
(1) A dose that differs from the prescribed dose
or dose that would have resulted from the prescribed dosage by more
than 0.05 Sievert (5 rem) effective dose equivalent, 0.5 Sievert (50 rem) to an
organ or tissue, or 0.5 Sievert (50 rem) shallow dose equivalent to the skin;
and
a. The total dose delivered
differs from the prescribed dose by 20 percent or more;
b. The total dosage delivered
differs from the prescribed dosage by 20 percent or more or falls outside the
prescribed dosage range; or
c. The fractionated dose
delivered differs from the prescribed dose, for a single fraction, by 50 percent
or more.
(2) A dose that exceeds 0.05 Sievert (5 rem)
effective dose equivalent, 0.5 Sievert (50 rem) to an organ or tissue, or 0.5
Sievert (50 rem) shallow dose equivalent to the skin from any of the following:
a. An administration of a wrong
radioactive drug containing byproduct material or the wrong radionuclide for a
brachytherapy procedure;
b. An administration of a
radioactive drug containing byproduct material by the wrong route of
administration;
c. An administration of a dose
or dosage to the wrong individual or human research subject;
d. An administration of a dose
or dosage delivered by the wrong mode of treatment; or
e. A leaking sealed source;
(3) A dose to the skin or an organ or tissue
other than the treatment site that exceeds by:
a. 0.5 Sievert (50 rem) or more
of the expected dose to that site from the procedure if the administration had
been given in accordance with the written directive prepared or revised before
administration; and
b. Fifty percent or more of the
expected dose to that site from the procedure if the administration had been
given in accordance with the written directive prepared or revised before
administration.
(4) For permanent implant brachytherapy, the
administration of byproduct material or radiation from byproduct material
(excluding sources that were implanted in the correct site but migrated outside
the treatment site) that results in:
a. The total source
strength administered differing by 20 percent or more from the total source
strength documented in the post-implantation portion of the written directive;
b. The total source strength administered
outside of the treatment site exceeding 20 percent of the total source strength
documented in the post-implantation portion of the written directive; or
c. An administration that includes the wrong
radionuclide; the wrong individual or human research subject; sealed source(s)
implanted directly into a location discontinuous from the treatment site,
as documented in the post-implantation portion of the written directive; or a
leaking sealed source resulting in a dose that exceeds 0.5 Sievert (50 rem) to
an organ or tissue.
(b) A licensee shall report any event resulting
from intervention of a patient or human subject in which the administration of
byproduct material or radiation from byproduct material results or will result
in unintended permanent functional damage to an organ or a physiological
system, as determined by a physician.
(c) The licensee shall notify by telephone the
DHHS/RHS no later than the next calendar day after the discovery of the medical
event.
(d) By an appropriate method listed in He-P
4001.08, the licensee shall submit a written report to the DHHS/RHS within 15
days after discovery of the medical event.
(e) The written report required in He-P
4035.14(b) shall contain:
(1) The licensee’s name;
(2) The name of the prescribing
physician;
(3) A brief description of the
medical event, why it occurred, the effect, if any, on the individual(s) who
received administration;
(4) What actions, if any, have
been taken or are planned to prevent recurrence;
(5) Certification that the
licensee notified the individual (or the individual’s responsible relative or
guardian) and if not, why not; and
(6) The report shall not
contain the individual’s name or any other information that could lead to
identification of the individual.
(f) The licensee shall provide notification of
the event to the referring physician and also notify the individual who is the subject
of the medical event no later than 24 hours after its discovery, unless the
referring physician personally informs the licensee either that he or she will
inform the individual or that, based on medical judgment, telling the
individual would be harmful. The licensee is not required to notify the
individual without first consulting the referring physician. If the referring
physician or the affected individual cannot be reached within 24 hours, the
licensee shall notify the individual as soon as possible thereafter. The
licensee may not delay any appropriate medical care for the individual,
including any necessary remedial care as a result of the medical event, because
of any delay in notification. To meet the requirements of He-P 4035.14(f), the
notification of the individual who is the subject of the medical event may be
made instead to that individual's responsible relative or guardian. If a verbal
notification is made, the licensee shall inform the individual, or appropriate
responsible relative or guardian that a written description of the event can be
obtained from the licensee upon request. The licensee shall provide such a
written description if requested.
(g) Aside from the notification requirement,
nothing in He-P 4035.14 affects any rights or duties of licensees and
physicians in relation to each other, to individuals affected by the medical
event, or the individual’s responsible relatives or guardians.
(h) A licensee shall annotate a copy of the
report provided to the DHHS/RHS with the name of the individual who is the
subject of the event and identification number or if no other identification
number is available, the social security number of the individual who is the
subject of the event. Provide a copy of
the annotated report to the referring physician, if other than the licensee, no
later than 15 days after the discovery of the event.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-23
He-P 4035.15 Suppliers for
Sealed Sources or Devices for Medical Use.
A licensee shall use for medical use only:
(a) Sealed sources, or devices
manufactured, produced, labeled, prepared, compounded, packaged, and
distributed in accordance with a license issued pursuant to He-P 4030 and He‑P
4032.07 or the equivalent regulations of an agreement state or the Nuclear
Regulatory Commission;
(b) Sealed sources, or devices
non-commercially transferred from a DHHS/RHS licensee, or an agreement state
medical use licensee or a Nuclear Regulatory Commission Part 35 licensee; and
(c) Teletherapy sources
manufactured and distributed in accordance with a license issued pursuant to He‑P
4030, He-P 4032.05, and He-P 4032.06 or the equivalent regulations of an
agreement state or the Nuclear Regulatory Commission.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-23
He-P 4035.16 RESERVED
rpld by #13473,
eff 10-25-22
He-P 4035.17 Possession, Use, Calibration, and Check of
Dose Calibrators.
(a) For direct measurements performed in
accordance with He-P 4035.19, a licensee shall possess and use instrumentation
to measure the activity of unsealed byproduct materials before it is
administered to each patient or human research subject.
(b) A licensee shall calibrate the instrumentation
required in He-P 4035.17(a) in accordance with nationally recognized standards
or the manufacturer’s instructions.
(c) A licensee shall retain a record of each
instrument calibration for 3 years. The
records shall include:
(1) The
model and serial number of the instrument;
(2) The
date of the calibration;
(3) The
results of the calibration; and
(4) The
name of the individual who performed the calibration.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.18 Calibration of
Survey Instruments.
(a) A licensee shall calibrate
the survey instruments used to show compliance with He-P 4020 through He-P 4023
before first use, at intervals not to exceed 12 months, and following repair
that affects the calibration.
(b) To satisfy the requirements
of He-P 4035.18(a), the licensee shall:
(1) Calibrate all required
scale readings up to 10 millisieverts (1000 mrem) per hour with a radiation
source;
(2) Calibrate 2 separated
readings on each scale or decade that will be used to show compliance; and
(3) Clearly mark the date of
calibration on the instrument.
(c) To satisfy the requirements
of He-P 4035.18(b), the licensee shall use survey instruments if the difference
between the indicated exposure rate and the calculated exposure rate is less
than 20 percent.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20; ss by #13473, eff 10-25-22
He-P 4035.19 Assay of
Dosages of Unsealed Byproduct Material for Medical Use. A licensee shall meet the following
requirements for determination of dosages of unsealed byproduct material:
(a) A licensee shall determine and record the
activity of each dosage prior to medical use;
(b) For
a unit dosage, this determination shall be made by:
(1)
Direct measurement of radioactivity; or
(2) A
decay correction, based on the activity or activity concentration determined
by:
a. A
manufacturer or preparer licensed under He-P 4032.05, or the equivalent
requirements of an agreement state, or the Nuclear Regulatory Commission;
b. A
DHHS/RHS, or an agreement state or a Nuclear
Regulatory Commission licensee for use in research in accordance with a
Radioactive Drug Research Committee-approved protocol or an Investigational New
Drug (IND) protocol accepted by FDA; or
c. A
PET radioactive drug producer licensed under He-P 4032.05, the equivalent
requirements of an agreement state, or the Nuclear Regulatory Commission;
(c) For
other than unit dosages, this determination shall be made by:
(1)
Direct measurement of radioactivity; and either
(2)
Combination of measurement of radioactivity and mathematical
calculations; or
(3) Combination of volumetric measurements and
mathematical calculations, based on the measurement made by:
a. A
manufacturer or preparer licensed under He-P 4032.05, or the equivalent requirements
of an agreement state, or the Nuclear Regulatory Commission; or
b. A
PET radioactive drug producer licensed under He-P 4032.05, the equivalent
requirements of an agreement state, or Nuclear
Regulatory Commission;
(d)
Unless otherwise directed by the authorized user, a licensee shall not
use a dosage if the dosage does not fall within the prescribed dosage range or
if the dosage differs from the prescribed dosage by more than 20 percent; and
(e) A
licensee shall retain a record of the dosage determination required by He-P
4035.19 for 3 years. The record shall include:
(1) The
radiopharmaceutical;
(2) The
patient’s or human research subject’s name, or identification number if one has
been assigned;
(3) The
prescribed dosage, the determined dosage, or a notation that the total activity
is less than 1.1 megabecquerels (30 microcuries);
(4) The
date and time of the dosage determination; and
(5) The
name of the individual who determined the dosage.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.20 Authorization
for Calibration, Transmission, and Reference Sources. Any person authorized by He‑P 4035.04
for medical use of byproduct material may receive, possess, and use the
following byproduct material for check, calibration, transmission, and
reference use:
(a) Sealed sources that do not
exceed 1.11 gigabecquerels (30 millicuries) each that are:
(1) Manufactured and
distributed by persons specifically licensed pursuant to He‑P 4032, or
the equivalent provisions of an agreement state, or the Nuclear Regulatory
Commission; or
(2) Redistributed by persons
specifically licensed to redistribute the sealed sources manufactured and
distributed by a person licensed pursuant to He-P 4032, or the equivalent
provisions of an agreement state, or the Nuclear Regulatory Commission,
providing the redistributed sealed sources are in the original packaging and
shielding and are accompanied by the manufacturer’s approved instructions;
(b) Any byproduct material with
a half-life of 120 days or less in individual amounts not to exceed 555
megabecquerels (15 millicuries);
(c) Any byproduct material with
a half-life greater than 120 days in individual amounts not to exceed 7.4
megabecquerels (200 microcuries) each or 1000 times the quantities listed in
He-P 4096.01; and
(d) Technetium-99m in
individual amounts as needed.
(e) Byproduct material in
sealed sources authorized by this provision shall not be:
(1) Used for medical use as defined in He-P
4035.03 except in accordance with the requirements in He-P 4035.39; or
(2) Combined (i.e. bundled or aggregated) to
create an activity greater than the maximum activity of any single sealed
source authorized under He-P 4035.20.
(f) A
licensee using calibration, transmission, and reference sources in accordance
with the requirements in He-P 4035.20(a) through (d) or He-P 4035.20(e) need
not list these sources on a specific medical use license.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.21 Requirements for Possession of Sealed
Sources and Brachytherapy Sources.
(a) A licensee in possession of any sealed source
or brachytherapy source shall follow the radiation safety and handling
instructions supplied by the manufacturer or equivalent instructions.
(b) A licensee in possession of a sealed source
shall ensure that:
(1) The source is tested for leakage before its
first use unless the licensee has a certificate from the supplier indicating
that the source was tested within 6 months before transfer to the licensee; and
(2) The source is tested for leakage at intervals
not to exceed 6 months or at intervals approved by DHHS/RHS, or another
agreement state or the Nuclear Regulatory Commission in the Sealed Source and
Device Registry.
(c) To satisfy the leak test requirements of He‑P
4035.21(b), the licensee shall ensure that leak tests are capable of detecting
the presence of 185 becquerels (0.005 microcurie) of radioactive material on
the test sample.
(d) A licensee shall retain leak test records for
3 years.
(e) The leak test records shall contain:
(1) The model number;
(2) Serial number, if assigned, of each source
tested;
(3) The identity of each source radionuclide;
(4) The estimated activity of each source
radionuclide;
(5) The measured activity of each test sample
expressed in becquerels (microcuries);
(6) The date of the test; and
(7) The name of the individual who performed the
test.
(f) If the leak test reveals the presence of 185 becquerels
(0.005 microcurie) or more of removable contamination, the licensee shall:
(1) Immediately withdraw the sealed source from
use and store, repair or dispose of it in accordance with the requirements of
He‑P 4023; and
(2) File a report as described in He-P 4035.21(e)
with DHHS/RHS within 5 days of receiving the leak test results describing the
equipment involved, the test results, and the action taken.
(g) A licensee:
(1) Shall not be required to perform a leak test
on the following sources:
a. Sources containing only
byproduct material with a half-life of less than 30 days;
b. Sources containing only
byproduct material as a gas;
c. Sources containing 3.7
megabecquerels (100 microcuries) or less of beta or gamma-emitting material or
370 kilobecquerels (10 microcuries) or less of alpha-emitting material;
d. Seeds of iridium-192 encased
in nylon ribbon; and
e. Sources stored and not being
used; but
(2) Shall test each such source in (g)(1) above
for leakage before any use or transfer unless it has been tested for leakage
within 6 months before the date of use or transfer.
(h) A licensee in possession of a sealed source
or brachytherapy source, except for gamma stereotactic radiosurgery sources,
shall conduct a physical inventory of all such sources in its possession at
intervals not to exceed 6 months.
(i) The licensee shall retain each sealed source
inventory record for 3 years.
(j) The sealed source inventory records shall
contain:
(1) The model number of each source;
(2) The serial number, if one has been assigned;
(3) The identity of each source radionuclide;
(4) The estimated activity of each source radionuclide;
(5) The location of each source;
(6) The date of the inventory; and
(7) The name of the individual who performed the
inventory.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.22 Reserved
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; rpld by #11011, eff 1-15-16
He-P 4035.23 Syringe and
Vial Shields and Labels.
(a) Each syringe and vial that
contains unsealed byproduct material shall be labeled to identify the
radioactive drug.
(b) Each syringe shield and
vial shield shall also be labeled unless the label on the syringe or vial is
visible when shielded.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13473, eff
10-25-22
He-P 4035.24 Surveys for
Ambient Radiation Exposure Rate.
(a) In addition to the surveys
required by He-P 4022, a licensee shall survey with a radiation detection
survey instrument at the end of each day of use all areas where unsealed
byproduct material requiring a written directive is prepared for use or
administered.
(b) A licensee shall not need
to perform the surveys required by He-P 4035.24(a) above in the area(s) where
patients or human research subjects are confined when they cannot be released
under He-P 4035.25.
(c) A licensee shall retain a
record of each survey required by He‑P 4035.24(a) for 3 years.
(d) The survey record required
in He-P 4035.24(a) shall include:
(1) The date of the survey;
(2) A sketch of each area
surveyed and the results of the survey;
(3) The serial number and the model number of the instrument used to
make the survey or analyze the samples; and
(4) The name of the individual
who performed the survey.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.25 Release of
Individuals Containing Unsealed Byproduct Material or Implants Containing
Byproduct Material.
(a) A licensee shall authorize
the release from its control any individual who has been administered unsealed
byproduct material or implants containing byproduct material if:
(1) The total effective dose
equivalent to any other individual from exposure to the released individual is
not likely to exceed 5 millisieverts (0.5 rem); or
(2) The calculated doses, based
on methods and tables of activities described in NUREG-1556 (Vol. 9),
“Consolidated Guidance about Materials Licenses: Program-Specific Guidance
About Medical Use Licenses” show that the total effective dose equivalent to
any other individual from exposure to the released individual is not likely to
exceed 5 millisieverts (0.5 rem).
(b) A licensee shall provide the released
individual, or the individual's parent or guardian, with instructions,
including written instructions, on actions recommended to maintain doses to
other individuals as low as is reasonably achievable if the total effective
dose equivalent to any other individual is likely to exceed 1 millisievert (0.1
rem).
(c) If
the total effective dose equivalent to a nursing infant or child could exceed 1
millisievert (0.1 rem), assuming there are no interruption of breast-feeding,
the instructions shall also include:
(1) Guidance
on the interruption or discontinuation of breast-feeding; and
(2)
Information on the potential consequences, if any, of failure to follow
the guidance.
(d) A
licensee shall maintain a record of the basis for authorizing the release of an
individual in accordance with He-P 4035.25(f)(1).
(e) The licensee shall
maintain a record of instructions provided to a breast-feeding female in
accordance with He-P 4035.25(f)(2).
(f)
Records of the released individuals containing unsealed byproduct
material or implants containing byproduct material:
(1) A licensee shall retain a record of the basis
for authorizing the release of an individual in accordance with He-P 4035.25,
if the total effective dose equivalent is calculated by:
a. Using
the retained activity rather than the activity administered;
b.
Using an occupancy factor less than 0.25 at 1 meter;
c.
Using the biological or effective half-life; or
d. Considering
the shielding by tissue;
(2) A
licensee shall retain a record that the instructions required by He-P
4035.25(b) and (c) were provided to a breast-feeding female if the radiation
dose to the infant or child from continued breast-feeding could result in a
total effective dose equivalent exceeding 5 millisieverts (0.5 rem); and
(3)
The records required by He-P 4035.25(f)(1) and (f)(2) above shall be
retained for 3 years after the date of release of the individual.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.26 Provision of
Mobile Medical Service.
(a) A licensee providing mobile
medical service shall:
(1) Obtain a letter signed by
the management of each client for which services are rendered that permits the
use of byproduct material at the client’s address and clearly delineates the
authority and responsibility of the licensee and the client;
(2) Check the instruments used
to measure the activity of unsealed byproduct material for proper function
before medical use at each client’s address, or on each day of use, whichever
is more frequent. At a minimum, the
check for proper function required by He-P 4035.26 shall include a constancy
check;
(3) Check the survey
instruments for proper operation with a dedicated check source before use at
each client’s address; and
(4) Before leaving a client’s
address, complete a survey all areas of use to ensure compliance with the
requirements of He-P 4020 through He-P 4023.
(b) A mobile medical service
shall not have byproduct material delivered from the manufacturer or the
distributor to the client’s address unless the client has a license allowing
possession of the byproduct material.
Byproduct material delivered to the client shall be received and handled
in conformance with the client’s license.
(c) A licensee providing mobile
medical services shall retain a copy of the letter required in He-P
4035.26(a)(1) and the record of each survey required in He-P 4035.26(a)(4) for
3 years. The records shall include:
(1) The copy of the letter that
clearly delineates the authority and responsibility of the licensee and the
client; and
(2) For each survey done, the
following:
a. The date of the survey;
b. The results of the survey;
c. The instrument used to make
the survey; and
d. The name of the individual
who performed the survey.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.27 Use of Unsealed
Byproduct Material for Uptake, Dilution, and Excretion Studies for Which a
Written Directive is Not Required.
(a) Except for quantities that
require a written directive under He-P 4035.13(c), a licensee may use any
unsealed byproduct material prepared for medical use for uptake, dilution, or
excretion studies that is:
(1) Obtained from:
a. A manufacturer or preparer
licensed under He-P 4032.05, or the equivalent requirements of an agreement
state, or the Nuclear Regulatory Commission;
b. A PET radioactive drug
producer licensed under He-P 4030.07(k), or the equivalent requirements of an
agreement state, or the Nuclear Regulatory Commission.
(2) Prepared by, excluding
production of PET radionuclides:
a. An authorized nuclear
pharmacist;
b. A physician who is an
authorized user and who meets the requirements specified in He-P 4035.64, or
He-P 4035.65 and He-P 4035.64(c)(1)b.7;
c. An individual under the
supervision, as specified in He-P 4035.11, of the authorized nuclear pharmacist
in He-P 4035.27(a)(2)a. or the physician who is an authorized user in He-P 4035.27(a)(2)b.; or
(3) Obtained from and prepared
by a DHHS/RHS, or an agreement state, or the Nuclear Regulatory Commission
licensee for use in research in accordance with a Radioactive Drug Research
Committee-approved protocol or an Investigational New Drug (IND) protocol
accepted by FDA; or
(4) Prepared by the licensee
for use in research in accordance with a Radioactive Drug Research
Committee-approved application or an Investigational New Drug (IND) protocol
accepted by FDA.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.28 Decay-In-Storage.
(a) A licensee may hold
byproduct material for decay-in-storage if the material has a physical
half-life of less than or equal to 120 days.
(b) Before disposal without
regard to its activity, a licensee shall hold byproduct material for
decay-in-storage and shall be exempt from the waste disposal requirements of He‑P
4023 if the licensee:
(1) Monitors byproduct material at the surface before disposal and
determines that its radioactivity cannot be distinguished from the background
radiation level with an appropriate radiation detection survey instrument set
on its most sensitive scale and with no interposed shielding;
(2) Removes or obliterates all
radiation labels, except for radiation labels on materials that are within
containers; and
(3) Manages as biomedical waste
after they have been released from the licensee.
(c) For licensed material
disposed in accordance with He‑P 4035.28(b), the licensee shall retain a
record of each disposal for 3 years.
(d) The disposal record shall
include:
(1) The date of the disposal;
(2) The model and serial number
of the survey instrument used;
(3) The background radiation
level;
(4) The radiation level
measured at the surface of each waste container; and
(5) The name of the individual
who performed the survey.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13473, eff
10-25-22
He-P 4035.29 Other Medical Uses of Byproduct Material or
Radiation From Byproduct Material. A licensee may use byproduct
material or a radiation source approved for medical use which is not
specifically addressed in He-P 4035 if:
(a) The
applicant or licensee has submitted the information required by He-P 4030; and
(b) The
applicant or licensee has received written approval from DHHS/RHS in a license
or license amendment and uses the material in accordance with the regulations
and specific conditions DHHS/RHS considers necessary for the medical use of the
material.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13473, eff
10-25-22
He-P 4035.30 RESERVED
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; rpld by #11011, eff 1-15-16
He‑P
4035.31 Use of Unsealed Byproduct
Material for Imaging and Localization Studies for Which a Written Directive Is
Not Required. Except for quantities
that require a written directive under He-P 4035.13(c), a licensee may use any
unsealed byproduct material prepared for medical use for imaging and
localization studies that is:
(a) Obtained from:
(1) A
manufacturer or preparer licensed under He-P 4032.05, the equivalent
requirements of an agreement state, or Nuclear Regulatory Commission; or
(2) A PET radioactive drug producer licensed
under He-P 4030.07(k), the equivalent requirements of an agreement state, or
Nuclear Regulatory Commission; or
(b) Prepared by, excluding production of PET
radionuclides:
(1) An authorized nuclear pharmacist;
(2) An authorized
user physician who meets the requirements of He-P 4035.64 or He-P
4035.64(c)(1)b.7 and He-P 4035.65; or
(3) An individual under the supervision, as
specified in He-P 4035.11, of the authorized nuclear pharmacist in He-P
4035.31(b)(1) or the physician who is an authorized user in He-P 4035.31(b)(2);
(c) Obtained from and prepared by DHHS/RHS,
another agreement state, or a Nuclear Regulatory Commission licensee for use in
research in accordance with a Radioactive Drug Research Committee-approved
protocol or an Investigational New Drug (IND) protocol accepted by FDA; or
(d) Prepared by the licensee for use in research
in accordance with a Radioactive Drug Research Committee-approved application
or an Investigational New Drug (IND) protocol accepted by FDA.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.32 Permissible
Molybdenum-99, Strontium-82, Strontium-85 Concentrations, and Strontium-90
Sources for Ophthalmic Treatments.
(a) A licensee shall
not administer to humans a radiopharmaceutical that contains:
(1) More than 0.15 kilobecquerel of molybdenum-99
per megabecquerel of technetium-99m (0.15 microcurie of molybdenum-99 per
millicurie of technetium-99m); or
(2) More than 0.02 kilobecquerel of strontium-82
per megabecquerel of rubidium-82 chloride injection (0.02 microcurie of
strontium-82 per millicurie of rubidium-82 chloride); or more than 0.2 kilobecquerel
of strontium-85 per megabequerel of rubidium-82 chloride injection (0.2
microcurie of strontium-85 per millicurie of rubidium-82).
(b) A licensee that uses
molybdenum-99/technetium-99m generators for preparing a technetium-99m
radiopharmaceutical shall measure the molybdenum-99 concentration in each
eluate from a generator to demonstrate compliance with He-P 4035.32(a).
(c)
A licensee that uses a strontium-82/rubidium-82 generator for preparing a
rubidium-82 radiopharmaceutical
shall, before the first patient use of the day, measure the concentration of
radionuclides strontium-82 and strontium-85 to demonstrate compliance with He-P
4035.32(a).
(d) If a licensee is required to measure the
molybdenum-99 concentration or strontium-82 and strontium-85
concentrations, the licensee shall retain a record of each measurement. A licensee shall maintain the record for 3
years. The record shall include:
(1)
For each measured elution of technetium-99m, the ratio of the measures
expressed as kilobecquerel of molybdenum-99 per megabecquerel of technetium-99m
(or microcuries of molybdenum per millicurie of technetium), the time and date
of the measurement, and the name of the individual who made the measurement; or
(2) For each measured elution of rubidium-82, the
ratio of the measures expressed as kilobecquerel of strontium-82 per
megabecquerel of rubidium-82 (or microcuries of strontium-82 per millicurie of
rubidium) and kilobecquerel of strontium-85 per megabecquerel of rubidium-82
(or microcuries of strontium-85 per millicurie of rubidium), the time and date
of the measurement, and the name of the individual who made the measurement.
(e) The licensee shall report any measurement
that exceeds the limits in He-P 4035.32(a) at the time of generator elution, in
accordance with the following:
(1) The licensee shall notify by telephone
DHHS/RHS and the distributor of the generator within 7 calendar days after
discovery that an eluate exceeded the permissible concentration listed in He-P
4035.32(a) at the time of generator elution. The telephone report to DHHS/RHS
shall include the manufacturer, model number, and serial number (or lot number)
of the generator; the results of the measurement; the date of the measurement;
whether dosages were administered to patients or human research subjects, when
the distributor was notified, and the action taken.
(2) By an appropriate method listed in He-P
4001.08, the licensee shall submit a written report to DHHS/RHS within 30
calendar days after discovery of an eluate exceeding the permissible
concentration at the time of generator elution. The written report shall
include the action taken by the licensee; the patient dose assessment; the
methodology used to make this dose assessment if the eluate was administered to
patients or human research subjects; and the probable cause and an assessment
of failure in the licensee's equipment, procedures or training that contributed
to the excessive readings if an error occurred in the licensee's breakthrough
determination; and the information in the telephone report as required by He-P
4035.32(e)(1).
(f) Licensees who use strontium-90 for ophthalmic
treatments shall ensure that certain activities as specified in He-P 4035.32(g)
and (h) are performed by either:
(1) An authorized medical physicist; or
(2) An individual who is identified as an
ophthalmic physicist on a specific medical use license issued by DHHS\RHS, an
agreement state, or the Nuclear Regulatory Commission; permit issued by
DHHS/RHS, an agreement state, or a Nuclear Regulatory Commission broad scope
medical use licensee; medical use permit issued by a Nuclear Regulatory
Commission master material license; or permit issued by a Nuclear Regulatory
Commission master material licensee broad scope medical use permittee; and
a. Holds a master’s or doctor’s
degree in physics, medical physics, other physical sciences, engineering, or
applied mathematics from an accredited college or university; and
b. Has successfully completed 1
year of full-time training in medical physics and an additional year of
full-time work experience under the supervision of a medical physicist; and has
documented training in:
1. The creation, modification,
and completion of written directives;
2. Procedures for
administrations requiring a written directive; and
3. Performing the calibration
measurements of brachytherapy sources as detailed in He-P 4035.46.
(g) The individuals who are identified in He-P
4035.32(f) shall calculate the activity of each strontium-90 source that is
used to determine the treatment times for ophthalmic treatments. The decay calculation shall be based on the
activity determined under He-P 4035.46.
(h)
The individuals who are identified in He-P 4035.32(f) shall assist the licensee
in developing, implementing, and maintaining written procedures to provide high
confidence that the administration is in accordance with the written
directives. These procedures shall
include the frequencies that the individual meeting the requirements in He-P
4035.32(f) will:
(1) Observe treatments;
(2) Review the treatment methodology;
(3) Calculate treatment time for the prescribed
dose; and
(4) Review records to verify that the
administrations were in accordance with the written directives.
(i) A licensee shall retain a record of the
activity of each strontium-90 source required by He-P 4035.32(f) and (g) for
the life of the source. The record shall
include:
(1) The date and initial activity of the source
as determined under He-P 4035.46; and
(2) For each decay calculation, the date and the
source activity as determined under He-P 4035.32(g).
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #11011, eff
1-15-16; ss by #13048, eff 6-2-20; ss by #13473, eff 10-25-22
He-P 4035.33 RESERVED
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; rpld by #13473, eff
10-25-22
He-P 4035.34 RESERVED
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; rpld by #11011, eff 1-15-16
He-P 4035.35 Use of Unsealed Byproduct Material—Written
Directive Required. A licensee shall
use any unsealed byproduct material identified in He-P 4035.65(b)(2)b.,
prepared for medical use and for which a written directive is required that is:
(a) Obtained from one of the following:
(1) A manufacturer or preparer licensed under He-P 4032.05, or the equivalent
requirements of an agreement state, or the Nuclear Regulatory Commission; or
(2) A PET radioactive drug producer licensed under He-P 4030.07(k), or
the equivalent requirements of an agreement state, or the Nuclear Regulatory
Commission; or
(b) Excluding production of PET radionuclides,
prepared by:
(1) An authorized nuclear
pharmacist;
(2) A physician who is an
authorized user and who meets the requirements specified under He-P 4035.64 or
He-P 4035.65; or
(3) An individual under the
supervision, as specified in He-P 4035.11, of the authorized nuclear pharmacist
in He-P 4035.35(b)(1) or the physician who is an authorized user in He-P
4035.35(b)(2); or
(c) Obtained from and prepared by a DHHS/RHS
licensee, or an equivalent agreement state, or a Nuclear Regulatory Commission
licensee for use in research in accordance with an Investigational New Drug
(IND) protocol accepted by FDA; or
(d) Is prepared by the licensee for use in
research in accordance with an Investigational New Drug (IND) protocol accepted
by FDA.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; amd by #12054, eff
11-19-16; ss by #13048, eff 6-2-20; ss by #13473, eff 10-25-22
He-P 4035.36 Safety Instruction for Use of Unsealed
Byproduct Material—Written Directive Required.
(a) A licensee shall provide oral and written
radiation safety instruction for all personnel caring for patients or human
research subjects who cannot be released under He-P 4035.25.
(b) Refresher training shall be provided at
intervals not to exceed 1 year.
(c) To satisfy the requirements of He‑P
4035.36(a), the instruction shall describe the licensee’s procedures for:
(1) Patient or human research subject control;
(2) Visitor control, including:
a. Routine visitation to
hospitalized individuals in accordance with He-P 4020.13(a)(1); and
b. Visitation authorized in
accordance with He-P 4020.13(c);
(3) Contamination control;
(4) Waste control;
(5) Notification of the radiation safety officer,
or his or her designee, and an authorized user in case of the patient’s or
human research subject’s death or medical emergency; and
(6) Training, which shall be commensurate with
the duties of the personnel, as required by He‑P 4019.
(d) A licensee shall keep a record of:
(1) Individuals receiving operational and safety
instructions required by He‑P 4035.36(a);
(2) A description of the instruction;
(3) The date of instruction; and
(4) The name(s) of the individual(s) who gave the
instruction.
(e) The record required in He‑P 4035.36(d)
shall be maintained for inspection by DHHS/RHS for 3 years.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.37 Safety Precautions for Use of Unsealed
Byproduct Material—Written Directive Required.
(a) For each patient or human research subject
who cannot be released under He‑P 4035.25, a licensee shall:
(1) Provide a private room, or share with another
individual who also cannot be released under He-P 4035.25, with a private
sanitary facility;
(2) Post the patient’s or human research
subject’s door with a “Caution: Radioactive Material” sign and note on the door
or on the patient’s or human research subject’s chart where and how long
visitors may stay in the patient’s or human research subject’s room; and
(3) Either monitor material and items removed
from the patient’s room or the human research subject’s room to determine that
their radioactivity cannot be distinguished from the natural background
radiation level with a radiation detection survey instrument set on its most
sensitive scale with no interposed shielding, or handle these materials and
items as radioactive waste.
(b) The radiation safety officer, or his or her
designee, and an authorized user shall be notified immediately if the patient
or human research subject dies or has a medical emergency.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.38 Report and Notification of a Dose to an
Embryo/Fetus or a Nursing Child.
(a) A licensee shall report any dose to an embryo/fetus,
that is greater than 50 millisieverts (5 rem) dose equivalent that is a result
of an administration of byproduct material or radiation from byproduct material
to a pregnant individual unless the dose to the embryo/fetus was specifically
approved, in advance, by the authorized user.
(b) A license shall report any dose to a nursing
child that is a result of an administration of byproduct material to a
breast-feeding individual that:
(1) Is greater than 50 millisieverts (5 rem)
total effective dose equivalent; or
(2)
Has resulted in unintended permanent functional damage to an organ or a
physiological system of the child, as determined by a physician.
(c)
The licensee shall notify by telephone DHHS/RHS no later than the next calendar
day after discovery of a dose to the embryo/fetus or nursing child that
requires a report in He-P 4035.38(a) or He-P 4035.38(b).
(d) The licensee shall submit a written report to
DHHS/RHS within 15 days after discovery of a dose to the embryo/fetus or
nursing child that requires a report in He-P 4035.38(a) or He-P 4035.38(b). The written report shall include:
(1) The licensee’s name;
(2) The name of the prescribing physician;
(3) A brief description of the event;
(4) Why the event occurred;
(5) The effect, if any, on the embryo/fetus or
the nursing child;
(6) What actions, if any, have been taken or are
planned to prevent recurrence;
(7) Certification that the licensee notified the
pregnant individual or mother (or the mother’s child’s responsible relative or
guardian), and if not, why not; and
(8) The report shall not contain the individual’s
or child’s name or any other information that could lead to identification of
the individual or child.
(e) The licensee shall provide notification of
the event to the referring physician and also notify the pregnant individual or
mother, both hereafter referred to as the mother, no later than 24 hours after
discovery of an event that would require reporting under He-P 4035.38(a) or He-P
4035.38(b), unless the referring physician personally informs the licensee
either that he or she will inform the mother or that, based on medical
judgment, telling the mother would be harmful.
The licensee shall:
(1) Not be required to notify the mother without
first consulting with the referring physician.
If the referring physician or mother cannot be reached within 24 hours,
the licensee shall make the appropriate notifications as soon as possible
thereafter;
(2)
Not delay any appropriate medical care for the embryo/fetus or for the nursing
child, including any necessary remedial care as a result of the event, because
of any delay in notification;
(3) Notify the mother’s or child’s responsible
relative or guardian instead of the mother;
(4)
Inform the mother, or the mother’s or child’s responsible relative or guardian,
if a verbal notification is made, that a written description of the event can
be obtained from the licensee upon request; and
(5) Provide such a written description if
requested.
(f) In the report, a licensee shall:
(1) Annotate a copy of the report provided to
DHHS/RHS with the following:
a. Name
of the pregnant individual or the nursing child who is the subject of the
event; and
b. Identification number or if no other identification number is
available, the social security number of the individual who is the subject of the event; and
(2) Provide a copy of the annotated report to the
referring physician, if other than the licensee, no later than 15 days after
the discovery of the event.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; amd by #12054, eff
11-19-16; ss by #13473, eff 10-25-22
He-P 4035.39 Use of Sealed
Sources and Medical Devices for Diagnosis.
A licensee shall use only:
(a)
Sealed sources that are not in medical devices for diagnostic medical
uses if the sealed sources are approved in the Sealed Source and Device
Registry for diagnostic medicine. The
sealed sources may be used for diagnostic medical uses that are not explicitly
listed in the Sealed Source and Device Registry but shall be used in accordance
with the radiation safety conditions and limitations described in the Sealed
Source and Device Registry;
(b)
Medical devices containing sealed sources for diagnostic medical uses if
both the sealed sources and medical devices are approved in the Sealed Source
and Device Registry for diagnostic medical uses. The diagnostic medical devices may be used
for diagnostic medical uses that are explicitly listed in the Sealed Source and
Device Registry but shall be used in accordance with the radiation safety
conditions and limitations described in the Sealed Source and Device Registry;
and
(c) Sealed sources and devices
for diagnostic medical uses in research in accordance with an active
Investigational Device Exemption (IDE) application accepted by the U.S. Food
and Drug Administration provided the requirements of He-P 4035.15(a) are met.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.40 RESERVED
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; rpld by #13058, eff
6-2-20
He-P 4035.41 Use of Sources for Manual Brachytherapy. A licensee shall use only brachytherapy
sources for therapeutic medical use:
(a) As approved in the Sealed Source and Device
Registry. The manual brachytherapy sources may be used for manual brachytherapy
uses that are not explicitly listed in the Sealed Source and Device Registry,
but shall be used in accordance with the radiation safety conditions and
limitations described in the Sealed Source and Device Registry; or
(b) In research to deliver therapeutic doses for
medical use, in accordance with an active Investigational Device Exemption
(IDE) application accepted by the FDA provided the requirements of He-P
4035.15(a) are met.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.42 Safety Instruction for Use of
Brachytherapy Sources. In addition
to the requirements of He-P 4019.04:
(a) The licensee shall provide radiation safety
instruction (commensurate with the duties of the personnel) initially to
personnel caring for patients or human research subjects who are receiving
brachytherapy and cannot be released under He-P 4035.25;
(b) Refresher training shall be provided at
intervals not to exceed one year;
(c) To satisfy He-P 4035.42(a), the instruction
shall describe:
(1) The size and appearance of the brachytherapy
sources;
(2) The safe handling and shielding instructions;
(3) The procedures for patient or human research
subject control;
(4) The procedures for visitor control;
including:
a. Routine visitation of
hospitalized individuals in accordance with He-P 4020.13(a)(1); and
b. Visitation authorized in accordance
with He-P 4020.13(c); and
(5) The procedures for notification of the
radiation safety officer, or his or her designee, and an authorized user if the
patient or human research subject dies or has a medical emergency.
(d) A licensee shall maintain a record of
individuals receiving instruction required by He‑P 4035.42(a), a
description of the instruction, the date of instruction, the name(s) of the
attendee(s), and the name(s) of the individual(s) who gave the instruction for
3 years.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; amd by #12054, eff
11-19-16; ss by #13048, eff 6-2-20; ss by #13473, eff 10-25-22
He-P 4035.43 Safety Precautions for Use of
Brachytherapy Sources.
(a) For each patient or human research subject
receiving brachytherapy and cannot be released under He-P 4035.25, a licensee
shall:
(1) Not place the patient or human research
subject in the same room with a patient who is not receiving brachytherapy; and
(2) Post the patient’s or human research
subject’s door with a “Caution: Radioactive Materials” sign and note on the
door or the patient’s or human research subject’s chart where and how long
visitors may stay in the patient’s or human research subject’s room.
(b) A licensee shall have applicable emergency
response equipment available near each treatment room to respond to a source:
(1) Dislodged from the patient; and
(2) Lodged within the patient following removal
of the source applicators.
(c) The radiation safety officer, or his or her designee,
and an authorized user shall be notified immediately if the hospitalized
patient or human research subject dies or has a medical emergency.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.44 Brachytherapy Sources Accountability.
(a) A licensee shall:
(1) Maintain accountability at all times for all
brachytherapy sources in storage or use; and
(2) As soon as possible after removing sources
from a patient or a human research subject, return brachytherapy sources to a
secure storage area.
(b) A licensee shall maintain a record of
brachytherapy source accountability for 3 years.
(1) For temporary implants, the record shall
include:
a. The number and activity of
sources removed from storage, the time and date they were removed from storage,
the name of the individual who removed the source(s) from storage, and the
location of use; and
b. The number and activity of sources returned to storage, the time
and date they were returned to storage, and the name of the individual who
returned the source(s) to storage.
(2) For permanent implants the record shall
include:
a. The number and activity of
sources removed from storage, the date they were removed from storage, and the
name of the individual who removed the source(s) from storage;
b. The number and activity of
sources not implanted, the date the source(s) were returned to storage, and the
name of the individual who returned the source(s) to storage; and
c. The number and activity of sources permanently implanted in the
patient or human research subject.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; amd by 12054, eff
11-19-16; ss by #13048, eff 6-2-20; ss by #13473, eff 10-25-22
He-P 4035.45 Surveys After Source Implant/Removal and
Surveys of Individuals Treated With a Remote Afterloader Unit.
(a) Immediately after implanting sources in a
patient or a human research subject, the licensee shall make a survey to locate
and account for all sources that have not been implanted.
(b) Immediately after removing the last temporary
implant source from a patient or a human research subject, the licensee shall
make a survey of the patient or the human research subject with a radiation
detection survey instrument to confirm that all sources have been removed.
(c) Before releasing a patient or a human
research subject from license control, a licensee shall survey the patient or
the human research subject and the remote afterloader unit with a portable
radiation detection survey instrument to confirm that the source(s) has been
removed from the patient or human research subject and returned to the safe
shielded position.
(d) A licensee shall maintain a record of patient
or human research subject surveys which demonstrate compliance with He‑P
4035.45(a) through (c) for 3 years, including the date and the results of the
survey, the survey instrument used, and the name of the individual who made the
survey.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13473, eff
10-25-22
He-P 4035.46 Calibration Measurements of Brachytherapy
Sources.
(a) Before the first medical use of a
brachytherapy source, a licensee shall have:
(1) Determined the source output or activity using a dosimetry system
that meets the requirements of He-P 4035.53(a) and (b);
(2) Determined source positioning accuracy within
applicators; and
(3) Used published
protocols currently accepted by nationally recognized bodies to meet the
requirements of He-P 4035.46(a)(1) and (a)(2); or
(4) Used
measurements provided by the source manufacturer or by a calibration laboratory
accredited by the American Association of Physicists in Medicine that are made
in accordance with He-P 4035.46(a).
(b) A licensee shall mathematically correct the
outputs or activities determined by He-P 4035.46(a) for physical decay at
intervals consistent with 1 percent physical decay.
(c) A licensee shall retain a record of each
calibration of brachytherapy source for 3 years after the last use of the source. The record shall include:
(1) The date of the calibration;
(2) The
manufacturer’s name, model number, and serial number for the source and the
instruments used to calibrate the source;
(3) The source output or activity;
(4) The source positioning accuracy within the
applicators; and
(5) The name of
the individual, the source manufacturer, or the calibration laboratory that
performed the calibration.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-0707; ss by #10897, INTERIM,
eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20;
ss by #13473, eff 10-25-22
He-P 4035.47 Use of a Sealed
Source in a Remote Afterloader Unit, Teletherapy Unit, or Gamma Stereotactic Radiosurgery Unit. A licensee shall use sealed sources in photon
emitting remote afterloader units, teletherapy units, or gamma stereotactic
radiosurgery units:
(a) As approved in the Sealed
Source and Device Registry to deliver therapeutic doses for medical uses, or in
research in accordance with an active Investigational Device Exemption (IDE)
application accepted
by the FDA provided the requirements of He-P 4035.15(a) are met; or
(b) Approved in the
Sealed Source Device Registry to deliver a therapeutic dose for medical
use. These devices may be used for:
(1) Therapeutic medical treatments that are not
explicitly provided for in the Sealed Source and Device Registry, but shall be
used in accordance with radiation safety conditions and limitations described
in the Sealed Source and Device Registry; or
(2) In research in accordance with an active Investigational Device
Exemption (IDE) application accepted by the FDA provided the requirements of He-P
4035.15(a) are met.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #11011, eff
1-15-16; ss by #13048, eff 6-2-20; ss by #13473, eff 10-25-22
He-P 4035.48 Installation, Maintenance, Adjustment, and
Repair of Remote Afterloader Units, Teletherapy Units, or Gamma Stereotactic Radiosurgery Units.
(a) Only a
person
specifically licensed by DHHS/RHS, or an agreement state, or the Nuclear
Regulatory Commission shall install, maintain, adjust, or repair a remote
afterloader unit, teletherapy unit, or gamma stereotactic radiosurgery unit
that involves work on the source(s) shielding, the source(s) driving unit, or
other electronic or mechanical component that could expose the source(s),
reduce the shielding around the source(s), or compromise the radiation safety
of the unit or the source(s).
(b) Except for low dose-rate
remote afterloader units, only a person specifically licensed by DHHS/RHS, or
an agreement state, or the Nuclear Regulatory Commission shall install,
replace, relocate, or remove a sealed source or source contained in other
remote afterloader units, teletherapy units, or gamma stereotactic radiosurgery
units.
(c) For a low dose-rate remote
afterloader unit, only a person specifically licensed by DHHS/RHS, an agreement
state, or the Nuclear Regulatory Commission, or an authorized medical physicist
shall install, replace, relocate, or remove a sealed source(s) contained in the
unit.
(d) A licensee shall retain a
record of the installation, maintenance, adjustment, and repair of remote
afterloader units, teletherapy units, and gamma stereotactic radiosurgery units
for 3 years. Each record shall include:
(1) The date;
(2) The description of the
service; and
(3) The name(s) of the
individual(s) who performed the work.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, 1-15-16; amd by #12054, eff 11-19-16;
ss by #13473, eff 10-25-22
He‑P 4035.49 RESERVED
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, 1-15-16; ss by #11011, 1-15-16; rpld
by #13473, eff 10-25-22
He-P 4035.50 Safety
Procedures and Instructions for Remote Afterloader Units, Teletherapy Units,
and Gamma Stereotactic Radiosurgery Units.
(a) A licensee shall:
(1) Secure the unit, the
console, the console keys, and the treatment room when not in use or
unattended;
(2) Permit only individuals approved by the authorized user, radiation
safety officer, or authorized medical physicist to be present in the treatment
room during treatment with the source(s);
(3) Prevent dual operation of
more than one radiation producing device in a treatment room if applicable; and
(4) Develop, implement, and
maintain written procedures for responding to an abnormal situation when the
operator is unable to place the source(s) in the shielded position, or remove
the patient or human research subject from the radiation field with controls
from outside the treatment room. The
procedures shall include:
a. Instructions for responding
to equipment failures and the names of the individuals responsible for
implementing corrective actions;
b. The process for restricting
access to and posting of the treatment area to minimize the risk of inadvertent
exposure; and
c. The names and telephone
numbers of the authorized users, the authorized medical physicist, and the
radiation safety officer to be contacted if the unit or console operates
abnormally.
(b) A copy of the procedures
required by He-P 4035.50(a)(4) shall be physically located at the unit console.
(c) A licensee shall post
instructions at the console to inform the operator of:
(1) The location of the
procedures required by He-P 4035.50(a)(4); and
(2) The names and telephone
numbers of the authorized users, the authorized medical physicist, and the
radiation safety officer to be contacted if the unit or console operates
abnormally.
(d) Prior to the first use for
patient treatment of a new unit or an existing unit with a manufacturer upgrade
that affects the operation and safety of the unit, a license shall ensure that
vendor operational and safety training is provided to all individuals who will
operate the unit. The vendor operational
and safety training shall be provided by the device manufacturer or by an
individual certified by the device manufacturer to provide the operational and
safety training.
(e) A licensee shall provide
operational and safety instruction, initially and annually, to all individuals
who operate the unit, as appropriate to the individual’s assigned duties. The instructions shall include:
(1) The procedures identified
in He-P 4035.50(a)(4); and
(2) The operating procedures
for the unit.
(f) A licensee shall ensure
that operators, authorized medical physicists, and authorized users participate
in drills of the emergency procedures, initially and at least annually.
(g) A licensee shall retain a
record of individuals receiving instruction required by He-P 4035.50(d) and (e)
for 3 years. The record shall include:
(1) A list of the topics
covered;
(2) The date of the
instruction;
(3) The name(s) of the
attendee(s); and
(4) The name(s) of the individual(s)
who provided the instruction.
(h) A licensee shall retain a
copy of the procedures required by He-P 4035.50(a)(4) and (e)(2) until the
licensee no longer possesses the remote afterloader unit, teletherapy unit, or
gamma stereotactic radiosurgery unit.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, 1-15-16; ss by #13048, eff 6-2-20; ss
by #13473, eff 10-25-22
*He-P 4035.51 Safety
Precautions for Remote Afterloader Units, Teletherapy Units and Gamma
Stereotactic Radiosurgery Units.
(a) A licensee shall control
access to the treatment room by a door at each entrance.
(b) A licensee shall equip each
entrance to the treatment room with an electrical interlock system that shall:
(1) Prevent the operator from
initiating the treatment cycle unless each treatment room entrance door is
closed;
(2) Cause the source(s) to be shielded
when an entrance door is opened; and
(3) Prevent the source(s) from
being exposed following an interlock interruption until all treatment room
entrance doors are closed and the beam “on-off” control is reset at the
console.
(c) A licensee shall require
any individual entering the treatment room to assure, through the use of
appropriate radiation monitors, that radiation levels have returned to ambient
levels.
(d) Except for low-dose remote
afterloader units, a licensee shall construct or equip each treatment room with
viewing and intercom systems to permit continuous observation of the patient or
the human research subject from the treatment console during irradiation.
(e) For licensed activities
where sources are placed within the patient’s or human research subject’s body,
a licensee shall only conduct treatments which allow for expeditious removal of
a decoupled or jammed Source.
(f) In addition to the
requirements specified in He-P 4035.51(a) through(e), a licensee shall:
(1) For medium dose-rate and
pulsed dose-rate remote afterloader units, shall require:
a. An authorized medical physicist
and either an authorized user or a physician, under the supervision of an
authorized user, who has been trained in the operation and emergency response
for the unit to be physically present during the initiation of all patient
treatment involving the unit; and
b. An authorized medical
physicist and either an authorized user or an individual, under the supervision
of an authorized user, who has been trained to remove the source applicator(s)
in the event of an emergency involving the unit, to be immediately available
during continuation of all patient treatments;
(2) For high dose-rate remote
afterloader units, shall require:
a. An authorized user and an
authorized medical physicist to be physically present during the initiation of
all patient treatments involving the unit; and
b. An authorized medical
physicist and either an authorized user or a physician, under the supervision
of an authorized user, who has been trained in the operation and emergency
response for the unit, to be physically present during continuation of all
patient treatments involving the unit;
(3) For gamma stereotactic
radiosurgery units, require an authorized user and an authorized medical
physicist to be physically present throughout all patient treatments involving
the unit; and
(4) Notify the radiation safety
officer, or his/her designee, and an authorized user immediately if the patient
or human research subject has a medical emergency or dies.
(g) A licensee shall have
applicable emergency response equipment available near each treatment room to
respond to a source:
(1) Remaining in the unshielded
position; or
(2) Lodged within the patient
following completion of the treatment.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P
4035.52 Technical Requirements for
Mobile Remote Afterloader.
(a) A licensee providing mobile remote
afterloader service shall:
(1) Check survey instruments before medical use
at each address of use or on each day of use, whichever is more frequent; and
(2) Account for all sources before departure from
a client’s address of use.
(b) In addition to the periodic spot-checks
required by He-P 4035.55(i) through (o), a licensee authorized to use mobile
afterloaders for medical use shall perform checks on each remote afterloader
unit before use at each address of use.
At a minimum, checks shall be made to verify the operation of:
(1) Electrical interlocks on treatment area
access points;
(2) Source exposure indicator lights on the
remote afterloader unit, on the control console, and in the facility;
(3) Viewing and intercom systems;
(4) Applicators, source transfer tubes, and
transfer tube-applicator interfaces;
(5) Radiation monitors used to indicate room
exposures;
(6) Source positioning (accuracy); and
(7) Radiation monitors used to indicate whether
the source has returned to a safe shielded position.
(c) In addition to the requirements for checks in
He-P 4035.52(b), a licensee shall ensure overall proper operation of the remote
afterloader unit by conducting a simulated cycle of treatment before use at
each address of use.
(d) If the results of the checks required in He-P
4035.52(b) indicate the malfunction of any system, a licensee shall lock the
control console in the “off” position and not use the unit except as may be
necessary to repair, replace, or check the malfunctioning system.
(e) A licensee shall retain a record of each
check required by He-P 4035.52(b) for 3 years.
The record shall include:
(1) The date of the check;
(2) The manufacturer’s name, model number, and
serial number of the remote afterloader unit;
(3) Notations accounting for all sources before
the licensee departs from a facility;
(4) Notations indicating the operability of each
entrance door electrical interlock, radiation monitors source exposure
indicator lights, viewing and intercom system, applicators source transfer
tubes, and transfer tube applicator interfaces, and source positioning
accuracy; and
(5) The name and the signature of the individual
who performed the check.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P 4035.53 Dosimetry Equipment.
(a) Except for low dose-rate remote afterloader
sources where the source output or activity is determined by the manufacturer,
a licensee shall have a calibrated dosimetry system available for use.
(b) To satisfy the requirement in He‑P
4035.53(a), one of the following two conditions shall be met:
(1) The system shall have been calibrated using a
system or source traceable to the National Institute of Standards and
Technology and published protocols accepted by nationally recognized bodies; or
by a calibration laboratory accredited by the American Association of
Physicists in Medicine. The calibration shall have been performed within the
previous 2 years and after any servicing that may have affected system
calibration; or
(2) The system shall have been calibrated within
the previous 4 years and 18 to 30 months after the calibration, intercompared
with another dosimetry system that was calibrated within the past 24 months by
the National Institute of Standards and Technology or by a calibration
laboratory accredited by the American Association of Physicists in Medicine.
(c) The results of a calibration intercomparison
shall have indicated that the calibration factor of the licensee’s system had
not changed by more than 2 percent.
(d) The licensee shall not use an intercomparison
result to change the calibration factor.
(e) When intercomparing dosimetry systems to be
used for calibrating sealed sources for teletherapy units, the licensee shall
use a comparable unit with beam attenuators or collimators, as applicable, and
sources of the same radionuclide as the source used at the licensee’s facility.
(f) The licensee shall have a dosimetry system
available for use for spot-check output measurements, if applicable. To satisfy this requirement:
(1) The system shall be compared with a system
that has been calibrated in accordance with He-P 4035.53(a) through (e);
(2) The comparison shall have been performed
within the previous year and after each servicing that may have affected system
calibration; and
(3) The spot-check system shall be the same
system used to meet the requirements in He-P 4035.53(a) through (e).
(g) The licensee shall retain a record of each
calibration, intercomparison, and comparison of its dosimetry equipment for the
duration of the license. For each
calibration, intercomparison, or comparison, the record shall include:
(1) The date;
(2) The manufacturer’s name, model numbers, and
serial numbers of the instruments that were calibrated, intercompared, or
compared as required by He-P 4035.53(a) through (f);
(3) The correction factor that was determined
from the calibration or comparison or the apparent correction factor that was
determined from an intercomparison; and
(4) The names of
the individuals who performed the calibration, intercomparison, or comparison.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P 4035.54 Full Calibration Measurements on
Teletherapy Units, Remote Afterloader Units, and Gamma Stereotactic
Radiosurgery Units.
(a) A licensee authorized to use a teletherapy
unit for medical use shall perform full calibration measurements on each
teletherapy unit as follows:
(1) Before the first medical use of the unit;
(2) Before medical use under the following
conditions:
a. Whenever spot check measurements indicate
that the output differs by more than 5 percent from the output obtained at the
last full calibration corrected mathematically for radioactive decay;
b. Following replacement of the source or
following reinstallation of the teletherapy unit in a new location; and
c. Following any repair of the teletherapy unit
that includes removal of the source or major repair of the components
associated with the source exposure assembly; and
(3) At intervals not exceeding one year.
(b) To satisfy the requirement of He‑P
4035.54(a), full calibration measurements shall include determination of:
(1) The output within +/- 3 percent for the range
of field sizes and for the distance or range of distances used for medical use;
(2) The coincidence of the radiation field and
the field indicated by the light beam-localizing device;
(3) The uniformity of the radiation field and its
dependence on the orientation of the useful beam;
(4) Timer accuracy and linearity over the range
use;
(5) “On-off” error; and
(6) The accuracy of all distance measuring and
localization devices in medical use.
(c) A licensee shall use the dosimetry system
described in He-P 4035.53(a) through (f) to measure the output for one set of
exposure conditions, and the remaining radiation measurements required in He-P
4035.54(b)(1) shall then be made using a dosimetry system that indicates
relative dose rates.
(d) A licensee shall make full calibration
measurements required by He‑P 4035.54(a) in accordance with published
protocols accepted by nationally recognized bodies.
(e) A licensee shall correct mathematically the
outputs determined in He‑P 4035.54(b)(1) for physical decay for intervals
not exceeding one month for cobalt-60, intervals not exceeding 6 months for
cesium-137, or at intervals consistent with one percent decay for all other
nuclides.
(f) Full calibration measurements required by
He-P 4035.54(a) and physical decay corrections required by He‑P
4035.54(e) shall be performed by an authorized medical physicist. A licensee
shall retain a record of each calibration in accordance with He-P 4035.54(u)
and (v).
(g) A licensee authorized to use a remote
afterloader unit for medical use shall perform full calibration measurements on
each unit:
(1) Before the first medical use of the unit;
(2) Before medical use under the following
conditions:
a. Following replacement of the source or
following reinstallation of the unit in a new location outside the facility;
and
b. Following any repair of the unit that
includes removal of the source or major repair of the components associated
with the source exposure assembly; and
(3) At intervals not exceeding 3 months for high
dose-rate, medium dose-rate, and pulsed dose-rate remote afterloader units with
sources whose half-life exceeds 75 days; and
(4) At intervals not exceeding 1 year for low
dose-rate remote afterloader units.
(h) To satisfy the requirement of He-P
4035.54(g), full calibration measurements shall include, as applicable,
determination of:
(1) The output within +/- 5 percent;
(2) Source positioning accuracy to within +/- 1 millimeter;
(3) Source retraction with backup battery upon
power failure;
(4) Length of the source transfer tubes;
(5) Timer accuracy and linearity over the typical
range of use;
(6) Length of the applicators; and
(7) Function of the source transfer tubes,
applicators, and transfer tube-applicator interfaces.
(i) A licensee shall use the dosimetry system
described in He-P 4035.53(a) through (f) to measure the output.
(j) A licensee shall make full calibration
measurements required in He-P 4035.54(g) in accordance with published protocols
accepted by nationally recognized bodies.
(k) In addition to the requirements for full
calibration for low dose-rate remote afterloaders in He-P 4035.54(h), a
licensee shall perform an autoradiograph of the source(s) to verify inventory
and source(s) arrangement at intervals not exceeding 3 months.
(l) For low dose-rate remote afterloader units, a
licensee shall use measurements provided by the source manufacturer that are
made in accordance with He-P 4035.54(g) through (k).
(m) A licensee shall mathematically correct the
outputs determined in He-P 4035.54(h)(1) for physical decay at intervals
consistent with 1 percent physical decay.
(n) Full calibration measurements required by
He-P 4035.54(g) and physical decay corrections required by He-P 4035.54(m)
shall be performed by the authorized medical physicist. A licensee shall retain
a record of each calibration in accordance with He-P 4035.54(u) and (v).
(o) A licensee authorized to use a gamma
stereotactic radiosurgery unit for medical use shall perform full calibration
measurements on each unit:
(1) Before the first medical use of the unit;
(2) Before medical use under the following
conditions:
a. Whenever spot check measurements indicate
that the output differs by more than 5 percent from the output obtained at the
last full calibration corrected mathematically for radioactive decay;
b. Following replacement of the sources or
following reinstallation of the gamma stereotactic radiosurgery unit in a new
location; and
c. Following any repair of the gamma
stereotactic radiosurgery unit that includes removal of the sources or major
repair of the components associated with the source assembly; and
(3) At intervals not exceeding 1 year, with the
exception that relative helmet factors need only be determined before the first
medical use of a helmet and following any damage to a helmet.
(p) To satisfy the requirement of He-P
4035.54(o), full calibration measurements shall include determination of:
(1) The output within +/- 3 percent;
(2) Relative helmet factors;
(3) Isocenter coincidence;
(4) Timer accuracy and linearity over the range
of use;
(5) “On-off” error;
(6) Trunnion centricity;
(7) Treatment table retraction mechanism, using
backup battery power or hydraulic backups with the unit off;
(8) Helmet microswitches;
(9) Emergency timing circuits; and
(10) Stereotactic frames and localizing devices
(trunnions).
(q) A licensee shall use the dosimetry system
described in He-P 4035.53(a) through (f) to measure the output for one set of
exposure conditions. The remaining
radiation measurements required in He-P 4035.54(p)(1) shall be made using a
dosimetry system that indicates relative dose rates.
(r) A licensee shall make full calibration
measurements required by He-P 4035.54(o) in accordance with published protocols
accepted by nationally recognized bodies.
(s) A licensee shall mathematically correct the
outputs determined in He-P 4035.54(p)(1) at interval not exceeding 1 month for
cobalt-60 and at intervals consistent with 1 percent physical decay for all
other radionuclides.
(t) Full calibration measurements required by
He-P 4035.54(o) and physical decay corrections by He-P 4035.54(s) shall be
performed by the authorized medical physicist. A licensee shall retain a record
of each calibration in accordance with He-P 4035.54(u) and (v).
(u) A licensee shall maintain a record of each
calibration of teletherapy unit, remote afterloader unit, and gamma
stereotactic radiosurgery unit for 3 years.
(v) The record in (u) above shall include the
date of the calibration, the manufacturer’s name, model number, and serial
number of the teletherapy, remote afterloader, and gamma stereotactic
radiosurgery unit(s), the source(s), and the instruments used to calibrated the
unit(s); the results and an assessment of the full calibrations; the results of
the autograph required for low dose-rate remote afterloader units; and the
signature of the authorized medical physicist who performed the full
calibration.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss
by #13048, eff 6-2-20
He-P 4035.55 Periodic Spot-Checks for Teletherapy
Units, Remote Afterloader Units, and Gamma Stereotactic Radiosurgery Units.
(a) A licensee authorized to
use teletherapy units for medical use shall perform output spot-checks on each
teletherapy unit once in each calendar month that include determination of:
(1) Timer accuracy and timer
linearity over the range of use;
(2) “On-off” error;
(3) The coincidence of the
radiation field and the field indicated by the light beam-localizing device;
(4) The accuracy of all
distance measuring and localization devices used for medical use;
(5) The output for 1 typical
set of operating conditions measured with the dosimetry system described in
He-P 4035.53(g); and
(6) The difference between the
measurement made in He‑P 4035.55(a)(5) and the anticipated output,
expressed as a percentage of the anticipated output (i.e., the value obtained at last full calibration corrected
mathematically for physical decay).
(b) A licensee shall perform spot-checks required
by He‑P 4035.55(a) in accordance with written procedures established by
the authorized medical physicist. That
individual need not actually perform the spot check measurements.
(c) A licensee shall have the
authorized medical physicist review the results of each output spot-check
within 15 days. The authorized medical
physicist shall promptly notify the licensee in writing of the results of each
output spot-check.
(d) A licensee authorized to
use a teletherapy unit for medical use shall perform safety spot-checks of each
teletherapy facility once in each calendar month and after each source
installation, to assure proper operation of:
(1) Electrical interlocks at
each teletherapy room entrance;
(2) Electrical or mechanical
stops installed for the purpose of limiting use of the primary beam of
radiation restriction of source housing angulation or elevation, carriage or
stand travel, and operation of the beam “on-off” mechanism;
(3) Source exposure indicator
lights on the teletherapy unit, on the control console, and in the facility;
(4) Viewing and intercom
systems;
(5) Treatment room doors from
inside and outside the treatment room; and
(6) Electrically assisted
treatment room doors with the teletherapy unit electrical power turned “off”.
(e) A licensee shall lock the control console in
the “off” position if the results of the checks required in He-P 4035.55(d)
indicates the malfunction of any system, and not use the unit except as may be
necessary to repair, replace, or check the malfunctioning system.
(f) A licensee shall maintain a
record of each spot-check required by He‑P 4035.55(a) and (d) for 3
years.
(g) The record shall include:
(1) The date of the spot-check;
(2) The manufacturer’s name,
model number, and serial number of the teletherapy unit, source, and instrument
used to measure the output of the teletherapy unit;
(3) An assessment of timer
linearity and constancy;
(4) The calculated “on-off”
error;
(5) A determination of the
coincidence of the radiation field and the field indicated by the light
beam-localizing device;
(6) The determined accuracy of
each distance measuring or localization device;
(7) The difference between the
anticipated output and the measured output;
(8) Notations indicating the
operability of each entrance door electrical interlock, each electrical or
mechanical stop, each source exposure indicator light, the viewing and intercom
system and doors; and
(9) The name of the individual
who performed the periodic spot-check and the signature of the authorized
medical physicist who reviewed the record of the spot-check.
(h) A licensee shall retain a
copy of the procedures required by He-P 4035.55(b) until the licensee no longer
possesses the teletherapy unit.
(i) A licensee authorized to
use a remote afterloader unit for medical use shall perform spot-checks of each
remote afterloader facility and on each unit:
(1) Before the first use of a
high dose-rate, medium dose-rate, or pulsed dose-rate afterloader
unit on a given day;
(2) Before each patient
treatment with a low dose-rate remote afterloader unit; and
(3) After each source
installation.
(j) A licensee shall perform
the measurements required by He-P 4035.55(i) in accordance with written
procedures established by the authorized medical physicist. That individual need not actually perform the
spot check measurements.
(k) A licensee shall have the
authorized medical physicist review the results of each spot-check within 15
days. The authorized medical physicist
shall promptly notify the licensee in writing of the results of each
spot-check.
(l) To satisfy the requirements
of He-P 4035.55(i), spot-checks shall, at a minimum, assure proper operation
of:
(1) Electrical interlocks at
each remote afterloader unit room entrance;
(2) Source exposure indicator
lights on the remote afterloader unit, on the control console, and in the
facility;
(3) Viewing and intercom
systems in each high dose-rate, medium dose-rate, and pulsed dose-rate remote
afterloader facility;
(4) Emergency response
equipment;
(5) Radiation monitors used to
indicate the source position;
(6) Timer accuracy;
(7) Clock (date and time) in
the unit’s computer; and
(8) Decay source(s) activity in
the unit’s computer.
(m) If the results of the checks
required in He-P 4035.55(l) indicate the malfunction of any system, a licensee
shall lock the control console in the “off” position and not use the unit
except as may be necessary to repair, replace, or check the malfunctioning
system.
(n) A licensee shall retain a
record of each check required by He-P 4035.55(l) for 3 years. The record shall include, as applicable:
(1) The date of the spot-check;
(2) The manufacturer’s name,
model number, and serial number for the remote afterloader unit and source;
(3) An assessment of timer
accuracy;
(4) Notations indicating the
operability of each entrance door electrical interlock, radiation monitors,
source exposure indicator lights, viewing and intercom systems, and clock and
decayed source activity in the unit’s computer; and
(5) The name of the individual
who performed the periodic spot-check and the signature of the authorized
medical physicist who reviewed the record of the spot-check.
(o) A licensee shall retain a
copy of the procedures required by He-P 4035.55(j) until the licensee no longer
possesses the remote afterloader unit.
(p) A licensee authorized to
use a gamma stereotactic radiosurgery unit for medical use shall perform
spot-checks of each gamma stereotactic radiosurgery facility and on each unit:
(1) Monthly;
(2) Before the first use of the
unit on a given day; and
(3) After each source
installation.
(q) A licensee shall:
(1) Perform the measurements
required by He-P 4035.55(p) in accordance with written procedures established
by the authorized medical physicist.
That individual need not actually perform the spot check measurements.
(2) Have the authorized medical
physicist review the results of each spot-check within 15 days. The authorized medical physicist shall
promptly notify the licensee in writing of the results of each spot-check.
(r) To satisfy the requirements of He-P
4035.55(p)(1), spot-checks shall, at a minimum:
(1) Assure proper operation of:
a. Treatment table retraction
mechanism, using backup battery power or hydraulic backups with the unit off:
b. Helmet microswitches;
c. Emergency timing circuits;
and
d. Stereotactic frames and
localizing devices (trunnions).
(2) Determine:
a. The output for one typical
set of operating conditions measured with the dosimetry system described in
He-P 4035.53(g);
b. The difference between the
measurement made in He-P 4035.55(r)(2)a. and the anticipated output, expressed
as a percentage of the anticipated output (i.e., the value obtained at last
full calibration corrected mathematically for physical decay);
c. Source output against
computer calculation;
d. Timer accuracy and linearity
over the range of use;
e. “On-off” error; and
f. Trunnion centricity.
(s) To satisfy the requirements of He-P
4035.55(p)(2) and (p)(3), spot-checks shall assure proper operation of:
(1) Electrical interlocks at
each gamma stereotactic radiosurgery room entrance;
(2) Source exposure indicator
lights on the gamma stereotactic radiosurgery unit, on the control console, and
in the facility;
(3) Viewing and intercom
systems;
(4) Timer termination;
(5) Emergency “off” buttons;
and
(6) Radiation monitors used to indicate room
exposures.
(t) A licensee shall arrange
for repair of any system identified in He-P 4035.55(r) that is not operating as
soon as possible.
(u) If the results of the
checks required in He-P 4035.55(s) indicate the malfunction of any system, a
licensee shall lock the control console in the “off” position and not use the
unit except as may be necessary to repair, replace, or check the malfunctioning
system.
(v) A licensee shall retain a
record of each check required by He-P 4035.55(r) and (s) for 3 years. The record shall include:
(1) The date of the spot-check;
(2) The manufacturer’s name, model number, and serial number for the
gamma stereotactic radiosurgery unit and the instrument used to measure the
output of the unit;
(3) An assessment of timer
linearity and accuracy;
(4) The calculated “on-off”
error;
(5) A determination of trunnion
centricity;
(6) The difference between the
anticipated output and the measured output;
(7) An assessment of source
output against computer calculations;
(8) Notations indicating the
operability of radiation monitors, helmet microswitches, emergency timing
circuits, emergency “off” buttons, electrical interlocks, source exposure
indicator lights, viewing and intercom systems, timer termination, treatment
table retraction mechanism, and stereotactic frames and localizing devices
(trunnions); and
(9) The name of the individual
who performed the periodic spot-check and the signature of the authorized
medical physicist who reviewed the record of the spot-check.
(w) A licensee shall retain a
copy of the procedures required by He-P 4035.55(r) and (s) until the licensee
no longer possesses the gamma stereotactic radiosurgery unit.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; amd by #12054, eff
11-19-16; ss by #13048, eff 6-2-20
He-P 4035.56 Radiation
Surveys for Therapy Facilities.
(a) In addition to the survey
requirements in He-P 4022.01, a licensee shall make surveys to ensure that the
maximum radiation levels and average radiation levels from the surface of the
main source safe with the source(s) in the shielded position do not exceed the
levels stated in the Sealed Source and Device Registry.
(b) The licensee shall make the survey required
by He-P 4035.56(a) at installation of a new source and following repairs to the
source(s) shielding, the source(s) driving unit, or other electronic or
mechanical component that could expose the source, reduce the shielding around
the source(s), or compromise the radiation safety of the unit or the source(s).
(c) A licensee shall retain a
record of the radiation surveys of treatment units made in accordance with He-P
4035.56(a) for the duration of use of the unit.
The record shall include:
(1) The date of the
measurements;
(2) The manufacturer’s name,
model number and serial number of the treatment unit, source, and instrument
used to measure radiation levels;
(3) Each dose rate measured
around the source while the unit is in the off position and the average of all
measurements; and
(4) The name and the signature
of the individual who performed the test.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; amd by #12054, eff
11-19-16
He-P 4035.57 Therapy-related
Computer Systems. The licensee shall
perform acceptance testing on the treatment planning system of therapy-related
computer systems in accordance with published protocols accepted by nationally
recognized bodies. At a minimum, the
acceptance testing shall include, as applicable, verification of:
(a) The source-specific input
parameters required by the dose calculation algorithm;
(b) The accuracy of dose, dwell
time, and treatment time calculations at representative points;
(c) The accuracy of isodose
plots and graphic displays;
(d) The accuracy of the
software used to determine sealed source positions from radiographic images;
and
(e) The accuracy of electronic
transfer of the treatment delivery parameters to the treatment delivery unit
from the treatment planning system.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16
He-P 4035.58 RESERVED
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; rpld by #11011, eff 1-15-16
He-P 4035.59 Training for Use of Remote Afterloader
Units, Teletherapy Units, and Gamma Stereotactic Radiosurgery Units. Except as provided in He-P 4035.71, the
licensee shall require an authorized user of a sealed source for use authorized
under He-P 4035.47 to be a physician who:
(a) Is certified by a medical specialty board
whose certification process has been recognized by the DHHS/RHS, an agreement
state, or the Nuclear Regulatory Commission and who meets the requirements in
He-P 4035.59(c). The names of board certifications that have been recognized by
DHHS/RHS, and agreement state, or the Nuclear Regulatory Commission are posted
on the NRC’s Medical Uses Licensee Toolkit webpage. To have its certification
process recognized, a specialty board shall require all candidates for certification
to:
(1) Successfully complete a
minimum of 3 years of residency training in a radiation therapy program
approved by the Residency Review Committee of the Accreditation Council for
Graduate Medical Education or the Royal College of Physicians and Surgeons of
Canada or the Committee on Post-Graduate Training of the American Osteopathic
Association; and
(2) Pass an examination,
administered by diplomats of the specialty board, which tests knowledge and
competence in radiation safety, radionuclide handling, treatment planning,
quality assurance, and clinical use of stereotactic radiosurgery, remote
afterloaders and external beam therapy; or
(b) Has completed a structured educational
program in basic radionuclide techniques applicable to the use of a sealed
source in a therapeutic medical unit that includes:
(1) 200 hours of classroom and laboratory
training in the following areas:
a. Radiation physics and
instrumentation;
b. Radiation protection;
c. Mathematics pertaining to
the use and measurement of radioactivity; and
d. Radiation biology; and
(2) 500 hours of work experience, under the
supervision of an authorized user who meets the requirements in He-P 4035.59,
He-P 4035.71, the equivalent requirements of an agreement state, or the Nuclear
Regulatory Commission at a medical facility that is authorized to use byproduct
materials in He-P 4035.47, involving:
a. Reviewing full calibration
measurements and periodic spot-checks;
b. Preparing treatment plans
and calculating treatment doses and times;
c. Using administrative
controls to prevent a medical event involving the use of byproduct material;
d. Implementing emergency
procedures to be followed in the event of the abnormal operation of the medical
unit or console;
e. Checking and using survey
meters; and
f. Selecting the proper dose
and how it is to be administered; and
(3) Has completed 3 years of supervised clinical
experience in radiation therapy, under an authorized user who meets the
requirements in He-P 4035.59, He-P 4035.71, the equivalent requirements of an
agreement state, or the Nuclear Regulatory Commission, as part of a formal
training program approved by the Residency Review Committee for Radiation
Oncology of the Accreditation Council for Graduate Medical Education or the
Royal College of Physicians and Surgeons of Canada or the Committee on
Postdoctoral Training of the American Osteopathic Association. This experience may be obtained concurrently
with the supervised work experience required by He-P 4035.59(b)(2); and
(4) Has obtained written
attestation that the individual has satisfactorily completed the requirements
in He-P 4035.59(b)(1), (b)(2), and (b)(3), and He-P 4035.59(c), and is able to independently fulfill the
radiation safety-related duties as an authorized user of each type of
therapeutic medical unit for which the individual is requesting authorized user
status. The written attestation shall
obtained from either:
a. A preceptor authorized user
who meets the requirements in He-P 4035.59, He-P 4035.71, the equivalent
requirements of an agreement state, or the Nuclear Regulatory Commission for
type(s) of therapeutic medical unit for which the individual is requesting
authorized user status; or
b. A residency program director
who affirms in writing that the attestation represents the consensus of the
residency program faculty where at least one faculty member is an authorized
user who meets the requirements in He-P 4035.59, He-P 4035.71, or the
equivalent requirements of an agreement state, or the Nuclear Regulatory
Commission, for the type(s) of therapeutic medical unit for which the
individual is requesting authorized user status, and concurs with the
attestation provided by the residency program director. The residency training program shall be
approved by the Residency Review Committee of the Accreditation Council for
Graduate Medical Education or the Royal College of Physicians and Surgeons of
Canada, or the Council on Postdoctoral Training of the American Osteopathic
Association and shall include training and experience specified in He-P
4035.59(b), (b)(1), (b)(2), and (b)(3).
(c) Has received training in device operation, safety procedures, and
clinical use for the type(s) of use for which authorization is sought. This training requirement may be satisfied by
satisfactory completion of a training program provided by the vendor for new
users or by receiving training supervised by an authorized user or authorized
medical physicist, as appropriate, who is authorized for the type(s) of use for
which the individual is seeking authorization.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P 4035.60 Full Inspection
Servicing for Teletherapy and Gamma Stereotactic Radiosurgery Units.
(a) A licensee shall have each teletherapy unit and gamma stereotactic
radiosurgery unit fully inspected and serviced during each source replacement
to assure proper functioning of the source exposure mechanism and other safety
components. The interval between each full-inspection servicing shall not
exceed 5 years for each teletherapy unit and shall not exceed 7 years for each
gamma stereotactic radiosurgery unit.
(b) This inspection and
servicing shall only be performed by persons specifically licensed to do so by
DHHS/RHS, an agreement state, or the Nuclear Regulatory Commission.
(c) A licensee shall maintain a
record of the full inspection servicing for teletherapy and gamma stereotactic
radiosurgery units for the duration of use of the unit.
(d) The record required in He-P
4035.60(c) shall contain:
(1) The inspector’s name;
(2) The inspector’s radioactive
materials license number;
(3) The date of inspection;
(4) The manufacturer’s name and
model number and serial number for both the treatment unit and source;
(5) A list of components
inspected;
(6) A list of components
serviced and the type of service;
(7) A list of components
replaced; and
(8) The signature of the
inspector.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P 4035.61 Training for Radiation
Safety Officer and Associate Radiation Safety Officer. Except as provided in He-P 4035.71, the
licensee shall require an individual fulfilling the responsibilities of the
radiation safety officer or an individual assigned duties and tasks as an
associate radiation safety officer as provided in He-P 4035.10 to be an
individual who:
(a) Is certified by a specialty board whose certification process has
been recognized by DHHS/RHS, or an agreement state, or the Nuclear Regulatory
Commission, and which meets the requirements in He-P 4035.61(e). The names of board certifications that have
been recognized by DHHS/RHS, an agreement state, or the Nuclear Regulatory
Commission are posted on the NRC’s Medical Uses Licensee Toolkit web page. To
have its certification process recognized, a specialty board shall require all
candidates for certification to:
(1) Hold a bachelor’s or
graduate degree from an accredited college or university in physical science or
engineering or biological science with a minimum of 20 college credits in
physical science;
(2) Have 5 or more years of
professional experience in health physics (graduate training may be substituted
for no more than 2 years of the required experience) including at least 3 years
in applied health physics; and
(3) Pass an examination
administered by diplomats of the specialty board, which evaluates knowledge and
competence in radiation physics and instrumentation, radiation protection,
mathematics pertaining to the use and measurement of radioactivity, radiation
biology, and radiation dosimetry; or
(4) Hold a master’s or
doctorate level degree in physics, medical physics, other physical science,
engineering, or applied mathematics from an accredited college or
university; and
(5) Have 2 years full-time
practical training; and supervised experience in medical physics; under either:
a. The supervision of a medical
physicist who is certified in medical physics by a specialty board recognized
by DHHS/RHS, or an agreement state or the Nuclear Regulatory Commission; or
b. In clinical nuclear medicine
facilities providing diagnostic and/or therapeutic services under the direction
of physicians who meet the requirements for authorized users in He-P 4035.64,
He-P 4035.65 or He-P 4035.71; and
(6) Pass an examination,
administered by diplomats of the specialty board, that assesses knowledge and
competence in clinical diagnostic radiological or nuclear medicine physics and
in radiation safety.
(b) Has completed a structured
educational program consisting of:
(1) 200 hours of classroom and
laboratory training in the following areas:
a. Radiation physics and
instrumentation;
b. Radiation protection;
c. Mathematics pertaining to
the use and measurements of radioactivity;
d. Radiation biology;
e. Radiation dosimetry; and
(2) One year of full-time
radiation safety experience under the supervision of the individual identified
as the radiation safety officer on a DHHS/RHS, or agreement state, or Nuclear
Regulatory Commission license, or permit issued by a Nuclear Regulatory
Commission master material license that authorized similar type(s) of use(s) of
byproduct material. An associate
radiation safety officer shall provide supervision for those areas for which
the associate radiation safety officer is authorized on a DHHS/RHS or an
agreement state license or permit issued by a Nuclear Regulatory Committee
master material license. The full radiation safety experience shall involve the
following:
a. Shipping, receiving, and
performing related radiation surveys;
b. Using and performing checks
for proper operation of instruments used to determine the activity of dosages,
survey meters, and instruments used to measure radionuclides;
c. Securing and controlling
byproduct material;
d. Using administrative controls to avoid mistakes in the
administration of byproduct material;
e. Using procedures to prevent
or minimize radioactive contamination and using proper decontamination
procedures;
f. Using emergency procedures
to control byproduct material; and
g. Disposing of byproduct
material; and
(3) Obtaining a written
attestation, signed by a preceptor radiation safety officer or associate
radiation Safety officer who has experience with the radiation safety aspects
of similar types of use of byproduct material for which the individual is
seeking approval as a radiation safety officer or an associate radiation safety
officer. The written attestation shall
state that the individual has satisfactorily completed the requirements in He-P
4035.61 (b)(1), and (b)(2), and is able to independently fulfill the radiation
safety-related duties as a radiation safety officer or as an associate
radiation safety officer for a medical use license; or
(c) Is a medical physicist who has been certified
by a specialty board whose certification process has been recognized by
DHHS/RHS under 4035.70(a), or an agreement state, or the Nuclear Regulatory
Commission, and has experience in radiation safety for similar types of use of
byproduct material for which the licensee is seeking the approval of the
individual as radiation safety officer or as associate radiation safety
officer, and who meets the requirements in He-P 4035.61€; or
(d) an authorized user, authorized medical
physicist, or authorized nuclear pharmacist identified on the DHHS/RHS or agreement state or Nuclear
Regulatory Commission license, a permit issued by a Nuclear Regulatory
Commission master material licensee, a permit issued by DHHS/RHS or agreement
state or Nuclear Regulatory Commission licensee of broad scope, or a permit
issued by a Nuclear Regulatory Commission master material license broad scope
permittee, and has experience with:
(1) The radiation safety aspects of similar types
of use of byproduct material for the licensee seeks the individual as the
radiation safety officer or associate
radiation safety officer, and meets the requirements in He-P 4035.61(e); or
(2) The radiation safety aspects of the types of
use of byproduct material for which the individual is seeking simultaneous
approval both as the radiation safety officer and the authorized user on the
same new medical use license or new medical use permit issued by a Nuclear
Regulatory Commission master material license.
The individual shall also meet the requirements in He-P 4035.61(e).
(e) Has training in the
radiation safety, regulatory issues, and emergency procedures for the types of
use for which a licensee seeks approval.
This training requirement may be satisfied by completing training that
is supervised by a radiation safety officer, associate radiation safety
officer, authorized medical physicist, authorize nuclear pharmacist, or
authorized user, as appropriate, who is authorized for the type(s) of use for
which the licensee is seeking approval.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P 4035.62 RESERVED
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; rpld by #11011, eff 1-15-16
He-P 4035.63 Training for Uptake,
Dilution, or Excretion Studies.
(a) Except as provided in He‑P
4035.71, the licensee shall require the authorized user of unsealed byproduct
material listed in He‑P 4035.27 to be a physician, whois certified by a
medical specialty board whose certification process has been recognized by
DHHS/RHS, or an agreement state, or the Nuclear Regulatory Commission. The
names of board certifications that have been recognized by DHHS/RHS, agreement
state, or Nuclear Regulatory Commission on the NRC’s Medical Uses Licensee
Toolkit web page. To have its certification process recognized, a specialty
board shall require all candidates for certification to:
(1) Complete 60 hours of
training and experience in basic radionuclide handling techniques and radiation
safety applicable to the use of unsealed byproduct material for uptake,
dilution, and excretion studies as described in He-P 4035.63(b)(1); and
(2) Pass an examination,
administered by diplomats of the specialty board, which assesses knowledge and competence
in radiation safety, radionuclide handling, and quality control; or
(b) Except as provided in He-P
4035.71, an authorized user of unsealed byproduct material for the uses
authorized under He-P 4035.64, He-P 4035.65, or the equivalent requirements of
an agreement state of the Nuclear Regulatory Commission to be a physician, who:
(1) Completed 60 hours of training and experience, including a minimum
of 8 hours of classroom and laboratory training, in basic radionuclide handling
techniques applicable to the medical use of unsealed byproduct material for
uptake, dilution, and excretion studies.
a. The training and experience
shall include classroom and laboratory training in the following areas:
1. Radiation physics and
instrumentation;
2. Radiation protection;
3. Mathematics pertaining to
the use and measurement of radioactivity;
4. Chemistry of byproduct
material for medical use;
5. Radiation biology; and
b. Work experience, under the
supervision of an authorized user who meets the requirements in He-P 4035.63,
He-P 4035.64, He-P 4035.65, He-P 4035.71, the equivalent requirements of an
agreement state, or the Nuclear Regulatory Commission involving:
1. Ordering, receiving, and
unpacking radioactive materials safely and performing the related radiation
surveys;
2. Performing quality control
procedures on instruments used to determine the activity of dosages and
performing checks for proper operation of survey meters;
3. Calculating, measuring, and safely preparing patient or human
research subject dosages;
4. Using administrative controls to prevent a medical event involving
the use of unsealed byproduct material;
5. Using procedures to contain spilled byproduct material safely and
using proper decontamination procedures;
6. Administering dosages of
radioactive drugs to patients or human research subjects; and
(2) Obtained written
attestation that the individual has satisfactorily completed the requirements
of He-P 4035.63(b)(1) and is able to independently fulfill the radiation
safety-related duties as an authorized user for the medical uses authorized
under He-P 4035.27. The attestation shall be obtained from either:
a. A preceptor
authorized user who meets the requirements in He-P 4035.63, He-P 4035.64, He-P
4035.65, or He-P 4035.71, the equivalent requirements of an agreement state, or
the Nuclear Regulatory Commission; or
b. A residency
program director who affirms in writing that the attestation represents the
consensus of the residency program faculty where at least one faculty member is
an authorized user who meets the requirements in He-P 4035.63, He-P 4035.64,
He-P 4035.65, or He-P 4035.71, the equivalent requirements of an agreement
state, or the Nuclear Regulatory Commission, and concurs with the attestation
provided by the residency program director; and
c. The residency training program shall be
approved by the Residency Review Committee of the Accreditation Council for
Graduate Medical Education or the Royal College of Physicians and Surgeons of
Canada or the Council on Postdoctoral Training of the American Osteopathic
Association and shall include training and experience specified in He-P
4035.63(b)(1).
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P 4035.64 Training for
Imaging and Localization Studies.
(a) Except as provided in He-P
4035.71, the licensee shall require the authorized user of unsealed byproduct
material listed in He‑P 4035.31 to be a physician who:
(1) Is certified by a medical
specialty board whose certification process has been recognized by DHHS/RHS, or
an agreement state, or the Nuclear Regulatory Commission. The names of board
certification have been recognized by DHHS/RHS, an agreement state, or the
Nuclear Regulatory Commission are posted on the NRC’s Medical Uses Licensee
Toolkit web page; or
(2) Is an authorized user under He-P 4035.62 and meets the
requirements in He-P 4035.64(c)(1)b.7, or the equivalent requirements of an
agreement state, or the Nuclear Regulatory Commission requirements.
(b) To have its certification
process recognized, a specialty board shall require all candidates for
certification to:
(1) Complete 700 hours of
training and experience in basic radionuclide handling techniques and radiation
safety applicable to the medical use of unsealed byproduct material for imaging
and localization studies as described in He-P 4035.64(c)(1)a. through
(c)(1)b.7.; and,
(2) Pass an examination, administered by diplomats of the specialty
board, which assesses knowledge and competence in radiation safety,
radionuclide handling, and quality control.
(c) Except as provided in He-P
4035.65 and meets the requirements in He-P 4035.64(c)(1)b.7., or the equivalent
requirements of an agreement state, or the Nuclear Regulatory Commission, an
authorized user who:
(1) Has completed 700 hours of training and experience, including a
minimum of 80 hours of classroom and laboratory training, in basic radionuclide
handling techniques applicable to the medical use of unsealed byproduct
material for imaging and localization studies.
The training and experience shall include, at a minimum:
a. Classroom and laboratory
training in the following areas:
1. Radiation physics and
instrumentation;
2. Radiation protection;
3. Mathematics pertaining to
the use and measurement of radioactivity;
4. Chemistry of byproduct
material for medical use;
5. Radiation biology and
b. Work experience, under the
supervision of an authorized user who meets the requirements in He-P 4035.64,
He-P 4035.71, or He-P 4035.65 and He-P 4035.64(c)(1)b.7, or the equivalent
requirements of an agreement state, or the Nuclear Regulatory Commission
requirements. An authorized nuclear pharmacist who meets the
requirements in He-P 4035.71 or He-P 4035.74, the equivalent requirements of an
agreement state, or the Nuclear Regulatory Commission may provide the
supervised work experience for He-P 4035.64(c)(1)b.7. Work experience shall
involve:
1. Ordering, receiving and
unpacking radioactive materials safely and performing the related radiation
surveys;
2. Performing quality control
procedures on instruments used to determine the activity of dosages and
performing checks for proper operation of survey meters;
3. Calculating, measuring and safely preparing patient or human
research subject dosages;
4. Using administrative
controls to prevent a medical event involving the use of unsealed byproduct
material;
5. Using procedures to contain spilled byproduct material safely and
using proper decontamination procedures;
6. Administering dosages of
radioactive drugs to patients or human research subjects; and
7. Eluting generator systems appropriate for preparation of
radioactive drugs for imaging and localization studies, measuring and testing
the eluate for radionuclide purity, and processing the eluate with reagent kits
to prepare labeled radioactive drugs; and
(2) Obtained a written
attestation that the individual has satisfactorily completed the requirements
in He-P 4035.64(c)(1) and is able to independently fulfill the radiation
safety-related duties as an authorized user for the medical uses authorized
under He-P 4035.27 and He-P 4035.31. The attestation shall be obtained from
either:
a. A preceptor authorized user who meets the
requirements in He-P 4035.64, He-P 4035.71, or He-P 4035.65 and He-P
4035.64(c)(1)b.7., or the equivalent requirements of an agreement state, or the
Nuclear Regulatory Commission; or
b. A residency program director who affirms in
writing that the attestation represents the consensus of the residency program
faculty where at least one faculty member is an authorized user who meets the
requirements in He-P 4035.64, He-P 4035.71, or He-P 4035.65 and He-P
4035.64(c)(1)b.7., or the equivalent requirements of an agreement state, or the
Nuclear Regulatory Commission, and concurs with the attestation provided by the
residency program director. The
residency training program shall be approved by the Residency Review Committee
of the Accreditation Council for Graduate Medical Education or the Royal
College of Physicians and Surgeons of Canada or the Council on Postdoctoral
Training of the American Osteopathic Association and shall include training and
experience specified in He-P 4035.64(c)(1).
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P 4035.65 Training for
Use of Unsealed Byproduct Material for Which a Written Directive Is Required.
(a) Except as provided in He-P
4035.71, the licensee shall require the authorized user of unsealed byproduct
material listed in He‑P 4035.35 to be a physician who:
(1) Is certified by a medical
specialty board whose certification process has been recognized by DHHS/RHS, or
an agreement state, or the Nuclear Regulatory Commission. The names of board
certifications that have been recognized by DHHS\RHS, an agreement state, or
the Nuclear Regulatory Commission are posted on the NRC’s Medical Uses Licensee
Toolkit web page; and
(2) Meets the requirements in
He-P 4035.65(c)(2)b. and He-P 4035.65(d) through (e).
(b) To have its certification
process recognized, a specialty board shall require all candidates for
certification to:
(1) Successfully complete
residency training in a radiation therapy or nuclear medicine training program
or a related medical specialty. These
residency training programs shall include 700 hours of training and experience
as described in He-P 4035.65(c)(1) through He-P 4035.65(c)(2)a.5. Eligible
training programs shall be approved by the Residency Review Committee of the
Accreditation Council for Graduate Medical Education, the Royal College of
Physicians and Surgeons of Canada, or the Committee on Post-Graduate Training
of the American Osteopathic Association; and,
(2) Pass an examination,
administered by diplomats of the specialty board, which assesses knowledge and
competence in radiation safety, radionuclide handling, and quality assurance
and clinical use of unsealed byproduct material for which a written directive
is required; or
(c) Except as provided in He-P
4035.71, an authorized user of unsealed byproduct material for the uses
authorized under He-P 4035.35 shall be a physician who has:
(1) Completed 700 hours of
training and experience, including a minimum of 200 hours of classroom and
laboratory training, in basic radionuclide handling techniques applicable to
the medical use of unsealed byproduct material requiring a written directive. The classroom and laboratory training shall
include:
a. Radiation physics and
instrumentation;
b. Radiation protection;
c. Mathematics pertaining to
the use and measurement of radioactivity;
d. Chemistry of byproduct
material for medical use;
e. Radiation biology; and
(2) Work experience, under the
supervision of an authorized user who meets the requirements in He-P 4035.65 or
He-P 4035.71, or the equivalent requirements of an agreement state, or the
Nuclear Regulatory Commission. A
supervising authorized user, who meets the requirements in He-P 4035.65(c)
through (e), shall also have experience in administering dosages in the same
dosage category or categories (i.e., He-P 4035.65(c)(2)b.) as the individual
requesting authorized user status.
a. The work experience shall
involve:
1. Ordering, receiving, and
unpacking radioactive materials safely and performing the related radiation
surveys;
2. Performing quality control
procedures on instruments used to determine the activity of dosages and
performing checks for proper operation of survey meters;
3. Calculating, measuring, and safely preparing patient or human
research subject dosages;
4. Using administrative controls to prevent a medical event involving
the use of unsealed byproduct material;
5. Using procedures to contain
spilled byproduct material safely and using proper decontamination procedures;
b. Administering dosages of
radioactive drugs to patients or human research subjects from the 3 categories
in this paragraph. Radioactive drugs containing radionuclides in categories not
included in this paragraph are regulated under He-P 4035.29. This work
experience shall involve a minimum of 3 cases in each of the following
categories for which the individual is requesting authorized user status:
1. Oral administration of less
than or equal to 1.22 gigabecquerels (33 millicuries) of sodium iodine I-131,
for which a written directive is required;
2. Oral administration of
greater than 1.22 gigabecquerels (33 millicuries) of sodium iodine
I-131[Experience with at least 3 cases in Category (c)(2)b.2. also satisfies
the requirement in Category(c)(2)b.1.]; or
3. Parenteral administration of
any radioactive drug that contains a radionuclide that is primarily used for
its electron emission, beta radiation characteristics, alpha radiation
characteristics, or a a photon energy less than 150 keV, for which a written
directive is required; and
(d) In addition to meeting the
requirements of (a) or (b) or (c) above, a licensee shall require an authorized
user to obtain a written attestation that the individual has satisfactorily
completed the requirements in He-P 4035.65(c) and is able to independently
fulfill the radiation safety-related duties as an authorized user for the
medical uses authorized under He-P 4035.35 for which the individual is
requesting authorized user status.
(e) The written attestation
shall be obtained from either:
(1) A preceptor authorized user
who meets the requirements in He-P 4035.65 or He-P 4035.71, or the equivalent
requirements of an agreement state, or the Nuclear Regulatory Commission and has
experience in administering dosages in the same dosage category or categories
as the individual requesting authorized user status; or
(2) A residency program
director who affirms in writing that the attestation represents the consensus
of the residency program faculty where at least one faculty member is an
authorized user who meets the requirements in He-P 4035.65 or He-P 4035.71, or
the equivalent requirements of an agreement state, or the Nuclear Regulatory
Commission, has experience in administering dosages in the same dosage category
or categories as the individual authorized user status, and concurs with the
attestation provided by the residency program director. The residency training program shall be
approved by the Residency Review Committee of the Accreditation Council for
Graduate Medical Education or the Royal College of Physicians and Surgeons of
Canada, or the Council on Postdoctoral Training of the American Osteopathic
Association and shall include and experience specified in He-P 4035.65(c).
Source. (See Revision Note at part
heading for He-P 4035)
#6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P 4035.66 Training for the Oral Administration of
Sodium Iodide I-131 and for the Parenteral Administration Requiring a Written
Directive.
(a) Except as provided in He‑P 4035.71, the
licensee shall require the authorized user for the oral administration of
sodium iodide I-131 requiring a written directive in quantities less than or
equal to 1.22 gigabecquerels (33 millicuries), to be a physician who:
(1) Is certified
by a medical specialty board whose certification process includes all the
requirements in He-P 4035.66(b)(1), (b)(2), and whose certification process has
been recognized by DHHS/RHS, an agreement state, or the Nuclear Regulatory
Commission. The names of board certifications that have been recognized by
DHHS/RHS, an agreement state, or Nuclear Regulatory Commission on the NRC’s
Medical Uses Licensee Toolkit web page; or
(2) Is an authorized user under
He-P 4035.65 for uses listed in He-P 4035.65(c)(2)b.1. or He-P 4035.65(c)(2)b.2., or He-P 4035.66(d) and (e), or equivalent
requirements of an agreement state, or the Nuclear Regulatory Commission; or
(b) Except as provided in He-P 4035.71, a
physician who does not meet the requirement of He-P 4035.66(a) above shall:
successfully complete 80 hours of classroom and laboratory training, applicable
to the medical use of sodium iodide I-131 for procedures requiring a written
directive.
(1) The training shall include:
a. Radiation physics and
instrumentation;
b. Radiation protection;
c. Mathematics pertaining to
the use and measurement of radioactivity;
d. Chemistry of byproduct
material for medical use; and
e. Radiation biology; and
(2) Has work experience, under the supervision of
an authorized user who meets the requirements in He-P 4035.65, He-P 4035.66(a)
through (e), He-P 4035.71, or the equivalent requirements of an agreement
state, or the Nuclear Regulatory Commission.
A supervising authorized user who meets the requirements in He-P
4035.65(c) through (e) shall also have experience in administering dosages as
specified in He-P 4035.65(c)(2)b.1. or (c)(2)b.2. The work experience shall include:
a. Ordering, receiving, and
unpacking radioactive materials safely and performing the related radiation
surveys;
b. Performing quality control
procedures on instruments used to determine the activity of dosages and
performing checks for proper operation of survey meters;
c. Calculating, measuring, and
safely preparing patients or human research subject dosages;
d. Using administrative
controls to prevent a medical event involving the use of byproduct material;
e. Using procedures to contain spilled byproduct material safely and
using proper decontamination procedures; and
f. Administering dosages to
patients or human research subjects, that includes at least 3 cases involving
the oral administration of less than or equal to 1.22 gigabecquerels (33
millicuries) of sodium iodide I-131; and
(3) Have obtained
a written attestation that the physician has satisfactorily completed the
requirements in He-P 4035.66(b)(1) and (b)(2), and is able to independently
fulfill the radiation safety-related duties as an authorized user for oral
administration of less than or equal to 1.22 gigabecquerel (33 millicuries) of
sodium iodide I-133 for medical uses authorized under He-P 4035.35.
(c) The written attestation shall be obtained
from either:
(1) A preceptor authorized user who meets
the requirements in He-P 4035.65, He-P 4035.66(a)through (e), He-P 4035.71, or
the equivalent requirements of an agreement state, or the Nuclear Regulatory
Commission; and
(2)
Has experience in administering dosages as specified in He-P
4035.65(c)(2)b.1. or 2.; or
(3)
A residency program director who affirms in
writing that the attestation represents the consensus of the residency program
faculty where at least one faculty member is an authorized user who meets the
requirements in He-P 4035.65, He-P 4035.66(a) through (e), He-P 4035.71, or the
equivalent requirements of an agreement state, or the Nuclear Regulatory
Commission, has experience in administering dosages as specified in He-P
4035.65(c)(2)b.1., or b.2., and concurs with the attestation provided by the
residency program director. The
residency training program shall be approved by the Residency Review Committee
of the Accreditation Council for Graduate Medical Education or the Royal
College of Physicians and Surgeons of Canada, or the Council on Postdoctoral
Training of the American Osteopathic Association and shall include and
experience specified in He-P 4035.66(b)(1) and (2).
(d) Except as provided in He‑P 4035.71, the
licensee shall require the authorized user for the oral administration of
sodium iodide I-131 requiring a written directive in quantities greater than
1.22 gigabecquerels (33 millicuries), to be a physician who:
(1) Is certified by a medical specialty board
whose certification process includes all of the requirements in He-P 4035.66(e)(1) and (2), and whose
certification has been recognized by the DHHS/RHS, or an agreement state, or
the Nuclear Regulatory Commission. The names
of board certifications that have been recognized by DHHS/RHS, an agreement
state, or the Nuclear Regulatory Commission are posted on the NRC’s Medical
Uses Licensee Toolkit web page; or
(2) Is an authorized user under
He-P 4035.65 for uses listed in He-P 4035.65(c)(2)b.2., or the equivalent
requirements of an agreement state, or the Nuclear Regulatory Commission; or
(e) Except as provided in He‑P 4035.71, the
licensee shall require the authorized user for the oral administration of
sodium iodide I-131 requiring a written directive in quantities greater than
1.22 gigabecquerels (33 millicuries), to be a physician who:
(1)
Has successfully completed 80 hours of classroom and laboratory
training, applicable to the medical use of sodium iodide I-131 for procedures
requiring a written directive. The
training shall include:
a. Radiation physics and
instrumentation;
b. Radiation protection;
c. Mathematics pertaining to
the use and measurement of radioactivity;
d. Chemistry of byproduct
material for medical use; and
e. Radiation biology; and
(2)
Has work experience, under the supervision of an authorized user who
meets the requirements in He-P 4035.65, He-P 4035.66(d) and (e), He-P 4035.71,
or the equivalent requirements of an agreement state, or the Nuclear Regulatory
Commission. A supervising authorized
user, who meets the requirements in He-P 4035.65(c) through (e), shall also
have experience in administering dosages as specified in He-P
4035.65(c)(2)b.2. The work experience
shall involve:
a. Ordering, receiving, and
unpacking radioactive materials safely and performing the related radiation
surveys;
b. Performing quality control
procedures on instruments used to determine the activity of dosages and
performing checks for proper operation of survey meters;
c. Calculating, measuring, and
safely preparing patient or human research subject dosages;
d. Using administrative
controls to prevent a medical event involving the use of byproduct material;
e. Using procedures to contain spilled byproduct material safely and
using proper decontamination procedures; and
f. Administering dosages to
patients or human research subjects, that include at least 3 cases involving
the oral administration of greater than 1.22 gigabecquerels (33 millicuries) of
sodium iodide I-131; and
(3) Has obtained written attestation that the
individual has satisfactorily completed the requirements in He-P 4035.66(e)(1)
and (e)(2), and has achieved a level of competency sufficient to function
independently as an authorized user for medical uses authorized under He-P
4035.35. The attestation shall be
obtained from either:
a. A preceptor authorized user
who meets the requirements in He-P 4035.65, He-P 4035.66(d), and (e), He-P
4035.71, the equivalent requirements of an agreement state, or the Nuclear Regulatory
Commission, and has experience in administering dosages as specified in He-P
4035.65(c)(2)b.2.; or
b. A residency program director
who affirms in writing that the attestation represents the consensus of the
residency program faculty where at least one faculty member is an authorized
user who meets the requirements in He-P 4035.65, He-P 4035.66(d) and (e), He-P
4035.71, or the equivalent requirements of an agreement state, or the Nuclear
Regulatory Commission, has experience in administering dosages as specified in
He-P 4035.65(c)(2)b.2., and concurs with the attestation provided by the
residency program director. The
residency training program shall be approved by the Residency Review Committee
of the Accreditation Council for Graduate Medical Education or the Royal
College of Physicians and Surgeons of Canada, or the Council on Postdoctoral
Training of the American Osteopathic Association and shall include and
experience specified in He-P 4035.66(e)(1) and (2).
(f) Except as provided in He-P 4035.71, the
licensee shall require an authorized user for the parenteral administration
requiring a written directive, to be a physician who:
(1) Is an
authorized user under He-P 4035.65 for uses listed in He-P 4035.65(c)(2)b.3.the
equivalent requirements of an agreement state, or the Nuclear Regulatory
Commission; or
(2) Is an authorized user under He-P 4035.59 or
He-P 4035.69, or the equivalent requirements of an agreement state, or Nuclear
Regulatory Commission and meets the requirements in He-P 4035.66(f)(4) –
(f)(6); or
(3) Is certified by a medical specialty board
whose certification process has been recognized by DHHS/RHS, under He-P 4035.59
or He-P 4035.69 or the equivalent requirements of an agreement state or the
Nuclear Regulatory Commission, and who meets the requirements in He-P
4035.66(f)(4) through (f)(6); and
(4) Shall have successfully completed 80 hours of
classroom and laboratory training, applicable to parenteral administrations
listed in He-P 4035.65(c)(2)b.3. The training shall include:
a. Radiation physics and instrumentation;
b. Radiation protection;
c. Mathematics pertaining to the use and
measurement of radioactivity;
d. Chemistry of byproduct material for medical
use; and
e. Radiation biology; and
(5) Has work experience, under the supervision of
an authorized user who meets the requirements in He-P 4035.65, He-P 4035.66(f)
and He-P 4035.71, or the equivalent requirements of an agreement state, or the
Nuclear Regulatory Commission, in the parenteral administration listed in He-P
4035.65(c)(2)b.3. A supervising
authorized user who meets the requirements in He-P 4035.65, He-P 4035.66(f), or
equivalent requirements of an agreement state, or the Nuclear Regulatory
Commission, shall have experience in administering dosages in the same category
or categories as the individual requesting authorized user status. The work experience shall involve:
a. Ordering, receiving, and unpacking
radioactive materials safely and performing the related radiation surveys;
b. Performing quality control procedures on
instruments used to determine the activity of dosages, and performing checks
for proper operation of survey meters;
c. Calculating, measuring, and safely preparing
patient or human research subject dosages;
d. Using administrative controls to prevent a
medical event involving the use of unsealed byproduct material;
e. Using
procedures to contain spilled byproduct material safely and using proper
decontamination procedures;
f. Administering dosages to patients or human
research subjects that include a minimum of 3 cases involving the parenteral
administration as specified in He-P 4035.65(c)(2)b.3.; and
(6) Has obtained written attestation that the
individual has satisfactorily completed the requirements in He-P 4035.66(f)(4)
and (f)(5) is able to independently fulfill the radiation safety-related duties
as an authorized user for the parenteral administration of unsealed byproduct
material requiring a written directive.
The written attestation shall be obtained from either:
a.
A preceptor authorized user who meets the requirements in He-P 4035.65,
He-P 4035.66(f), He-P 4035.71, the equivalent requirements of an agreement
state, or the Nuclear Regulatory Commission
A preceptor authorized user who meets the requirements in He-P 4035.65,
He-P 4035.66(f), the equivalent requirements of an agreement state, or the
Nuclear Regulatory Commission shall have experience in administering
dosages in the same category or
categories as the individual requesting authorized user status; or
b. A residency program director who affirms in writing that the
attestation represents the consensus of the residency program faculty where at
least one faculty member is an authorized user who meets the requirements in
He-P 4035.65, He-P 4035.66(f), He-P 4035.71, or the equivalent requirements of
an agreement state, or the Nuclear Regulatory Commission, has experience in
administering dosages in the same dosage category or categories as the
individual requesting authorized user status, and concurs with the attestation
provided by the residency program director.
The residency training program shall be approved by the Residency Review
Committee of the Accreditation Council for Graduate Medical Education or the
Royal College of Physicians and Surgeons of Canada, or the Council on
Postdoctoral Training of the American Osteopathic Association and shall include
and experience specified in He-P 4035.66(f)(4) and (5).
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; amd by #12054, eff
11-19-16; ss by #13048, eff 6-2-20
He-P 4035.67 Training for Ophthalmic Use of
Strontium-90.
(a) Except as provided in He‑P 4035.71, the
licensee shall require the authorized user of strontium-90 for ophthalmic
radiotherapy to be a physician who:
(1) Is an authorized user under He-P 4035.69, or
the equivalent requirements of an agreement state or the Nuclear Regulatory
Commission; or
(2) Has completed 24 hours of instruction
applicable to the medical use of strontium-90 for ophthalmic radiotherapy, and
a period of supervised clinical training in ophthalmic radiotherapy, as
follows:
a. To satisfy the requirement for instruction,
the classroom and laboratory training shall include:
1. Radiation physics and instrumentation;
2. Radiation protection;
3. Mathematics pertaining to the use and
measurement of radioactivity; and
4. Radiation biology; and
b. To satisfy the requirement for a period of
supervised clinical training in ophthalmic radiotherapy, training shall be
under the supervision of an authorized user at a medical institution, clinic,
or private practice and shall include the use of strontium-90 for the
ophthalmic treatment of 5 individuals that includes:
1. Examination of each individual to be treated;
2. Calculation of the dose to be administered;
3. Administration of the dose; and
4. Follow-up and review of each individual’s
case history.
(b) In accordance with He-P 4035.67(a) above, an
authorized user who is a physician shall:
(1) Obtain a written attestation, signed by a preceptor authorized user
who meets the requirements in He-P 4035.67, He-P 4035.69, He-P 4035.71, or the
equivalent requirements of an agreement state, or the Nuclear Regulatory
Commission , that the individual has satisfactorily completed the requirements
in He-P 4035.67(a)(2); and
(2) Is able to independently fulfill the
radiation safety-related duties as an authorized user of strontium-90 for
ophthalmic use.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P 4035.68 Training for Use of Sealed Sources and Medical
Devices for Diagnosis. Except as
provided in He‑P 4035.71 the licensee shall require the authorized user
of a diagnostic sealed source in a device specified in He‑P 4035.39 to be
a physician, dentist, or podiatrist who:
(a) Is certified by a specialty board whose
certification process includes all the requirements in He-P 4035.68(c) and (d)
and whose certification has been recognized by DHHS/RHS, an agreement state, or
the Nuclear Regulatory Commission. The names of board certifications that have
been recognized by the DHHS/RHS, an agreement state, or the Nuclear Regulatory
Commission are posted on the NRC’s Medical Uses Licensee Toolkit web page;
(b) Is an authorized user for uses listed in He-P
4035.31, or the equivalent requirements of an agreement state or the Nuclear
Regulatory Commission; or
(c) Has completed 8 hours of classroom and
laboratory training in basic radionuclide handling techniques specifically
applicable to the use of the device, including training in:
(1) Radiation physics, mathematics pertaining to
the use and measurement of radioactivity, and instrumentation;
(2) Radiation biology; and
(3) Radiation protection.
(d) Has completed training in the use of the
device for the uses requested.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; amd by #12054, eff
11-19-16; ss by #13048, eff 6-2-20
He-P 4035.69 Training for
Use of Manual Brachytherapy Sources.
(a) Except as provided in He‑P
4035.71, the licensee shall require the authorized user of a manual
brachytherapy source for the uses authorized under He-P 4035.41 to be a physician
who:
(1) Is certified by a medical
specialty board whose certification process has been recognized by the
DHHS/RHS, or an agreement state, or the Nuclear Regulatory Commission. The names of board certifications that have
been recognized by DHHS/RHS, an agreement state, or the Nuclear Regulatory
Commission are posted on the NRC’s Medical Uses Licensee Toolkit web page. To have
its certification process recognized, a specialty board shall require all
candidates for certification to:
a. Successfully complete a
minimum of 3 years of residency training in a radiation oncology program
approved by the Residency Review Committee of the Accreditation Council for
Graduate Medical Education or the Royal College of Physicians and Surgeons of
Canada or the Committee on Post-Graduate Training of the American Osteopathic
Association; and
b. Pass an examination,
administering by diplomats of the specialty board, that tests knowledge and
competence in radiation safety, radionuclide handling, treatment planning,
quality assurance, and clinical use of manual brachytherapy; or
(2) Meets the requirements in
He-P 4035.69(b); or
(b) Has completed a structured
educational program in basic radionuclide handling techniques applicable to the
use of manual brachytherapy sources that includes:
(1) 200 hours of classroom and
laboratory training in the following:
a. Radiation physics and
instrumentation;
b. Radiation protection;
c. Mathematics pertaining to
the use and measurement of radioactivity;
d. Radiation biology; and
(2) 500 hours of work
experience, under the supervision of an authorized user who meets the
requirements in He-P 4035.69, He-P 4035.71, or the equivalent agreement state,
or the Nuclear Regulatory Commission requirements at a medical facility
authorized to use byproduct materials under He-P 4035.41, involving:
a. Ordering, receiving, and
unpacking radioactive materials safely and performing the related radiation
surveys;
b. Checking survey meters for
proper operation;
c. Preparing, implanting, and
removing brachytherapy sources;
d. Maintaining running
inventories of material on hand;
e. Using administrative
controls to prevent a medical event involving the use of byproduct material;
f. Using emergency procedures
to control byproduct material; and
(3) Has completed 3 years of
supervised clinical experience in radiation oncology, under an authorized user
who meets the requirements in He-P 4035.69, He-P 4035.71, or the equivalent
requirements of an agreement state, or the Nuclear Regulatory Commission, as
part of a formal training program approved by the Residency Review Committee
for Radiation Oncology of the Accreditation Council for Graduate Medical
Education or the Royal College of Physicians and Surgeons of Canada or the
Committee on Postdoctoral Training of the American Osteopathic
Association. This experience may be
obtained concurrently with the supervised work experience required by He-P
4035.69(b)(2); and
(4) Has obtained a written attestation that the individual has
satisfactorily completed the requirements in He-P 4035.69 (b)(1), (b)(2), and
(b)(3) and is able to independently
fulfill the radiation safety-related duties as an authorized user of manual
brachytherapy sources for the medical uses authorized under He-P 4035.41. The
attestation shall be obtained from either:
a. A preceptor authorized user who meets the
requirements in He-P 4035.69, He-P 4035.71, or the equivalent requirements of
an agreement state, or the Nuclear Regulatory Commission; or
b. A residency program director who affirms in
writing that the attestation represents the consensus of the residency program
faculty where at least one faculty member is an authorized user who meets the
requirements in He-P 4035.69, He-P 4035.71, or the equivalent requirements of
an agreement state, or the Nuclear Regulatory Commission, and concurs with the
attestation provided by the residency program director. The residency training program shall be
approved by the Residency Review Committee of the Accreditation Council for Graduate
Medical Education or the Royal College of Physicians and Surgeons of Canada or
the Council on Postdoctoral Training of the American Osteopathic Association
and shall include training and experience specified in He-P 4035.69(b)(1)
through (b)(3).
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P 4035.70 Training for Authorized Medical Physicist. Excepted as provided in He-P 4035.71, the
licensee shall require the authorized medical physicist to be an individual
who:
(a) Is certified by a specialty board whose
certification process has been recognized by DHHS/RHS, or an agreement state,
or the Nuclear Regulatory Commission, and who meets the requirements in He-P
4035.70;
(b) The name of board
certifications that have been recognized by DHHS/RHS, an agreement state, or
the Nuclear Regulatory Commission are posted on the NRC’s Medical Uses Licensee
Toolkit web page. To have its certification process recognized, a specialty
board shall require all candidates for certification to:
(1) Hold a master’s or doctor’s
degree in physics, medical physics, other physical science, engineering, or
applied mathematics from an accredited college or university; and
(2) Have 2 years of full-time
practical training and/or supervised experience in medical physics:
a. Under the supervision of a
medical physicist who is certified in medical physics by a specialty board
recognized by the DHHS/RHS, or an agreement state, or the Nuclear Regulatory
Commission; or
b. In clinical radiation
facilities providing high-energy, external beam therapy (photons and electrons
with energies greater than or equal to 1 million electron volts) and
brachytherapy services under the direction of physicians who meet the
requirements in He-P 4035.59, He-P 4035.69, or He-P 4035.71; and
(3) Pass an examination,
administered by diplomats of the specialty board, that assesses knowledge and
competence in clinical radiation therapy, radiation safety, calibration,
quality assurance, and treatment planning for external beam therapy,
brachytherapy, and stereotactic radiosurgery; or
(4) Hold a master’s or doctor’s
degree in physics, medical physics, other physical science, engineering, or
applied mathematics from an accredited college or university has completed 1
year of full-time training in medical physics; and
a. An additional year of
full-time work experience under the supervision of an individual who meets the
requirements for an authorized medical physicist for the type(s) of use for
which the individual is seeking authorization; and
b. This training and work
experience shall be conducted in clinical radiation facilities that provide
high-energy, external beam therapy (photons and electrons with energies greater
than or equal to 1 million electron volts) and brachytherapy services and shall
include:
1. Performing sealed source
leak tests and inventories;
2. Performing decay
corrections;
3. Performing full calibration
and periodic spot checks of external beam treatment units, stereotactic
radiosurgery units, and remote afterloading units as applicable; and
4. Conducting radiation surveys
around external beam treatment units, stereotactic radiosurgery units, and
remote afteloading units as applicable; and
(5) Have obtained written
attestation that the individual has satisfactorily completed the requirements
in He-P 4035.70(b)(1) and (c), and is able to independently fulfill the
radiation safety-related duties as an authorized medical physicist for each
type of therapeutic medical unit for which the individual is requesting
authorized medical physicist status. The written attestation shall be signed by
a preceptor authorized medical physicist who meets the requirements in He-P
4035.70, He-P 4035.71, or the equivalent requirements of an agreement state, or
the Nuclear Regulatory Commission for an authorized medical physicist for each
type of therapeutic medical unit for which the individual is requesting
authorized medical physicist status.
(c) Has training for the type(s) of use for which
authorization is sought that includes hands-on device operation, safety
procedures, clinical use, and the operation of a treatment planning system. This training requirement may be satisfied by
satisfactorily completing either a training program provided by the vendor or
by training supervised by an authorized medical physicist authorized for the
type(s) of use for which the individual is seeking authorization.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; amd by #12054, eff
11-19-16; ss by #13048, eff 6-2-20
He-P 4035.71 Training for Experienced Radiation Safety
Officer, Teletherapy or Medical Physicist, Authorized Medical Physicist,
Authorized User, Nuclear Pharmacist, and Authorized Nuclear Pharmacist.
(a) An individual identified as:
(1) A radiation safety officer, a teletherapy or
medical physicist, an authorized medical physicist, a nuclear pharmacist, or an
authorized nuclear pharmacist on a DHHS/RHS, or an agreement state, or a
Nuclear Regulatory Commission license or a permit issued by DHHS/RHS, or a
Nuclear Regulatory Commission broad scope licensee or master material license
permit, or by a master material license permittee of broad scope before January
14, 2019, need not comply with the training requirements of He-P 4035.61, He-P
4035.70, or He-P 4035.74, respectively except the radiation safety officers and
authorized medical physicists identified in He-P 4035.71(a)(1) shall meet the
training requirements in He-P 4035.61(e)
or He-P 4035.70(c), as appropriate, for any material or uses for which they
were not authorized prior to this date;
(2) An individual certified by the American Board of Health Physics in comprehensive
health physics; American Board of Radiology; American Board of Nuclear
Medicine; American Board of Science in Nuclear Medicine; Board of
Pharmaceutical Specialties in Nuclear Pharmacy; American Board of Medical
Physics in radiation oncology physics;
Royal College of Physicians and Surgeons of Canada in nuclear medicine;
American Osteopathic Board of Radiology; or American Osteopathic Board of
Nuclear Medicine on or before October 24, 2005, need not comply with the
training requirements of He-P 4035.61 to be identified as a radiation safety
officer or as an associate radiation safety officer on a DHHS/RHS, an agreement
state, or Nuclear Regulatory Commission license or Nuclear Regulatory
Commission master material license permit for those materials and uses that
these individuals performed on or before October 24, 2005; or
(3) An individual certified by the American Board
of Radiology in therapeutic radiological physics, Roentgen ray and gamma ray
physics, x-ray and radium physics, or radiological physics, or certified by the
American Board of Medical Physics in radiation oncology physics, on or before
October 24, 2005, need not comply with the training requirements for an
authorized medical physicist described in He-P 4035.70, for those materials and
uses that these individuals performed on or before October 24, 2005.
(b) Physicians, dentists, or podiatrists
identified as authorized users for the medical use of byproduct material on a
license issued by the DHHS/RHS, an agreement state, or the Nuclear Regulatory
Commission, or a permit issued by a Nuclear Regulatory Commission master
material licensee, a permit issued by the DHHS/RHS, or an agreement state, or
the Nuclear Regulatory Commission broad scope licensee, or a permit issued by a
Nuclear Regulatory Commission master material license broad scope permittee
before January 14, 2019, who perform
only those medical uses for which they were authorized on that date need not
comply with the training requirements of He-P 4035 subparts equivalent to 10
CFR 35 Subparts D through H.
(c) Physicians, dentists, or podiatrists not
identified as authorized users for the medical use of byproduct material on a
license issued by DHHS/RHS, an agreement state, or the Nuclear Regulatory
Commission, or a permit issued by a Nuclear Regulatory Commission master
material licensee, a permit issued by DHHS/RHS, an agreement state, or Nuclear Regulatory Commission broad scope
licensee, or a permit issued by a Nuclear Regulatory Commission master material
license of broad scope on or before
October 24, 2005, need not comply with the training requirements of He-P 4035
subparts equivalent to 10 CFR 35 Subparts D through H for
those materials and uses that these individuals performed on or before October
24, 2005, as follows:
(1) For uses authorized under He-P 4035.27 or
He-P 4035.31, or oral administration of sodium iodide I-131 requiring a written
directive for imaging and localization purposes, a physician who was certified
on or before October 24, 2005, in nuclear medicine by the American Board of
Nuclear Medicine; diagnostic radiology by the American Board of Radiology;
diagnostic radiology or radiology by the American Osteopathic Board of
Radiology; nuclear medicine by the Royal College of Physicians and Surgeons of
Canada; or American Osteopathic Board of Nuclear Medicine in nuclear medicine;
(2) For uses authorized under He-P 4035.35, a
physician who was certified on or before October 24, 2005, by the American
Board of Nuclear Medicine; the American Board of Radiology in radiology,
therapeutic radiology, or radiation oncology; nuclear medicine by the Royal
College of Physicians and Surgeons of Canada; or the American Osteopathic Board
of Radiology after 1984;
(3) For uses authorized under He-P 4035.41 or
He-P 4035.47, a physician who was certified on or before October 24, 2005, in
radiology, therapeutic radiology or radiation oncology by the American Board of
Radiology; radiation oncology by the American Osteopathic Board of Radiology;
radiology, with specialization in radiotherapy, as a British “Fellow of the
Faculty of Radiology” or “Fellow of the Royal College of Radiology”; or
therapeutic radiology by the Canadian Royal College of Physicians and Surgeons;
and
(4) For uses authorized under He-P 4035.39, a
physician who was certified on or before October 24, 2005, in radiology,
diagnostic radiology, therapeutic radiology, or radiation oncology by the
American Board of Radiology; nuclear medicine by the American Board of Nuclear
Medicine; diagnostic radiology or radiology by the American Osteopathic Board
of Radiology; or nuclear medicine by the Royal College of Physicians and
Surgeons of Canada.
(d) Physicians, dentists, or podiatrists who used
only accelerator-produced radioactive materials, discrete sources of
radium-226, or both, for medical uses performed at locations of use before
August 8, 2009, or an earlier date as noticed by DHHS/RHS, need not comply with
the training requirements of He-P 4035 subparts equivalent to 10 CFR 35
Subparts D through H when performing the same medical uses. A physician,
dentist, or podiatrist, who used only accelerator-produced radioactive
materials, discrete sources of radium-226, or both, for medical uses at the
locations and time period identified in this paragraph, qualifies as an
authorized user for those materials and uses performed before these dates, for
the purposes of He-P 4035.
(e) Individuals who need not comply with training
requirements as described in He-P 4035.71(a) through (d) above may serve as
preceptors for, and supervisors of, applicants seeking authorization on
DHHS/RHS licenses for the same uses for which these individuals are authorized.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P 4035.72 Reserved
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; rpld by #11011, eff 1-15-16
He-P 4035.73 Recentness of
Training. The training and
experience specified in the requirements of He-P 4035, subparts equivalent to
10 CFR 35 Subparts B and D through H shall have been obtained within the 7
years preceding the date of application, or the individual shall have had
related continuing education and experience since the required training and
experience was completed.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; rpld by #11011, eff 1-15-16; ss by #11108, eff
5-25-16; ss by #13048, eff 6-2-20
He-P 4035.74 Training for an Authorized Nuclear
Pharmacist. Except as provided He-P
4035.71, the licensee shall require the authorized nuclear pharmacist to be a
licensed pharmacist, as defined in RSA 318:1, VII, who:
(a) Is certified by a specialty
board whose certification process has been recognized by DHHS/RHS, or an
agreement state, or the Nuclear Regulatory Commission. The names of board
certifications that have been recognized by DHHS/RHS, an agreement state, or
the Nuclear Regulatory Commission are posted on the NRC’s medical use licensee
toolkit web page. To have its certification process recognized, a specialty
board shall require all candidates for certification to:
(1) Have graduated from a pharmacy program accredited by the American
Council on Pharmaceutical Education (ACPE) or have passed the Foreign Pharmacy
Graduate Examination Committee (FPGEC) examination;
(2) Hold a current, active
license to practice pharmacy;
(3) Provide evidence of having
acquired at least 4000 hours of training/experience in nuclear pharmacy
practice. Academic training may be
substituted for no more than 2000 hours of the required training and
experience; and
(4) Pass an examination in
nuclear pharmacy administered by diplomats of the specialty board, that
assesses knowledge and competency in procurement, compounding, quality
assurance, dispensing, distribution, health and safety, radiation safety,
provision of information and consultation, monitoring patient outcomes,
research and development; or
(b) Has met the following requirements:
(1) Have completed 700 hours in a structured
educational program consisting of both:
a. 200 hours of classroom and laboratory
training in the following areas:
1. Radiation physics and
instrumentation;
2. Radiation protection;
3. Mathematics pertaining to
the use and measurement of radioactivity;
4. Chemistry of byproduct
material for medical use; and
5. Radiation biology; and
b. Supervised practical experience in a nuclear
pharmacy involving the following:
1. Shipping, receiving, and
performing related radiation surveys;
2. Using and performing checks
for proper operation of instruments used to determine the activity of dosages,
survey meters, and, if appropriate, instruments used to measure alpha- or
beta-emitting radionuclides;
3 Calculating, assaying, and
safely preparing dosages for patients or human research subjects;
4 Using administrative controls
to avoid medical events in the administration of byproduct material;
5. Using procedures to prevent
or minimize radioactive contamination and using proper .decontamination
procedures; and
(2) Has obtained a written attestation, signed by a preceptor authorized nuclear pharmacist, that the individual has
satisfactorily completed the requirements in He-P 4035.74(b)(1) and is able to
independently operate as an authorized nuclear pharmacist.
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff 1-15-16; ss by #13048, eff 6-2-20
He-P 4035.75 RESERVED
Source. (See Revision Note at part heading for He-P
4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07; ss by #10897, INTERIM, eff
7-22-15, EXPIRES: 1-18-16; ss by #11011, eff eff 1-15-16
PART He-P
4036 Licensing
and Radiation Safety Requirements for Irradiators
He P 4036.01 Purpose. The purpose of this rule is to set forth the
requirements for issuance of a license authorizing the use of sealed sources
containing radioactive materials in irradiators used to irradiate objects or
materials using gamma radiation, and the radiation safety requirements for operating
irradiators. The requirements of this
section are in addition to, and not in substitution for, the requirements of
Parts He-P 4003, 4019, 4020, 4021, 4022, 4023, 4024, 4030, and 4038 of this
chapter.
Source. #8211, eff 11-23-04; ss by #10188, eff
9-26-12; ss by #13542, eff 1-28-23
He-P 4036.02 Scope.
This part shall apply to persons using sealed sources containing
radioactive material in irradiators as specified in Title 10, Code of Federal
Regulations (CFR), Part 36, “Licenses and Radiation Safety Requirements for
Irradiators”.
Source. #8211, eff 11-23-04; ss by #10188, eff
9-26-12; ss by #13542, eff 1-28-23
He P 4036.03 Definitions. To reconcile differences between this part
and the incorporated sections of 10 CFR Part 36 relating to using sealed
sources containing radioactive sources in irradiators, the following words and
phrases shall be substituted for the language in 10 CFR Part 36 as follows:
(a) All references to “NRC” or “Commission” shall
mean the New Hampshire department of health and human services;
(b) The definition of “licensed material” shall
be as defined in He-P 4003 of this chapter; and
(c) The definition of “sealed source” shall be as
defined in He-P 4003 of this chapter.
Source. #8211, eff 11-23-04; ss by #10188, eff
9-26-12; ss by #13542, eff 1-28-23
He-P 4036.04 Incorporation of 10 CFR Part 36.
(a) Except for the sections noted in (b) below
and He-P 4036.03 above, persons using sealed sources containing radioactive
material in irradiators shall comply with Title 10, Code of Federal Regulations
(CFR), Part 36, “Licenses and Radiation Safety Requirements for Irradiators”.
(b) The following sections of the Title 10 CRF
Part 36 shall not apply to those persons using sealed sources containing
radioactive material in irradiators:
(1) Title 10 CFR Part 36.5 relating to
interpretations;
(2) Title 10 CFR Part 36.8 relating to
information collection;
(3) Title 10 CFR Part 36.91 relating to
violations; and
(4) Title 10 CFR Part 36.93 relating to criminal
penalties.
Source. #8211, eff 11-23-04; ss by #10188, eff
9-26-12; ss by #13542, eff 1-28-23
PART He-P
4037 TRANSPORTATION OF RADIOACTIVE
MATERIAL
He-P 4037.01 Purpose. The purpose of this rule is to set forth the
requirements for packaging, preparation for shipment, and transportation of
licensed material. The requirements of
this section are in addition to, and not in substitution for, the requirements
of He-P 4003, 4019, 4020, 4021, 4022, 4023, 4024, and 4030 of this chapter.
Source. #7980, eff 10-22-03; ss by #9621, eff
12-24-09; ss by #12447, eff 1-5-18
He-P 4037.02 Scope.
This part shall apply to any person who transports radioactive material
or delivers radioactive material to a carrier for transport, including common
and contract carriers not subject to the requirements of the U.S. Department of
Transportation or U.S. Postal Service, as specified in Title 10, Code of
Federal Regulations (CFR), Part 71, “Packaging and Transportation of
Radioactive Material.”
(a)
The rules in He-P 4037 shall apply to any licensee authorized by
specific or general license issued by DHHS/RHS to receive, possess, use or
transfer licensed material if the licensee:
(1) Delivers that material to a carrier for
transport;
(2) Transports the material outside the site of
usage as specified in the license; or
(3) Transports that material on public highways.
(b) No provision of He-P 4037 authorizes
possession of licensed material.
Source. #7980, eff 10-22-03; ss by #9621, eff
12-24-09; ss by #12447, eff 1-5-18
He-P
4037.03 Definitions. To reconcile differences between this part
and the incorporated sections of 10 CFR Part 71 relating to packaging,
preparation for shipment, and transportation of radioactive material, the
following words and phrases shall be substituted for the language in 10 CFR
Part 71 as follows:
(a)
“Communications” means all communications, reports, and applications
described in He-P 4001.08.
(b)
“Licensed material” means “licensed material” as defined in He-P 4003 of
this chapter.
(c) “NRC”, “Commission”, or
“Authority” mean the department of health and human services, radiological
health section as defined in He-P 4003 of this chapter (DHHS/RHS).
(d)
“Sealed source” means “sealed source” as defined in He-P 4003.01 of this
chapter.
Source. #7980, eff 10-22-03; ss by #9621, eff
12-24-09; ss by #12447, eff 1-5-18
He-P 4037.04 Incorporation of 10 CFR Part 71.
(a)
Except for the sections noted in (b) below and He-P 4037.03 above, all
persons or any licensee authorized by specific or general license issued by
DHHS/RHS who transports radioactive material or delivers radioactive material
to a carrier for transport, including common and contract carriers not subject
to the requirements of the U.S. Department of Transportation or U.S. Postal
Service, shall comply with Title 10, Code of Federal Regulations (CFR), Part
71, “Relating to Packaging and Transportation of Radioactive Material.”
(b)
The following sections of the Title 10 CFR Part 71 shall not apply to
persons or any licensee authorized by specific or general license issued by
DHHS/RHS who transports radioactive material or delivers radioactive material
to a carrier for transport, including common and contract carriers not subject
to the requirements of the U.S. Department of Transportation or U.S. Postal
Service:
(1) Title 10 CFR Part 71.2, relating to
interpretations;
(2) Title 10 CFR Part 71.6, relating to
information collection;
(3) Title 10 CFR Part 71.11, relating to
protection of safeguards information;
(4) Title 10 CFR Part 71.14(b), relating to low
level material exemption;
(5) Title 10 CFR Part 71.19, relating to
previously approved packages;
(6) Title 10 CFR Part 71 Subpart D, relating to
application for package approval;
(7) Title 10 CFR Parts 71.41, 71.43, 71.45,
71.51, 71.55, 71.59, 71.61, 71.63, 71.64, and 71.65, relating to package
approval standards;
(8) Title 10 CFR Part 71 Subpart F, relating to
package, special form, and LSA-III tests;
(9) Title 10 CFR Part 71.85(a)-(c) relating to
preliminary determinations;
(10) Title 10 CFR 71.91(b), relating to records;
(11) Title 10 CFR Part 71.99, relating to
violations;
(12) Title 10 CFR Part 71.100, relating to
criminal penalties;
(13) Title 10 CFR Part 71.101(c)(2), (d), and (e),
relating to quality assurance requirements; and
(14) Title 10 CFR Parts 71.107, 71.109, 71.111,
71.113, 71.115, 71.117, 71.119, 71.121, 71.123, and 71.125, relating to quality
assurance.
Source. #7980, eff 10-22-03; ss by #9621, eff
12-24-09; ss by #12447, eff 1-5-18
PART He-P 4038 THE PHYSICAL
PROTECTION OF CATEGORY 1 AND CATEGORY 2 QUANTITIES OF RADIOACTIVE MATERIAL
He-P 4038.01 Purpose. The purpose of this rule is to set forth the
requirements for the physical protection program for any licensee that
possesses an aggregated category 1 or category 2 quantity of radioactive
material listed in Table 4038.1 in this section. These requirements provide reasonable
assurance of the security of category 1 or category 2 quantities of radioactive
material by protecting these materials from theft or diversion. Specific requirements for access to material,
use of material, transfer of material, and transport of material are
included. No provision of this part
authorizes possession of licensed material.
Source. #11105, eff 5-25-16
He-P 4038.02 Scope.
(a)
He-P 4038.07 through He-P 4038.22 apply to any person who, under the
regulations in He-P 4038, possesses or uses at any site, an aggregated category
1 or category 2 quantity of radioactive material.
(b)
He-P 4038.23 through He-P
4038.28 applies to any person who, under the regulations of He-P 4038:
(1) Transports or delivers to a carrier for
transport in a single shipment, a category 1 or category 2 quantity of
radioactive material; or
(2) Imports or exports a category 1 or category 2
quantity of radioactive material; the provisions only apply to the domestic
portion of the transport.
Source. #11105, eff 5-25-16
He-P 4038.03 Definitions. As
used in He-P 4038:
(a) “Access control” means a system for allowing only
approved individuals to have unescorted access to the security zone and for
ensuring that all other individuals are subject to escorted access.
(b) “Aggregated” means accessible by the breach of a single
physical barrier that would allow access to radioactive material in any form,
including any devices that contain the radioactive material, when the total
activity equals or exceeds a category 2 quantity of radioactive material.
(c) “Approved individual” means an individual whom the
licensee has determined to be trustworthy and reliable for unescorted access in
accordance with He-P 4038.07 through 4038.13 and who has completed the training
required by He-P 4038.15(c).
(d) “Background investigation” means the investigation
conducted by a licensee or applicant to support the determination of
trustworthiness and reliability as defined in (z) below.
(e) “Carrier” means a person engaged in the transportation of passengers or
property by land or water as a common, contract, or private carrier, or by
civil aircraft.
(f) “Category
1 quantity of radioactive material” means a quantity of
radioactive material meeting or exceeding the category 1 threshold in Table
4038.1 in He-P 4038.31. This is determined by calculating the ratio
of the total activity of each radionuclide to the category 1 threshold for that
radionuclide and adding the ratios together. If the sum is equal to
or exceeds one, the quantity would be considered a category 1
quantity. Category 1 quantities of radioactive material do not
include the radioactive material contained in any fuel assembly, subassembly,
fuel rod, or fuel pellet.
(g) “Category
2 quantity of radioactive material” means a quantity of radioactive
material meeting or exceeding the category 2 threshold but less than
the category 1 threshold in Table 4038.1 in He-P 4038.31. This is
determined by calculating the ratio of the total activity of each radionuclide
to the category 2 threshold for that radionuclide and adding the ratios together. If the sum is equal to or
exceeds one, the quantity would be considered a category 2
quantity. Category 2 quantities of radioactive material do not
include the radioactive material contained in any fuel assembly, subassembly,
fuel rod, or fuel pellet.
(h) “Diversion” means the unauthorized movement of radioactive material subject
to this part to a location different from the material's authorized
destination inside or outside of the site at which the material is used or
stored.
(i)
“DHHS/RHS” means the state of New Hampshire department of health and human
services/radiological health section.
(j) “Escorted
access” means accompaniment while in a security zone by an approved
individual who maintains continuous direct visual surveillance at all times
over an individual who is not approved for unescorted access.
(k) “Fingerprint
orders” means the legally binding requirements issued by DHHS/RHS, an
agreement state, or the Nuclear Regulatory Commission
(NRC) that require fingerprints and criminal history records checks for
individuals with unescorted access to category 1 and category 2 quantities of
radioactive material or safeguards information-modified handling.
(l) “License”,
except where otherwise specified, means a license for byproduct
material issued pursuant to the rules in He-P 4030 through He-P 4036 and He-P
4039;
(m) “License
issuing authority” means the licensing agency that issued the license,
i.e. DHHS/RHS, the appropriate agency of an agreement state, or the NRC;
(n) “Local
law enforcement agency” (LLEA)” means a public or private organization
that has been approved by a federal, state, or local government to carry
firearms and make arrests, and is authorized and has the capability to provide
an armed response in the jurisdiction where the licensed category 1 or category
2 quantity of radioactive material is used, stored, or transported.
(o) “Mobile
device” means a piece of equipment containing licensed
radioactive material that is either mounted on wheels or casters, or otherwise
equipped for moving without a need for disassembly or dismounting, or is
designed to be hand carried. Mobile devices do not include
stationary equipment installed in a fixed location.
(p) “Movement
control center” means an operations center that is remote from transport
activity and that maintains position information
on the movement of radioactive material, receives reports of attempted attacks
or thefts, provides a means for reporting these and other problems to
appropriate agencies and can request and coordinate appropriate aid.
(q) “No-later-than
arrival time” means the date and time that the shipping licensee and
receiving licensee have established as the time at which an investigation shall
be initiated if the shipment has not arrived at the receiving
facility. The no-later-than arrival time may not be more than 6
hours after the estimated arrival time for shipments of category 2 quantities
of radioactive material.
(r) “Non-agreement state” means any state that has not entered into an
effective agreement under subsection 274b. of the Atomic Energy Act of 1954, as
Amended (73 Stat. 689).
(s) “Person” means:
(1) Person
as defined in RSA 125-F:3, XII; and
(2) Any
individual, corporation, partnership, firm, association, trust, estate, public
or private institution, group, government agency other than the NRC or the
Department of Energy (DOE), except that the DOE shall be considered a person
within the meaning of the regulations in 10 CFR chapter I to the extent that
its facilities and activities are subject to the licensing and related
regulatory authority of the NRC under section 202 of the Energy Reorganization
Act of 1974 (88 Stat. 1244), the Uranium Mill Tailings Radiation Control Act of
1978 (92 Stat. 3021), the Nuclear Waste Policy Act of 1982 (96 Stat. 2201), and
section 3(b)(2) of the Low-Level Radioactive Waste Policy Amendments Act of
1985 (99 Stat. 1842), any state or any political subdivision of or any
political entity within a state, any foreign government or nation or any
political subdivision of any such government or nation, or other entity; and
(3) Any legal successor, representative, agent, or
agency of the foregoing.
(t) “Reviewing
official” means the individual authorized by the licensee who shall make
the trustworthiness and reliability determination, as defined in (z) below, of
an individual to determine whether the individual may have, or continue to
have, unescorted access to the category 1 or category 2 quantities of
radioactive materials that are possessed by the licensee.
(u) “Sabotage” means
deliberate damage, with malevolent intent, to a category 1 or category 2
quantity of radioactive material, a device that contains a category 1 or category 2
quantity of radioactive material, or the components of the security system.
(v) “Safe
haven” means a readily recognizable and readily accessible
site at which security is present or from which, in the event of an emergency,
the transport crew can notify and wait for the local law enforcement
authorities.
(w) “Security
zone” means any temporary or permanent area determined and established by
the licensee for the physical protection of category 1 or
category 2 quantities of radioactive material.
(x) “State” means
a state of the United States, the District of Columbia, the Commonwealth of
Puerto Rico, the Virgin Islands, Guam, American Samoa, and the Commonwealth of the
Northern Mariana Islands.
(y) “Telemetric
position monitoring system” means a data transfer system that captures
information by instrumentation or measuring
devices about the location and status of a transport vehicle or package between
the departure and destination locations.
(z) “Trustworthiness
and reliability” are characteristics of an individual considered
dependable in judgment, character, and performance, such that unescorted access
to category 1 or category 2 quantities of radioactive material by that individual
does not constitute an unreasonable risk to the public health and safety or
security. A determination of trustworthiness and reliability for
this purpose is based upon the results from a background investigation.
(aa) “Unescorted access” means solitary access to an aggregated
category 1 or category 2 quantities of radioactive material or the devices that
contain the material.
Source. #11105, eff 5-25-16; amd by #12055, eff
11-19-16; ss by #13598, eff 3-24-23
He-P 4038.04 Communications. All communications and reports concerning
the rules in He-P 4038 shall be sent as follows:
(a)
By mail addressed to: ATTN: Radioactive Materials Manager,
DHHS/Radiological Health Section, 29 Hazen Drive, Concord, NH 03301-6504; or
(b) By hand delivery to the above address.
Source. #11105, eff 5-25-16; amd by #12744, eff
3-20-19
He-P 4038.05 Interpretations. Except as specifically authorized by
DHHS/RHS in writing, no interpretation of the meaning of He-P 4038 by any
officer or employee of DHHS/RHS other than a written interpretation by the
Attorney General’s Office shall be recognized as binding upon DHHS/RHS.
Source. #11105, eff 5-25-16
He-P 4038.06 Specific Exemptions.
(a)
The DHHS/RHS may, upon application of any interested person or upon its
own initiative, grant such exemptions from the requirements of the rules in
He-P 4038 as it determines are authorized by law and will not endanger life or
property and are otherwise in the public interest.
(b)
Any licensee's, DHHS/RHS, or NRC-licensed activities are exempt from the
requirements of He-P 4038.07 through He-P 4038.22 to the extent that the
activities are included in a security plan required by He-P 4038 or the Nuclear
Regulatory Commission in accordance with 10 CFR 73.
(c)
A licensee that possesses radioactive waste that contains category 1 or
category 2 quantities of radioactive material is exempt from the requirements
of He-P 4038.07 through He-P 4038.28 of this part. Except that any radioactive waste that
contains discrete sources, ion-exchange resins, or activated material that
weighs less than 2,000 kg (4,409 lbs.) is not exempt from the requirements of
this part. The licensee shall implement
the following requirements to secure the radioactive waste:
(1) Use continuous physical barriers that allow
access to the radioactive waste only through established access control points;
(2) Use a locked door or gate with monitored
alarm at the access control point;
(3) Assess and respond to each actual or
attempted unauthorized access to determine whether an actual or attempted
theft, sabotage, or diversion occurred; and
(4) Immediately
notify the LLEA and request an armed response from the LLEA upon determination
that there was an actual or attempted theft, sabotage, or diversion of the
radioactive waste that contains category 1 or category 2 quantities of
radioactive material.
Source. #11105, eff 5-25-16; amd by #12744, eff
3-20-19
He-P
4038.07 Personnel Access Authorization
Requirements for Category 1 or Category 2 Quantities of Radioactive Material.
(a)
Any licensee or applicant:
(1) That possesses an aggregated quantity of
radioactive material at or above the category 2 threshold shall establish,
implement, and maintain an access authorization program in accordance with the
requirements of He-P 4038.07 through He-P 4038.13;
(2) That becomes newly subject to the
requirements of He-P 4038.07 through He-P 4038.13 upon application for
modification of its license shall implement the requirements of He-P 4038, as
appropriate, before taking possession of an aggregated category 1 or category 2
quantity of radioactive material; or
(3) That has not previously implemented the
security orders or been subject to the
requirements in He-P 4038.07 through He-P 4038.13 shall implement the
provisions of He-P 4038.07 through He-P 4038.13 before aggregating radioactive
material to a quantity that equals or exceeds the category 2 threshold.
(b)
The licensee's access authorization program shall ensure that the
individuals specified in He-P 4038.07(c)(1) and (c)(2) are trustworthy and
reliable.
(c)
Licensees shall subject the following individuals to the access
authorization program:
(1) Any individual whose assigned duties require
unescorted access to category 1 or category 2 quantities of radioactive
material or to any device that contains the radioactive material; and
(2) All reviewing officials.
(d)
Licensees are not required to subject the categories of individuals
listed in He-P 4038.11(a)(1) through (a)(13) to the investigation elements of
the access authorization program.
(e)
Licensees shall approve for unescorted access to category 1 or category
2 quantities of radioactive material only those individuals with job duties
that require unescorted access to category 1 or category 2 quantities of
radioactive material.
(f)
Licensees shall include individuals needing access to safeguards
information-modified handling under He-P 4038 in the access authorization
program under He-P 4038.07 through He-P 4038.13.
Source. #11105, eff 5-25-16
He-P 4038.08 Access Authorization Program Requirements.
(a)
Licensees shall implement the requirements of He-P 4038.07 through He-P
4038.13 for granting initial or reinstated unescorted access authorization.
(b)
Individuals who have been determined to be trustworthy and reliable
shall also complete the security training required by He-P 4038.15(c) before
being allowed unescorted access to category 1 or category 2 quantities of
radioactive material.
(c)
Reviewing officials are the only individuals who may make
trustworthiness and reliability determinations that allow individuals to have
unescorted access to category 1 or category 2 quantities of radioactive materials
possessed by the licensee.
(d)
Each licensee shall name one or more individuals to be reviewing
officials. After completing the background
investigation on the reviewing official, the licensee shall provide under oath
or affirmation, a certification that the reviewing official is deemed
trustworthy and reliable by the licensee.
Provide oath or affirmation certifications to DHHS/RHS. The fingerprints
of the named reviewing official must be taken by a law enforcement agency,
Federal or state agencies that provide fingerprinting services to the public,
or commercial fingerprinting services authorized by New Hampshire to take
fingerprints. The licensee shall
recertify that the reviewing official is deemed trustworthy and reliable every
10 years in accordance with He-P 4038.09(d).
(e)
Reviewing official shall:
(1) Be permitted to have unescorted access to
category 1 or category 2 quantities of radioactive materials or access to
safeguards information or safeguards information-modified handling, if the
licensee possesses safeguards information or safeguards information-modified
handling;
(2) Not approve other individuals to act as
reviewing officials;
(3) Not need to undergo a new background
investigation before being named by the licensee as the reviewing official if:
a. The individual has undergone a background
investigation that include fingerprinting and an FBI criminal history records
check and has been previously determined to be trustworthy and reliable by the
licensee; or
b. The individual is subject to a category
listed in He-P 4038.11(a).
(f)
Licensees shall not initiate a background investigation without the
informed and signed consent of the subject individual. This consent shall include authorization to
share personal information with other individuals or organizations as necessary
to complete the background investigation.
Before a final adverse determination, the licensee shall provide the
individual with an opportunity to correct any inaccurate or incomplete
information that is developed during the background investigation. Licensees shall not need to obtain signed
consent from those individuals that meet the requirements of He-P 4038.09(b)
and (c). A signed consent must be
obtained prior to any reinvestigation.
(g)
The subject individual may withdraw his or her consent at any time. Licensees shall inform the individual that:
(1) If an individual withdraws his or her
consent, the licensee may not initiate any elements of the background
investigation that were not in progress at the time the individual withdrew his
or her consent; and
(2) The withdrawal of consent for the background
investigation is sufficient cause for denial or termination of unescorted
access authorization.
(h) Any individual who is applying for
unescorted access authorization shall disclose the personal history information
that is required by the licensee's access authorization program for the
reviewing official to make a determination of the individual's trustworthiness
and reliability. Refusal to provide, or
the falsification of, any personal history information required by this He-P
4038.07 through He-P 4038.13 is sufficient cause for denial or termination of
unescorted access.
(i)
The licensee shall:
(1) Determine whether to permit, deny,
unfavorably terminate, maintain, or administratively withdraw an individual's
unescorted access authorization based on an evaluation of all of the
information collected to meet the requirements of He-P 4038.07 through He-P
4038.13;
(2) Not permit any individual to have unescorted
access until the licensee has evaluated all of the information collected to
meet the requirements of He-P 4038.07 through He-P 4038.13 and determined that
the individual is trustworthy and reliable. The reviewing official may deny
unescorted access to any individual based on information obtained at any time
during the background investigation;
(3) Document the basis for concluding whether or
not there is reasonable assurance that an individual is trustworthy and
reliable;
(4) May terminate or administratively withdraw an
individual's unescorted access authorization based on information obtained
after the background investigation has been completed and the individual
granted unescorted access authorization; and
(5) Maintain a list of persons currently approved
for unescorted access authorization.
When a licensee determines that a person no longer requires unescorted
access or meets the access authorization requirement, the licensee shall remove
the person from the approved list as soon as possible, but no later than 7
working days, and take prompt measures to ensure that the individual is unable
to have unescorted access to the material.
(j)
Licensees shall develop, implement, and maintain written procedures for
implementing the access authorization program.
The procedures shall include:
(1) Provisions for the notification of
individuals who are denied unescorted access. The procedures shall include
provisions for the review, at the request of the affected individual, of a
denial or termination of unescorted access authorization; and
(2) Provision to ensure that the individual is
informed of the grounds for the denial or termination of unescorted access
authorization and allow the individual an opportunity to provide additional
relevant information.
(k)
Prior to any final adverse determination, licensees shall provide:
(1) Each individual subject to He-P 4038.07
through He-P 4038.13 with the right to complete, correct, and explain
information obtained as a result of the licensee's background investigation;
(2) A confirmation of receipt by the individual
of this notification to be maintained by the licensee for a period of 1 year
from the date of the notification;
(3) Each individual with an
opportunity to make revisions, corrections, updates to, or explanations of
information in his or her criminal history record, if the individual believes
it is incorrect or incomplete in any respect.
The individual may initiate challenge procedures to change, correct,
update, or explain anything in the record.
The individual may initiate a challenge which shall include:
a. A direct application by the individual
challenging the record to the law enforcement agency that contributed the questioned
information or a direct challenge as to the accuracy or completeness of any
entry on the criminal history record to the Federal Bureau of Investigation,
Criminal Justice Information Services (CJIS) Division, ATTN: SCU, Mod. D–2,
1000 Custer Hollow Road, Clarksburg, WV 26306 as set forth in 28 CFR 16.30
through 16.34. In the latter case, the
Federal Bureau of Investigation (FBI) will forward the challenge to the agency
that submitted the data, and will request that the agency verify or correct the
challenged entry; and
b. Upon receipt of an official communication
directly from the law enforcement agency that contributed the original
information, the FBI Identification Division shall make any changes necessary
in accordance with the information supplied by that law enforcement agency;
(4) Provide at least 10 days for an individual to
initiate action to challenge the results of an FBI criminal history records
check after the record being made available for his or her review; and
(5) Make a final adverse determination based upon
the criminal history records shall be made only after receipt of the FBI's
confirmation or correction of the record; and
(l)
The licensee shall retain:
(1) Documentation regarding the trustworthiness
and reliability of individual employees for 3 years from the date the
individual no longer requires unescorted access to category 1 or category 2
quantities of radioactive material;
(2) A copy of the current access authorization
program procedures as a record for 3 years after the procedure is no longer
needed. If any portion of the procedure is superseded, the licensee shall
retain the superseded material for 3 years after the record is superseded; and
(3) The list of persons approved for unescorted
access authorization for 3 years after the list is superseded or replaced.
Source. #11105, eff 5-25-16; amd by #12055, eff
11-19-16; amd by #12744, eff 3-20-19
He-P 4038.09 Background Investigations.
(a) Before
allowing an individual unescorted access to category 1 or category 2 quantities
of radioactive material or to the devices that contain the
material, licensees shall complete a background investigation of the individual
seeking unescorted access authorization. The scope of the
investigation shall encompass at least the 7 years preceding the date of the background
investigation or since the individual's eighteenth birthday, whichever is
shorter. The background investigation shall include at a minimum:
(1) Fingerprinting and an FBI identification and criminal history records
check in accordance with He-P 4038.10;
(2) Verification
of the true identity of the individual who is applying for unescorted access
authorization to ensure that the applicant is who he or she claims to
be. A licensee shall:
a. Review
official identification documents such as a driver's license, passport,
government identification, or a certificate of birth issued by the state,
province, or country of birth, and compare the documents to personal
information data provided by the individual to identify any discrepancy in the
information;
b. Document
the type, expiration, and identification number of the
identification document, or maintain a photocopy of identifying documents on
file in accordance with He-P 4038.12;
c. Certify
in writing that the identification was properly reviewed, and maintain the
certification and all related documents for review upon inspection;
d. Complete
an employment history verification, including military history and verify the
individual's employment with each previous employer for the most recent 7 years
before the date of application;
e. Verify that the individual participated in the education process during the
claimed period;
f. Complete
reference checks as required:
(i) To determine the character and reputation of the individual
who has applied for unescorted access authorization;
(ii) To conduct reference checks with any person who is not
a close member of the individual’s family when other references are not available, including but not
limited to the individual's spouse, parents, siblings, or children, or any
individual who resides in the individual's permanent household; and
(iii) Performing reference checks shall be limited to whether
the individual has been and continues to be trustworthy and reliable;
g. To
the extent possible, obtain independent information by seeking references not
supplied by the individual to corroborate that information which has been provided by
the individual; and
h. Obtain from an alternative source:
(i) If a previous employer, educational
institution, or any other entity with which the individual claims to have been engaged fails to provide
information or indicates an inability or unwillingness to provide information
within a time frame deemed appropriate by the licensee but at least after 10
business days of the request; or
(ii) If the licensee is unable to reach the entity,
document the refusal, unwillingness, or inability in the record of
investigation.
(b) The
individuals who have been determined to be trustworthy and reliable for
unescorted access to category 1 or category 2 quantities of radioactive
material under the fingerprint orders shall continue to have unescorted access
to category 1 and category 2 quantities of radioactive material without further
investigation. These individuals shall be:
(1) Subjected to the reinvestigation requirement in (d) below; and
(2) Trustworthy
and reliable under the provisions of He-P 4038, the regulations of an
equivalent agreement state, the NRC 10 CFR 73, or security orders for access to
safeguards information, safeguards information-modified handling, or
risk-significant material may have unescorted access to category 1 and category
2 quantities of radioactive material without further investigation.
(c) The
licensee shall document that the individual was determined to be trustworthy
and reliable under the provisions of He-P 4038, the regulations of an
equivalent agreement state, the NRC 10 CFR 73, or a security
order. Security order, in this context, means any order that was
issued by the NRC that required fingerprints and an FBI criminal history
records check for access to safeguards information, safeguards
information-modified handling, or risk significant material such as special
nuclear material or large quantities of uranium hexafluoride. These individuals shall be subject to the
reinvestigation requirement.
(d) Licensees shall conduct a reinvestigation every 10 years for any
individual with unescorted access to category 1 or category 2 quantities of
radioactive material. The reinvestigation shall:
(1) Consist of fingerprinting and an FBI identification and criminal
history records check in accordance with He-P 4038.10; and
(2) Be
completed within 10 years of the date on which these elements were
last completed.
Source. #11105, eff 5-25-16; amd by #12055, eff
11-19-16; amd by #12744, eff 3-20-19; amd by #12931, eff 11-26-19; ss by
#13598, eff 3-24-23
He-P
4038.10 Requirements for Criminal History Records Checks of
Individuals Granted Unescorted Access to Category
1 or Category 2 Quantities of Radioactive Material.
(a) General performance
objective and requirements shall include the following:
(1) Except
for those individuals listed in He-P 4038.11 and those individuals
grandfathered under He-P 4038.09(b), each licensee subject to the provisions of
He-P 4038.07 through He-P 4038.13, shall fingerprint each
individual who is to be permitted unescorted access to category 1 or category 2
quantities of radioactive material. Licensees shall transmit all collected
fingerprints to the NRC for transmission to the FBI. The licensee
shall use the information received from the FBI as part of the required background
investigation to determine whether to grant or deny further unescorted access
to category 1 or category 2 quantities of radioactive materials for that
individual;
(2) The
licensee shall notify each affected individual that the individual’s
fingerprints shall be used to secure a review of the
individual’s criminal history record, and shall inform the individual of the
procedures for revising the record or adding explanations to the record;
(3) Fingerprinting is not required if a licensee is reinstating an
individual's unescorted access authorization to category 1 or category 2
quantities of radioactive materials if:
a. The
individual returns to the same facility that granted unescorted access
authorization within 365 days of the termination of the individual’s unescorted
access authorization; and
b. The
previous access was terminated under favorable conditions;
(4) Fingerprints
do not need to be taken if an individual who is an employee of a licensee,
contractor, manufacturer, or supplier has been granted unescorted access to
category 1 or category 2 quantities of radioactive material, access to safeguards
information, or safeguards information-modified handling by another licensee,
based upon a background investigation and fingerprinting orders, conducted under He-P 4038.07 through He-P 4038.13, the regulations
of an equivalent agreement state, or the NRC 10 CFR 73. An existing
criminal history records check file may be transferred to the licensee asked to
grant unescorted access in accordance with the provisions of He-P 4038.12(c);
and
(5) Licensees shall use the information obtained as part of a criminal
history records check solely for the purpose of determining an individual's
suitability for unescorted access authorization to category 1 or category 2
quantities of radioactive materials, access to safeguards information, or
safeguards information-modified handling.
(b) A
licensee shall not:
(1) Base
a final determination to deny an individual unescorted access authorization to
category 1 or category 2 quantities of radioactive material solely on the basis
of information received from the FBI involving:
a. An
arrest more than 1 year old for which there is no information of the
disposition of the case; or
b. An
arrest that resulted in dismissal of the charge or an acquittal; or
(2) Use
information received from a criminal history records check obtained under He-P
4038 in a manner that would infringe upon the rights of any individual under the
First Amendment to the Constitution of the United States, nor shall licensees
use the information in any way that would discriminate among individuals on the
basis of race, religion, national origin, gender, or age.
(c) When processing fingerprint checks, the licensee shall:
(1) Use
an appropriate method listed in the NRC 10 CFR 37.7 to submit to
the NRC, Director, Division of Physical and Cyber Security Policy,
11545 Rockville Pike, ATTN: Criminal History Program/Mail Stop T-07D04M,
Rockville, Maryland 20852, one completed, legible standard fingerprint card,
Form FD–258, ORIMDNRCOOOZ provided by the NRC, electronic fingerprint scan or,
where practicable, other fingerprint record for each individual requiring
unescorted access to category 1 or category 2 quantities of radioactive
material. Copies of these forms may be obtained by NRCemailing a request
to MAILSVS.Resource@nrc.gov. Guidance on submitting electronic
fingerprints can be found at https://www.nrc.gov/security/chp.html;
(2) Submit
payment with the application for the processing of fingerprints through
corporate check, certified check, cashier's check, money order, or electronic
payment, made payable to "U.S. NRC." For guidance on making
electronic payments, contact the Division of Physical and Cyber Security Policy
by emailing Crimhist.Resource@nrc.gov. Combined payment for multiple
applications is acceptable. The Commission publishes the amount of
the fingerprint check application fee on the NRC's public website. To find the
current fee amount, go to the licensee criminal history records checks and
firearms background check information page at https://www.nrc.gov/security/chp.html and
see the link for “How do I determine how much to pay for the request?”; and
(3) The NRC will forward to the
submitting licensee all data received from the FBI as a result of the
licensee's application(s) for criminal history records checks.
Source. #11105, eff 5-25-16; amd by #12055, eff
11-19-16; amd by #12744, eff 3-20-19; ss by #13598, eff 3-24-23
He-P 4038.11 Relief from Fingerprinting,
Identification, and Criminal History Records Checks and Other Elements of
Background Investigations for Designated Categories of Individuals Permitted
Unescorted Access to Certain Radioactive Materials.
(a)
Fingerprinting, and the identification and criminal history records
checks required by Section 149 of the Atomic Energy Act of 1954, as amended,
and other elements of the background investigation are not required for the
following individuals prior to granting unescorted access to category 1 or
category 2 quantities of radioactive materials:
(1) An employee of the Nuclear Regulatory
Commission or of the Executive Branch of the U.S. Government who has undergone
fingerprinting for a prior U.S. Government criminal history records check;
(2) A member of Congress;
(3) An employee of a member of Congress or
Congressional committee who has undergone fingerprinting for a prior U.S.
Government criminal history records check;
(4) The Governor of New Hampshire or his or her
designated state employee representative;
(5) Federal, state, or local law enforcement
personnel;
(6) State Radiation Control Program Directors and
State Homeland Security Advisors or their designated State employee
representatives;
(7) Employees of the state of New Hampshire or an
agreement state conducting security inspections on behalf of the NRC under an
agreement executed under section 274.i. of the Atomic Energy Act;
(8) Representatives of the International Atomic
Energy Agency (IAEA) engaged in activities associated with the U.S. IAEA
Safeguards Agreement who have been certified by the NRC;
(9) Emergency response personnel who are responding
to an emergency;
(10) Commercial vehicle drivers for road shipments
of category 1 and category 2 quantities of radioactive material;
(11) Package handlers at transportation facilities
such as freight terminals and railroad yards;
(12) Any individual who has an active Federal
security clearance, provided that he or she makes available the appropriate
documentation. Written confirmation from
the agency/employer that granted the Federal security clearance or reviewed the
criminal history records check shall be provided to the licensee. The licensee shall retain this documentation
for a period of 3 years from the date the individual no longer requires
unescorted access to category 1 or category 2 quantities of radioactive
material; and
(13) Any individual employed by a service provider
licensee for which the service provider licensee has conducted the background
investigation for the individual and approved the individual for unescorted
access to category 1 or category 2 quantities of radioactive material. Written
verification from the service provider shall be provided to the licensee. The licensee shall retain the documentation
for a period of 3 years from the date the individual no longer requires
unescorted access to category 1 or category 2 quantities of radioactive
material.
(b)
Fingerprinting, and the identification and criminal history records
checks required by section 149 of the Atomic Energy Act of 1954, as amended,
are not required for an individual who has had a favorably adjudicated U.S.
Government criminal history records check within the last 5 years, under a
comparable U.S. Government program involving fingerprinting and an FBI
identification and criminal history records check provided that he or she makes
available the appropriate documentation.
Written confirmation from the agency/employer that reviewed the criminal
history records check shall be provided to the licensee. The licensee shall retain this documentation
for a period of 3 years from the date the individual no longer requires
unescorted access to category 1 or category 2 quantities of radioactive
material. These programs include, but
are not limited to:
(1) National Agency Check;
(2) Transportation Worker Identification
Credentials (TWIC) under 49 CFR part 1572;
(3) Bureau of Alcohol, Tobacco, Firearms, and
Explosives background check and clearances under 27 CFR part 555;
(4) Health and Human Services security risk
assessments for possession and use of select agents and toxins under 42 CFR
part 73;
(5) Hazardous Material security threat assessment
for hazardous material endorsement to commercial driver’s license under 49 CFR
part 1572; and
(6) Customs and Border Protection's Free and
Secure Trade (FAST) Program.
Source. #11105, eff 5-25-16; amd by #12744, eff
3-20-19
He-P 4038.12 Protection of Information.
(a)
Each licensee who obtains background information on an individual under
He-P 4038.07 through He-P 4038.13 shall establish and maintain a system of
files and written procedures for protection of the record and the personal
information from unauthorized disclosure.
(b)
The licensee shall not disclose the record or personal information
collected and maintained to persons other than the subject individual, his or
her representative, or to those who have a need to have access to the
information in performing assigned duties in the process of granting or denying
unescorted access to category 1 or category 2 quantities of radioactive
material, safeguards information, or safeguards information-modified handling. No individual authorized to have access to
the information shall disseminate the information to any other individual who
does not have a need to know.
(c)
The personal information obtained on an individual from a background
investigation may be provided to another licensee:
(1) Upon the individual's written request to the
licensee holding the data to disseminate the information contained in his or
her file; and
(2) The recipient licensee verifies information
such as name, date of birth, social security number, gender, and other
applicable physical characteristics.
(d)
The licensee shall make background investigation records obtained under
He-P 4038.07 through He-P 4038.13 available for examination by DHHS/RHS to
determine compliance with the regulations and laws.
(e) The licensee shall retain all fingerprint and
criminal history records (including data indicating no record) received from
the FBI, or a copy of these records if the individual's file has been
transferred, on an individual for 3 years from the date the individual no
longer requires unescorted access to category 1 or category 2 quantities of
radioactive material.
Source. #11105, eff 5-25-16; amd by #12055, eff
11-19-16
He-P 4038.13
Access Authorization Program Review.
(a) Each licensee shall be responsible for:
(1) Continuing effectiveness of the access
authorization program;
(2) Ensuring that access authorization programs
are reviewed to confirm compliance with the requirements of He-P 4038.07
through He-P 4038.13 and that comprehensive actions are taken to correct any
noncompliance that is identified;
(3) Evaluating all program performance objectives
and requirements; and
(4) Reviewing annually the access program content
and implementation.
(b)
The results of the reviews, along with any recommendations, shall:
(1) Be documented;
(2) Identify conditions that are adverse to the
proper performance of the access authorization program, the cause of the
condition(s), and, when appropriate, recommend corrective actions, and
corrective actions taken; and
(3) Review the finding and take any additional
corrective actions necessary to preclude repetition of the condition, including
reassessment of the deficient areas where indicated.
(c)
Review records shall be maintained for 3 years.
Source. #11105, eff 5-25-16; amd by #12744, eff
3-20-19
He-P
4038.14 Security Program.
(a) Each licensee that possesses an aggregated category
1 or category 2 quantity of radioactive material shall establish, implement,
and maintain a security program in accordance with the requirements
of He-P 4038.14 through He-P 4038.22. In addition to those requirements, the
licensee shall be subjected to the following:
(1) An
applicant for a new license and each licensee that would become newly subject
to the requirements of He-P 4038.14 through He-P 4038.22 upon application for
modification of its license shall implement the requirements of He-P 4038.14
through He-P 4038.22, as appropriate, before taking possession of an aggregated
category 1 or category 2 quantity of radioactive material; and
(b) Each
licensee shall establish, implement, and maintain a security program that is
designed to monitor and, without delay, detect, assess, and respond to an
actual or attempted unauthorized access to category 1 or category 2 quantities
of radioactive material.
(c) Each
licensee's security program shall include the program features, as
appropriate, described in He-P 4038.15 through He-P 4038.21.
Source. #11105, eff 5-25-16; amd by #12744, eff
3-20-19; ss by #13598, eff 3-24-23
He-P
4038.15 General Security Program
Requirements.
(a)
The security plan shall require:
(1) Each
licensee identified in He-P 4038.14(a) to develop a written security plan
specific to its facilities and operations.
The purpose of the security plan shall be to establish the licensee's
overall security strategy to ensure the integrated and effective functioning of
the security program required by He-P 4038.14 through He-P 4038.22. The security plan shall, at a minimum:
a. Describe the
measures and strategies used to implement the requirements of this He-P 4038.14
through He-P 4038.22; and
b. Identify the security resources, equipment,
and technology used to satisfy the requirements of He-P 4038.14 through He-P
4038.22.
(2) A review
and approval by the individual with overall responsibility for the security
program;
(3) The
security plan shall be revised by the licensee as necessary to ensure the
effective implementation of DHHS/RHS requirements. The licensee shall ensure that:
a. The revision has been reviewed and approved by the
individual with overall responsibility for the security program; and
b. The affected individuals are instructed on the
revised plan before the changes are implemented.
(b) The security plan shall be implemented by the
following procedures:
(1) The licensee shall develop and maintain written
procedures that document how the requirements of He-P 4038.14 through He-P
4038.22 and the security plan will be met;
(2) The
implementing procedures and revisions to these procedures shall be approved in
writing by the individual with overall responsibility for the security program;
and
(3) The
licensee shall retain a copy of the current procedure as a record for 3 years
after the procedure is no longer needed.
Superseded portions of the procedure shall be retained for 3 years after
the record is superseded.
(c) The security plan
shall include the following training requirements:
(1) Each licensee shall conduct training to
ensure that those individuals implementing the security program possess and
maintain the knowledge, skills, and abilities to carry out their assigned
duties and responsibilities effectively.
The training shall include instruction in:
a. The licensee's security program and
procedures to secure category 1 or category 2 quantities of radioactive
material, and in the purposes and functions of the security measures employed;
c. The
responsibility of the licensee to report promptly to the local law enforcement
agency and licensee any actual or attempted theft, sabotage, or diversion of
category 1 or category 2 quantities of radioactive material; and
d. The
appropriate response to security alarms.
(2) In
determining those individuals who shall be trained on the security program, the
licensee shall consider each individual's assigned activities during authorized
use and response to potential situations involving actual or attempted theft,
diversion, or sabotage of category 1 or category 2 quantities of radioactive
material. The extent of the training
shall be commensurate with the individual's potential involvement in the
security of category 1 or category 2 quantities of radioactive material; and
(3) Refresher
training shall be provided at a frequency not to exceed 12 months and when
significant changes have been made to the security program. This training shall include:
a. Review of
the training requirements of paragraph (c) of this section and any changes made
to the security program since the last training;
b. Reports on
any relevant security issues, problems, and lessons learned;
c. Relevant
results of DHHS/RHS inspections; and
d. Relevant
results of the licensee's program review and testing and maintenance.
(4) The
licensee shall maintain records of the initial and refresher training for 3
years from the date of the training. The
training records shall include dates of the training, topics covered, a list of
licensee personnel in attendance, and related information.
(d) All information and implementing procedures
included as part of a security plan shall be protected as follows:
(1) Licensees
authorized to possess category 1 or category 2 quantities of radioactive
material shall limit access to and unauthorized disclosure of their security
plan, implementing procedures, and the list of individuals that have been
approved for unescorted access;
(2) Efforts to
limit access shall include the development, implementation, and maintenance of
written policies and procedures for controlling access to, and for proper
handling and protection against unauthorized disclosure of, the security plan,
implementing procedures, and the list of individuals that have been approved
for unescorted access;
(3) Before
granting an individual access to the security plan, implementing procedures, or
the list of individuals that have been approved for unescorted access,
licensees shall:
a. Evaluate an
individual's need to know the security plan, implementing procedures, or the
list of individuals that have been approved of unescorted access; and
b. If the
individual has not been authorized for unescorted access to category 1 or
category 2 quantities of radioactive material, safeguards information, or
safeguards information-modified handling, the licensee shall complete a
background investigation to determine the individual's trustworthiness and
reliability. A trustworthiness and
reliability determination shall be conducted by the reviewing official and
shall include the background investigation elements contained in He-P
4038.09(a)(2).
(4) Licensees
need not subject the following individuals to the background investigation
elements for protection of information:
a. The
categories of individuals listed in He-P 4038.11(a)(1) through (a)(13); or
b. Security
service provider employees, provided written verification that the employee has
been determined to be trustworthy and reliable, by the required background
investigation in He-P 4038.09(a)(2), has been provided by the security service
provider.
(5) The
licensee shall document the basis for concluding that an individual is
trustworthy and reliable and should be granted access to the security plan,
implementing procedures, or the list of individuals that have been approved for
unescorted access;
(6) Licensees
shall maintain a list of persons currently approved for access to the security
plan, implementing procedures, or the list of individuals that have been
approved for unescorted access. When a
licensee determines that a person no longer needs access to the security plan
or implementing procedures, or the list of individuals that have been approved
for unescorted access, or no longer meets the access authorization requirements
for access to the information, the licensee shall remove the person from the
approved list as soon as possible, but no later than 7 working days, and take
prompt measures to ensure that the individual is unable to obtain the security
plan, implementing procedures, or the list of individuals that have been
approved for unescorted access;
(7) When not in
use, the licensee shall store its security plan, implementing procedures, and
the list of individuals that have been approved for unescorted access in a
manner to prevent unauthorized access.
Information stored in non-removable electronic form shall be password
protected; and
(8) The licensee shall retain as a record for 3 years
after the document is no longer needed:
a. A copy of
the information protection procedures; and
b. The list of individuals approved for access
to the security plan, implementing procedures, or the list of individuals that
have been approved for unescorted access.
Source. #11105, eff
5-25-16; amd by #12744, eff 3-20-19; amd by #12931, eff 11-26-19
He-P 4038.16 Local Law Enforcement Agency (LLEA) Coordination.
(a)
A licensee subject to He-P 4038.14 through He-P 4038.22 shall
coordinate, to the extent practicable, with a licensed law enforcement agency
(LLEA) for responding to threats to the licensee's facility, including any
necessary armed response. The
information provided to the LLEA shall include:
(1) A description of the facilities and the
category 1 and category 2 quantities of radioactive materials along with a
description of the licensee's security measures that have been implemented to
comply with He-P 4038.14 through He-P 4038.22; and
(2) A notification that the licensee will request
a timely armed response by the LLEA to any actual or attempted theft, sabotage,
or diversion of category 1 or category 2 quantities of material.
(b)
The licensee shall notify the DHHS/RHS as specified in He-P 4038.04,
within 3 business days if:
(1) The LLEA has
not responded to the request for coordination within 60 days of the
coordination request; or
(2) The LLEA notifies the licensee that the LLEA
does not plan to participate in coordination activities.
(c)
The licensee shall document its efforts to coordinate with the
LLEA. The documentation shall be kept
for 3 years.
(d)
The licensee shall coordinate with the LLEA at least every 12 months, or
when changes to the facility design or operation adversely affect the potential
vulnerability of the licensee's material to theft, sabotage, or diversion.
Source. #11105, eff 5-25-16; amd by #12744, eff
3-20-19
He-P 4038.17 Security Zones.
(a) Licensees shall ensure that all aggregated
category 1 and category 2 quantities of radioactive material are used or stored
within licensee established security zones.
Security zones shall be permanent or temporary.
(b)
Temporary security zones shall be established as necessary to meet the
licensee's transitory or intermittent business activities, such as periods of
maintenance, source delivery, and source replacement.
(c)
Security zones shall, at a minimum, allow unescorted access only to
approved individuals through:
(1) Isolation of category 1 and
category 2 quantities of radioactive materials by the use of continuous
physical barriers that allow access to the security zone only through
established access control points. A
physical barrier is a natural or man-made structure or formation sufficient for
the isolation of the category 1 or category 2 quantities of radioactive
material within a security zone; or
(2) Direct control of the security zone by
approved individuals at all times; or
(3) A combination of continuous physical barriers
and direct control.
(d)
For category 1 quantities of radioactive material during periods of
maintenance, source receipt, preparation for shipment, installation, or source
removal or exchange, the licensee shall, at a minimum, provide sufficient
individuals approved for unescorted access to maintain continuous surveillance
of sources in temporary security zones and in any security zone in which
physical barriers or intrusion detection systems have been disabled to allow
such activities.
(e)
Individuals not approved for unescorted access to category 1 or category
2 quantities of radioactive material shall be escorted by an approved
individual when in a security zone.
Source. #11105, eff 5-25-16
He-P
4038.18 Monitoring, Detection, and Assessment.
(a) Security zones shall be
assessed as follows:
(1) Licensees
shall establish and maintain the capability to continuously monitor and detect
without delay all unauthorized entries into its security
zones. Licensees shall provide the means to maintain continuous
monitoring and detection capability in the event of a loss of the primary power
source, or provide for an alarm and response in the event of a loss of this
capability to continuously monitor and detect unauthorized entries.
(2) Monitoring and detection shall be performed by:
a. A
monitored intrusion detection system that is linked to an onsite or offsite
central monitoring facility;
b. Electronic
devices for intrusion detection alarms that alert nearby facility personnel;
c. A
monitored video surveillance system;
d. Direct
visual surveillance by approved individuals located within the
security zone; or
e. Direct
visual surveillance by a licensee designated individual located outside the
security zone.
(3) A
licensee subject to He-P 4038.14 through He-P 4038.22 shall also
have a means to detect unauthorized removal of the radioactive material from
the security zone. This detection capability shall provide:
a. For
category 1 quantities of radioactive material, immediate detection of any
attempted unauthorized removal of the radioactive material from the security
zone. Such immediate detection capability shall be provided by:
1. Electronic sensors linked to an alarm;
2. Continuous
monitored video surveillance; or
3. Direct visual surveillance.
b. For
category 2 quantities of radioactive material, weekly verification through
physical checks, tamper indicating devices, use, or other means to ensure that the
radioactive material is present.
(b) Licensees
shall immediately assess each actual or attempted unauthorized entry into the
security zone to determine whether the unauthorized access was an actual or attempted
theft, sabotage, or diversion.
(c) For personnel and automated or electronic
systems supporting the licensee's monitoring, detection, and assessment
systems, licensees shall:
(1) Maintain continuous capability for personnel
communication and electronic data transmission and processing among site
security systems; and
(2) Provide an alternative communication capability for
personnel, and an alternative data transmission and processing capability, in
the event of a loss of the primary means of communication or data transmission
and processing. Alternative communications and data transmission
systems shall not be subject to the same failure modes as the primary systems.
(d) Licensees
shall immediately respond to any actual or attempted unauthorized access to the
security zones, or actual or attempted theft, sabotage, or diversion of
category 1 or category 2 quantities of radioactive material at licensee facilities or temporary job sites. For
any unauthorized access involving an actual or attempted theft, sabotage, or
diversion of category 1 or category 2 quantities of radioactive material, the
licensee's response shall include requesting, without delay, an armed response
from the LLEA.
Source. #11105, eff 5-25-16; ss by #13598, eff
3-24-23
He-P 4038.19 Maintenance and Testing.
(a)
Each licensee subject to He-P 4038.14 through He-P 4038.22 shall implement
a maintenance and testing program to ensure that intrusion alarms, associated
communication systems, and other physical components of the systems used to
secure or detect unauthorized access to radioactive material are maintained in
operable condition and are capable of performing their intended function when
needed. The equipment relied on to meet
the security requirements of He-P 4038 shall be inspected and tested:
(1) For operability and performance at the
manufacturer's suggested frequency; or
(2) If there is no suggested manufacturer's
suggested frequency, at least annually, not to exceed 12 months.
(b)
The licensee shall maintain records on the maintenance and testing
activities for 3 years.
Source. #11105, eff 5-25-16
He-P 4038.20 Requirements for Mobile Devices. Each licensee that
possesses mobile devices containing category 1 or category 2 quantities of
radioactive material shall:
(a) Have two independent physical controls that
form tangible barriers to secure the material from unauthorized removal when
the device is not under direct control and constant surveillance by the
licensee; and
(b)
For devices in or on a vehicle or trailer, unless the health and safety
requirements for a site prohibit the disabling of the vehicle, the licensee
shall utilize a method to disable the vehicle or trailer when not under direct
control and constant surveillance by the licensee. Licensees shall not rely on the removal of an
ignition key to meet this requirement.
Source. #11105, eff 5-25-16
He-P 4038.21 Security Program Review.
(1) Be responsible for the continuing
effectiveness of the security program;
(2) Ensure that the security program is reviewed
to confirm compliance with the requirements of He-P 4038.14 through He-P
4038.22 and that comprehensive actions are taken to correct any noncompliance
that is identified;
(3) Review the radioactive material security
program content and implementation; and
(4) Periodically, meaning at least annually, review
the security program content and implementation.
(b)
The results of the review, along with any recommendations, shall be
documented. Each review report shall:
(1) Identify conditions that are adverse to the
proper performance of the security program, the cause of the condition(s), and,
when appropriate, recommend corrective actions, and corrective actions taken;
and
(2) Review the findings and take any additional
corrective actions necessary to preclude repetition of the condition, including
reassessment of the deficient areas where indicated.
(c)
The licensee shall maintain the review documentation for 3 years.
Source. #11105, eff 5-25-16; amd by #12744, eff
3-20-19
He-P 4038.22 Reporting of Events.
(a)
The licensee shall immediately notify the LLEA after determining that an
unauthorized entry resulted in an actual or attempted theft, sabotage, or
diversion of a category 1 or category 2 quantity of radioactive material. As soon as possible after initiating a
response, but not at the expense of causing delay or interfering with the LLEA
response to the event, the licensee shall notify DHHS/RHS by calling
(603-271-4588) Monday through Friday during regular working hours, 8:00 a.m. -
4:30 p.m., or at any other time shall notify the NH State Police by calling
(603-271-3636). In no case shall the
notification to DHHS/RHS be later than 4 hours after the discovery of any
attempted or actual theft, sabotage, or diversion.
(b)
The licensee shall assess any suspicious activity related to possible
theft, sabotage, or diversion of category 1 or category 2 quantities of
radioactive material and notify the LLEA as appropriate. As soon as possible but not later than 4
hours after notifying the LLEA, the licensee shall notify DHHS/RHS by calling
(603-271-4588) Monday through Friday during regular business hours, 8:00 a.m. –
4:00 p.m., or at any other time shall notify the NH State Police by calling
(603-271-3636).
(c)
The initial telephonic notification required by He-P 4038.22(a) shall be
followed within a period of 30 days by a written report submitted to DHHS/RHS
by an appropriate method listed in He-P 4038.04. The report shall include sufficient
information for DHHS/RHS analysis and evaluation, including identification of
any necessary corrective actions to prevent future instances.
Source. #11105, eff 5-25-16; ss by #12744, eff
3-20-19
He-P
4038.23 Additional Requirements for Transfer of Category 1 and
Category 2 Quantities of Radioactive Material. A licensee transferring a category 1 or
category 2 quantity of radioactive material to a licensee of DHHS/RHS, an
agreement state, or the U.S. NRC shall meet the license verification provisions
listed below instead of those listed in He-P 4030.16(d) or 10 CFR 30.41(d):
(a) Any
licensee transferring category 1 quantities of radioactive material to a
licensee of the DHHS/RHS, an agreement state, or the NRC, prior to conducting such
transfer, shall verify with the DHHS/RHS’, an agreement state’s, or NRC's
license verification system or the license issuing authority that the
transferee's license authorizes the receipt of the type, form, and quantity of
radioactive material to be transferred and that the licensee is authorized to
receive radioactive material at the location requested for
delivery. If the verification is conducted by contacting the license
issuing authority, the transferor shall document the
verification. For transfers within the same organization, the
licensee does not need to verify the transfer.
(b) Any
licensee transferring category 2 quantities of radioactive material to a
licensee of the DHHS/RHS, an agreement state, or the NRC, prior to conducting
such transfer, shall verify with the DHHS/RHS’s, an agreement state’s, or NRC's
license verification system or the license issuing authority that the
transferee's license authorizes the receipt of the type, form, and quantity of
radioactive material to be transferred. If the verification is
conducted by contacting the license issuing authority, the transferor shall
document the verification. For transfers within the same
organization, the licensee does not need to verify the transfer.
(c) In
an emergency where the licensee cannot reach the license issuing authority and
the license verification system is nonfunctional, the licensee may accept a written
certification by the transferee that it is authorized by license to receive the
type, form, and quantity of radioactive material to be transferred. The
certification shall:
(1) Include the license number, current revision number, issuing
agency, expiration date, and for a category 1 shipment the authorized address;
(2) Be
retained by the licensee; and
(3) Be
confirmed by use of the DHHS/RHS’s, an agreement state’s, or NRC's
license verification system or by contacting the license issuing authority by
the end of the next business day.
(d) The transferor shall keep a copy of the verification
documentation on record for 3 years.
Source. #11105, eff 5-25-16; ss by #13598, eff
3-24-23
He-P 4038.24 Applicability of Physical Protection of
Category 1 and Category 2 Quantities of Radioactive Material During Transfer.
(a)
For shipments of category 1 quantities of radioactive material, each
shipping licensee shall comply with the requirements for physical protection
contained in He-P 4038.25(a) and (e); He-P 4038.26; He-P 4038.27(a)(1), (b)(1),
and (c); and He-P 4038.28(a), (c), (e), (g), and (h).
(b) For shipments of category 2 quantities of
radioactive material, each shipping licensee shall comply with the requirements
for physical protection contained in He-P 4038.25(b) through (e); He-P
4038.27(a)(2), (a)(3), (b)(2), and (c); and He-P 4038.28(b), (d), (f), (g), and
(h). For those shipments of category 2
quantities of radioactive material that meet the criteria of the Nuclear
Regulatory Commission 10 CFR 71.97(b).
(c) The shipping licensee
shall comply with He-P 4038.23 through He-P 4038.28 unless the receiving
licensee has agreed in writing to arrange for the in-transit physical
protection required under He-P 4038.23 through He-P 4038.28.
(d)
Each licensee that imports or exports category 1 quantities of
radioactive material shall comply with the requirements for physical protection
during transit contained in He-P 4038.25(a)(2) and (e); He-P 4038.26; He-P
4038.27(a)(1), (b)(1), and (c); and He-P 4038.28(a), (c), (e), (g), and (h) for
the domestic portion of the shipment.
(e)
Each licensee that imports or exports category 2 quantities of
radioactive material shall comply with the requirements for physical protection
during transit contained in He-P 4038.27(a)(2), (a)(3), and (b)(2); and He-P
4038.28(b), (d), (f), (g), and (h) for the domestic portion of the shipment.
Source. #11105, eff 5-25-16; ss by #12744, eff
3-20-19
He-P 4038.25 Preplanning and Coordination of Shipment
of Category 1 or Category 2 Quantities of Radioactive Material.
(a)
Each licensee that plans to transport, or deliver to a carrier for
transport, licensed material that is a category 1 quantity of radioactive
material outside the confines of the licensee's facility or other place of use
or storage shall:
(1) Preplan and coordinate shipment arrival and
departure times with the receiving licensee;
(2) Preplan and coordinate shipment information
with the governor of New Hampshire or the governor's designee of New Hampshire
or any state through which the shipment will pass to:
a. Discuss the state's intention to provide law
enforcement escorts; and
b. Identify safe havens; and
(3) Document the preplanning and coordination
activities.
(b)
Each licensee that plans to transport, or deliver to a carrier for
transport, licensed material that is a category 2 quantity of radioactive
material outside the confines of the licensee's facility or other place of use
or storage shall coordinate the shipment no-later-than arrival time and the
expected shipment arrival with the receiving licensee. The licensee shall document the coordination
activities.
(c)
Each licensee who receives a shipment of a category 2 quantity of
radioactive material shall confirm receipt of the shipment with the
originator. If the shipment has not arrived
by the no-later-than arrival time, the receiving licensee shall notify the
originator.
(d) Each licensee, who transports or plans to
transport a shipment of a category 2 quantity of radioactive material, and
determines that the shipment will arrive after the no-later-than arrival time
provided pursuant to He-P 4038.25(b), shall promptly notify the receiving
licensee of the new no-later-than arrival time.
(e)
The licensee shall retain a copy of the documentation for preplanning
and coordination and any revision thereof, as a record for 3 years.
Source. #11105, eff 5-25-16
He-P 4038.26 Advance
Notification of Shipment of Category 1 Quantities of Radioactive Material. As specified in He-P 4038.26(a) and (b), each
licensee shall provide advance notification to the governor of a state, or the
governor's designee and DHHS/RHS of the shipment of licensed material in a
category 1 quantity, through or across the boundary of New Hampshire, before
the transport, or delivery to a carrier for transport of the licensed material
outside the confines of the licensee's facility or other place of use or
storage.
(a) Procedures for submitting
advance notification shall be:
(1) Made to DHHS/RHS, and the
office of each appropriate governor or governor's
designee. Notification to DHHS/RHS shall be as specified in He-P
4038.04. The contact information, including telephone and mailing addresses, of
governors and governors’ designees, is available on the NRC’s website at https://scp.nrc.gov/special/designee.pdf. A list of the contact
information is also available upon request by sending the request to the Director, Division of
Material Safety, Security, State, and Tribal Programs, Office of Nuclear Material Safety and
Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001. The
notification to the NRC may also be made by email to RAMQC_SHIPMENTS@nrc.gov or by fax to 301-816-5151;
(2) Delivered by mail and shall
be postmarked at least 7 days before transport of the shipment commences at the
shipping facility; and
(3) Delivered by any means
other than mail and shall reach DHHS/RHS at least 4 days before the transport
of the shipment commences and shall reach the office of the governor or the
governor's designee at least 4 days before transport of a shipment within or
through the state.
(b) Each advance notification of shipment of
category 1 quantities of radioactive material shall contain the following
information, if available at the time of notification:
(1) The name, address, and
telephone number of the shipper, carrier, and receiver of the category 1
radioactive material;
(2) The license numbers of the
shipper and receiver;
(3)
A description of the radioactive material contained in the shipment,
including the radionuclides and quantity;
(4)
The point of origin of the shipment and the estimated time and date that
shipment shall commence;
(5) The estimated time and date
that the shipment is expected to enter each state along the route;
(6) The estimated time and date
of arrival of the shipment at the destination; and
(7) A point of contact, with a
telephone number, for current shipment information.
(c) Notices shall be revised according to the
following:
(1) The licensee shall provide
any information not previously available at the time of the initial
notification, as soon as the information becomes available but not later than
commencement of the shipment, to the governor of the state or the governor's
designee, and to DHHS/RHS.
(2) A licensee shall promptly
notify the governor of the state or the governor's designee of any changes to
the information provided in accordance with He-P 4038.26(b) and (c)(1) of this
section. The licensee shall also immediately notify DHHS/RHS of any
such changes.
(d) Each licensee who cancels a
shipment for which advance notification has been sent shall send a cancellation
notice to the governor of each state or to the governor's designee previously
notified, and to DHHS/RHS. The licensee shall send the cancellation
notice before the shipment would have commenced or as soon as possible
thereafter. The licensee shall state in the notice that there is a
cancellation of shipment and as a result the advance notification of shipment is
no longer applicable and the shipment is being withdrawn.
(e) The licensee shall retain, and
make available for review, a copy of the advance notification and any revision
and cancellation notices as a record for 3 years.
(f) State officials, state employees,
and other individuals, whether or not licensees of the DHHS/RHS, an agreement
state, or the NRC, who receive schedule information of the kind specified in
He-P 4038.26(b) shall protect that information against unauthorized disclosure
as specified in He-P 4038.15(d)
Source. #11105, eff
5-25-16; amd by #12055, eff 11-19-16; amd by #12744, eff 3-20-19; amd by
#12931, eff 11-26-19; ss by #13598, eff 3-24-23
He-P 4038.27 Requirements for Physical Protection of
Category 1 and Category 2 Quantities of Radioactive Material During Shipment.
(a)
For any shipment made by road:
(1) Each licensee who transports, or delivers to
a carrier for transport, in a single shipment, a category 1 quantity of radioactive
material shall:
a. Ensure that movement control centers are
established that maintain position information from a remote location. These control centers shall monitor shipments
24 hours a day, 7 days a week, and have the ability to communicate immediately,
in an emergency, with the appropriate law enforcement agencies;
b. Ensure that redundant communications are
established that allow the transport to contact the escort vehicle (when used)
and movement control center at all times.
Redundant communications shall not be subject to the same interference
factors as the primary communication;
c. Ensure that shipments are
continuously and actively monitored by a telemetric position monitoring system
or an alternative tracking system reporting to a movement control center. A movement control center shall provide
positive confirmation of the location, status, and control over the
shipment. The movement control center
shall be prepared to promptly implement preplanned procedures in response to
deviations from the authorized route or a notification of actual, attempted, or
suspicious activities related to the theft, loss, or diversion of a
shipment. These procedures will include,
but not be limited to, the identification of and contact information for the
appropriate LLEA along the shipment route;
d. Provide an individual to accompany the driver
for those highway shipments with a driving time period greater than the maximum
number of allowable hours of service in a 24-hour duty day as established by
the Department of Transportation Federal Motor Carrier Safety Administration.
The accompanying individual may be another driver;
e. Develop written normal and contingency
procedures to address:
1. Notifications to the communication center and
law enforcement agencies;
2. Communication protocols. Communication protocols shall include a
strategy for the use of authentication codes and duress codes and provisions
for refueling or other stops, detours, and locations where communication is
expected to be temporarily lost;
3. Loss of communications; and
4. Responses to an actual or attempted theft or
diversion of a shipment.
f. Each licensee who makes arrangements for the
shipment of category 1 quantities of radioactive material shall ensure that
drivers, accompanying personnel, and movement control center personnel have
access to the normal and contingency procedures.
(2) Each licensee that transports category 2
quantities of radioactive material shall maintain constant control and/or
surveillance during transit and have the capability for immediate communication
to summon appropriate response or assistance.
(3) Each licensee who delivers to a carrier for
transport, in a single shipment, a category 2 quantity of radioactive material
shall:
a. Use carriers that have
established package tracking systems. An
established package tracking system is a documented, proven, and reliable
system routinely used to transport objects of value. In order for a package tracking system to
maintain constant control and/or surveillance, the package tracking system
shall allow the shipper or transporter to identify when and where the package
was last and when it should arrive at the next point of control.
b. Use carriers that maintain
constant control and/or surveillance during transit and have the capability for
immediate communication to summon appropriate response or assistance; and
c. Use carriers that have established tracking
systems that require an authorized signature prior to releasing the package for
delivery or return.
(b)
For any shipment made by rail:
(1) Each licensee who transports, or delivers to
a carrier for transport, in a single shipment, a category 1 quantity of
radioactive material shall:
a. Ensure that rail shipments are
monitored by a telemetric position monitoring system or an alternative tracking
system reporting to the licensee, third-party, or railroad communications
center. The communications center shall
provide positive confirmation of the location of the shipment and its
status. The communications center shall
implement preplanned procedures in response to deviations from the authorized
route or to a notification of actual, attempted, or suspicious activities
related to the theft or diversion of a shipment. These procedures shall include, but not be
limited to, the identification of and contact information for the appropriate
LLEA along the shipment route.
b. Ensure that periodic reports to the
communications center are made at preset intervals.
(2) Each licensee who transports, or delivers to
a carrier for transport, in a single shipment, a category 2 quantity of
radioactive material shall:
a. Use carriers that have
established package tracking systems. An
established package tracking system is a documented, proven, and reliable
system routinely used to transport objects of value. In order for a package tracking system to
maintain constant control and/or surveillance, the package tracking system
shall allow the shipper or transporter to identify when and where the package
was last and when it should arrive at the next point of control.
b. Use carriers that maintain
constant control and/or surveillance during transit and have the capability for
immediate communication to summon appropriate response or assistance; and
c. Use carriers that have established tracking
systems that require an authorized signature prior to releasing the package for
delivery or return.
(c)
Each licensee who makes arrangements for the shipment of category 1
quantities of radioactive material shall immediately conduct an investigation
upon the discovery that a category 1 shipment is lost or missing. Each licensee who makes arrangements for the
shipment of category 2 quantities of radioactive material shall immediately
conduct an investigation, in coordination with the receiving licensee, of any
shipment that has not arrived by the designated no-later-than arrival time.
Source. #11105, eff 5-25-16
He-P 4038.28 Reporting of Shipping Events.
(a) The shipping licensee shall notify the appropriate
LLEA and DHHS/RHS within 1 hour of its determination that a shipment of category 1 quantities of radioactive
material is lost or missing. The appropriate LLEA shallbe the law
enforcement agency in the area of the shipment's last confirmed location.
During the investigation required by He-P 4038.27(c), the shipping licensee
shall provide agreed upon updates to DHHS/RHS on the status of the
investigation.
(b) The shipping licensee shall notify
DHHS/RHS by calling 603-271-4588 Monday through Friday during regular business
hours, 8:00 a.m.- 4:00 p.m., or at any other time outside of the aforementioned
hours, shall notify the NH state police by calling 603-271-3636 within 4 hours of its determination that a
shipment of category 2 quantities of radioactive material is lost or
missing. If, after 24 hours of its determination that the shipment
is lost or missing, the radioactive material has not been located and secured,
the licensee shall immediately notify DHHS/RHS that the missing radioactive
material cannot be found.
(c) The
shipping licensee shall notify the designated LLEA along the shipment route as
soon as possible upon discovery of any actual or attempted theft or diversion
of a shipment or suspicious activities related to the theft or diversion of a shipment
of a category 1 quantity of radioactive material. As soon as
possible after notifying the LLEA, the licensee shall
notify DHHS/RHS by calling 603-271-4588 Monday through Friday during regular
business hours, 8:00 a.m. – 4:00 p.m., or at any other time outside of the aforementioned hours, shall
notify the NH state police by calling 603-271-3636 upon discovery of any actual
or attempted theft or diversion of a shipment, or any suspicious activity
related to the shipment of category 1 radioactive material.
(d) The
shipping licensee shall notify DHHS/RHS by calling 603-271-4588 Monday through
Friday during regular business hours, 8:00 a.m. – 4:00 p.m., or at any other time outside of the aforementioned hours, shall
notify the NH state police by calling 603-271-3636 as soon as possible upon
discovery of any actual or attempted theft or diversion of a shipment, or any
suspicious activity related to the shipment, of a category 2 quantity of
radioactive material.
(e) The
shipping licensee shall notify DHHS/RHS by calling 603-271-4588
Monday through Friday during regular business hours, 8:00 a.m. – 4:00 p.m., and
at any other time shall notify the NH state police by calling 603-271-3636, and
the LLEA as soon as possible upon recovery of any lost or missing category 1
quantities of radioactive material.
(f) The
shipping licensee shall notify DHHS/RHS by calling 603-271-4588 Monday through
Friday during regular business hours, 8:00 a.m. – 4:00 p.m., and at any other time shall
notify the NH state police by calling 603-271-3636 as soon as possible upon
recovery of any lost or missing category 2 quantities of radioactive material.
(g) The initial telephonic notification
required by He-P 4038.28(a) through (d) shall be followed within a period of 30
days by a written report submitted to
DHHS/RHS by an appropriate method listed in He-P 4038.04. A written report is
not required for notifications on suspicious activities required by He-P
4038.38(c) and (d). In addition, the written report provided to
DHHS/RHS shall set forth the following information:
(1) A
description of the licensed material involved, including kind, quantity, and
chemical and physical form;
(2) A
description of the circumstances under which the loss or theft occurred;
(3) A
statement of disposition, or probable disposition, of the licensed material
involved;
(4) Actions
that have been taken, or shall be taken, to recover the material; and
(5) Procedures
or measures that have been, or shall be, adopted to ensure against a recurrence
of the loss or theft of licensed material.
(h) Subsequent to filing the written report, the licensee shall also
report any additional substantive information on the loss or theft within 30
days after the licensee learns of such information.
Source. #11105, eff 5-25-16; amd by #12744, eff
3-20-19; ss by #13598, eff 3-24-23
He-P
4038.29 Forms of Records.
(a)
Any record or document required by He-P 4038 shall be legible throughout
the retention period specified by He-P 4038.
(b)
The record may be the original or a reproduced copy or a microform,
provided that the copy or microform is authenticated by authorized personnel
and that the microform is capable of producing a clear copy throughout the
required retention period.
(c)
The record may also be stored in electronic media with the capability
for producing legible, accurate, and complete records during the required
retention period.
(d)
Records such as letters, drawings, and specifications, shall include all
pertinent information such as stamps, initials, and signatures.
(e)
The licensee shall maintain adequate safeguards against tampering with
and loss of records.
Source. #11105, eff 5-25-16
He-P 4038.30 Record Retention.
(a)
Licensees shall maintain the records or documents that are required by
He-P 4038 for the period specified by the appropriate section.
(b)
If a retention period is not otherwise specified, these records shall be
retained until the DHHS/RHS terminates the facility's license.
(c)
All records related to He-P 4038.30(a) may be destroyed upon DHHS/RHS
termination of the facility license.
Source. #11105, eff 5-25-16
He-P 4038.31 Inspections. Each
licensee shall make available to DHHS/RHS for inspection, upon reasonable
notice, records kept by the licensee pertaining to its receipt, possession,
use, acquisition, import, export, or transfer of category 1 or category 2
quantities of radioactive material.
Table 4038.1—Category 1 and
Category 2 Threshold
The terabecquerel (TBq) values are the regulatory standard. The
curie (Ci) values specified are obtained by converting from the TBq value. The
curie values are provided for practical usefulness only.
Radioactive
material |
Category
1(TBq) |
Category
1(Ci) |
Category
2(TBq) |
Category
2(Ci) |
Americium-241 |
60 |
1,620 |
0.6 |
16.2 |
Americium-241/Be |
60 |
1,620 |
0.6 |
16.2 |
Californium-252 |
20 |
540 |
0.2 |
5.40 |
Cobalt-60 |
30 |
810 |
0.3 |
8.10 |
Curium-244 |
50 |
1,350 |
0.5 |
13.5 |
Cesium-137 |
100 |
2,700 |
1 |
27.0 |
Gadolinium-153 |
1,000 |
27,000 |
10 |
270 |
Iridium-192 |
80 |
2,160 |
0.8 |
21.6 |
Plutonium-238 |
60 |
1,620 |
0.6 |
16.2 |
Plutonium-239/Be |
60 |
1,620 |
0.6 |
16.2 |
Promethium-147 |
40,000 |
1,080,000 |
400 |
10,800 |
Radium-226 |
40 |
1,080 |
0.4 |
10.8 |
Selenium-75 |
200 |
5,400 |
2 |
54.0 |
Strontium-90 |
1,000 |
27,000 |
10 |
270 |
Thulium-170 |
20,000 |
540,000 |
200 |
5,400 |
Ytterbium-169 |
300 |
8,100 |
3 |
81.0 |
Note: Calculations Concerning Multiple Sources or Multiple
Radionuclides
The "sum of fractions" methodology for evaluating
combinations of multiple sources or multiple radionuclides is to be used in determining
whether a location meets or exceeds the threshold and is thus subject to the
requirements of this part.
I. If multiple sources of the same radionuclide and/or
multiple radionuclides are aggregated at a location, the sum of the ratios of
the total activity of each of the radionuclides must be determined to verify
whether the activity at the location is less than the category 1 or category 2
thresholds of Table 4038.1, as appropriate. If the calculated sum of
the ratios, using the equation below, is greater than or equal to 1.0, then the
applicable requirements of this part apply.
II. First determine the total activity for each
radionuclide from Table 4038.1. This is done by adding the activity
of each individual source, material in any device, and any loose or bulk
material that contains the radionuclide. Then use the equation below
to calculate the sum of the ratios by inserting the total activity of the
applicable radionuclides from Table 4038.1 in the numerator of the equation and
the corresponding threshold activity from Table 4038.1 in the denominator of
the equation.
Calculations must be performed in metric values, i.e., TBq, and
the numerator and denominator values must be in the same units.
R1 =
total activity for radionuclide 1
R2 =
total activity for radionuclide 2
RN =
total activity for radionuclide n
AR1 =
activity threshold for radionuclide 1
AR2 =
activity threshold for radionuclide 2
ARN =
activity threshold for radionuclide n
Source. #11105, eff 5-25-16; ss by #13598, eff
3-24-23
PART He-P
4039 Radiation
Safety Requirements for Wireline
Services Operations and Subsurface Tracer Studies
He-P 4039.01 Purpose. The purpose of this rule is to set forth the
requirements for wireline services operations and subsurface tracer
studies. The requirements of this
section are in addition to, and not in substitution for, the requirements of
He-P 4003, 4019, 4020, 4021, 4022, 4023, 4024, 4030, 4031, and 4038 of this
chapter.
Source. #5903, eff 12-1-94, EXPIRED: 12-1-00
New. #8212, eff 11-23-04; ss by #10188, eff
9-26-12; ss by #13541, eff 1-28-31
He-P 4039.02 Scope.
This part shall apply to persons using sources of radiation for wireline
service operations including mineral logging, radioactive markers, and
subsurface tracer studies as specified in Title 10, Code of Federal Regulations
(CFR), Part 39, “Licenses and Radiation Safety Requirements for Well Logging”.
Source. #5903, eff 12-1-94, EXPIRED: 12-1-00
New. #8212, eff 11-23-04; ss by #10188, eff
9-26-12; ss by #13541, eff 1-28-31; ss by #13541, eff 1-28-31
He-P 4039.03. Definitions. To reconcile differences between this part
and the incorporated sections of 10 CFR Part 39 relating to using sources of
radiation for wireline service operations including mineral logging,
radioactive markers, and subsurface tracer studies, the following words and
phrases shall be substituted for the language in 10 CFR Part 39 as follows:
(a) All references to “NRC” or “Commission” shall
mean the New Hampshire department of health and human services;
(b) The definition of “licensed material” shall
be as defined in He-P 4003 of this chapter; and
(c) The definition of “sealed source” shall be as
defined in He-P 4003 of this chapter.
Source. #5903, eff 12-1-94, EXPIRED: 12-1-00
New. #8212, eff 11-23-04; ss by #10188, eff
9-26-12; ss by #13541, eff 1-28-31
He-P 4039.04 Incorporation of 10 CFR Part 39.
(a) Except for the sections noted in (b) below
and He-P 4039.03 above, persons using sources of radiation for wireline service
operations including mineral logging, radioactive markers, and subsurface
tracer studies shall comply with Title 10, Code of Federal Regulations (CFR),
Part 39, “Licenses and Radiation Safety Requirements for Well Logging”.
(b) The following sections of the Title 10 CRF
Part 39 shall not apply to those persons using sources of radiation for
wireline service operations:
(1) Title 10 CFR Part 39.5 relating to
interpretations;
(2) Title 10 CFR Part 39.8 relating to
information collection;
(3) Title 10 CFR Part 39.101 relating to
violations; and
(4) Title 10 CFR Part 39.103 relating to criminal
penalties.
Source. #5903, eff 12-1-94, EXPIRED: 12-1-00
New. #8212, eff 11-23-04; ss by #10188, eff
9-26-12; ss by #13541, eff 1-28-31